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Abstract 
Introduction: Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy 
(TMA) that has a predilection to present in the kidney. It is a triad of microangiopathic 
haemolytic anaemia, thrombocytopenia, and acute kidney injury. In 90% of cases, HUS 
follows gastroenteritis secondary to infection with Shiga toxin (Stx) producing bacteria 
such as Escherichia coli. Stx HUS is the leading cause of acute kidney injury in children with 
a mortality of 5%. The precise pathophysiological mechanisms following Stx infection that 
lead to TMA are poorly understood.  
 
Objective: To investigate whether Stx acts via the podocyte globotriaosylceramide (Gb3) 
receptor to cause HUS.  
 
Results: To interrogate the pathways activated by Stx in podocytes, total and phospho-
proteomic studies in human podocytes versus Gb3 knockout controls were performed. 
Ingenuity Pathway Analysis showed a significant reduction in VEGF-A signalling in wild 
type podocytes treated with Stx; suggesting VEGF-A maybe a critical coordinator of Stx 
HUS.  
 
To illustrate that Gb3 is the receptor for Stx in vivo, a constitutive whole body Gb3 
knockout mouse (Gb3KO) was generated. Gb3KO mice were completely protected from 
the toxicity of intraperitoneal Stx even at x400 the lethal dose. All wild type control mice 
died within 4 days of receiving Stx from extra-glomerular dehydration, as demonstrated 
by ATN on renal histology.  
 
To determine the role of the podocyte Gb3 receptor in vivo, an inducible podocyte 
expressing Gb3 mouse on a Gb3 null background (PodGb3) was generated. PodGb3 mice 
given intraperitoneal Stx developed HUS (thrombocytopenia, haemolytic anaemia, and 
uraemia p<0.05) at day 10. Renal histology demonstrated glomerular TMA, with 
intracapillary thrombus on electron microscopy. Immunofluorescence demonstrated 
increased glomerular fibrinogen and C3b deposition vs. controls. Additionally, glomerular 
complement regulator factor H was significantly reduced in PodGb3 mice. Fascinatingly, 
administration of a C5 inhibitor in this model rescued the HUS phenotype.   
 
Conclusions: The discovery that the podocyte is capable of causing Stx HUS, with 
activation of complement observed on the glomerular endothelium; is compelling 
evidence for the importance of glomerular cell cross-talk within the kidney in the 
development of the disease. This may explain why the glomerulus is the prime target of 
systemic Stx driven infection and lead to the development of novel therapies to help treat 
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Chapter 1 : Introduction 
Haemolytic uremic syndrome (HUS) is a major global healthcare issue as it is the leading 
cause of acute kidney injury in children [1]. The syndrome presents clinically as a triad of 
acute kidney injury, microangiopathic haemolytic anaemia and thrombocytopenia. It is 
classified histopathologically, as a glomerular thrombotic microangiopathy (TMA) [2]. In 
recent years, there have been major advances in our understanding of rare, complement 
driven, inherited forms of HUS. However 90% of HUS cases are associated with Shiga toxin 
producing enteric pathogens [3]. The precise pathological pathways in this setting are yet 
to be elucidated. The purpose of my research is to determine the glomerular mechanisms 
underlying the action of Shiga toxin. Hence, an understanding of the function of the 
kidneys in health is required; before the effects of Shiga toxin on this vital organ are 
explored. 
1.1 The kidney 
The kidneys are a pair of two “kidney bean shaped” organs located in the retroperitoneal 
space within the abdominal cavity (Figure 1-1). Together they filter 180 litres of blood a 
day [4]. The major function of the kidneys is to remove waste products and excess water 
from the blood via the urine. The production of urine involves a complex series of steps 
of not only excretion, but also reabsorption of electrolytes and water which is critical to 
maintain homeostasis [5]. The kidneys also release hormones that regulate blood 
pressure, control erythropoiesis, maintain acid-base balance and hydroxylate vitamin D 
to its active form to ensure calcium homeostasis and bone health [5]. 
 The nephron 
The functional filtration unit of the kidney is the nephron. Each kidney contains up to 1 
million nephrons that consist of a long fine tubule; closed at one end to form Bowman’s 
capsule which encapsulate a tuft of microscopic blood vessels known as the glomerulus 
[6]. From the Bowman’s capsule arises: the proximal tubule, the descending and 
ascending limbs of the Loop of Henle, the distal tubule and finally the collecting duct [7]. 
The glomerulus filters the blood and provides a physical barrier to prevent the passage of 
erythrocytes and protein into the urine. The filtrate is produced in the glomerulus and 
enters the tubule. As it passes through each section of the nephron the urinary filtrate is 
modified through reabsorption and secretion of fluid and electrolytes to maintain body 
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fluid homeostasis [7]. Urine then passes from the collecting ducts into papillary ducts 
which drain into the central renal pelvis and form here into the bladder via the ureter 
(Figure 1-2) [8].  
 
 
Figure 1-1: The anatomy of the kidney 
The retroperitoneal anatomical location of both kidneys are shown. A coronal section through one 
kidney reveals the outer cortex enclosing a pyramid-shaped medulla. The apex of the medulla 
protrudes into the renal calyces which drain into the renal pelvis. Urine passes from the renal pelvis 




Figure 1-2: The nephron 
The functional unit of the kidney is the nephron, which is shown traversing the renal cortex and 
medulla. The nephron consists of the glomerulus which is enclosed by Bowman’s capsule. From 
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the Bowman’s capsule arises in succession: the proximal tubule, the descending and ascending 
limbs of the Loop of Henle, the distal tubule and finally the collecting duct. Figure reproduced from 
Field et al [7].  
 
 The glomerulus 
The glomerulus is a network of specialised capillaries attached to the mesangium which 
together are enclosed by Bowman’s capsule. It is here that plasma ultrafiltration occurs 
to form urine [8]. The glomerular capillaries are unique as they are located between two 
arterioles: the afferent arteriole which supplies the glomerular tuft and the efferent 
arteriole that drains the glomerular capillary bed (Figure 1-3) [9]. This allows glomerular 
capillary pressure (via constriction of the efferent arteriole) and therefore glomerular 
filtration to be maintained regardless of fluctuations in blood flow to the kidney [10].  
The glomerular capillaries and outer mesangium are covered by epithelial cells which form 
part of the visceral epithelium of Bowman’s capsule. These terminally differentiated 
epithelial cells are known as podocytes. Separating the fenestrated glomerular 
endothelial cells (GEnC) and the epithelial podocyte cells is the glomerular basement 
membrane (GBM). Together, these three components form the glomerular filtration 
barrier (Figure 1-4). The integrity of the glomerular filtration barrier is maintained through 
chemical cross-talk between these three cell types. In the event of mutation or injury to 
any of these constituent parts, the glomerular filtration barrier is damaged and there is 
leakage of macromolecules (typically albumin). Albuminuria itself is known to correlate 





Figure 1-3: The glomerulus 
The glomerulus is a network of specialised capillaries attached to the mesangium which is 
encapsulated by Bowman’s capsule. It is here that plasma ultrafiltration occurs to form urine [8]. 
Together the glomerulus and Bowman’s capsule are known as the renal corpuscle. The glomerular 
capillaries and outer mesangium are covered by epithelial cells which form part of the visceral 
epithelium of Bowman’s capsule. These terminally differentiated epithelial cells are known as 
podocytes. Image downloaded from https://www.studyblue.com. 
 
 
Figure 1-4: Electron Microscopy (EM) cross-sectional image of the glomerular filtration barrier 
The podocyte foot processes are clearly seen on the urinary side of the lumen, with their slit 
diaphragms visible. The glomerular endothelial cells sit on the on the blood side with fenestrations 
indicated by the arrow heads. Lying between these two cells is the GBM (glomerular basement 
membrane). Urinary filtrate passes from the blood lumen to the urinary space. Figure adapted 









 The podocyte 
Podocytes are highly specialised, terminally differentiated epithelial cells of mesenchymal 
origin [10]. As such they are unable to replicate and cannot be replaced after birth [8]. 
They constitute the visceral epithelium of Bowman’s capsule and are formed of a cell body 
which gives rise to long extensions known as primary processes, which end in multiple 
interdigitating foot processes (Figure 1-5). These rest upon the basement membrane 
surface of the glomerular capillary [8]. The foot processes of one podocyte interact with 
another at specialised cell to cell junctions known as ‘slit diaphragms’ [12]. Several 
proteins (including nephrin, podocin and P-cadherin) have been shown to form the slit 
diaphragm. Exactly how these molecules interact to form a size-selective filtration barrier 
and signal to the podocyte cytoskeleton is yet to be fully determined [8].  
Distortion of podocyte foot process architecture termed ‘foot process effacement’ due to 
injury or mutation in slit diaphragm proteins causes glomerular proteinuria [10]. It has 
been shown to be a result of active actin cytoskeleton reorganisation in response to 
intracellular signalling [10]. Podocyte injury is known to be the origin of many glomerular 
diseases [13]. However, there are a few conditions where nephrotic proteinuria occurs 
without evidence of foot process effacement, most notably in pre-eclampsia (a pregnancy 
associated TMA). Furthermore, the degree of foot process effacement quantified upon 
morphometry does not appear to correlate with the level of proteinuria observed in 
disease states [10]. This has prompted an alternative hypothesis from Kriz et al. who 
suggest that podocyte effacement represents an attempt to re-model and prevent 
detachment from the GBM [14]. This is an interesting concept, which if correct suggests 





Figure 1-5: Scanning electron micrograph of the podocyte 
Each podocyte consists of a cell body which gives rise to long extensions known as primary 
processes (PP) which end in multiple interdigitating foot processes (FP). The glomerular capillary 
loop is entirely covered by podocyte foot processes [12]. Image downloaded from 
http://medcell.med.yale.edu.php.  
 
 The glomerular basement membrane  
As seen in Figure 1-4, glomerular endothelial cells line the inner surface of the glomerulus 
and are in direct contact with the bloodstream within the kidney [15]. At the edges of the 
glomerular capillary loop, these highly specialised endothelial cells are flattened and share 
a common glomerular basement membrane (GBM) with adjacent podocytes. Thus, the 
GBM is formed from the fusion of the basal laminae of the glomerular endothelium and 
the basal cell membrane of the podocyte foot processes [16]. The GBM consists of a 
complex gel meshwork consisting of laminin isotypes, type IV collagen, nidogen and 
heparin sulphate proteoglycans. These matrix molecules provide structural support for 
the glomerulus and act as ligands for receptors found on the surface of endothelial cells, 
podocytes and the mesangium [16][17]. The GBM is clearly an important part of the 
glomerular filtration barrier as genetic mutations in GBM genes are known to result in 
albuminuria and progress to end stage renal disease. The most well-known being Alport 
syndrome, caused by an X-linked mutation in the COL4A5 gene in 80% of cases [17].  
 The glomerular endothelial cell 
The glomerular endothelium is characterised by the presence of large fenestrations which 
give it a high permeability to water and small solutes [16]. These circular transmembrane 
pores make up 30 to 50% of the entire endothelial cell surface, and facilitate the flow of 
7 
 
filtrate through the glomerular filtration barrier across the GBM to the podocyte [15]. Due 
to the size of these pores it was initially thought that the glomerular endothelium 
represented a non-selective permeable layer within the glomerular filtration barrier. 
However, glomerular endothelium and their fenestrae are now known to be covered in a 
layer of negatively charged proteins which contribute to the selective permeability of the 
glomerular filtration barrier [18]. These are either anchored to the cell membrane of the 
endothelial cell to form a glycocalyx or are non-covalently bound to associated proteins 
on the endothelial cell surface [16].  
 
 
Figure 1-6: The glomerular endothelial cell and glycocalyx 
The glycocalyx is a complex structure of core proteoglycans with attached hyaluronan, heparin 
sulphate and chondroitin sulphate chains (as shown). Circulating plasma proteins in the lumen of 
the glomerular capillary are adsorbed from the circulation and adhere to the surface of the 
glycocalyx. This generates a layer (indicated in pink) of protein deplete filtrate that is adjacent to 
the endothelial cell membrane. This acts to reduce the oncotic pressure across the endothelium, 
controlling transcapillary fluid exchange. Figure reproduced from Butler et al. [19].  
 
The glycocalyx is made up of a complex structure of sulphated proteoglycans, hyaluronan, 
glycoproteins and various other circulating plasma proteins from the blood that adhere 
to the surface of the endothelium [18]. This generates a layer of protein deplete filtrate 
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that is adjacent to the endothelial cell membrane (Figure 1-6) [19]. It is this layer that 
reduces the loss of plasma macromolecules such as albumin into the urinary filtrate and 
that maintains oncotic pressure regulating transcapillary fluid exchange within the 
glomerulus [18][19].  
Disruption to the glycocalyx has been shown to contribute to a number of vascular 
diseases including diabetic kidney disease, hypertension and atherosclerosis [20]. The 
Bristol Renal endothelial research group has demonstrated (both in conditionally 
immortalised endothelial cells in vitro and in murine models in vivo), that loss of 
glycosaminoglycans occurs under diabetic conditions [21]. More recently, in a diabetic 
mouse model, this group has also shown that blocking matrix metalloproteinase (MMP) 
mediated syndecan-4 shedding restored the glomerular endothelial glycocalyx; which led 
to the attenuation of diabetes induced albuminuria [21]. This work highlights the 
importance of the glomerular endothelium and a healthy glycocalyx in maintaining the 
glomerular filtration barrier.  
Of interest to my research, loss of endothelial cell fenestrations together with degradation 
of the endothelial glycocalyx have also been shown to be associated with the vascular 
injury of early onset pre-eclampsia (a pregnancy associated TMA) [22][23]. Furthermore, 
being the primary interface between the circulation and the endothelium, the glycocalyx 
also plays a key part in the inflammatory response within the glomerulus [18]. Indeed, it 
is known that the glomerular glycocalyx can inhibit leukocyte capture and extravasation, 
acting as a physical barrier regulating the recruitment of inflammatory cells to the kidney 
[18]. Moreover, the endothelial cell itself is known to be particularly susceptible to 
complement mediated injury and reliant upon the protection of membrane bound 
complement regulators (such as membrane co-factor protein: MCP) as well as fluid phase 
regulators such as complement factor H to maintain immune homeostasis [18]. Acquired 
or genetic deficiency in these complement regulators results in a wide range of glomerular 
diseases: from dense deposit disease (DDD) to atypical haemolytic uraemic syndrome 
(aHUS) [10]. Thus, although my research has focused upon the role of the podocyte in 
Shiga toxin HUS, the importance of the glomerular endothelial cell in the pathogenesis of 
this disease cannot be overlooked. As such, an increase in glomerular endothelial cell 
susceptibility to complement attack forms a key concept within my research hypothesis; 
which aims to improve understanding of the mechanisms responsible for glomerular TMA 
in Shiga toxin HUS.   
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 Cellular interactions within the glomerulus 
It is an over-simplification to think of the three major constituents of the glomerular 
filtration barrier as independent elements. Through recent advances in targeted cell-
specific transgenic animal models there has been great advancement in the 
understanding of the communication and cross-talk within the glomerulus in vivo [24]. 
Key pathways that have been identified to date include: vascular endothelial and platelet 
derived-growth factors as well as novel paracrine pathways such as IL-6 and CXC 
chemokine ligand 12 signalling [24]. Indeed, there is mounting evidence in support of the 
glomerular filtration barrier being a fluid, constantly adapting inter-cellular 
communication unit to maintain glomerular function [25]. My work expands on this 
concept, being founded upon the hypothesis that in Shiga toxin HUS the podocyte is 
capable of inducing changes in neighbouring endothelium to cause a glomerular TMA (the 
histopathological hallmark of the disease). This hypothesis has been generated on the 
basis of work published by Eremina et al. that described the development of a glomerular 
TMA following targeted podocyte specific VEGF-A deletion in vivo [11]. The precise role 
of VEGF-A in maintaining glomerular health and its association with glomerular TMA will 
be re-visited in detail in subsequent sections. 
1.2 Haemolytic Uraemic Syndrome 
Haemolytic uremic syndrome (HUS) is the leading cause of acute kidney injury in children. 
It is a triad of acute kidney injury, microangiopathic haemolytic anaemia and 
thrombocytopenia; first described in 1955 by Gasser et al [26]. Over 90% of childhood 
HUS cases are associated with infection [3]. Shiga toxin-producing Escherichia Coli found 
in contaminated food and water supplies is typically the infective trigger; although HUS 
has also been reported following exposure to Shigella, Campylobacter and Streptococcus 
Pneumoniae [3]. In England, Shiga toxin associated HUS affects 1.8 people per 100,000 
population per year. The majority of these cases are reported in children under 5 years of 
age in whom the incidence is considerably higher at 7.6 per 100,000 population per year 
[27]. 
The remaining 10% of HUS cases are termed ‘atypical’. These include familial cases which 
are due to genetic abnormalities in complement regulation and other non-infective 
causes such as pregnancy, drugs, malignancy, connective tissue disorders and 
transplantation [28]. Over the last decade there has been a renewed appreciation and 
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considerable interest in the role of the complement system in renal disease which has 
been magnified by the effectiveness of eculizumab (a monoclonal humanised antibody 
against C5) in the treatment of atypical HUS. Eculizumab was first used in atypical HUS in 
2009 and there have been numerous case reports detailing the success of the drug in 
controlling the disease. A landmark prospective Phase 2 trial published in 2013, further 
consolidated the evidence for significant improvement in renal function in atypical HUS 
patients treated with eculizumab [29]. 
 The classification of HUS 
HUS is categorised histopathologically as a thrombotic microangiopathy (TMA).  This term 
was first introduced in 1952 by Symmers to describe: capillary wall thickening, swelling 
and detachment of the endothelial cell from the basement membrane, accumulation of 
debris in the subendothelial space and intraluminal platelet thrombosis (Figure 1-7) [2]. 
The microangiopathic haemolytic anaemia that ensues is a consequence of erythrocyte 
sheer stress resulting in red cell fragmentation. Platelet activation and entrapment in 
microthrombi, as well as trafficking to the reticuloendothelial system leads to 
thrombocytopenia, local thrombosis and organ ischaemia [3]. When this process occurs 
in the microvasculature of the kidney (as is the case in HUS) renal impairment is seen due 
to organ ischaemia. In contrast, in thrombotic thrombocytopenic purpura (TTP) 
neurological impairment is observed as the predominant microvascular bed affected is 
the brain [3]. Therefore, TMA represents a final common pathway in a number of disease 
processes which amongst others include HUS and thrombotic thrombocytopenic purpura 
(TTP) (Figure 1-8). The clinical sequelae observed is dependent upon the vascular bed and 





Figure 1-7: The pathophysiology of TMA 
TMA is the final common pathway of many disease processes but is most often seen in the context 
of HUS and TTP. The pathological features of TMA include increased vessel wall thickening, swelling 
and detachment of endothelial cells within the target organ and platelet aggregation as shown. 
This leads to accumulation of debris in the subendothelial space. Clinically this presents as a 
consumptive thrombocytopenia, microangiopathic haemolytic anaemia and organ ischaemia. 
Figure reproduced from Keir et al. with permission [3]. 
 
Although HUS and TTP both result in TMA, they are different diseases with distinct 
underlying mechanisms [30]. TTP results from a deficiency in ADAMTS13 due to the 
presence of an acquired antibody or inherited due to an autosomal recessive mutation in 
the gene [31]. ADAMTS13 is a metalloproteinase enzyme that cleaves von Willebrand 
Factor (vWF) preventing unregulated platelet aggregation and adhesion at sites of 
vascular injury. When this enzyme is deficient (as is the case in TTP) vascular homeostasis 
is lost, large multimers of vWF form and coagulation occurs resulting in a consumptive 
thrombocytopenia and end organ ischaemia [31]. In TTP there is no evidence of 
endothelial swelling and von Willebrand factor is the primary constituent of the capillary 
thrombi that form in the microvasculature of the affected organs. This is in contrast to 
HUS where fibrin predominates in these lesions [31]. Classically, TTP is associated with a 
pentad of microangiopathic anaemia, thrombocytopenia and acute kidney injury (AKI), 
fever and neurological features [1]. However, HUS can also present with extra-renal 
manifestations that include neurological sequalae and fever [32]. Hence, patients need to 
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be tested for ADAMTS13 levels to identify those with TTP (ADAMTS13 <10%) vs. those 
with HUS which have normal levels and function of the ADAMTS13 metalloproteinase 
enzyme [31].  
 
 
Figure 1-8: Classification of thrombotic microangiopathy 
It is now widely accepted that classification of TMA according to aetiology (rather than clinical 
features) is a more useful guide to prognosis and treatment. TMA represents a final common 
pathway in many disease processes [3]. Figure reproduced from Bowen et al. with permission [1]. 
 
 Infection Associated HUS 
By far the commonest cause of HUS, is infection associated HUS which accounts for 90% 
of cases [3]. Within this group the majority follow exposure to contaminated food or 
water with Shiga toxin producing Escherichia Coli (E.coli) [33]. Conventionally this form of 
HUS has been known as ‘typical’ or ‘diarrhoea associated’. However, these terms have 
proved unhelpful given that up to half of patients with atypical HUS can present with an 
initial diarrhoeal illness [34]. Given the need for clarity in terminology, the definition ‘STEC 
HUS’ is now used to describe HUS secondary to Shiga toxin producing Escherichia coli. This 
is distinct from other infective causes of HUS such as Streptococcal pneumoniae-related 




Diagnosis of STEC HUS is reliant upon faecal testing in the laboratory using stool culture, 
serum detection of E.coli O157 antibodies, immunoassays, and PCR (polymerase chain 
reaction) assay to detect Shiga toxin genes. These tests together will identify up to 70% of 
cases [36]. Diagnosis of atypical HUS is therefore often implied by the absence of STEC. As 
a result, patients presenting with a microangiopathic anaemia, thrombocytopenia and 
acute kidney injury may initially be commenced on plasma exchange. Once TTP has been 
excluded (ADAMTS13 activity above 5-10%) and if STEC testing is negative then a diagnosis 
of atypical HUS is considered likely and eculizumab started; whilst levels of complement 
factor H, I and MCP are awaited along with subsequent targeted genetic analysis 
sequencing to identify specific complement mutations [37].  
 Epidemiology of STEC HUS 
The latest available figures from Public Health England (PHE) report a total of 1219 
confirmed cases of STEC in England and Wales in 2018 [38]. There were an additional 334 
cases reported that were positive for Shiga toxin genes on PCR, but no organism was 
identified. As with previous years, the highest incidence of infection with was in children 
under 5 years of age at 3.36 per 100,000 population. The most common serogroup of STEC 
that caused illness in England was O157 (although other serogroups such as 026, 091 and 
0146) were also detected due to more widespread use of PCR testing of stool samples. 
Almost one third of STEC O157 cases were hospitalised, with 2% recorded as developing 
HUS [38].  
Prior to the introduction of PCR testing, the majority of laboratories were using culture 
methods to identify STEC O157 infection by its inability to ferment sorbitol on MacConkey 
agar. This is satisfactory for identification of STEC O157 but not for non-O157 serogroups 
which do ferment sorbitol. The only way to differentiate between non-O157 STEC that 
cause disease versus those that are non-pathogenic is to perform PCR testing. It is of no 
surprise therefore, that since the introduction of PCR testing in 2013 there has been an 
increase in the number of pathogenic non-O157 STEC cases identified in England; with 9% 
of these developing HUS [38]. The variation in ability to cause serious illness of each STEC 
serogroup is known to be due to differences in virulence. This itself is influenced by the 
subtype of Shiga toxin produced by E.coli; with the release of Shiga toxin subtype 2 known 
to be more likely to cause HUS [39].  
The incidence of STEC O157 cases has been following a downward trajectory in England 
and Wales since 2015 (Figure 1-9). However, incidence in England differs according to 
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region. The highest incidence in 2018, was in the North East of England with 1.99 cases 
per 100,000 population [38]. The lowest incidence reported was in London as indicated 
from the map shown in Figure 1-10. Interestingly, in 2018 of the recorded STEC O157 
cases in England 58% were female. In fact, across all age groups (except those over 80 
years) females had a higher incidence (Figure 1-11) [38]. However, in terms of 
development of STEC HUS, larger pooled data retrospective studies in Europe have 
reported no statistically significant increase STEC HUS in women [40]. It is clear, that STEC 
infections follow seasonal variation and peak during the warmer summer months; a trend 
also observed over previous years (Figure 1-12) [38]. 
 
 
Figure 1-9: Incidence of STEC O157 cases in England and Wales from 2006 to 2018 
The incidence of STEC O157 cases has been following a downward trajectory in England and Wales 
since 2015. Higher rates of STEC O157 infection correspond to higher rates of STEC HUS by 
definition. Graph reproduced from https://www.gov.uk/government/publications/escherichia-





Figure 1-10: Regional incidence of STEC O157 in England 
Incidence of STEC O157 infection in England differs according to region. The highest incidence in 
2018, was in the North East of England with 1.99 cases per 100,000 population (dark blue on map). 
The lowest incidence reported was in London at 0.56 cases per 100,000 population (pale blue on 
map). Map reproduced from https://www.gov.uk/government/publications/escherichia-coli-e-
coli-o157-annual-totals [38].  
 
 
Figure 1-11: Age and gender specific incidence of STEC O157 cases in England during 2018 
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In 2018, of the recorded STEC O157 cases in England 58% were female. In fact, across all age groups 
(except those over 80 years) females had a higher incidence. As with previous years, the highest 
incidence of infection with was in children under 5 years of age at 3.36 per 100,000 population.  




Figure 1-12: Seasonal variation in STEC O157 cases in England 2015 to 2018 
Data collected by Public Health England confirms that STEC O157 infections follow seasonal 
variation and peak during the warner summer months. This is a trend also observed over previous 
years. Graph reproduced from https://www.gov.uk/government/publications/escherichia-coli-e-
coli-o157-annual-totals [38]. 
 
 Clinical sequelae of Shiga toxin HUS 
Patients with Shiga toxin associated HUS classically present with a diarrhoeal illness, 
followed by the non-specific symptoms of an acute kidney injury [41].  These include pallor 
and breathless from anaemia as well as oliguria and oedema from acute onset renal 
failure [32]. The diarrhoeal prodrome of STEC HUS is bloody in nature in 80% of cases and 
characteristically associated with painful abdominal cramps [32]. The mean interval from 
exposure to the bacteria and onset of symptoms is 3 days, with almost all cases diagnosed 
within 2 weeks of onset of diarrhoea [31][41]. Patients may also have associated vomiting 
and in 30% fever is present. Blood tests reveal an elevated white cell count (leucocytosis) 
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in most patients and the classical HUS triad of thrombocytopenia, anaemia and uraemia 
[41].  
In contrast to STEC HUS, atypical HUS tends to follow a history of a trigger event such as 
pregnancy, influenza, or viral gastroenteritis in one third of patients. Atypical HUS is seen 
as frequently in children as in adults, whereas Shiga toxin HUS predominates in children 
(usually under 3 years of age). Interestingly, in atypical HUS thrombocytopenia is less 
pronounced and even absent in up to 20% of cases [32]. HUS regardless of aetiology is far 
from benign, with 50% of patients requiring prompt initiation of renal replacement 
therapy at diagnosis [41]. In Shiga toxin HUS there is no specific treatment for the disease 
with up to 5% of patients dying during the acute phase of the illness, despite best available 
supportive care [41].  
Although the kidney is the primary target of HUS, extra-renal manifestations including 
central nervous system involvement, pancreatitis, ischaemic cardiomyopathy and 
necrotic skin lesions are also a feature of the disease [32][42]. Thus, the symptoms 
apparent at presentation are dependent upon the organ systems affected by TMA. In 
Shiga toxin HUS neurological involvement is reported to be one of the most life-
threatening complications and can be as high as 20% in paediatric populations [32]. In the 
infamous German STEC HUS outbreak of 2011, neurological manifestations of HUS were 
present in 50% of adult patients and included seizures, hemiplegia, extrapyramidal 
syndrome and coma [32][43].   
The prognosis for STEC HUS patients is dependent upon the clinical trajectory of the 
disease. Acute mortality outcomes for STEC HUS have improved with the introduction of 
early dialysis from 30% to 5%. However, of those patients that survive the initial insult, up 
to 30% develop proteinuria and 18% progress to chronic renal failure [44]. Furthermore, 
some patients develop extra-renal sequelae such as diabetes mellitus following 
pancreatitis, colonic strictures due to gastrointestinal inflammation and devastating 
neurological disease with long term sequelae [44]. Thus, long-term follow up of all STEC 
HUS cases is prudent, as some patients who are apparently fully recovered from the initial 
insult go on to develop complications such as hypertension and proteinuria several years 
on from their initial diagnosis [45].  
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 Source of infection in STEC HUS 
Healthy cattle are the natural reservoir of Shiga toxin producing E.coli, although other 
animals such as sheep also harbour the bacteria in their intestinal tract [46]. As such 
under-cooked beef and unpasteurised cow’s milk are the main sources of STEC infection 
in humans [42].  Transmission occurs through consumption of infected food and water or 
exposure to contamination from animal faeces. This can be either via an indirect faecal 
oral route e.g. unwashed vegetables and salad products; (bean sprouts were found to be 
the source in the 2011 German outbreak) or directly through contact with the infected 
animal or their environment itself [46][47]. Less than 100 E.coli bacteria are required to 
cause infection in humans, meaning outbreaks of STEC can occur with ease from person 
to person due to such a low infectious dose [42][46].  
The seasonal variation in STEC cases (both O157 serotype as well as pathogenic non-O157 
serotypes) is observed globally, with higher incidence in warmer summer months 
[38][48]. This is likely due to a combination of the higher level of bacterial faecal shedding 
from livestock in warmer climates and the increase in barbeque cooking during 
summertime which is known to be associated with consumption of undercooked food 
[49]. Preventing E.coli food poisoning is a priority of public health agencies worldwide. It 
requires vigilance and careful preparation of food and water at all stages of the food chain 
[42]. Although the pathogenic E.coli responsible for STEC HUS colonise the gut of healthy 
livestock animals and are resistant to acidic and high salt conditions; correct cooking 
procedures will destroy the bacteria and dramatically reduce the risk of infection [42]. 
Despite this several large outbreaks of STEC have occurred and continue to be reported 
across the world with devastating consequences [47][49].   
 Escherichia coli bacteria  
Escherichia coli (E.coli) are Gram negative, rod shaped bacteria that inhabit the intestinal 
tract of animals and reptiles. They are the predominant aerobic bacteria in the gut of 
humans, being one of the first bacterial species to colonise the intestine in childhood [50]. 
E.coli is an example of a facultative anaerobe, it will generate ATP from aerobic respiration 
in the presence of oxygen but can switch to fermentation or anaerobic respiration should 
oxygen be absent [51]. The importance of the presence of non-pathogenic strains of E.coli 
in the human gut has only recently been recognised. This subgroup of E.coli not only 
provide a source of vitamin K and B12 for their human host, but are now also known to 
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contribute to the diversity of the human intestinal microbiome which influences our 
immune response, appetite and metabolism [52][53].  
A lack of bacterial diversity has been reported in patients with inflammatory conditions 
such as Crohn’s disease and psoriatic arthritis, as well as in type 1 and type 2 diabetics and 
those with atopic conditions such as eczema [53][54]. Moreover, in neurodegenerative 
conditions such as Parkinson’s disease there is mounting evidence that a pro-
inflammatory intestinal microbiota may act as a trigger for the condition [55]. Hence, our 
immune system has co-evolved to exist in a relationship of commensalism with E.coli, 
whereby the bacteria provide a healthy species-rich intestinal ecosystem preventing 
infection by pathogens through the production of bacteriocins; and we as the human host 
provide a steady supply of nutrients and a stable environment [50][53].  
However, some E.coli strains have acquired virulence through the transfer of DNA 
encoded within mobile genetic elements such as bacteriophages, plasmids and 
transposons; to become pathogenic and cause diarrhoeal disease [56]. To assist in 
identification of pathogenic strains, E.coli has historically been classified by serotype (a 
system initially used in the 1940s, prior to PCR based genetic sequencing). This is based 
upon the presence of the major surface antigens O-polysaccharide, K-capsular and H-
flagellar [50]. For example, as already eluded to the most prevalent serotype in the UK 
that causes HUS is E.coli O157 [38]. Given the vast number of different E.coli surface 
antigens and their combinations (there are 186 different O antigens alone) serotyping 
E.coli has become rather complex [57]. Additionally, in the last decade to further 
complicate matters, next generation sequencing technologies have made it possible to 
genetically subdivide E.coli in a more robust and discriminatory fashion. This has vastly 
improved our understanding of the evolutionary processes that have occurred to give rise 
to the variety of E.coli populations; as well as providing a way to investigate and contact 
trace to source E.coli food poisoning outbreaks [50][57]. 
For simplicity in published literature, often the terms ‘extra-intestinal’ and 
‘diarrhoeagenic’ E.coli are used to differentiate between E.coli that cause disease outside 
the gastrointestinal tract (urinary infections and neonatal meningitis for example) and 
those that cause gastrointestinal infection, respectively. Diarrhoeagenic E.coli have been 
further subdivided into pathovars according to their mode of pathogenesis and the 
presence of typical virulence factors (Table 1) [57][58][59]. It is the Shiga toxin producing 
E.coli (STEC) pathotype that is of interest to my work. The discovery of this group of E.coli 
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can be traced back to 1927, to the description of an outbreak of E.coli in children 
associated with haemorrhagic colitis and organ failure by Albert Adam [41]. He noted that 
the bacterium present in these cases was unique, and that its fermentation properties 
varied from previously known strains of E.coli [41]. Indeed, until recently we still used the 
technique of culturing E.coli on MacConkey agar plates to identify E.coli O157 by its 
inability to ferment sorbitol [38]. 
 
 
Table 1: E.coli Pathovars 
Table summarising the different pathovars of E.coli which have been classified according to their 
pathogenesis and presence of typical virulence factors. Of interest to my research are the STEC 
pathovar group that release Shiga toxin. Of note some STEC strains are also types of EHEC, so there 
is an element of crossover within these groups [60]. Table compiled from several sources 
[58][59][61]. 
 
It was not until some twenty years later, that E.coli was noted to be present in the stool 
samples of 90% of children with this bloody diarrhoeal disease but never in their blood.  
This led to the hypothesis that a filterable agent (now known to be Shiga toxin) was being 
produced by this group of E.coli bacteria. Subsequent animal research demonstrated that 
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if this agent was isolated from the stool samples of affected children and injected into 
mice it was fatal [41]. Autopsy studies in humans with haemorrhagic colitis and organ 
failure later confirmed that thrombosis of capillaries was occurring and predominated in 
the kidney microvasculature [41]. However, it was not until many years later at the end 
of the 1970s, that Konowalciuck et al. discovered that these pathogenic E.coli released a 
toxin similar to that produced by the bacteria Shigella dysenteriae [41]. The toxin was 
named ‘Shiga-like toxin’ due to these similarities; but was also known as ‘verotoxin’ due 
to its cytotoxicity in African monkey kidney cells (Vero cells) [62]. Further support for the 
pathogenicity of Shiga-like toxin came from work by Karmali et al. who found a high rate 
of toxin activity in the faecal samples of children with E.coli O157 HUS and antibodies to 
the toxin in their blood [41].  
 Shiga toxin 
Shiga toxin is an A-B exotoxin that was first isolated from Shigella dysenteriae in 1898 by 
Dr. Kiyoshi Shiga [62]. As already discussed, it was not until almost a century later that the 
same toxin (now known as Stx1 but initially named ‘Shiga-like toxin’) was found to be 
released from a pathogenic strain of E.coli [63]. This group of Shiga toxin producing E.coli 
(STEC) caused a haemorrhagic colitis and in some patients led to the development of HUS 
[1]. Further research led to the discovery of two main E.coli Shiga toxin variants Stx1 and 
Stx2 [63]. These are the most common types of Shiga toxin that are associated with human 
disease [33]. However, as more STEC serotypes were identified and the Shiga toxin strains 
they released sequenced, a further 10 variants of Shiga toxin were named (Table 2) [63]. 
Of particular interest are the variants Stx1, 1c, 2, 2c, 2d and 2e which are produced not 
only by E.coli but other bacteria including Aeromonas hydrophila, Citrobacter freundii, 
Enterobacter cloacae and Campylobacter jejuni [62][64]. These Shiga toxin releasing 
bacterial species can also cause Shiga toxin HUS, but by far the most common bacteria 





Table 2: Shiga toxin variants 
Summary table of Shiga toxin (Stx) subtypes and whether they are associated with human disease. 
Phylogenetic analysis and PCR typing has resulted in the identification of 10 variants of Shiga toxin 
as shown. Table modified from Melton-Celsa et al [63].  
 
1.2.7.1 Shiga toxin structure 
Shiga toxins are either encoded by lambdoid bacteriophages (as is the case for Stx1 and 
Stx2) or chromosomal DNA (as is the case for Stx and Stx2e) [1][65]. They consist of a 
single 30 kDa enzymatic A subunit in non-covalent association with five identical B 
subunits of 7 kDa each to form a 70 kDa A-B5 holotoxin [66]. It is the B subunits of the 
toxin that bind to the galactose disaccharides of the Gb3 (globotriaosylceramide) receptor 
on target eukaryotic cells [41]. Shiga toxin encoding bacteriophage have been shown to 
be capable of lateral transfer of enterotoxicity to non-pathogenic E.coli; a process thought 
to be key in the evolution of new pathogens [65]. Consequently, non-pathogenic 
commensal E.coli within the gut are now thought to be potential amplifiers of Shiga toxin 
production within the gastrointestinal tract of susceptible patients [67]. Toxin release 
from E.coli is reliant upon phage-mediated bacterial lysis as there is no dedicated toxin 
secretion system in gram negative bacteria [67].  
Interestingly, the nucleotide sequence homology of the A and B subunits of Stx1 and Stx2 
is almost 60% with an amino acid sequence homology of 50% [41]. However, Stx1 and 
Stx2 are immunologically distinct, with neither being recognised by a polyclonal antibody 
raised to the other toxin [65]. Stx1 and Stx2 also result in a variable level of tissue damage 
within the host and target different organs [33]. STEC that produce Stx2 are well 
documented to be associated with a more severe clinical presentation and more likely to 
lead to the development of HUS than those that produce Stx1. This observation is also the 
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case in primate and mouse models of Shiga toxin HUS [41]. For this reason, Stx2 is 
considered to be the primary variant of Shiga toxin associated with human disease; 
prompting my decision to use Stx2 throughout my research project into the study of Shiga 
toxin HUS.  
1.2.7.2 The cellular response to Shiga toxin  
Irrespective of their subtype, Shiga toxins bind to the glycosphingolipid Gb3 to facilitate 
entry into target cell [63]. Following binding to Gb3, the Shiga toxin-receptor complex is 
endocytosed and transported in a retrograde manner from the endosome to the trans-
Golgi network. From here it is transported to the endoplasmic reticulum (ER), where the 
A subunit of the toxin is cleaved by a protease produced by the ER’s own degradation 
machinery. This results in the release of the A subunit into the host cell cytoplasm where 
it can enzymatically inactivate ribosomes [68]. There is also some evidence that the 
endocytosed Shiga toxin receptor complex can also be transported directly to the nucleus 
of the target cell. However, the effect of Shiga toxin in the nucleus is yet to be elucidated 
[33].  
The three specific ways that Shiga toxin acts to affect cellular processes are as follows: 
firstly, it inactivates ribosomes by enzymatically removing an adenine residue from 28S 
ribosomal RNA. The damaged ribosome is unable to associate with elongation factor 1 
resulting in cessation of protein synthesis [63]. This triggers the ribotoxic stress response 
leading to MAPK (mitogen-activated protein kinase) signalling and activation of cytokines 
and chemokines that result in pro-inflammatory and pro-apoptotic pathways [33][66]. 
Secondly, the unfolded protein response may be triggered by Shiga toxin unfolding within 
the ER. Prolonged signalling via the unfolded protein response will induce apoptosis in 
cells [66]. Finally, the binding of the B subunit itself can initiate a cytoplasmic transduction 
cascade that is distinct from the ribotoxic stress response but that also result in a pro-
thrombotic, pro-inflammatory cellular environment (Figure 1-13) [33]. 
The precise apoptotic pathways that are triggered by Shiga toxins are thought to vary 
according to individual cell type [69].  Apoptosis is a specific form of programmed cell 
death characterised by changes in the nucleus that include chromatin condensation and 
DNA fragmentation [69]. The pathways that culminate in apoptosis involve sequential 
activation of cysteine dependent, aspartate specific proteases known as ‘caspases.’ For 
example, in monocytic THP1 cells, HeLa cells and human brain microvascular endothelial 
cells (HBMECs); Shiga toxin has been shown to activate similar apoptotic pathways in vitro 
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[69]. In these cells, Stx1 induces caspase 8, 6 and 3 signalling as well as expression of XIAP 
(a caspase 9 inhibitor of apoptosis protein). In contrast, Stx2 causes DNA fragmentation 
and cleavage of caspase 3, 6, 8 and 9 mediated by the upregulation of ER stress 
transcription factor CHOP (C/EBP homologous protein) in these cell lines [70]. Stx2 has 
also been shown to enhance activation of caspase 8 through complete degradation of the 
major anti-apoptotic protein FLIP (FLICE-like inhibitory protein) [69]. FLIP is known to be 
an important mediator in suppressing cytokine-induced apoptosis [71].  
 
 
Figure 1-13: Cellular responses to Shiga toxin 
The B subunit of Shiga toxin binds to the glycosphingolipid Gb3 in the target cell membrane. 
Following binding Shiga toxin is endocytosed and transported in a retrograde manner to the trans-
Golgi network. From here it is transported to the endoplasmic reticulum (ER) where it triggers 3 
responses: the ribotoxic stress response, proinflammatory cytokine release and the unfolded 
protein response. ATF6=activating transcription factor 6, PERK=protein kinase R (PKR)-like 
endoplasmic reticulum kinase,  IRE=iron-response element, MAPK=mitogen-activated protein 
kinase. Figure reproduced from Bowen et al. with permission [1].  
 
Although several studies have shown that the glomerular and tubular cells of the kidney 
undergo apoptosis in response to incubation with Shiga toxin, the specific apoptotic 
pathways activated in glomerular endothelial cells and podocytes are yet to be extensively 
delineated [72][73]. However, a paper published by Psotka et al. has demonstrated that 
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caspase 3 activity is increased in human conditionally immortalised glomerular 
endothelial cells and podocytes treated with Stx2 for 12 hours; suggesting that this is the 
major effector caspase responsible for apoptosis in these cells [74].  Hence, despite the 
fact that Shiga toxin does not cause apoptosis in all cell types, there is sufficient evidence 
to support a role for apoptosis in the generation of vascular injury and tissue damage 
within the human kidney due to the action of Shiga toxin in the glomerulus [69].  
 Globotriaosylceramide (Gb3) 
As already established, the neutral glycosphingolipid Gb3 is the receptor for Shiga toxin 
and therefore of vital importance in the pathogenesis of Shiga toxin HUS [63]. Gb3 is also 
known as CD77, Burkitt lymphoma-associated antigen and Pk blood group antigen [75]. 
Glycosphingolipids consist of a carbohydrate hydrophilic moiety (containing at least one 
oligosaccharide residue) and a hydrophobic lipid ceramide tail [76]. The glycosphingolipid 
Gb3 is primarily found in the plasma membrane of eukaryotic cells, where its ceramide 
tail is anchored within the lipid bilayer and hydrophilic head exposed to the extracellular 
environment [77]. The specific physiological cellular function of Gb3 is currently unknown. 
However, Gb3 is thought to be involved in the maintenance of plasma membrane 
structure [63]. It is also known to regulate cell signalling, acting as a receptor for 
pathogens; not just Shiga toxin but also as a co-receptor for the gp120 envelope protein 
of the HIV virus, facilitating its entry into CD4+ T cells [78][79].   
In support of the specificity of Gb3 as the receptor for Shiga toxin, cells lacking Gb3 
expression have been shown to be resistant its toxic effects [33]. Consequently, the 
pattern of expression of Gb3 in different cell types is a reliable predictor of the site of 
action of Shiga toxin [42]. However, the relationship between the amount of Gb3 present 
in the cell membrane and the corresponding sensitivity of the cell to Shiga toxin is not 
linear. This is thought to be due to the bioavailability of Gb3 within the membrane 
microenvironment [33]. Binding studies modelling the crystal structure of Shiga toxin, 
together with enzyme-linked immunosorbent assays (ELISAs) have shown that to bind to 
the cell membrane; the B subunit of Shiga toxin must interact with the terminal alpha-1,4 
di-galactose of the trisaccharide within the Gb3 molecule [80]. This interaction is sufficient 
for Stx1 binding to Gb3 but Stx2 requires an additional interaction between its A subunit 
and the ceramide tail residue of Gb3 [81][82]. Given each Shiga toxin molecule has 5 B 
subunits, theoretically each B subunit could bind to one or more Gb3 receptors [33]. 
Crystal modelling studies have in fact shown high affinity binding with an equilibrium 
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dissociation constant (Kd) of 0.1nM; and 3 potential binding sites per B subunit of Shiga 
toxin taking this theoretical total to 15 possible binding sites in a single Shiga toxin 
molecule [81].  
More recent Shiga toxin binding studies have demonstrated that Shiga toxin preferentially 
binds to Gb3 in the presence of cholesterol [81][82]. Hence, it is becoming increasingly 
evident that the affinity of Shiga toxin to bind to Gb3 is influenced by the plasma 
membrane microenvironment. This would further explain the dissociation between the 
amount of Gb3 extractable from a tissue and the lack of correlation in Shiga toxin 
sensitivity. Interestingly, Gb3 has been found to cluster within lipid raft sections of the 
plasma membrane in vitro [63]. Lipid rafts are dynamic entities formed from cholesterol 
and the ganglioside GM1 [80]. Assembly of lipid rafts occurs in the Golgi of the cell 
(cholesterol first synthesized in the ER and sphingolipids in the Golgi) before delivery to 
the plasma membrane. Lipid raft trafficking is under continuous endocytosis and 
turnover. This is one of the reasons that lipid raft existence has been so difficult to prove, 
along with the inability to visualise them with light microscopy [83]. What is clear from 
this work, is that the binding of Shiga toxin to Gb3 is complex and influenced by the 
specific membrane microenvironment at the time Shiga toxin is encountered by the host 
cell [63]. 
In recent years, the metabolic pathways involved in glycosphingolipid synthesis have been 
studied, facilitating the generation of several knockout mouse models to improve our 
understanding of their role in vivo (Figure 1-14). The synthesis of the Shiga toxin receptor 
Gb3, is catalysed by the enzyme Gb3 synthase also known as α-1,4-galactosyltransferase 
(A4GALT). Gb3 synthase is encoded by the A4GALT gene found on chromosome 22 and is 
responsible for catalysing the addition of an α-1,4 galactose residue to lactosylceramide 
to form globotriaosylceramide (Figure 1-15) [77].  In order to assess the role of Gb3 in 
vivo, Okuda et al. generated an A4GALT knockout mouse that was deficient in Gb3 using 
a neomycin-resistant gene targeting the open reading frame of A4GALT gene [75]. These 
mice did not appear to have any obvious phenotype, other than absence of Gb3 
expression in their tissues [75]. These constitutive A4GALT knockout mice were found to 
be completely protected from the toxic effects of Shiga toxin; demonstrating for the first 





Figure 1-14: Targeted glycosphingolipid synthesis pathways in knockout mouse models 
Genes that have been targeted are shown in the coloured boxes. The major mouse phenotypes 
due to genetic knockout in the glycosphingolipid synthesis pathway are show in red text. The only 
phenotype detected in A4GALT knockout mice was protection against Shiga toxin (or verotoxin) 
toxicity. Cer=ceramide, GalCer=galactosylceramide, GlcCer=glucosylceramide, 
LacCer=lactosylceramide, NeuNAc = neuraminic acid. Figure reproduced from Allende et al. [77]. 
 
 
Figure 1-15: The Gb3 synthesis pathway 
The biosynthetic pathway of Gb3 in eukaryotic cells is shown. The enzyme Gb3 synthase (A4GALT) 
is the enzyme responsible for catalysing the addition of an α-1,4 galactose residue to 
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lactosylceramide to form globotriaosylceramide. Gb3 is the primary receptor for Stx1 and Stx2. 
Figure reproduced from Obrig et al. [84] 
 
Due to a number of studies reporting that a subset of immature B cells express Gb3 and 
that it may play a role in the differentiation of B cells; Okuda et al. also performed 
immunological profiling of the serum, thymus and spleen of the A4GALT knockout mice 
to ensure that this was not the reason for their resistance to Shiga toxin toxicity [75]. 
There were no significant differences in these profiles and no abnormalities evident vs. 
wild type age matched control mice (Table 3). Interestingly, the total neutral 
glycosphingolipid present in the kidney of the A4GALT knockout mice was the same as 
that of wild type mice, but with no Gb3 or globo-series glycosphingolipids present [75]. 
This suggests a possible redundancy in the glycosphingolipid synthesis pathway to 
facilitate the synthesis of other neutral glycosphingolipids in some sort of compensatory 
mechanism for the absence of Gb3. In support of this, increased ceramide monohexoside 
and dihexoside levels were seen in the A4GALT knockout mice [75]. 
 
 
Table 3: Lymphocyte populations and serum antibody levels in A4GALT knockout mice  
No significant difference in immunological profiling between the A4GALT knockout mice vs. wild 
type age-matched controls could be detected. This demonstrated that the protection of the 
A4GALT knockout mice against the lethal effects of Shiga toxin was due to the absence of Gb3 
expression in the tissues and not due to the immunological profile of the mice. Data represents 
n=3 of each genotype (A4GALT knockout vs. wild type), mice were all female 4 weeks of age. Table 
reproduced form Okuda et al. [75]. 
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 Anderson-Fabry disease (over expression of Gb3) 
Anderson-Fabry Disease (also known simply as Fabry disease) is an X-linked lysosomal 
storage disorder with an incidence of 1 in 50,000 males born in the UK [85].  In Fabry 
disease, there is an accumulation of Gb3 and galabiosylceramide in the lysosomes of 
affected organs due to deficiency in the enzyme α-galactosidase (Figure 1-16) [86]. 
Patients classically present with multi-system disease due to the skin, heart, nerves, brain, 
and kidneys all being affected. Diagnostic features include numbness of the fingers and 
toes, conjunctival telangiectasia, corneal opacities, angiokeratomas of the skin, anhidrosis 
and albuminuria [86]. Affected males usually develop cardiac abnormalities such as 
conduction defects or mitral valve disease by the age of 30 years; by which time they may 
have progressed to renal failure or suffer a stroke [86]. This pattern of symptoms reflects 
the distribution of Gb3 in the human body and has provided much insight into the 
physiological role of Gb3 and other globo-series glycosphingolipids [86].  
 
 
Figure 1-16: Pathways of glycosphingolipid metabolism 
The biosynthesis of the carbohydrate core of glycosphingolipids from ceramide is shown by the 
blue arrows and catalysed by the glycosyltransferases denoted in blue boxes (α-galT=A4GALT) is 
circled in red. Catabolism is the reverse pathway and shown by the purple arrows, with the 
lysosomal enzymes denoted in purple boxes. α-gal= α-galactosidase which is deficient in Fabry 
disease and leads to accumulation of Gb3. Diseases that are caused by deficiency in the enzymes 
in the catabolic pathway are shown in yellow (Fabry disease is circled in red). CGT=ceramide 
glucosyltransferase; β-GalT= β-galactosyltransferase; α-galT=A4GALT; β-galNAcT=β-N-
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acetylgalactosaminyltransferase; α-gal=α-galactosidase; β-gal=β-galactosidase; βhex=β-
hexosaminidase; GM1= GM1 gangliosidosis. Figure adapted from Butters et al. [87] 
 
There is currently no cure for Fabry disease, but intravenous recombinant α-galactosidase 
enzyme preparations (Fabrazyme® and Replagal®) are currently available for use in the 
treatment of the condition in the UK. An oral pharmacological agent migalastat 
hydrochloride, that facilitates trafficking of the α-galactosidase enzyme to lysosomes is 
also available. However, any effect of these treatments on the mortality of Fabry patients 
is not clear [88]. Of relevance to my work, the Fabry mouse (an α-galactosidase knockout) 
that over-expresses Gb3 in its organs (including the kidney) is protected from Shiga toxin 
toxicity, even when given a lethal dose of intraperitoneal Shiga toxin [89][90]. 
Furthermore, when Gb3 levels were reduced in these α-galactosidase knockout mice 
using an intravenous recombinant α-galactosidase enzyme, they became susceptible to 
the lethal effects of Shiga toxin [90].  
This work clearly demonstrates that Gb3 is the receptor responsible for Shiga toxin toxicity 
in vivo. This finding is potentially explained by the accumulation of Gb3 in Fabry disease 
resulting in reduced delivery of Shiga toxin to target cells, due to re-direction of the toxin 
to multiple organs within the body, thereby neutralising its effect. However, given 
attempts to block Shiga toxin binding therapeutically in humans, with synthetic toxin 
binders such as STARFISH or Synsorb-Pk have been unsuccessful; it is unlikely that a 
scavenger effect is solely responsible for the observed protection of the Fabry’s mouse 
against the lethal effects of Shiga toxin [64]. An alternative theory is that Gb3 
accumulation in Fabry disease may lead to alterations in the intracellular trafficking of the 
toxin due to changes in Gb3 sub-populations [63][90]. Interestingly, to date there has 
never been a case of Shiga toxin HUS reported in a patient with Fabry disease.  
 Gb3 Expression in the kidney  
From the studies discussed so far, it is clear that specific and high affinity binding of Shiga 
toxin to the Gb3 receptor is necessary in order for the toxin to exert its cytotoxic effects 
on a target cell [72]. Furthermore, the level of expression of the Gb3 receptor in a tissue 
correlates with the clinical manifestations of the disease even if this is not stoichiometric 
[33]. Methods of Gb3 detection include thin layer chromatography, lipid mass 
spectrometry and anti-Gb3 antibody techniques such as immunofluorescence and 
immunohistochemistry. These techniques have all been used to analyse the differential 
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expression of Gb3 in vivo [33]. In humans, the greatest concentration of Gb3 is found 
within the glomerulus of the kidney, with other cells including the colonic microvascular 
endothelium and the cerebellar endothelium also known to have high Gb3 expression 
[91]. Gb3 is also present in the lung, pancreas, heart and liver [91][92][93]. This pattern 
of expression could well explain the extra-renal manifestations that are known to occur 
in STEC HUS; although as already established the local microenvironment of the plasma 
membrane plays a key role in how sensitive a cell will be to the effects of Shiga toxin, not 
just the expression of the receptor itself [94].  
1.2.10.1 Gb3 expression in glomerular endothelial cells 
The general consensus amongst experts in the field of STEC HUS research is that it is a 
disease of the glomerular endothelium [33]. The first endothelial cells to be studied were 
large vessel endothelial cells from human umbilical vein endothelial cell (HUVEC) primary 
cultures. These were later found to be relatively resistant to the effects of Shiga toxin in 
comparison to microvascular glomerular endothelial cells [95]. Perhaps unsurprisingly, 
subsequent work found glomerular endothelial cells express 50 times more Gb3 on their 
cell surface than HUVECs which is thought to account for this difference in cytotoxicity 
[72]. Other endothelial cell types that have since been evaluated include human brain 
microvascular endothelial cells which apotose in response to Shiga toxin challenge; as well 
as dermal microvascular endothelial cells and lung microvascular endothelial cells both of 
which express Gb3 and are sensitive to Shiga toxin [93][96][97].  
Why Shiga toxin exhibits a predilection for the kidney microvasculature remains unknown. 
It is likely due to a combination of factors including glomerular expression of Gb3, the 
specific properties of the membrane microenvironment in which Gb3 is located on the 
cellular surface, and local glomerular inflammatory responses to Shiga toxin. The 
differences in the baseline characteristics of individual endothelial cells according to both 
the vascular bed in which they are located and their individual gene expression profile is 
also likely to be of importance [98]. Together, these factors will influence glomerular 
endothelial extracellular matrix remodelling, angiogenesis and lipid metabolism which are 
all known to play a part in the cellular sensitivity and response to Shiga toxin exposure 
[98].  
Several studies have demonstrated the importance of the host inflammatory response to 
infection with STEC and the development of HUS [99][100]. In vitro work has shown that 
leukocytes and monocytes release the pro-inflammatory cytokines TNFα and IL-1β in 
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response to Shiga toxin [101].  When glomerular endothelial cells are incubated with 
these cytokines, it results in upregulation of the expression of the Gb3 receptor, leading 
to an increase in the sensitivity of the cells to Shiga toxin. [72][98]. Interestingly, TNFα, IL-
1β and bacterial LPS (lipopolysaccharide, found in the outer membrane of the cell wall of 
gram negative bacteria) were also found to increase the expression of Gb3 in HUVECs and 
increase their sensitivity to Shiga toxin in vitro [98]. Human in vivo data supports the role 
of inflammatory cytokines in the development of STEC HUS; with urinary levels of TNFα, 
IL-6 and IL-8 found to be increased in STEC HUS patients vs. healthy controls [72].  
In vivo research into the role of local glomerular inflammatory responses in the kidney is 
somewhat limited however, due to the lack of small animal models that recapitulate STEC 
HUS and a paucity of human renal biopsy studies (which are rarely taken due to 
concomitant thrombocytopenia and the associated high risk of bleeding). In vitro culture 
of human glomerular endothelial cells under flow conditions (in an attempt to simulate 
the in vivo environment) by Zoja et al. has demonstrated that Shiga toxin stimulated 
leukocytes induce the upregulation of cell adhesion molecules E-selectin, ICAM-1, and 
VCAM-1 on the cell surface of glomerular endothelial cells [98]. The role of inflammatory 
cytokines, chemokines and cell adhesion molecules was further supported by gene 
expression studies in human glomerular endothelial cells treated with Shiga toxin, which 
also showed these signalling pathways were upregulated [98]. Clearly, local inflammatory 
responses within the kidney due to Shiga toxin play a key part in creating a local 
environment that favours the persistence of endothelial damage, platelet activation, and 
amplification of the microvascular injury within the kidney [98].  
The specialised anatomy of the glomerular filtration barrier also needs to be considered 
in relation to development of STEC HUS. In vitro, human glomerular endothelial cells 
undergo apoptosis and are exquisitely sensitive to the cytotoxic effects of Shiga toxin [72]. 
In contrast damage to endothelial cells by Shiga toxin in vivo results in swelling and 
detachment of the cells from the glomerular basement membrane [33]. This type of injury 
is seemingly less severe than that observed in vitro. However,  glomerular endothelium is 
dependent upon attachment to the basement membrane to remain viable; as well as 
being heavily reliant upon a supply of VEGF from neighbouring podocytes [72][102]. Thus, 
disruption in these survival signals will result in an increase in the glomerular endothelial 
susceptibility to Shiga toxin and may represent more severe injury than initially apparent. 
This observed discrepancy between the effects of Shiga toxin on glomerular endothelial 
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cells in culture vs. that observed in vivo, may however, suggest a protective mechanism 
within the glomerulus that is not present in vitro [33]. Hence, the functional symbiosis and 
biological cross-talk known to exist between glomerular endothelial cells and podocytes 
within the glomerular filtration barrier in vivo, is likely to play a part in the pathogenesis 
of Shiga toxin HUS [33][102].  
1.2.10.2 Gb3 expression in podocytes 
Human podocytes are known to express the Gb3 receptor and are sensitive to Shiga toxin 
[1]. Work by Psotka et al. has confirmed that in vitro, human conditionally immortalised 
podocytes are almost as sensitive as human conditionally immortalised glomerular 
endothelial cells to Shiga toxin; with a CD50 (50% cytotoxic dose) of 0.5 pM versus 0.1 pM 
respectively [74]. However, the precise role of the podocyte in Shiga toxin HUS in vivo is 
yet to be elucidated. This is likely due to a lack of animal models of the disease, together 
with a general consensus that HUS is primarily an endothelial disorder.  
In recent years, podocyte damage has been shown to be key in the development of a 
number of glomerular diseases including focal segmental glomerular sclerosis (FSGS), 
polycystic kidney disease (PKD) and diabetic nephropathy [33]. Furthermore, of particular 
relevance to my work, podocyte injury with increased podocyte turnover is now thought 
to be a key feature in the development of pre-eclampsia [103]. This is of interest because 
pre-eclampsia shares some clinical features with HUS, namely acute kidney injury and 
thrombocytopenia; and is also believed to be a disease of systemic endothelial 
dysfunction [33][104]. Further evidence in support of a key role of the podocyte in pre-
eclampsia includes significant podocyturia in pre-eclamptic women compared to controls, 
and structural podocyte changes including down-regulation of podocyte associated 
proteins in human kidney biopsies at post-mortem [103][105]. In Shiga toxin HUS, markers 
of podocyte damage have also been detected in the urine of patients with the disease 
[106][107].   
An interesting parallel has also been drawn between the biological features podocytes in 
the kidney and neurons in the brain, that has captured the attention of glomerular 
researchers [108]. Both cell types are terminally differentiated and are structurally similar 
with long microtubule protrusions and shorter actin cytoskeleton foot processes or 
dendritic spines. Furthermore, both podocytes and neurons express several tissue specific 
proteins including synaptopodin, drebin and podocin and have been shown to use 
glutamatergic intercellular signalling systems [108][109]. Fascinatingly, neurons and 
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podocytes both express the Gb3 receptor and are sensitive to Shiga toxin [72]. Indeed, 
the neurological sequelae seen in Shiga toxin HUS may well reflect the interaction 
between neurons and brain microvascular endothelial cells within the blood brain barrier; 
mirroring the cross-talk between podocytes and the glomerular endothelium within the 
glomerular filtration barrier resulting in TMA. Clearly, the interaction between these 
highly specialised epithelial cells and the neighbouring endothelium warrants further 
study to delineate the contribution of the podocyte in the pathogenesis of Shiga toxin 
HUS.  
1.2.10.3 Gb3 expression in mesangial cells 
Mesangial cells act as a glomerular scaffold, providing structural support for the 
glomerular capillaries and secreting a mesangial matrix of soluble factors to ensure 
glomerular homeostasis [110]. They are also known to regulate the glomerular filtration 
surface area and to phagocytose interglomerular apoptotic cells and debris [110]. Their 
role in Shiga toxin HUS is yet to be studied in detail. However, mesangial cells do express 
the Gb3 receptor and bind Shiga toxin in vitro. Shiga toxin acts to inhibit protein synthesis 
in these cells but does not result in apoptosis [72].   
1.2.10.4 Extra-glomerular Gb3 expression  
As already discussed, Shiga toxin HUS is a disease of the renal glomeruli, characterised by 
the histopathological lesion of glomerular TMA. However, the Gb3 receptor is found 
throughout the human nephron and highly expressed in renal tubular cells [94]. In fact in 
vitro, human proximal renal tubular cells are also sensitive to picomolar concentrations of 
Shiga toxin with a CD50 of 10 pM [74]. When exposed to Shiga toxin in vitro, proximal 
tubule cells release pro-inflammatory cytokines including TNFα and IL-6, chemokines, 
tissue factor and undergo apoptosis [33]. Shiga toxin also results in the inhibition of 
protein synthesis in these cells [72]. The physiological function of the proximal tubule is 
to reabsorb urinary filtrate solutes and water that have passed through the glomerular 
filtration barrier, maintaining fluid and electrolyte homeostasis [111]. Hence, proximal 
tubule injury from Shiga toxin may contribute to the dehydration and oliguria seen in 
patients with Shiga toxin HUS [72].  
Similarly, human distal renal tubular cells and human collecting duct cells have also been 
reported to express the Gb3 receptor and bind Shiga toxin. These cell types have not been 
studied in significant detail in humans but again may play a part in the dehydration 
observed in Shiga toxin HUS patients [72]. What is interesting however, is that despite the 
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effects of Shiga toxin in human extra-glomerular cells in vitro, the disease is highly 
selective in vivo causing injury only within the glomerulus. Work by Lingwood et al. has 
shown that only glomerular Gb3 (not tubular epithelial cell Gb3) is detergent resistant; 
and that intracellular retrograde transport of the Shiga toxin-Gb3 complex is dependent 
upon Gb3 being located within lipid rafts (i.e. within a detergent resistant membrane) 
[94]. Thus, the selectivity of Shiga toxin to cause glomerular injury in vivo, may well be 
explained by the expression of glomerular Gb3 within detergent resistant membrane 
domains; rendering it highly susceptible to Shiga toxin toxicity [94]. Therefore, care must 
be taken in the interpretation of cell culture studies of Shiga toxin binding and 
cytotoxicity; as the plasma membrane microenvironment appears to be a significant 
factor in the pathogenesis of Shiga toxin HUS in vivo.   
 Animal models of Shiga toxin HUS 
Currently, there are no small animal models that recapitulate all of the key pathological 
features of Shiga toxin HUS seen in human disease. Animal models of Shiga toxin HUS are 
needed to provide a better understanding of the mechanisms that lead to the 
development of acute kidney injury, in the hope of identifying new drug targets to treat 
the disease [112]. As already eluded to, information from human studies is limited due to 
the difficulty of obtaining kidney biopsies from patients due to high risk of associated 
bleeding from thrombocytopenia. Thus, any insight into the pathogenesis of Shiga toxin 
HUS in humans has been obtained from the analysis of kidney tissue at post-mortem; 
which represents only the final stages of the disease and is less helpful in determining 
important signalling pathways that result in development of the syndrome [33].  
To date, the most common animal models used to study Shiga toxin HUS include those 
administering Shiga toxin or E.coli to mice, rabbits, gnotobiotic piglets and non-human 
primates such as the baboon [113]. Each model has a distinct response to Shiga toxin and 
differs in the predominant site of organ damage [33]. This observation likely reflects the 
species variation in Gb3 expression in vivo. For example, in contrast to humans, mouse 
and rat glomerular cells (including endothelial cells and podocytes) do not express Gb3 
(Figure 1-17) [68]. Consequently, mice challenged with Shiga toxin (orally or 
intraperitoneally) develop lethal tubular disease without histological evidence of 
glomerular TMA [1]. In a mouse model reported by Keepers et al. administration of both 
Shiga toxin and LPS (lipopolysaccharide) was shown to cause some evidence of thrombus 
formation in glomeruli, but the predominant lesions were tubular and led to dehydration; 
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a phenomenon that is not seen in human disease [69]. Subsequent, work by Locatelli et 
al. in the same mouse model found C3 deposition on podocytes, which was associated 
with podocyte injury and loss [114]. The authors suggest that this was a consequence of 
alternative complement pathway activation, due to the fact that pre-treatment of the 
mice with a factor B inhibitory antibody prevented podocyte loss [114].   
 
 
Figure 1-17: Thin layer chromatography (TLC) of neutral glycosphingolipids  
Top panel shows TLC of total neutral glycosphingolipids with Shiga toxin overlay to specifically 
detect Gb3. Of note Gb3 is only present in human proximal tubule cells (RPTECs), glomerular 
endothelial cells and podocytes and is absent from mouse glomerular and renal proximal tubular 
cells (TKPTS). Bottom panel shows TLC with total neutral glycosphingolipids visualised with cupric 
acid sulphate to demonstrate loading in each lane of similar total lipid content. Lipid standards 
were used in the first column as a positive control for TLC with cupric acid. HUVEC=human umbilical 
vein endothelial cells, CMH=ceramide monohexoside (also known as glucosylceramide), 
CDH=ceramide dihexoside (also known as lactosylceramide). Figure reproduced from Psotka et al 
[74]. 
 
In an effort to circumvent the dehydration and tubular necrosis that occurs in rodent 
models; Dennhardt et al. administered intermittent subcutaneous Hartmann’s solution as 
a volume substitute following intravenous administration of Stx2 in their 3 day and 7 day 
mouse models [113]. Despite this, a rise in haematocrit, profound weight loss and tubular 
injury remained the primary features of the disease that developed [113]. It has since 
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been shown that any vascular changes seen in rodent models are driven by the combined 
action of Shiga toxin and LPS. It is LPS that induces chemokine release (MCP-1, RANTES 
and MIP-1α) in the proximal tubule. If these chemokines are neutralised with monoclonal 
antibodies it results in the prevention of any thrombus formation and coagulation cascade 
activation [33][115]. Thus, at present mouse models of Shiga toxin HUS are significantly 
limited due to the absence of Gb3 expression in their glomeruli and as such do not 
recapitulate human disease.  
Several other animal species have been used in an attempt to provide a more useful in 
vivo model of Shiga toxin HUS. In rabbits a naturally occurring species specific variant of 
STEC exists which can be used for oral inoculation. In response to this, rabbits develop 
acute renal failure, but this is a highly variable and inconsistent finding [33]. Porcine 
models have not been described in detail but, similar to murine models, tubular lesions 
predominate [1]. Primate studies most closely recapitulate the disease process observed 
in human kidneys but only following intravenous infusion with Shiga toxin [1][116]. Enteric 
bacterial infection with Shiga toxin-producing E.coli in primates does not lead to HUS, and 
bacterial translocation from the gut is not seen baboons [1][117][118]. This is in contrast 
to humans where STEC induce attaching and effacing lesions and inflammatory cytokine 
production in intestinal epithelial cells [1][119]. As such, non-human primate models are 
of use in the validation of observations in mouse studies but are expensive and impractical 
given the need for intravenous toxin administration. Furthermore, the lack of intestinal 
injury observed in baboons is a limitation of this model and suggests species-specific host 
factors are likely to be key in the pathogenesis of Shiga toxin HUS [1].  
 Pathogenesis of Shiga toxin HUS 
The most important virulence trait of E.coli that leads to the development of Shiga toxin 
HUS is the production of a potent Shiga toxin [120]. However, this is not the only element 
that determines the pathogenesis of Shiga toxin HUS. It is a multi-step process, influenced 
by a number of both host and bacterial factors [98]. Firstly, STEC must be ingested and 
survive the acidic environment of the stomach to transit through the gastrointestinal tract 
to the large intestine. This is achieved through several mechanisms including the presence 
of an acid-tolerance response system (ATR) found within both E.coli and Shigella bacteria 
[65]. The ATR consists of a glutamate decarboxylase and glutamate/g-aminobutyrate 
antiporter, that facilitates transport of glutamate into the bacterium where it is 
decarboxylated in a reaction that requires a proton. The antiporter then expels the 
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reaction product to maintain a neutral pH within the bacteria [65]. A second mechanism 
is STEC production of the exopolysaccharide colonic acid. This enhances the buffering 
capacity of the bacterial cell wall through formation of a negatively charged mucoid matrix 
layer [65].  
Upon arrival at the large intestine, STEC must compete with human commensal gut 
organisms to establish colonisation [120]. Colonisation involves the formation of 
attaching and effacing lesions (AE) between STEC and the intestinal epithelium. The genes 
responsible for this interaction are located within the locus of the enterocyte effacement 
(LEE) pathogenicity island, which has also been found within the EPEC E.coli pathovar 
[98][120]. The formation of AE lesions facilitates a non-invasive interaction between the 
bacteria and host, allowing STEC to remain within the colon and release Shiga toxin in to 
the gut lumen [120].  Shiga toxin not only causes direct damage to colonic blood vessels 
which results in bloody diarrhoea, but also translocate across the intestinal epithelium to 
enter the systemic circulation [98]. Exactly how Shiga toxin is taken up by human intestinal 
epithelial cells has been under much discussion, due to the fact these cells were initially 
thought to lack expression of the Gb3 receptor [1].  
Early investigations of Gb3 expression in colonic epithelium involved thin layer 
chromatography analysis to determine the total glycosphingolipid content of the mucosal 
layer of a section of human large intestine [91]. Unfortunately, conclusive evidence could 
not be drawn from this work as samples were contaminated with intestinal endothelial 
cells which are also found within the mucosal layer of the intestine. Hence, there was 
considerable uncertainty as to whether the trace amounts of Gb3 that were detected 
were of epithelial on endothelial origin [91]. However, later work by Holgersson et al. 
using an anti-Gb3 antibody failed to detect any Gb3 expression on the cell surface of 
intestinal epithelium [121]. Several theories of Gb3 independent translocation pathways 
across the intestinal epithelium have subsequently been put forward as a result of this 
finding.  
The first hypothesis is that Shiga toxin translocates through paracellular junctions, 
following the route of immune cell infiltrates activated by the toxin and LPS found in the 
cell wall of E.coli. The second, is that AE lesions made by STEC allow the passage of the 
toxin into the bloodstream via holes in the mucosa [91]. The third is that a Gb3 
independent transcellular route exists, a theory supported by the finding that Shiga toxins 
are capable of cross-polarising intestinal epithelial cells in vitro despite apparent absence 
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of Gb3 expression in the cell line [120]. However, more recent work by Zumbrun et al. has 
now shown that Gb3 synthase (A4GALT) mRNA is detectable in human epithelial cells 
extracted from human colon tissue [91]. Through the use of laser capture microdissection, 
this group were able to circumvent the issue of intestinal endothelium contamination of 
the mucosal layer to study intestinal epithelium in isolation [91]. This finding suggests that 
some Gb3 is expressed on the intestinal epithelial cell surface in vivo, and that this may 
mediate Shiga toxin uptake in these cells.  
To date, there is no evidence that Shiga toxin itself or the pro-inflammatory cytokines 
released in response to STEC infection (TNFα and IL-1β) cause upregulation of Gb3 
receptor synthesis in colonic epithelium [122]. However, given the fact that Gb3 has only 
been found in small quantities on the surface of human intestinal epithelial cells; it is 
highly likely that inflammatory cell infiltrates and pro-inflammatory cytokines play a key 
role in priming these cells to enhance Shiga toxin translocation [65]. Certainly, in many 
other inflammatory diarrhoeal illnesses there is evidence of neutrophil transmigration 
across the intestinal epithelium with a breakdown in the epithelial barrier resulting in 
leakage of the contents from the gastrointestinal tract into the systemic circulation [65]. 
Furthermore, in vitro data has confirmed that STEC induced neutrophil migration 
augments the translocation of Shiga toxin across epithelial cells [65]. There are still many 
unknowns as to the mechanism of Shiga toxin uptake from the from the gut. However, 
much interest surrounds this area of research in the hope of finding a potential 
therapeutic intervention that could prevent Shiga toxin uptake from the intestinal lumen; 
thereby avoiding the subsequent clinical sequelae of STEC HUS [122].  
 Shiga toxin transportation to the kidney  
Precisely how Shiga toxin is transported in the bloodstream to the kidney and other target 
organs such as the brain and pancreas is yet to be established [1]. Free Shiga toxin 
molecules have been isolated from the serum of human STEC HUS patients but in trace 
amounts only [123]. Therefore, current consensus is that that Shiga toxin prefers to 
circulate in Gb3 receptor cell bound complexes [123]. The interactions between Shiga 
toxin and human blood cell constituents, including red blood cells, platelets and 
monocytes have been investigated. All of these cells express Gb3 on their cell surface and 
are capable of binding Shiga toxin [98]. However, it is the role of neutrophils in the 
carriage of Shiga toxin that has generated the most interest in recent years; despite the 
fact these cells lack the Gb3 receptor [124]. This interest was initially prompted by in vitro 
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studies performed by te Loo et al. which demonstrated preferential binding of Shiga toxin 
to neutrophils in whole blood samples and in the systemic circulation of STEC HUS patients 
[98]. Notably, this work has never been reproduced (even by the same group); hence 
some uncertainty as to the validity of this finding exists [65].  
Subsequent in vitro work has shown that direct incubation of Stx1 with neutrophils from 
healthy patients led to a reduction in their capacity to phagocytose pathogens but did not 
cause neutrophil apoptosis [125]. Incubation with Stx2, caused a delayed neutrophil 
apoptotic response that was abrogated by the protein kinase C inhibitor staurosporine 
[126]. Additionally, in human clinical observational studies, a high neutrophil count at 
initial presentation with STEC HUS, correlated with a worse clinical outcome [65]. Raised 
levels of IL-8 (a neutrophil chemoattractant) together with neutrophil activation have also 
been reported in patients with STEC HUS [65]. Furthermore, in the few human renal 
biopsy samples that are available from STEC HUS patients, a neutrophil rich glomerular 
inflammatory cell infiltrate has been observed early on in the disease process [127].  
More recent work has identified the pattern recognition receptor, toll-like receptor 4 
(TLR4) as the receptor that binds to Shiga toxin on human neutrophils [123]. Interestingly, 
TLR4 polymorphisms are known to influence both the frequency and severity of some 
other infectious diseases, including parasitic infections and urinary tract infections [128]. 
Hence, it is conceivable that these polymorphisms could explain the difference in 
individual susceptibility amongst human populations to develop STEC HUS following STEC 
infection [124]. Soluble forms of TLR4 have also been found to circulate in the 
bloodstream in humans with the capacity to bind to Shiga toxin and LPS, potentially 
attenuating the pro-inflammatory cytokine response of host macrophages and monocytes 
to STEC [129].  
An alternative theory for the transport of Shiga toxin to target organs has been proposed 
by Stahl et al. This involves Shiga toxin containing microvesicles from infected 
erythrocytes, monocytes and platelets [130]. Stahl and colleagues demonstrated that 
these microvesicles were present in blood samples of patients with STEC HUS and 
generated in vivo by mice infected with E.coli O157. Moreover, they were also able to 
isolate Shiga toxin containing microvesicles from both human and mouse kidney tissue in 
these experiments [130]. Therefore, microvesicle transfer could explain the way in which 
STEC evades the host immune response to invade target Gb3 rich tissues. There remains 
much uncertainty as to the mechanism of Shiga toxin transfer to target organs in humans. 
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As discussed, many theories have been presented in the literature; it may be that these 
co-exist with each contributing to the overall pathogenicity of STEC HUS. For this reason, 
the generation of an animal model that recapitulates the disease would be invaluable to 
further dissect these mechanisms.  
 Microvascular thrombosis and fibrinolysis in Shiga toxin HUS 
As previously eluded to, a key feature of Shiga toxin HUS is the formation of microvascular 
thrombi in the glomerulus and an impairment of fibrinolysis that results in a consumptive 
thrombocytopenia [72]. This process is known to be a result of an interaction between 
the glomerular endothelium and circulating platelets, with the role of other cell types and 
inflammatory cytokines yet to be fully understood. It has been established that platelet 
activation occurs in the early stages of the disease, with evidence of increased platelet 
degranulation, β thromboglobulin, platelet factor 4 and P-selectin in STEC HUS patient 
plasma [98]. Shiga toxin is thought to exert an indirect effect on platelets via induction of 
platelet stimulatory signals from monocytes. This is supported by in vitro studies, that 
have found Shiga toxin is only capable of inducing platelet aggregation in the presence of 
co-stimulation with thrombin or ADP [131].  
The interaction between platelets and microvascular endothelial cells has also been 
investigated. It is now widely accepted that it is loss of endothelial cell thrombo-resistance 
that leads to the formation of microthrombi in target organs; rather than direct activation 
of platelets by Shiga toxin itself [98]. Indeed, co-culture studies performed in a high shear 
stress environment to mimic that of the glomerular capillaries, have confirmed that Shiga 
toxin acts to promote platelet adhesion in TNFα activated microvascular endothelial cells 
[98][132]. Von Willebrand factor has since been found to be responsible for this 
observation. In vitro, Shiga toxin induced the release of vWF multimers from endothelial 
cells which when pharmacokinetically blocked, reduced the formation of platelet 
microthrombi on the endothelium [72]. Shiga toxin has also been shown to delay the 
cleavage (and therefore inactivation of vWF) by ADAMTS13 in vitro [98]. Pro-inflammatory 
cytokines and chemokines produced by human endothelial cells and monocytes in 
response to Shiga toxin have also been reported to stimulate platelet adhesion [98]. Thus, 
the coagulation-inflammation-thrombosis network is likely to be of key importance in the 
formation of microthrombi in target organs in STEC HUS.  
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 Potential treatments targeting Shiga toxin HUS 
To date there are no specific treatments for Shiga toxin HUS, despite years of research to 
delineate the molecular pathways underlying the cellular response to Shiga toxin. Use of 
antibiotic treatment for STEC HUS is generally avoided at present due to lack of clinical 
evidence of efficacy [133]. Additionally, there is potential to worsen the clinical outcome 
for the patient as a result of accelerating Shiga toxin release from E.coli that are lysed by 
the antimicrobial itself [64]. Progress in development of potential pharmacological 
therapeutic agents has been challenging due to the sporadic, geographically dispersed 
nature of STEC HUS outbreaks and a lack in the availability of animal models that 
recapitulate the disease in which to test potential treatments. Moreover, there is little 
financial incentive for drug companies to develop treatments given that STEC HUS is 
relatively rare and affects a diverse patient population [134].  
However, attempts have been made to block toxin binding with synthetic Shiga toxin 
binders such as STARFISH or Synsorb-Pk; and to inhibit intracellular transport of the toxin 
with molecules such as Exo1 and Golgicide A (Figure 1-18) [64]. Other agents have 
included the use of probiotic recombinant non-pathogenic E.coli strains with a high 
affinity receptor for Shiga toxin subunit B, designed to compete for Shiga toxin binding in 
the gut. When orally administered to mice, these bacterium efficiently neutralised the 
lethal effects of Shiga toxin [64]. Monoclonal antibodies targeting both Stx1 and Stx2 have 
also looked promising in animal models; with gnotobiotic piglets completely protected 





   
Figure 1-18: Shiga toxin treatments targeting Gb3 binding and retrograde intracellular trafficking 
Therapeutic attempts have been made to neutralise Shiga toxin binding to Gb3 at the B subunit of 
the receptor. These include the binders STARFISH and Synsorb-Pk. Once internalised Shiga toxin 
undergoes retrograde trafficking from endosomes through the Golgi network to the endoplasmic 
reticulum (ER). The toxin is processed as a result of this trafficking to release the A subunits in to 
the cytoplasm which interact with ribosomes to depurinate them, resulting in ribotoxicity. 
Inhibitors that have been developed to target Shiga toxin trafficking include Exo1 and Golgicide A. 
Figure adapted from Hall et al [134]. 
 
A summary of therapeutic agents that have been developed as potential therapies for 
STEC HUS are shown in Table 4. Notably, very few treatments have made it through to 
clinical trial and of these (namely Synsorb-Pk and Urtoxezumab®) not one has progressed 
beyond Phase II [134]. In both cases this was attributable to the fact that although the 
drug therapy was safe to administer to humans, there was no prevention of death or 
serious extra-renal manifestations in STEC HUS patients seen with either treatment. 
Furthermore, there was no evidence for a reduction in the need or duration of renal 
replacement therapy for STEC HUS patients [136] [137]. The role of complement inhibitors 
(such as C5 inhibitor eculizumab) in STEC HUS represents an area of controversy and will 









Table 4: Shiga toxin therapies in early development 
Many treatments are under development or in pre-clinical trials in an attempt to neutralise Shiga 
toxin binding or prevent retrograde intracellular trafficking once endocytosed by the cell. To date, 
not one of these therapies has been shown to improve outcome in patients with Shiga toxin HUS. 
Table adapted from Hall et al [134].    
 
 Atypical HUS  
Accounting for 10% of HUS cases, atypical HUS (aHUS) is a rare condition associated with 
significant morbidity and mortality. In up to 50% of patients aHUS leads to end-stage renal 
disease [138]. Accurate estimates of the incidence of aHUS are difficult to ascertain, as 
many cases remain undiagnosed and the figures that are reported often include similar 
disorders such as STEC HUS and TTP [139]. A recent systemic review into the epidemiology 
of aHUS by Yan et al. has reported a worldwide incidence of between 0.23 to 1.9 per 
million population [140]. Interestingly, in children aHUS occurs in females and males 
equally, whilst in adults a female preponderance is observed [140].  
Atypical HUS is known to be associated with complement pathway dysregulation, with at 
least 50% of cases found to be due to an underlying inherited or acquired complement 
gene abnormality [141]. These may be loss of function mutations in complement 
regulatory factors or gain of function mutations in C3 or factor B [142]. Auto-antibodies 
against complement regulatory factors (including the most well characterised factor H 
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auto-antibodies) have also been found to cause an acquired form of aHUS [1]. In aHUS 
patients with complement gene abnormalities, there is a loss of protection of the 
glomerular endothelium against complement attack and the development of glomerular 
TMA. Often, a trigger event is required to unmask this underlying genetic predisposition 
prior to clinical presentation with the disease [141]. Such trigger events include: 
autoimmune conditions, transplantation, pregnancy, infection, malignancy and drugs 
such as the oral contraceptive pill and chemotherapy agents [143].  
In some patients, identifying the specific complement abnormality that has led to aHUS 
can be a challenge; both due to the vast number of genetic variants and risk haplotypes 
for complement genes that have been described, and due to the possibility of a co-
existent trigger event having occurred [141]. Additional uncertainty exists as a high 
proportion of the mutations that are found in patients tested for aHUS, may not be of 
biological or clinical relevance in the development of the disease [144]. Consequently, 
genetic variants are now classified internationally as ‘benign, variant of uncertain 
significance, likely pathogenic and pathogenic’ to aid in this process [141]. Given the 
complexity of diagnosis and the requirement to identify pathogenic genetic variations, 
hybrid genes, and genomic rearrangements in CFH/CFHR genes with accuracy; a National 
rapid diagnostic genetic testing centre for aHUS has been set up in the UK [145].   
Inheritance of pathogenic genetic variants in aHUS may be sporadic, autosomal recessive 
or autosomal dominant with incomplete penetrance [144]. Through international 
collaboration, the study of hundreds of aHUS patients and their underlying genetic 
variation in complement regulation has been made possible. This work has provided 
powerful prognostic information to clinicians, allowing them to give aHUS patients an 
indication of their individual risk of disease progression, response to therapy and post-
transplantation recurrence [28][141][146]. For example, mutations in complement factor 
H (CFH) are known to be associated with the worst outcomes, whereas those with 
membrane cofactor protein (MCP) mutations do far better. This is perhaps not surprising 
given that MCP is a transmembrane protein which is highly expressed in the kidney; hence 
kidney transplantation corrects the MCP defect and restores MCP solid phase activity. This 
is in contrast to mutations in circulating (fluid phase) complement factors H and I, which 
are predominantly of hepatic origin [2].  
A minority of atypical HUS cases have been attributed to dysfunction in the degradation 
of von Willebrand factor, thrombomodulin mutations or loss of function mutations in 
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diacylglycerol kinase ε (DGKε) [146]. Indeed, the discovery in 2013 by Lemaire et al. that 
recessive mutations in DGKε cause aHUS in a significant proportion of children; led to a 
conceptual change in the pathophysiology of aHUS and recognition that an inheritable, 
non-complement driven mechanism could cause the disease [147]. DGKε was the first 
gene to be associated with HUS that did not have a direct role in alternative pathway 
complement activation [148][149]. Diacylglycerol kinases (DGKs) are intracellular lipid 
kinases that phosphorylate diacylglycerol (DAG) to phosphatidic acid (PA) leading to 
termination of DAG signalling [148]. The DGKε isoform preferentially phosphorylates 
arachidonic acid containing DAG (AADAG) to PA thereby terminating AADAG signalling 
(Figure 1-19) [148]. 
 
 
Figure 1-19: The AADAG signalling pathway 
DGKε is an intracellular kinase that preferentially phosphorylates AADAG to PA which terminates 
AADAG signalling. Loss-of-function mutations in DGKε therefore, lead to unregulated AADAG 
signalling and PKC dependent platelet activation with an increase in production of prothrombotic 
factors including vWF and TF. PIP=phosphatidylinositol, PIP2=phosphatidylinositol-4,5-
bisphosphate, PLC=phospholipase C, AADAG=arachidonic acid diacylglycerol, ATP=adenosine 
triphosphate, ADP=adenosine diphosphate, DGKε=diacylglycerol kinase ε, PA=phosphatidic acid, 
TRCP6=transient receptor potential cation channel 6, PKC=protein kinase C, vWF=von Willebrand 




















phospholipase A2, AA=arachidonic acid, COX=cyclooxygenase enzyme. Figure reproduced from 
Bowen et al. with permission [1]. 
 
AADAG is a key intracellular signalling molecule that activates protein kinase C (PKC). 
AADAG-dependent PKC signalling promotes thrombin-induced platelet activation. In 
endothelial cells it has been shown to increase production of prothrombotic factors such 
as von Willebrand factor and tissue factor; as well as downregulating VEGF receptor 
VEGFR2 signalling, which has been linked to TMAs previously [147][149]. Bruneau et al. 
have demonstrated in endothelial cells that knockdown of DGKε results in a 
proinflammatory and prothrombotic state via over activation of p38 and p44/42 MAP 
kinases [148]. In podocytes DAGs have been shown to modify slit diaphragm function and 
through PKC-dependent pathways downregulate expression of VEGFR2 [149]. Hence, the 
hypothesis that loss of function mutations in DGKε results in sustained AADAG signalling 
and a subsequent prothrombotic state. This finding has important implications for the 
management of atypical HUS, which to date have focused upon complement blockade.  
1.3 The Complement Cascade 
The complement system has been implicated in a number of renal diseases and 
represents an area of great interest amongst the nephrological community [150]. As 
already discussed, in the majority of cases atypical HUS is caused by impaired regulation 
of complement activation on glomerular endothelial cell surfaces [151][138]. 
Complement hyperactivation following Shiga toxin exposure has also been proposed as a 
mechanism in the development of infection associated HUS although this yet to be proven 
[2]. A recent study from Ozaki et al. has demonstrated that inhibition of the mannose 
binding lectin (MBL) complement pathway protected mice against renal injury due to 
Shiga toxin exposure [152]. Thus, an understanding of the complement pathway is 
essential prior to delving into the pathophysiology of HUS irrespective of aetiology. 
The complement pathway forms part of the innate immune response and consists of 60 
proteins which play a vital role in the host defence against pathogens and in the 
maintenance of tissue homeostasis [2]. These proteins can be plasmatic (fluid) or 
membrane bound receptors (solid) [3][153]. The complement system has several key 
functions which include: lysis of target cells through opsonisation, production of pro-
inflammatory mediators and regulation of the adaptive immune response [154]. Three 
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pathways leading to activation of the complement cascade have been described: classical, 
lectin and alternative (Figure 1-20). All three culminate with the formation of the 
membrane attack complex (MAC) leading to the insertion of pores in the target cell 
membrane resulting in osmotic lysis and cell death [2][153].  
The classical pathway is activated by binding of C1q to the Fc portion of complement-
fixing antibodies (usually IgM or IgG) that are attached to the surface of a pathogen; 
leading to the formation of antibody-antigen immune complexes (Figure 1-20). The lectin 
pathway is triggered by the binding of germline encoded pattern recognition receptors 
(PRRs) such as MBL, ficolins and cytokeratin; to mannose containing carbohydrates on 
microbial surfaces which activate MASP 1 (mannan-binding lectin serine protease 1) and 
MASP 2 [2][155]. Mannose containing carbohydrates are an example of pathogen 
associated molecular patterns (PAMPs). Other examples of PAMPs recognised by the 
lectin pathway include: LPS found in gram negative bacterial walls, peptidoglycan, 
lipoteichoic acid (LTA) of gram positive bacteria and β-glucan of fungi [156].  
In contrast to the incredibly diverse adaptive immune response, capable of recognising an 
almost infinite number of invading pathogens due to somatic gene rearrangements in 
lymphocyte antigen receptor gene segments; PRRs in the lectin pathway are focused on 
the recognition of a few highly conserved PAMPs that are present in large numbers of 
microorganisms [156][157]. This results in a system where a number of PRRs recognise a 
given pathogen to ensure a rapid and effective inflammatory response whilst maintaining 
some specificity [158]. Both the classical and lectin pathways lead to the generation of the 
same C3 convertase, C4b2a on target cell surfaces resulting in proteolytic cleavage of C3 
into anaphylatoxin C3a and opsonin C3b [2][153].  
The alternative pathway differs from the other two, in that it is continually active at low 
levels in the plasma. This is due to spontaneous hydrolysis of C3 (circulating in abundant 
amounts in human plasma) to C3b analogue C3(H20). This conformationally rearranged 
product of C3 cleavage shares functional similarity with C3b and is able to bind to Factor 
B, activating its cleavage into Ba and Bb by Factor D [159]. This facilitates the formation 
of the alternative pathway C3 convertase C3bBb. C3bBb forms the basis of a positive 
feedback loop, amplifying alternative complement pathway activity; which can be further 
potentiated by Factor P (properdin) which acts to stabilise the C3bBb complex [156]. Thus, 
the generation of C3 convertase is the central point at which all three sub-divisions of the 
complement pathway converge (Figure 1-20). The cleavage of C3 into C3b (whether by 
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C4b2a or C3bBb) exposes an internal thioester bond which facilitates stable covalent 
binding of C3b to hydroxyl groups on the target cell surface via trans-esterification [160]. 
This action effectively underpins the entire complement cascade; with C3b opsonisation 
marking pathogens as foreign, resulting in further amplification of the complement 
system which terminates in the assembly of the C5b-C9 MAC and cell lysis [156].      
Of note, the alternative complement cascade may account for as much as 80% of MAC 
terminal pathway activity [155]. This is due to the efficiency of the positive feedback 
amplification loop within the system. Hence, the alternative complement cascade has 
great potential for non-specific destruction once activated; hence it is vital that host cells 
are protected. Under physiological conditions, complement activation is tightly regulated 
by a number of plasma and membrane bound factors [2][153]. As evident in atypical HUS, 
if these regulatory mechanisms fail there is uncontrolled alternative complement 
pathway activity leading to glomerular endothelial cell injury and TMA [161]. 
 
 
Figure 1-20 The complement cascade 
Three pathways have been described leading to activation of the complement pathway; classical, 
lectin and alternative. All culminate with the formation of the membrane attack complex (MAC) 
leading to the insertion of pores into the target cell membrane resulting in osmotic lysis and cell 
death. The alternative pathway differs from the other two in that it is continually active at low 
levels in the plasma and is activated by spontaneous hydrolysis of a thioester bond in C3. To protect 































(CFH, CFI) and membrane bound factors [2][153][155]. Figure reproduced from Bowen et al. with 
permission [1]. 
 
 Complement Regulation 
It is essential that complement activation is regulated to prevent excessive cell injury and 
inflammation [138][155]. Host cells are protected by surface bound and soluble plasma 
complement regulatory proteins. Of particular importance are the plasma proteins factor 
H and factor I which negatively regulate the C3b amplification loop (Figure 1-20). Although 
found in the plasma both can act in the fluid phase and on cellular surfaces. Their role on 
cell surfaces that lack membrane bound complement regulators e.g. the glomerular 
basement membrane in the kidney is vital as they are the only defence against 
complement attack and thrombus formation [138][162]. Notable membrane bound 
complement factors include CD46 (MCP – membrane co-factor protein), CD55 (DAF – 
decay activating factor), CD59 and CR1. By definition, these surface bound complement 
regulatory proteins are restricted in activity by their cellular expression and distribution. 
The exception being CR1 which is expressed by neutrophils, lymphocytes and erythrocytes 
which circulate throughout the body rather than being tissue bound [162]. The role of the 
key regulatory factors involved in the modulation of complement activation are discussed 
below. 
1.3.1.1 Serum based complement regulator: complement factor H 
Complement factor H is a 150 kDa glycoprotein, synthesized in the liver and found 
circulating in the serum at a high concentration [161]. It is thought to be the most 
important fluid phase regulator of the alternative complement pathway [163]. The 
structure of human factor H has been well characterised and is known to consist of 20 
complement control protein domains (CCPs) (Figure 1-21) [164]. CCP domains 1-4 are 
located at the N-terminal of the protein forming a C3b binding site. CCP 7 contains several 
binding sites, recognising ligands found on host cell surfaces including: 
glycosaminoglycans, pentraxins and malondialdehyde epitopes that facilitate self / non-
self discrimination. C-terminal CCP 19-20 regions also include binding sites for C3b (and 
C3d) which act to securely anchor factor H to host cell surfaces that are under 





Figure 1-21: Structure of complement factor H 
Complement factor H consists of 20 complement control protein domains (CCPs) outlined in 
purple. CCP domains 1-4 are located at the N-terminal of the protein forming a C3b binding site as 
indicated. CCP 7 contains several binding sites, recognising ligands found on host cell surfaces such 
as glycosaminoglycans (GAGs). C-terminal CCP 19-20 regions also include binding sites for C3b (and 
C3d) which act to securely anchor factor H to host cell surfaces that are under complement attack. 
Many mutations in factor H CCP domains have been reported in association with disease; * indicate 
the key mutation CCP sites associated with aHUS and age-related macular degeneration (AMD). 
Figure adapted from Morgan et al [164].    
 
The regulatory activity of factor H occurs via several mechanisms. Firstly, it competes with 
factor B to bind to C3b preventing formation of the C3 convertase complex (C3bBb). 
Secondly, it accelerates the irreversible degradation of C3 convertase into its constituents. 
Finally, it acts as a co-factor for factor I-mediated C3b proteolytic cleavage, inactivating 
C3b so that it cannot bind to circulating factor B [163][164]. Interestingly, it has been 
demonstrated through factor H binding assays, that attachment of factor H to C3b or C3 
convertase (C3bBb) is enhanced when these molecules are bound to host cell negatively 
charged glycosaminoglycans, sialic acid and heparin sulphate; i.e. the constituents of the 
glycocalyx found on many cells including the glomerular endothelium [161][166]. It is this 
high affinity interaction between factor H and host cell bound C3b or C3bBb, that 
facilitates factor H enrichment on host cells, ensuring self-recognition and protection 
against the innate immune system complement response [164].  
The importance of factor H regulation in complement pathway activation is evident from 
genetic analysis of aHUS patients. Indeed, it was the finding by Warwicker et al. in 1998 
that a mutation in factor H led to the development of aHUS, that prompted the search 
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and subsequent discovery of over 200 mutations in complement regulatory genes 
responsible for the disease [2]. Today, up to 60% of cases of aHUS are associated with 
identifiable mutations in complement cascade activation or its regulation [161]. Of these, 
25% are associated with the genes encoding factor H; making it the most frequent genetic 
abnormality associated with the condition [161]. These mutations are usually 
heterozygous, with the majority affecting the C-terminus of the protein and therefore 
factor H protection of the host cell surface [163]. Mutations in factor H are associated 
with a poor prognosis, with 60-70% of patients reaching end stage renal failure or dying 
within one year of diagnosis [161].     
The factor H mutations associated with aHUS have been extensively studied, with 
functional red blood cell lysis assays confirming that mutations in the C-terminal region of 
the protein, lead to failure to control C3 activation at the glomerular endothelial cell 
surface [163]. Interestingly, in the majority of patients mutations in factor H do not result 
in a reduction of detectable plasma levels of the protein [154]. Additional work by Stahl 
et al. has shown that C-terminal factor H mutations can also result in the loss of factor H 
protection of platelets from complement attack [167]. Consequently, platelets are 
activated and aggregate to form microthrombi. Combined, this loss of factor H protection 
on both glomerular endothelial cells and circulating platelets is thought to give rise to a 
pro-coagulant state which culminate in aHUS [163].  
To date, in vivo work has centred around two transgenic genetic mouse models: the 
complement factor H homozygote knockout mouse (CFH -/-) and a homozygote factor H 
C-terminal (CCP 16-20) knockout mouse. The former has been reported to have incredibly 
low C3 levels as a consequence of uncontrolled alternative complement pathway 
activation; and displays a renal phenotype reminiscent of membranoproliferative 
glomerulonephritis (MPGN) i.e. accumulation of C3 and electron dense material along the 
renal glomerular basement membrane [163][168]. The latter spontaneously develops 
aHUS and has much higher levels of circulating C3. This work suggests that mutations in 
complement factor H C-terminal regions in vivo, result in local glomerular complement 
dysregulation but control of alternative pathway activity in the plasma [168]. 
Fascinatingly, crossing the factor H C-terminal knockout mouse with a C5 deficient mouse 
resulted in protection from the aHUS phenotype; suggesting that C5 activity is vital in the 
development of aHUS and perhaps explaining the success of eculizumab in treatment of 
the disease [169].  
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1.3.1.2 The factor H protein family 
The complement regulator factor H is a member of the factor H protein family, which 
consists of 8 glycoproteins that are encoded by 6 genes [170]. All CFH family proteins are 
produced in the liver and consist of distinct, individual folding domains known as 
complement control protein domains (CCPs). The CFH family share common features 
which are reflected at a genomic level by the tandem arrangement of the CFH gene and 
the 6 factor H-related protein encoding regions which are all found within the CFH gene 
cluster on human chromosome 1 [171]. The CFH gene cluster itself, is located within an 
even larger gene cluster on chromosome 1 referred to as the ‘regulators of complement 
activation’ (RCA) cluster [172]. The RCA cluster encodes more than 60 genes, of which 15 
are related to complement regulation, including not only the genes for factor H and the 
family of factor H proteins; but also, membrane bound complement regulators MCP, CD55 
and CR1. Thus, complement regulatory genes that are encoded in the RCA share a 
common genetic ancestral motif from which they originated by multiple genetic 
duplication events [172].  
Complement factor H-like protein (FHL-1) is the most similar in structure to factor H, 
generated from an alternatively spliced mRNA transcript derived from the CFH gene [170]. 
FHL-1 contains the 7 CCPs from the N terminal of factor H, together with 4 unique amino 
acids located at its C-terminus. Therefore, it is hardly surprising given FHL-1 shares such 
genetic homology with CFH, that it emulates both the complement inhibiting and C3b or 
C3bBb ligand binding capabilities of factor H [171]. The role of FHL-1 was largely 
undetermined until research by Clark et al. demonstrated that this protein is the main 
complement regulator of the human retinal pigment epithelium of the eye and that only 
in this truncated form (not the fully sized glycosylated factor H form) is it able to passively 
diffuse into Bruch’s membrane [173]. Bruch’s area is the innermost layer of the choroid 
of the eye and a key site at which age-related macular degeneration (AMD) occurs [174].  
Factor H gene polymorphisms are known to be associated with an increased risk of AMD, 
a condition characterised by the formation of drusen (aggregates containing activated 
complement factors and inflammatory mediators) within Bruch’s membrane [173]. Clark 
et al. went on to demonstrate that the binding of FHL-1 to retinal epithelium involved 
interactions between FHL-1 and heparin sulphate on the cell surface. Moreover, the 
commonest CFH polymorphism associated with AMD (Y402H) was shown to significantly 
reduce this interaction, resulting in loss of FHL-1 protection against complement attack 
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[173]. Interestingly, the drusen of AMD are structurally similar to the dense deposits seen 
in the glomerular basement membrane of the kidney in patients with MPGN type II [175]. 
In fact, MPGN type II patients are often found to have co-existent drusen in their eyes and 
may develop visual impairment alongside renal failure [176]. Together, these 
observations imply that dysregulation of the alternative complement pathway secondary 
to Factor H (or indeed FHL-1 mutations) contributes to the development of both AMD and 
MPGN type II [175].    
The remaining members of the factor H family are known as the complement factor H 
related proteins (CFHR). In stark contrast to factor H, they lack potent complement 
regulatory activity; although some have been reported to be involved in modulatory 
activity as potential co-factors for factor H [171][177]. The CFHR proteins all lack the N-
terminal CCPs of Factor H which is likely to account for the observed loss of C3 convertase 
decay accelerating activity [165]. Further work is required into the precise roles of each 
CFHR protein; with most recent work suggesting that some of these glycoproteins may in 
fact be antagonists of Factor H, acting to fine-tune the host’s complement regulatory 
response [170].  
1.3.1.3 Serum based complement regulator: complement factor I 
Factor I is an 88 kDa glycoprotein predominantly synthesized in the liver; unlike the 
majority of other complement regulatory proteins, the factor I gene is located on 
chromosome 4 and not within the RCA of chromosome 1 [178]. Prior to its secretion it 
undergoes proteolytic cleavage of its linker protein by furin; to produce a 37 kDa 
enzymatic light chain bound to a 55 kDa heavy chain residue of unknown function 
[163][178]. However despite this post-translational processing, factor I remains 
proteolytically inactive and circulates in the plasma in a ‘zymogen-like’ state [179]. Studies 
by Roversi et al. mapping the crystal structure of the factor I molecule, suggest that the 
heavy chain allosterically inhibits the serine protease activity of the light chain until the 
C3b/cofactor complex engages [179].  
Factor I is recruited to sites of complement activation to regulate the host immune 
response [178]. It requires the presence of a co-factor (such as Factor H, MCP, CR1) in 
order to cleave the α chains of C3b or C4b. These co-factors are either found intrinsically 
expressed on host cells or have mechanisms to ensure preferential recognition of host cell 
surfaces. The need for co-factor presence to facilitate Factor I complement regulation, 
ensures host tissue is protected from injury whilst preventing non-specific C3b 
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degradation in the context of appropriate complement activation by a microbe [156]. The 
proteolytic cleavage of C3b and C4b by Factor I, inactivates them and prevents the 
formation of C3 and C5 convertases, respectively [163]. Thus, Factor I prevents 
amplification of the complement cascade, regulating both the classical and alternative 
complement pathways [178].  
Mutations in Factor I are responsible for up to 10% of aHUS cases. The majority of these 
are heterozygous and located in the serine protease region of the glycoprotein [161]. 
Factor I mutations lead to a decrease in regulatory activity and impaired degradation of 
C3b and C4b [154]. Serum factor I levels in these patients is usually within normal range 
[163]. Patients with factor I mutations have a poor prognosis, with 50% progressing to 
end stage renal failure or dying within 2 years of initial presentation. Often factor I 
mutations are present in association with other complement regulatory gene 
polymorphisms [161].   
1.3.1.4 Membrane bound complement regulator: MCP (CD46)  
Membrane bound co-factor protein (MCP) also known as CD46 is a cell surface bound 
glycoprotein, expressed on nucleated host cells (i.e. it is absent from red blood cells). MCP 
consists of 4 CCPs which form the extracellular component of the protein, a 
transmembrane region and an alternatively spliced cytoplasmic tail residue [163]. The 
MCP gene is located on chromosome 1 within the regulators of complement activation 
(RCA) cluster [172]. As aforementioned, MCP is a co-factor for factor I, facilitating the 
inactivation of C3b and C4b that has bound to host cells [163]. Mutations in MCP are 
identified in up to 15% of aHUS patients. These are predominantly heterozygous and 
located within the extracellular domain of the protein, resulting in reduced MCP activity 
and dysregulation of complement activation on host cell surfaces [154]. Interestingly, 
MCP mutations are more often reported in paediatric cohorts and are associated with a 
lower risk of progression to end stage renal failure than in other fluid phase complement 
regulatory mutations [161]. Furthermore, in those patients that do require kidney 
transplantation, prognosis (i.e. likelihood of recurrence of TMA) is significantly better than 
in aHUS patients with fluid phase complement regulator mutations [161].  
1.3.1.5 Membrane bound complement regulators: CD55, CD59 and CR1 
CD55 or decay activating factor (DAF) is another membrane bound complement regulator, 
which acts to prevent the amplification of the alternative complement cascade through 
inhibition of C3 convertase assembly [156]. It is a 70 kDa protein, attached to the host cell 
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surface by a glycophosphatidylinositol (GPI) anchor [180]. Unlike MCP, DAF is expressed 
on the surface of erythrocytes. In fact, the importance of DAF protection on host red blood 
cells is evident from the occurrence of the rare condition, paroxysmal nocturnal 
haemoglobinuria (PNH). In PNH, there is a reduction of DAF expression on erythrocytes 
(due to mutations in the enzymes required to catalyse GPI synthesis); with subsequent 
loss of protection from destruction by the complement system [181]. In aHUS patients, 
very few mutations in DAF have been described and to date these mutations have not 
been linked to any functional abnormalities in complement regulation [182]. Interestingly, 
in the DAF knockout mouse model although erythrocytes were susceptible to increased 
complement attack, no evidence of glomerular TMA or renal disease was reported 
[182][183]. These findings suggest that DAF is likely to be a key regulator of complement 
activation on the surface of red blood cells but is perhaps less important in the 
pathogenesis of aHUS.    
Other membrane bound complement regulators expressed on circulating blood cells 
include CD59 (also known as MAC inhibitory protein) and CR1. CD59 is a GPI anchored 
protein that prevents the polymerisation of C9 and subsequent MAC formation [184]. As 
such, reduction in CD59 expression on erythrocytes (again due to mutations in the 
enzymes required to catalyse GPI synthesis) is also associated with PNH [185]. Currently, 
no functional mutations in CD59 have been identified in aHUS patient cohorts [186][187]. 
CR1 is a glycoprotein encoded by the RCA cluster region on chromosome 1, that is 
expressed by many human cells including erythrocytes, leukocytes, dendritic cells, and 
podocytes [188]. CR1 binds C3b to deactivate alternative complement pathway 
convertases and acts to accelerate the decay of the classical and lectin pathway 
convertases through binding of C4b. In addition to shortening the half-life of preformed 
C3 and C5 convertases and preventing the assembly of new C3 convertases; CR1 also acts 
a co-factor for the cleavage of C3b and C4b by Factor I [156].  
Fascinatingly, the podocyte is the only epithelial cell that has been identified to express 
CR1; resulting in much interest as to its physiological role in the kidney. To date in vitro 
research in this area has been hindered by the fact that conditionally immortalised 
podocytes do not express CR1 (of note its expression has been demonstrated reproducibly 
in human kidney sections using immunohistochemistry and in human kidney biopsy 
samples by PCR and western blotting). To circumvent this issue, Java et al. transfected a 
Chinese hamster ovary epithelial cell line (CHO) with a CR1 cDNA expression vector and 
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assessed complement activity using flow cytometry and ELISA [189]. This study found CR1 
to be a potent regulator of the alternative complement pathway, reducing C3b deposition 
on the cell surface by over 95% compared to CHO control cells lacking CR1 expression 
[189]. Further work is needed to explore the role of CR1 in glomerular disease and to 
improve current understanding of how a reduction in CR1 expression on the podocyte cell 
surface may contribute to complement mediated injury in the kidney [189]. Notably, no 
mutations in CR1 have been identified in aHUS patient cohorts to date, and crystal 
structure analysis of C3-CR1 mutant complexes against factor I activity have not shown a 
significant impact on regulatory activity [163][190]. 
 Complement Blockade 
Prior to the era of C5 inhibition with eculizumab in 2009, the gold standard treatment for 
aHUS had been plasma exchange [143]. This involved replacement of non-functional 
complement proteins and the removal of activated complement components and auto-
antibodies against complement regulators with donor plasma. In many developing 
countries plasmapheresis remains the only treatment option available, due to the cost 
implications of eculizumab therapy [191]. In contrast to TTP where the response to plasma 
exchange is in the region of 80-90%; atypical HUS patients undergoing plasma exchange 
may see initial improvement in platelet count and anaemia but only transiently; with 
underlying TMA and complement activation persisting [37]. Indeed, end-stage renal 
disease or death occurs in up to 40% of atypical HUS patients at first presentation despite 
plasma exchange [29]. Eculizumab has transformed treatment for these patients and is 
increasingly being reported to be efficacious in cases of HUS associated with medications, 
pregnancy and connective tissue disorders such as systemic lupus erythematosus (SLE) 
[192][193]. 
Therefore, in the UK all patients with a diagnosis of aHUS should be considered for 
treatment with the recombinant humanised monoclonal antibody eculizumab [141]. The 
earlier eculizumab therapy is started the better, in terms of preservation of renal function. 
Hence, current recommendations are that treatment begins as soon as STEC HUS and TTP 
have been excluded [143][194]. Eculizumab is reported to be highly effective in aHUS, 
with 85% of eculizumab treated patients entering remission [143]. Eculizumab is 
produced from mouse myeloma cells through recombinant DNA technology [194]. It has 
been humanised by replacing the murine heavy chain constant region of the antibody 
with a human IgG2/IgG4 hybrid. The design of this humanised IgG hybrid has been 
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carefully considered to ensure that any inherent pro-inflammatory potential of the 
antibody has been minimised [191]. Through high affinity binding to C5, inhibition of C5 
cleavage occurs, preventing formation of the membrane attack complex (MAC) and 
glomerular TMA [195]. As such it acts as a terminal complement pathway inhibitor, with 
proximal functions of immune clearance remaining intact [37]. 
The success of eculizumab in the treatment of atypical HUS is reflected in expert 
consensus, which includes NICE approval in the UK with eculizumab currently the most 
expensive treatment endorsed by this National guidance body. UK NICE guidelines 
advocate early use in patients with atypical HUS so as to achieve optimal chance of renal 
recovery [34].  The question as to whether eculizumab use should be extended to other 
forms of TMA remains controversial [196]. However, it should be highlighted that 
eculizumab treatment is not without risk of serious side effects. Several have been 
reported including: peritonitis, influenza, severe hypertension and the well-recognised 
risk of meningococcal infection [191]. Patients treated with eculizumab, therefore receive 
vaccination for the available serogroups of Neisseria meningitidis (A,C,Y,W135 and now 
B); with prophylactic oral penicillin cover for the duration of treatment and 3 months after 
discontinuation of therapy [141].  
A more recent discussion amongst experts in the field of aHUS, has been surrounding the 
optimal duration of eculizumab therapy. Data in this area are lacking and there is 
considerable concern over the potential for disease recurrence and loss of patient native 
or transplanted kidney function if therapy is withdrawn. However, there is no evidence 
for lifelong treatment with eculizumab and the risks of long term C5 blockade need to be 
considered [141]. A recently published large, prospective long-term (over 6 years) 
observational study in aHUS patients treated with eculizumab was conducted by Menne 
et al [195]. The investigators reported eculizumab to be a safe and efficacious form of 
treatment for aHUS; with a higher risk of glomerular TMA and trend toward reduction in 
eGFR in patients that were discontinued on eculizumab [195]. However, the strength of 
this work (together with that of the global aHUS registry) is the insight it has provided into 
which aHUS patient sub-groups are at highest risk of relapse following discontinuation of 
eculizumab treatment. At risk aHUS sub-groups were identified as those who presented 
in childhood, those with identified genetic complement  mutations or factor H 
autoantibodies and those patients with a history of multi-organ TMA [195]. Such 
knowledge is invaluable in determining eculizumab treatment strategies, disease 
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monitoring and in which patients it may be safe to withdraw treatment. Further work in 
this area is ongoing in the form of the multicentre prospective ‘Stopping Eculizumab 
Treatment Safely in aHUS’ (SETS) clinical trial; led by Professor Sheerin and the team at 
the National Renal Complement Therapeutics Centre in Newcastle [197].  
 Evidence of complement activation in STEC HUS 
In the last decade, evidence has been mounting in support of a role for complement 
activation in the development of Shiga toxin associated HUS. In vitro studies have 
demonstrated that Shiga toxin directly activates the complement pathway, leading to 
increased soluble C5b-9 when incubated with normal human serum [124]. Shiga toxin has 
also been demonstrated to bind to factor H, reducing its cell surface co-factor activity; 
leading to an increase in C3b deposition and activation of the alternative complement 
system [124]. Additionally, in human glomerular endothelial cells treated with Shiga toxin, 
surface expression of CD59 was found to be lower than that of renal tubular cells cultured 
under the same conditions [124][198].  
Most STEC HUS patients have also been found to express increased markers of 
compliment activation including high levels of plasma Bb and soluble C5b-9; both of which 
have been found to correlate with STEC HUS activity and the presence of oliguria [124]. In 
addition to systemic complement activation, intra-glomerular deposits of C3 and C5b-C9 
have also been identified in kidney biopsies of STEC HUS patients [124]. Moreover, the 
detection of complement containing microvesicles within platelets, leucocytes, and 
erythrocytes in STEC HUS patient plasma; further supports a direct interaction between 
Shiga toxin and complement activation in vivo [198]. More recent work by Ozaki et al. has 
demonstrated in a humanised MBL expressing mouse model, that monoclonal antibody 
treatment against MBL was protective against complement activation and renal injury 
induced by Stx2 [152]. However, clinical validation in favour of compliment blockade with 
the C5 inhibitor eculizumab is inconsistent. A few case series in paediatric STEC HUS 
patients with neurological sequelae have suggested benefit from eculizumab treatment. 
Yet, retrospective analysis of eculizumab therapy in adults with STEC HUS (such as those 
affected by the 2011 German outbreak) has failed to demonstrate any benefit in outcome 
[199]. Indeed, unravelling any meaningful answers as to the effectiveness of eculizumab 
in such studies is difficult. Only the most severely affected patients were administered 
eculizumab and it is unclear as to whether they would have recovered without it [200]. 
Thus, despite compelling evidence that the alternative complement pathway is activated 
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in STEC HUS patients in vivo, the extent to which this activation contributes to the 
pathogenesis of the disease remains unclear [198].  
In an attempt to address this issue a national (NIHR and MRC funded) randomised, double-
blind, placebo controlled trial ‘ECUSTEC’ (international trial no: ISRCTN89553116) is now 
open and recruiting in the United Kingdom [201]. This will attempt to definitively answer 
whether eculizumab treatment in children with STEC HUS is of benefit. Throughout the 
course of my PhD, I have been involved in the analysis of patient ECUSTEC samples that 
were sent to Bristol Renal for exploratory studies. These were additional, optional blood 
and urine samples from patients who are enrolled in the study. These samples were 
analysed in an attempt to investigate several areas of interest including: the role of 
neutrophils in transport of Shiga toxin to the kidney through in vitro co-culture 
experiments; whether complement activation correlates with markers of acute kidney 
injury; and whether urinary VEGF-A levels are altered in STEC HUS patients compared to 
healthy age-matched controls. Pre-liminary results from this work are discussed in the 
relevant results chapters.    
 The interaction between complement and coagulation  
In recent years, there have been several reports of interactions between the complement 
system and the coagulation cascade. Indeed, there are similarities between the two, with 
both pathways featuring a series of proteolytic enzyme reactions that are tightly regulated 
by activator and inhibitor signals which ensure physiological homeostasis [202]. The 
interaction of the coagulation system and complement pathway is well established in 
sepsis; where uncontrolled systemic activation can lead to development of disseminated 
intravascular coagulopathy (DIC) with multi-organ failure and death [203]. Furthermore, 
concept changing work by Huber-Lang et al. demonstrated that C5 can be directly 
activated by proteases within the coagulation system independent of the complement 
cascade. Through a C3 knockout mouse IgG immune complex-induced lung injury model, 
it was observed that kallikrein and thrombin proteolytically cleaved C5 to produce 
anaphylatoxin C5a. Fascinatingly, plasma thrombin activity in C3 knockout mice 
(compared to wild type mice) was found to be threefold higher [204].  
The same group went on to perform in vitro and ex-vivo studies, in which the human 
coagulation factors XIa, Xa, IXa, thrombin and plasmin were all found to cleave C3 and C5 
[205]. The cleavage products generated in these experiments (C3a and C5a) were 
subsequently shown to exhibit chemoattractant properties known to be involved in mast 
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cell and neutrophil recruitment [205]. Together this work has provided evidence to 
support a novel connection between the complement cascade and coagulation system; 
with the coagulation system able to provide a compensatory pathway for complement 
activation that is independent of the complement cascade itself [156].  
Equally, the complement system has been shown to influence the activity of the 
coagulation cascade. The enzyme MASP-2 (generated in the initial activation stages of the 
lectin pathway) has been shown to generate thrombin via direct cleavage of pro-thrombin 
in vitro [206]. Notably, MASP-2 is able to facilitate this cleavage in the absence of the 
coagulation cascade co-factor, factor V [202]. In addition, platelets treated with purified 
C5b-C9 proteins have also been shown to cleave prothrombin to form thrombin, thereby 
promoting fibrin deposition and clot formation at sites of complement activation [202]. 
Furthermore, both C5a and the C5b-C9 complex, promote coagulation through 
upregulation of tissue factor from endothelial cells and neutrophils [207].  
In STEC HUS, there is also evidence of complement cascade and coagulation system cross-
talk. In vitro, Shiga toxin has been shown to increase expression of the cell adhesion 
molecule, P-selectin in human microvascular endothelial cells [198]. P-selectin is known 
to play a key role in both the recruitment of neutrophils in the presence of inflammation 
and in the aggregation of platelets at sites of vascular injury. Whilst inactive it is stored in 
granules within the endothelial cell, known as Weibel-Palade bodies (WPBs). In vitro work 
by Morigi et al. has demonstrated that P-selectin can bind to and activate C3 in human 
microvascular endothelial cells, leading to thrombus formation under flow conditions 
[208]. This group went on to show that in a STEC HUS mouse model, there was 
upregulation of glomerular endothelial cell P-selectin that was associated with C3 and 
fibrinogen deposits, platelet aggregation and a reduction in thrombomodulin. 
Additionally, anti-P-selectin antibody treatment led to an attenuation of these findings, 
with limited C3 accumulation evident in the glomerulus [208].  
In contrast to these findings, Khursigara et al. have shown that in blood outgrowth 
endothelial cells (BOECs) derived from healthy donors, terminal complement activation 
led to mobilisation of WPBs and the release of vWF [209]. Interestingly, these cells were 
protected from complement-mediated injury; an affect that was lost in BOECs derived 
from patients with von Willebrand disease which lack WPB expression [209]. Hence, in 
BOECs the expression of P-selectin via mobilisation of WPBs to the cell surface, appears 
to protect the vascular endothelium from complement-mediated attack [209]. Clearly, 
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there is substantial experimental evidence in favour of cross-talk between the 
complement and coagulation cascades both in health and disease; with these data 
supporting further investigation into the role that this interaction may play in 
development of glomerular TMA in STEC HUS. 
1.4 Vascular Endothelial Growth Factor (VEGF)  
Human vascular endothelial growth factors (VEGFs) are a family of five related 
glycoproteins, that include: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor 
(PIGF) [210]. Each of these proteins are secreted to form covalently linked homodimers 
which interact with one of three cell surface tyrosine kinase VEGF receptors (VEGFRs) [16]. 
The VEGFRs consist of seven extracellular domains, with a transmembrane region and 
intracellular tyrosine kinase receptor. Each VEGF glycoprotein preferentially binds to a 
specific VEGFR (Figure 1-22), to induce receptor dimerization and transphosphorylation 
[16]. Enhancement of VEGFR signalling has been shown to occur through co-receptors 
neuropilin-1 and 2 upon VEGF binding; but these co-receptors do not have any 
independent signalling capacity [16]. The initial description of VEGF was as a regulator of 
microvascular vascular permeability [211]. It is now known that VEGF also acts as a vital 
regulator of angiogenesis [212]. It acts to stimulate endothelial cell differentiation and 
proliferation as well as to promote endothelial cell survival through anti-apoptotic 
signalling [212]. It also increases vascular permeability through an effect on endothelial 
fenestration density and regulates endothelial vasodilation by increasing nitric oxide 





Figure 1-22: The human vascular endothelial growth factor family and receptors 
Human vascular endothelial growth factors (VEGFs) are a family of five related glycoproteins, that 
include: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF) [210]. Each of these 
proteins are secreted to form covalently linked homodimers which interact with one of three cell 
surface tyrosine kinase VEGF receptors known as VEGFR1, VEGFR2 and VEGFR3 (VEGFRs) [16]. As 
shown, VEGFR1 (also known as Flt-1) can interact with PIGF, VEGF-A and VEGF-B. VEGFR2 (also 
known as Flk-1 or KDR) can interact with VEGF-A, VEGF-C and VEGF-D. VEGFR3 (also known as Flt-
4) can bind VEFF-C and VEGF-D. Flt-1=fms-like tyrosine kinase 1, Flk-1=fetal liver kinase, KDR=kinase 
insert domain. Figure reproduced from Pandey et al [210].  
 
 VEGF-A 
Within the VEGF family, the glycoprotein VEGF-A is the most studied and considered to 
be the key stimulatory factor in both physiological and pathological angiogenesis [16]. In 
the kidney, podocytes are the major source of VEGF-A, which is essential for maintaining 
the nearby glomerular endothelium [11]. VEGF-A mRNA is also detectable in renal tubular 
epithelial cells to a much lesser extent; with VEGFR expression predominantly located on 
glomerular endothelium. This distribution of VEGF secretion and VEGFR expression 
supports the concept of a paracrine signalling loop within the glomerulus between the 
podocyte and  glomerular endothelial cell [213]. The importance of VEGF-A in both 
glomerular development and maintenance is evident from VEGF-A mouse models. In both 
homozygous and heterozygous VEGF-A knockout mice, major vascular defects are 
observed leading to death within 10-12 days [214]. Equally, in mouse models of podocyte 
VEGF-A over-expression, worsening of diabetic nephropathy was reported [24]. Clearly, a 
64 
 
fine balance exists in the regulation of podocyte VEGF-A production, that if impaired may 
lead to glomerular injury.  
VEGF-A is encoded by a single gene of 8 exons, with alternative mRNA splicing of the gene 
giving rise to at least seven different VEGF-A isoforms in humans (Figure 1-23) [215]. Each 
isoform has unique properties of varying diffusability and binding affinity to heparin 
sulphate on the cell surface and neuropilin-1 and 2; and is named after the number of 
amino acids (excluding the signal peptide) that it possesses [216]. For example, VEGF-A 
165 isoform contains 165 amino acids and is the major VEGF-A isoform expressed in the 
kidney. All isoforms bind to VEGF-A receptors: VEGFR1 (also known as Flt-1) and VEGFR2 
(also known as Flk-1/KDR or fetal liver kinase) [217]. 
 
 
Figure 1-23: The human VEGF-A isoforms produced by alternative splicing of the VEGF-A gene 
In humans VEGF-A is encoded by a single gene of 8 exons (1-8). As shown all VEGF-A isoforms 
contain exons 1-5 with alternative mRNA splicing of the VEGF-A gene resulting in different 
combinations of exons thereafter; giving rise to at least seven different VEGF-A isoforms. 
Alternative splicing of exon 8 results in either the generation of pro-angiogenic isoforms (exon 8a) 
or anti-angiogenic ‘b’ isoforms (exon 8b). Figure reproduced from McFee et al [215]. 
 
To add to the complexity of VEGF signalling, further VEGF-A isoforms have been described 
that originate from the alternative splicing of exon 8 of the VEGF-A gene; leading to a set 
of sister inhibitory VEGF-A isoforms [215]. These inhibitory or VEGF-A b isoforms vary 
from the pro-angiogenic VEGF-A a isoforms already described, by only six amino acids 
located at the C-terminus of the protein. However, this difference is enough to confer 
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anti-angiogenic properties to the VEGF-A b isoforms. In humans, such b isoforms 
constitute at least 50% of the total VEGF-A expressed in a tissue [215]. It is the careful 
regulation of VEGF-A pro-angiogenic isoform expression versus the inhibitory VEGF-A b 
isoform expression within a specific tissue that will determine the level of active 
angiogenesis occurring. In fact, it is well known that in some malignancies there is a down-
regulation of inhibitory VEGF-A b isoform expression; which has led to the development 
of VEGF-A inhibitors for use in various solid tumour cancer treatments [215].  
 VEGF-A and thrombotic microangiopathy 
In the last decade, advances in the generation of targeted, glomerular cell specific, genetic 
mouse models have greatly increased our understanding of the cellular interactions 
between podocytes and glomerular endothelial cells [24]. Eremina et al. have shown that 
post-natal disruption of VEGF-A signalling in mature, fully developed podocyte-specific 
VEGF-A knockout mice results in a glomerular TMA; with a phenotype that recapitulates 
the glomerular injury seen in HUS [11]. In further support of this finding, Eremina et al. 
also demonstrate the occurrence of glomerular TMA in human cancer patients treated 
with the VEGF-A inhibitor bevacizumab [11]. Interestingly, in these patients renal 
function, proteinuria and hypertension improved when bevacizumab was withdrawn. 
Eremina and colleagues draw parallels in this observation between VEGF-A inhibitor 
effects and pre-eclampsia; where delivery of the placenta (and therefore removal of the 
source of excess sFLT (a soluble form of the VEGFR1 receptor which binds to and 
inactivates VEGF-A) results in resolution of the condition [11]. No such recovery was seen 
in the podocyte-specific VEGF-A knockout mice in the study, even upon systemic 
administration of VEGF-A [11].  
In further support of the complexity of local VEGF-A signalling, Jin et al. have shown that 
sFLT1 is not only produced by the placenta but also by podocytes [218][219]. Though the 
use of a specific podocyte promoter driven Cre recombinase Flt1flox/flox mouse model; this 
group went on to demonstrate that sFLT1 deletion in podocytes causes actin cytoskeleton 
rearrangement with damage to the glomerular filtration barrier and massive proteinuria 
[218]. This work not only illustrates the autocrine function of sFLT1 in the regulation of 
podocyte behaviour, but also highlights the complexity of VEGF-A signalling within the 
kidney [218].  
Given these findings, the potential role of VEGF-A in the pathogenesis of Shiga toxin 
associated HUS cannot be overlooked. To date, this association is yet to be fully evaluated, 
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but there have been several studies investigating the link between VEGF-A levels and 
development of glomerular TMA in response to Shiga toxin. In vitro work by Psotka et al. 
has demonstrated that Shiga toxin treatment of human conditionally immortalised 
podocytes led to a 60% reduction of VEGF-A in expression in comparison to untreated 
control cells (Figure 1-24) [74]. Furthermore, in conditionally immortalised mouse 
podocytes (which lack the Shiga toxin receptor Gb3), no such reduction in VEGF-A was 
apparent, even following treatment with Shiga toxin at x1000 higher concentrations than 
that used in human podocyte experiments [218].  
 
 
Figure 1-24: Shiga toxin treatment reduces VEGF-A expression in human podocytes 
In vitro experiments performed by Psotka et al. measuring VEGF-A concentrations in human and 
mouse podocytes (as indicated) following 12 hr treatment with Stx2 as detected by ELISA. Control 
human or mouse podocytes were treated with a vehicle control for 12 hrs instead of Stx2. A 
statistically significant reduction (*p value <0.01) in VEGF-A release of 60% was seen in human 
podocytes treated with Stx2 vs. vehicle control treated human podocytes. No change was seen in 
mouse podocytes, despite treatment with x1000 times the dose of Stx2. Figure reproduced from 
Psotka et al [74].   
 
In a paediatric study of 40 Shiga toxin HUS patients, immunohistochemical staining of 
renal biopsies revealed that glomerular VEGF-A expression was reduced; with an 
accompanying increase in the expression of VEGF-A receptors VEGFR1 and VEGFR2 [220]. 
Interestingly, plasma VEGF-A levels in the same cohort increased during the second and 
third weeks following STEC HUS diagnosis. The authors hypothesize this to be a marker of 




model of glomerular TMA (utilising selective renal artery perfusion with an anti-
endothelial cell antibody), VEGF-A treatment has been shown to accelerate recovery of 
renal TMA [221]. What remains unclear however, is the degree to which changes in VEGF-
A are causative or simply consequential of glomerular pathological processes [212].  
Finally, in more recent work performed by Keir et al. the interaction between VEGF-A and 
the complement cascade has been investigated. In patients with disease associated 
complement factor H genetic mutations (resulting in either AMD or aHUS), retinal 
pigment epithelial cells or podocytes, were cultured and (perhaps expectedly) shown to 
have more C3d cell surface deposits (indicative of alternative complement pathway 
activation) than controls [222]. Fascinatingly, these deposits were increased by VEGF-A 
antagonism with either bevacizumab or aflibercept; suggesting that VEGF-A inhibition is 
capable of causing a further reduction in complement regulatory activity. Keir et al. went 
on to show that in podocyte specific VEGF-A knockout mice, lack of podocyte VEGF-A led 
to a decrease in glomerular complement factor H expression by both podocytes and 
glomerular endothelial cells which predisposed them to complement deposition [222]. 
Together, these findings demonstrate a link between VEGF-A, complement regulation and 
the development of glomerular TMA. In light of such the podocyte may well prove to be 







Chapter 2 : Hypothesis 
The central hypothesis of my research is that Shiga toxin produced by E.coli acts via the 
Gb3 receptor on podocytes to cause STEC HUS. Following binding of Shiga toxin to Gb3 on 
the podocyte there is an increase in glomerular endothelial cell susceptibility to 
complement attack. An acute reduction in local glomerular VEGF-A production is one 
possible mechanism that could be driving this; resulting in the development of a 
glomerular thrombotic microangiopathy (TMA). This manifests clinically as haemolytic 
uraemic syndrome (HUS). 
 
 
Figure 2-1: Central hypothesis  
Shiga toxin enters the circulation and is transported to the glomerulus, where it targets the Gb3 
receptor on the podocyte. This results in reduced VEGF-A expression which leads to glomerular 
TMA due to complement mediated attack on the glomerular endothelial cell surface. Figure 
reproduced from Dr. Lindsay Keir PhD Thesis [61].  
 
I will test this hypothesis with the following research aims: 
1. Prove that Shiga toxin acts through the podocyte Gb3 receptor to cause HUS. 
2. Therapeutically rescue STEC-HUS with a C5 inhibitor (analogous to eculizumab). 
69 
 
3. Determine the cellular mechanisms underlying the action of Shiga toxin. 
The summary of my experimental approach to address these aims is shown in Figure 2-2. 
 
 
Figure 2-2: Summary of experimental plan 
My experimental plan will involve both an in vitro and in vivo approach. To determine the 
mechanism responsible for glomerular TMA in Shiga toxin HUS, I will perform total and phospho-
proteomic studies in conditionally immortalised human podocytes exposed to Shiga toxin. These 
experiments will be run in parallel using tandem mass tag (TMT). Any target proteins identified will 
be validated by western blot and phospho-protein blotting. To control for non-specific, non-Gb3 
binding I will also study the proteomic changes in a human Gb3 synthase knockdown podocyte cell 
line. To prove that Shiga toxin acts through the podocyte Gb3 receptor to cause HUS, I will cross 
the podocyte expressing Gb3 synthase mouse with a constitutive Gb3 knockout mouse to produce 
a podocyte specific Gb3 mutant on a Gb3 null background. These mice will be given intraperitoneal 
Shiga toxin and their phenotype studied. Should they develop a glomerular TMA, I will attempt to 






Chapter 3 :  Materials and Methods 
All reagents are from Sigma-Aldrich UK unless stated. 
3.1 Materials and methods in vitro 
 Cell Culture 
Human and mouse conditionally immortalised podocytes and glomerular endothelial cells 
have been used for my in vitro work [223][224][225]. They are an established resource in 
Bristol and considered the gold standard for the study of these specialised cells. The cells 
are derived from glomeruli isolated (by sieving) from nephrectomised human or mouse 
kidneys. Once a pure population of cells (podocytes or endothelial cells) have been 
isolated they are transfected with the temperature sensitive SV40 large T antigen gene 
construct (which also contains the hTERT telomerase gene to maintain telomere length) 
to immortalise them. This results in cell lines that will proliferate at 33°C and terminally 
differentiate at 37°C. For the specific details of this technique see the paper from Li et al 
[226]. All cells used were at a passage less than 20. 
Conditionally immortalised podocytes were grown in humidified incubators in the 
presence of 5% CO2 at 33°C in standard podocyte media: RPMI 1640 (ThermoFisher 
ScientificTM) with 10% foetal bovine serum (FBS) and 2% penicillin and streptomycin (at 
10mg/ml). They were grown until 70-80% confluent and thermo-switched to 37°C to 
differentiate for 10-14 days before use. Conditionally immortalised human glomerular 
endothelial cells (GEnCs) were also grown at 33°C in humidified incubators in the presence 
of 5% CO2 in standard glomerular endothelial cell media: EGM-2MV (Lonza) with 5% FBS 
and additives (hEGF, hydrocortisone, hFGF-B, ascorbic acid and gentamicin – see 
appendix). They were grown until 70-80% confluent and thermos-switched to 37°C to 
differentiate for 5-7 days. All cells were used at a passage less than 25.  
 Splitting Cells 
Once the conditionally immortalised cells reached confluency, in order to keep a supply 
of ‘stock’ flasks some of the cells were trypsinised (split) and re-seeded into new tissue 
culture flasks or cryopreserved for later use. Stock flasks were standard tissue culture T75 
flasks with a vented cap purchased from Sarstedt Inc. Germany. Initially, media was 
removed from the cells which were then washed with sterile phosphate buffered saline 
71 
 
(PBS) to ensure any residual media present was removed. This is an important step as any 
residual media would de-activate trypsin. Trypsin-EDTA (1% for podocytes or 0.25% for 
GEnCs) purchased from (Lonza) was then added to the flask; just enough to coat the 
bottom of the T75 and the cells placed back into the incubator at 33°C to allow the trypsin 
to work.  
After 5 minutes, light microscopy was used to ascertain whether the cells had been lifted 
off the bottom of the flask (visible as round cells within the trypsin suspension) and 5mls 
of standard cell culture media appropriate for each cell type quickly added to de-activate 
the trypsin which would damage the cells if left on for too long. New tissue culture flasks 
were then labelled with cell type, date and an increased passage number by 1; with 1ml 
of the trypsinised cell suspension added to each new flask and media added to give a total 
volume in each T75 of 12mls. A T75 flask of 70-80% confluency would usually be sufficient 
to seed 5 new T75 flasks.  
When seeding INCell 96 well plates and six well plates for experiments, it was necessary 
to know the number of cells present per ml of media to ensure the same number of cells 
were present in each well. To achieve this, following trypsinisation as described above; 
the trypsin/media cell suspension was removed from the T75 flask and pipetted into a 
15ml falcon tube. This was centrifuged at 1200 rpm for 5 minutes to generate a cell pellet 
at the bottom of the tube. The supernatant was removed, and cells resuspended in a small 
volume of media (typically 3-5mls). 10µl of this resuspension was then pipetted on to a 
Luna-FL™ automated cell counter slide from LabTech International. The cell counter 
calculated the number of cells present per ml. Trypan blue stain was used to give an 
estimation of dead cells which the cell counter also calculated. Knowing the number of 
viable cells present per ml allowed me to dilute the resuspension to seed the cells at the 
desired concentration per well for my experiments.  
 Cell cryopreservation 
To ensure that I had a supply of conditionally immortalised cell lines available at a low 
passage, cells were cryopreserved using a freezing solution of 50% cell specific media, 40% 
fetal bovine serum and 10% dimethyl sulphoxide (DMSO). Cells were trypsinised as 
described previously and centrifuged to generate a cell pellet. The supernatant was 
removed, and the cells re-suspended in cell media. Equal volumes of freezing solution and 
cell suspension were aliquoted into cryovials (0.5mls of each) and transferred for storage 
at -80°C for short term purposes and liquid nitrogen for storage if required for longer than 
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a few months. To resuscitate cells from -80°C storage, they were thawed on ice until liquid 
and pipetted into a T75 flask along with 11mls of cell specific media. Cells were left to 
incubate at 33°C overnight to allow attachment to the tissue culture flask surface. After 
12 hours cell media was refreshed so that any DMSO in the freezing solution was 
removed. Cells were then cultured under standard conditions. 
 Co-culture transwell experiments  
Conditionally immortalised human podocytes and glomerular endothelial cells were 
cultured together in transwells (Corning 3µm pore Transwell® permeable supports). 
Endothelial cells were seeded onto coverslips at the bottom of the well and podocytes 
were seeded into the transwell support. Cells were cultured in standard endothelial media 
without VEGF and allowed to differentiate. Shiga toxin 0.1ng/ml was added to the 
podocyte transwell support at intervals of 30 min to 6 hours. Shiga toxin containing media 
was then removed and cells washed once with PBS. Human C7 deficient serum (40% in 
gelatine veronal buffer) was then added for 30 minutes. Cells were subsequently washed 
x3 before being fixed in 4% PFA and immunofluorescence performed for CFH or C3d and 
co-stained for DAPI (see appendix for antibody specifications). Glomerular endothelial 
cells were then imaged in the Wolfson Bioimaging Facility on confocal multi-laser Leica 
SP5II microscope.    
 Shiga toxin cell treatment 
Shiga toxin was obtained commercially from the USA through List Biological Laboratories 
Inc. This toxin is tightly regulated and protected by anti-terrorism laws. To import Shiga 
toxin an export license was completed, and the anti-terrorism police informed that we 
would be receiving it. The toxin was stored in a labelled locked fridge, with a record kept 
of the volume and concentration present at all times. Access to the toxin was restricted 
and when the toxin was being used in the laboratory signs were displayed to warn other 
lab users. When using the toxin: a mask, eye protection, gloves and a protective clothing 
were worn at all times. All work involving the toxin was performed in a biological cabinet 
under category 3 facilities. Prior to any toxin work commencing, a ‘control of substances 
hazardous to health regulations’ (COSHH) risk assessment was completed which was 
submitted and reviewed by the biological and genetic safety committee.   
Shiga toxins are classified into two major antigenic forms: Shiga toxin 1 and Shiga toxin 2 
[227]. Shiga toxin 2 has been chosen for the purposes of my research as this is the subtype 
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that is associated with a more severe clinical phenotype and widely used in published 
literature [227]. Throughout the remainder of this report unless otherwise stated Shiga 
toxin refers to Shiga toxin 2. Upon receipt of Shiga toxin from List Labs, the lyophilized 
powder was reconstituted with 100µl distilled water and gently mixed by inversion in-
keeping with the manufacturer’s instructions. This resulted in a stock concentration of 
10µg/100µls which was aliquoted into 20µl stock eppendorfs and stored at -20°C until 
use. The toxin was assessed for purity on 12% SDS-PAGE and was found to have two major 
bands at molecular weights of 33 kDa and 8 kDa corresponding to A and B toxin subunits, 
respectively. Purity was >98% and the endotoxin content determined on kinetic 
chromogenic LAL assay at List Labs was <90EU/mg.  
All Shiga toxin cell treatments were performed on differentiated cells. Doses ranging from 
0.01ng/ml to 100ng/ml were used. Once Shiga toxin treatment was removed (incubation 
period ranged from 0.5 to 72 hours) the supernatant was transferred to a waste flask of 
0.1M of sodium hydroxide prior to disposal after 24 hours. Cells were then washed 3 times 
in PBS and this waste also disposed of in 0.1M sodium hydroxide. Filtered pipette tips 
were used throughout this work. Cells could then be analysed as described below. 
 Immunofluorescence on coverslips 
Cells were grown in 6 well plates with glass coverslips placed in each well. Once fully 
differentiated cell treatments were applied, and toxin removed as described. Cells were 
washed 3 times in PBS and fixed with ice-cold 4% PFA (paraformaldehyde). After 10-15 
minutes PFA was washed off with PBS and permeabilised with 0.3% triton for 10 minutes. 
All cells were blocked in 3% BSA for 30-60 minutes. Primary antibodies (see appendix for 
antibody details and concentrations) were then applied to the coverslips which were left 
at 4°C overnight. The following day, cells were washed 3 times in PBS and secondary 
fluorescent antibodies (see appendix) applied for 1 hour at room temperature. Coverslips 
were then washed again 3 times and mounted with VECTA Shield hard setting mount with 
DAPI nuclear stain (Vector Lab Inc H100). Slides were then imaged using the Leica DMI 
6000B microscope or Leica Confocal SP5-II confocal laser scanning microscope at the 
Wolfson Imaging Institute, University of Bristol.  
 Immunofluorescence using the IN Cell 
Cells were grown in 96 well Corning® IN Cell plates and once fully differentiated treated 
with Shiga toxin as described. Cells were then washed 3 times in ice cold PBS and fixed in 
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4% PFA for 5 minutes at 4°C. PFA was then removed and cells permeabilised with 50µl ice-
cold methanol per well. Plates were placed into the freezer at -20°C for 5 minutes. 
Methanol was then removed and replaced with PBS. Non-specific binding sites were then 
blocked with 5% NGS (normal goat serum) for 1-2 hours at room temperature. Primary 
antibodies were then applied and left overnight at 4°C. The following day, cells were 
washed 3 time in PBS and secondary Alexa Fluor antibodies applied at 1:200 concentration 
for 90 minutes at room temperature. Cells were then washed twice in PBS and DAPI 
solution 1:10,000 concentration applied for 20 minutes at room temperature. DAPI was 
subsequently washed off with PBS and cells imaged using the IN Cell analyser 2000 (GE 
Healthcare). 
 Image J Analysis 
To ensure that microscopy images were comparable across experimental conditions, cells 
were treated at the same time and immunofluorescence staining performed 
simultaneously. Images were taken on the same day under the same microscope settings. 
For each experiment, the control slide was imaged first with exposure, intensity and gain 
set accordingly. These parameters remained unchanged throughout image analysis. To 
calculate the corrected total cell fluorescence (CTCF) (or corrected total glomerular 
fluorescence (CTGF) for my in vivo work) the following formula was used:  
CTCF or CTGF = integrated density – (area of selected cell or glomerulus x mean 
fluorescence intensity (MFI) of background). 
Image J software and Fiji plugin device was used to calculate the integrated density and 
MFI from microscope images saved as TIFF files. DAPI nuclear stain (in cells) or nephrin (in 
glomeruli) were used as co-localisation markers to allow accurate measurement of total 
cell number or glomerular area, respectively. The use of Image J and the CTCF/CTGF 
formula facilitated the comparison of immunofluorescence microscopy images between 
different experimental conditions and subsequent statistical analysis.  
 Western Blotting 
Western blotting was used to determine the protein expression of cells under different 
experimental conditions. To control for total protein loading differences between samples 
a housekeeping gene (β actin) was detected in each lysate.  
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3.1.9.1 Cell lysates 
Cell lysates were made using radio-immunoprecipitation assay (RIPA) lysis buffer (see 
appendix for details). Protease inhibitor and phosphatase inhibitors (A and B) were added 
at a 1% concentration to RIPA buffer to prevent unregulated proteolytic and 
phosphorylation of the sample proteins. Cells were washed 3 times in ice cold PBS after 
removal of media. 500µl of lysis buffer cocktail was then added to each flask and the cells 
kept on ice. Cells were removed by scraping the bottom of the flask vigorously and 
pipetted up into eppendorfs which were centrifuged at 13,200rpm for 5 minutes at 4°C. 
The supernatant was then transferred to a new eppendorf and the cell pellet discarded. 
All cell lysates were kept at -80°C until use. 
3.1.9.2 Reducing western blots 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to size and charge. 10 well gels were made according to the 
recipe given in the Appendix. Cell lysates were taken from storage at -80°C and thawed 
on ice. Loading buffer (containing SDS and mercaptoethanol) was added to each sample 
prior to boiling at 95°C on a hot block for 5-10 minutes to reduce and denature the 
proteins. 30 µl of each sample was loaded per well and the first well of each gel loaded 
with 3µl of ladder (Bio Rad). Gels were electrophoresed for 60-90 minutes at 150 mV in 
running buffer. Proteins were then transferred from the gel to a PVDF (polyvinylidene 
fluoride) membrane (Millipore) for 60-90 minutes at 250 mA in transfer buffer. 
Membranes were blocked in 5% BSA (bovine serum albumin) for 1 hr at room 
temperature. Blots were probed with primary antibodies (see appendix) in 5% BSA or 5% 
skimmed milk at 4°C overnight. 
The following day membranes were washed 3 times in TBS-T (Tris-buffered saline with 
Tween 20). Then incubated with secondary HRP (horseradish peroxidase) conjugated 
antibodies diluted at 1:10,000 for 1 hr at room temperature; followed by 3 more washes 
in TBS-T and imaged using chemiluminescence (Biorad) and viewed on the Amersham 600 
imager. 
3.1.9.3 Non-reducing western blots 
Western blotting was also performed in non-reducing conditions. The same gel recipe was 
followed as for reducing western blots, but no Sodium dodecyl sulphate (SDS) was added. 
Cell protein lysates were taken from storage at -80°C and thawed on ice. Loading buffer 
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was made without SDS or mercaptoethanol and the samples were not boiled on a hot 
block prior to being loaded on the gel. Electrophoresis was performed for 2 hours at 90 
mV in running buffer, again with no addition of SDS in the buffer. Proteins were then 
transferred from the gel to a methanol activated PVDF membrane for 60-90 minutes at 
250 mA in transfer buffer. The remainder of the western blot protocol was the same as 
for reducing blots. Non-reducing immunoblotting was performed when probing for the 
presence of complement factor H in cell lysates. This was necessary because the antibody 
used for human complement factor H did not recognise the protein in its reduced form 
(see appendix for antibody specifications).  
3.1.9.4 Densitometry 
Western blots (both reducing and non-reducing) were quantified using Image J software. 
Images of each immunoblot were saved a TIFF files and opened in Image J. No changes to 
the resolution or contrast of the images were made. The image transform tool was used 
to rotate images if they appeared to be off centre to enable the software to detect each 
protein band more accurately. The rectangle tool was then selected and used to draw a 
box around the first band on the blot. This box was duplicated and moved along the blot 
covering each band in turn. This set an area of analysis for the band intensity to be 
measured in each lane (Figure 3-1).  
The same process was followed for β actin control band intensity measurements. Using 
the analyse tool in Image J, each box was plotted to give a single peak which was then 
analysed for the area under the curve as shown in Figure 3-1. The calculated densitometry 
measurements were then copied into a spreadsheet on Microsoft Excel and normalised 
to those of the corresponding β actin loading control, followed by normalisation to the 
experimental control to give a relative fold change. All western blots were performed as 





Figure 3-1: Densitometry analysis used in western blotting 
Panel A shows boxes drawn around each protein band detected on western blotting, using Image 
J software. These boxes were drawn very carefully to ensure the entire band was contained within 
it and no other bands that were present included in the analysis. All boxes were of the same size 
to allow accurate comparison between lanes. The same process was performed for β actin loading 
controls (not shown). Panel B shows a representative graph plotted by the analysis tool in Image J, 
that gives an easily identifiable single peak. Panel C shows how the area under the curve for each 
graph is selected, by drawing a line across the bottom of the peak and through the middle of the 
peak. The area used to calculate a densitometry reading using the wand tool in Image J is 
highlighted in yellow. The densitometry readouts generated from Image J in this way were then 
copied into a Microsoft Excel worksheet for normalisation.  
 
 Protein Quantification Assay 
Cell lysate samples and cell supernatant protein content was quantified using a 
Bicinchonic Acid (BCA) Thermo Scientific Protein Assay kit. BSA standards were made up 
with a starting solution of 1mg/ml in distilled water. From this starting solution serial 





500µg/ml, 250µg/ml, 125µg/ml, 62.5µg/ml and so on until the final eppendorf contained 
only distilled water. Sample lysate or supernatant dilutions were then prepared in 
eppendorfs. These began at a 1 in 50 dilution, 1 in 100 dilution, 1 in 200 dilution and so 
on until a 1 in 32000 dilution was reached. 25µl of BSA standard or protein sample to be 
tested was then pipetted into a 96 well cell culture microplate (Corning®) in duplicate to 
give a technical repeat. Two wells per 96 well plate were used as blanks (containing just 
distilled water) to give a negative control.  
A working assay master mix solution was made according to manufacturer’s instructions. 
This involved mixing 50 parts reagent A with 1 part reagent B. 200µl of master mix solution 
was then added to each well of the 96 well plate using a multichannel pipette. The plate 
was wrapped in foil to protect it from the light and left for 30 minutes at room 
temperature. The colorimetric change was read by a plate reader using Revelation® 
software at a wavelength of 570nm. Protein concentrations in the samples could then be 
calculated using a plot of the standard curve obtained from the BSA standards on the 
same plate.  
 Quantitative polymerase chain reaction (qPCR) and Endpoint PCR 
Polymerase chain reaction (PCR), both quantitative and endpoint was used to compare 
gene expression in cells and tissues. Messenger RNA (mRNA) was extracted from these 
samples and changes in mRNA levels used as a marker of gene transcription.  
3.1.11.1 RNA extraction 
Commercially available Qiagen RNeasy kits were used to extract mRNA from both cell and 
tissue samples. Cells were grown in T75 flasks and differentiated before treatment and 
mRNA extraction. Media was removed and 700µl of QIAzol lysis buffer added to each 
flask. After 5 minutes the cells and lysis buffer were transferred to an eppendorf and 140µl 
of chloroform added. Eppendorfs were shaken vigorously for 15 seconds and left at room 
temperature for 3-5 minutes. Samples were then centrifuged at 12000g at 4°C for 15 
minutes to separate the sample into 3 phases. The upper aqueous phase contains RNA 
and was extracted off with a pipette being careful to avoid contamination with the interval 
protein phase or lower organic phase containing DNA. 100% ethanol was then added at 




A maximum of 700µl of this solution was loaded onto an RNeasy mini column (any more 
risks overloading the binding capacity of the column) and centrifuged at ≥8000g for 15 
seconds at room temperature. The RNA binds to the column and the solvent that passes 
through discarded into a beaker. 500µL of RPE buffer was added to the column which was 
centrifuged at ≥8000g for 15 seconds, any flow through was then discarded. This step was 
repeated to wash out any remaining ethanol. Centrifugation was then performed for 2 
minutes at ≥8000g and any flow through discarded. The RNeasy column was transferred 
to a new collection tube and centrifuged at ≥8000g for 1 minute to dry the membrane.  
Finally, the RNeasy column was transferred to an eppendorf and 30µl of RNAse free water 
pipetted into the column which was centrifuged at ≥8000g for 1 minute to elute the RNA. 
The RNA sample was kept on ice and the concentration and purity of RNA measured using 
the nanophotometer 1000 Pearl machine (ThermoFisher™). An absorbance ratio of 2 at 
260nm/280nm was deemed acceptable as this indicates purity of the RNA sample (free 
from phenol or protein contamination). A secondary measure of purity of the sample the 
260/230nm absorbance ratio was deemed satisfactory if >1.6; indicating a low 
concentration of contaminants such as carbohydrate carry over or residual phenol [228]. 
All RNA samples were stored at -80°C until further use. 
3.1.11.2 Complementary DNA synthesis 
Before qPCR or endpoint PCR could be performed, I converted extracted mRNA to 
complimentary DNA (cDNA) using the AB systems high capacity mRNA to cDNA kit. This 
required the use of a reverse transcription enzyme and buffer. Volumes of each reagent 
used were dependent upon the concentration of RNA in my sample and followed the 
manufacturer’s instructions. 
3.1.11.3 Primer design 
Primers were ordered from Eurofins after determining the optimal sequences for the 
amplification of the gene of interest from the Harvard Primer Bank: 
https://pga.mgh.harvard.edu/primerbank. Sequences were verified using the online 
National Centre for Biotechnology Information (NCBI) Primer Blast resource: 
https://www.ncbi.nlm.nih.gov/tools/primer-blast. Once received, primers were made up 
to a concentration of 10µM and kept at -20°C until use. For all new primers, a serial 
dilution standard curve reaction was performed with either untreated cellular cDNA or 
WT mouse kidney cDNA. This was to determine the optimal concentration of cDNA 
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required for the primers to work efficiently and to ensure that the primers could detect a 
product in the control samples (Figure 3-2).  
A negative control sample, containing no cDNA (just RNAse free water) was also included 
to reveal any contamination or non-specific amplification. A standard curve was then 
drawn to calculate the R2 value. The CT value should increase by 3 cycles for each ten-fold 
dilution so that the standard curve is a straight line with R2 >0.95 for very good primers 




Figure 3-2: Example of standard curve analysis: A4GALT mouse and human primers 
Each primer pair used for qPCR were tested for efficiency at serial dilutions of cDNA starting at a 1 
in 5 dilution (dilution 1) and then serially diluted up to 6 times to give a final dilution of 1 in 5625 
(dilution 6). A non-template control (containing no cDNA) was also run alongside these dilutions as 
a negative control. Each condition was run in triplicate. The standard curve was drawn from the 





















Standard Curve for A4GALT mouse 
Primers 

























average CT (cycle threshold) value obtained from each reaction at each dilution. The example 
shown is for the A4GALT primer pairs using both mouse primers and human primers, respectively.  
 
 
Figure 3-3: Standard curve analysis for B-actin primers (mouse and human) 
β actin primers were tested in the same way as described for the A4GALT primers. An R2 value of 
0.95 equates to very good primer efficiency.  
 
 Quantitative PCR 
QPCR was performed using SYBR green from Sigma-Aldrich according to their instructions. 
SYBR green is a fluorescent cyanine dye that binds to double stranded DNA between base 
pairs and fluoresces. This fluorescence is detected at the end of the annealing or extension 
step in the PCR reaction when there is maximal double stranded DNA present. This 
reaction is non-specific as any double stranded DNA present will be detected; therefore, 
the primers used must be carefully designed so as to produce a gene specific amplification 
product [229]. In both qPCR and endpoint PCR reactions, I sequenced the amplified 
product as a way of validating my results for each target gene.  
QPCR was performed using the optimal cDNA concentration as determined from my 
standard curve for each set of primers used.  Annealing temperatures were set according 
to the Tm (melting temperature) provided by Eurofins specific for each primer pair. All 
experiments included a housekeeping gene (β-actin) as a control to allow comparison 
between samples. Melt curves (Figure 3-4) were inspected with each experiment to 
ensure the cycle thresholds detected from SYBR green fluorescence were specific. The 
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Applied Biosystems Step One Plus real time PCR machine was used for all qPCR 
experiments.  
The ΔΔCT method for calculating relative gene expression was used in all qPCR 
experiments. This first requires normalisation of all samples to β-actin (housekeeping 
gene) with subsequent comparison of the expression of the gene of interest under 
different experimental conditions to calculate a fold change or relative expression. Details 
of this method are found in the paper by Haimes et al [230]. Data was analysed to ensure 
consistency between each triplicate repeat or a single outlier that could be excluded from 
the dataset, a single product on the melt curve of each sample and negative control wells.  
3.1.12.1 Endpoint PCR 
Endpoint PCR was performed using the Hotmaster Taqman DNA kit from AB systems 
according to their instructions. Primers were used at a concentration of 10µM and 1µl of 
cDNA sample used as standard for each reaction. The Tm was set according to Eurofins 
data sheet which was provided with my primers (see appendix). Amplification products 
were run on a 2% agarose gel alongside a 100 base pair DNA ladder from New England 
Biolabs. Midori green (Geneflow) was added to the agarose gel to stain the DNA 
amplification product to enable visualisation using the Amersham 600 imager. Endpoint 
PCR was used to confirm the presence (or absence) of a gene of interest. This was a 
particularly useful technique in analysing expression of Gb3 synthase in A4GALT knockout 
mouse tissues. The amplification product (after PCR clean up using Qiagen PCR 
purification kit) was sent for sequencing to Eurofins Genomics in Germany to confirm the 





Figure 3-4: Examples of melt curves from qPCR reactions 
A – shows the melt curve obtained from a qPCR reaction in glomerular isolates from mice using 
mouse A4GALT primers. B – shows the melt curve obtained from a qPCR reaction in human 
podocytes using β actin primers. The peak present in each sample tested (represented by a 
different colour for each) corresponds to the cycle threshold detectable from SYBR green 
fluorescence. Given this is a single peak it is specific for the amplification product of the primers. 
 
 Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) is a technique used to separate lipids based on their 
relative affinity towards the stationary and mobile phase. I went to UCL to learn this 
technique from lipid expert Prof. Shamshad Cockcroft.  
Hela cells were radio-labelled with H3 sphingosine for 4 hours in fatty acid free BSA DMEM 
media. Cells were trypsinised, washed in PBS and centrifuged at 2300 rpm for 3 minutes. 
The supernatant was aspirated and re-suspended in 600µl of PBS. 1.5mls of chloroform: 
methanol mixture (ratio of 1:2) was added to the suspension. A further 0.5mls of 
chloroform followed by 0.5mls of 100mM KCL and 20mM acetic acid solution was then 
added, and the sample mixed well. After 20 minutes at room temperature, to allow 
separation of the chloroform and water soluble phase the suspension was centrifuged at 




extracted and transferred to another eppendorf. The sample was then evaporated 
overnight in the Savant Speed Vac machine.  
The following day, 50µl of chloroform was added to each sample and loaded on to the TLC 
silica glass plate. The TLC plate was run with commercially available standards from 
Matreya Inc. These included the following lipids: Gb3, sphingomyelin, PE 
(glycerophosphoethanolamine) and PC (glycerophosphocholine). This is necessary to 
allow identification of the lipids present in the samples. Of note, only my samples contain 
radio-labelled sphingosine and so these standards are not visible when the TLC plate is 
developed. For optimal glycosphingolipid TLC development, a chloroform: methanol: 
water solvent was prepared in a ratio of 65:25:4 and poured into the TLC glass column. 
The lipid loaded TLC plate was then placed inside and left to run for 1-2 hours. The TLC 
plate was then placed in iodine to confirm that separation had occurred (bands seen along 
the plate). The TLC plate was then placed on top of a specialised photographic film in a 
secure case to develop for 7-14 days. The film was then imaged using a scintillation 
detector.  
 Generation of an A4GALT knockdown podocyte cell line 
Commercially available GIPZ lentiviral short hairpin RNA (ShRNA) particles from 
Dharmacon were used to create a Gb3 synthase (A4GALT) knockdown human podocyte 
cell line (Figure 3-6). There are several advantages of this system, firstly the ShRNA is 
micro-RNA adapted for specific knockdown; the transfected cells are marked by a GFP tag 
and a stable cell line can be maintained through the use of puromycin resistance due to 
presence of a puromycin resistance gene. In addition, there is experience of the use of 
these constructs in conditionally immortalised human podocytes in our laboratory. The 
manufacturer’s protocol was followed as outlined below [231].  
Initially, the puromycin dose response (kill curve) in wild type human conditionally 
immortalised podocytes was determined (Figure 3-5). Cells were plated on 6 well plates 
at a confluency of 80% and thermo-switched the following day and left to differentiate 
for 10-14 days. Podocytes were then incubated with puromycin at doses ranging from 
0.1µg/ml to 5µg/ml for 24-96 hours. At each time point the cells were assessed for cell 
viability using the trypan blue dye exclusion test. This involved trypsinising the cells and 
adding 10µl of 0.4% trypan blue (Biosystems) to 10µl of cell suspension and counting the 
number of cells on the automated cell counter (Luna II automated cell counter, 
Biosytems).  Cells that were viable did not take up the blue dye. This was performed in 
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triplicate to ensure accuracy of results. Based on these experiments the minimum amount 
of antibiotic to kill all wild type cells at 72 hours was 1µg/ml. Thus, the dose of puromycin 
used for selection of my A4GALT knockdown cells was 1µg/ml, which was added to the 
standard podocyte media when growing these mutant cells.  
 
 
Figure 3-5: Puromycin kill curves for wild type human podocytes 
As described the minimal dose of puromycin required to kill all non-transfected (i.e. wild type) 
human podocytes was determined. Results shown are representative of each experimental 
condition in triplicate. The dose chosen for selection of mutant A4GALT knockdown podocytes was 
1µl/ml. At 72 hours all wild type podocytes are dead, leaving only the mutants with the puromycin 
resistance gene viable. 
 
Subsequently, the titre of lentiviral stock required for transduction of human podocytes 
to successfully knockdown A4GALT synthase was determined. The day before 
transduction 6 well plates of wild type human podocytes (passage 9) were seeded at less 
than 50% confluency. The following day dilutions of the lentiviral stock were made in a 
‘working 96 well plate’ using serum free media to produce a series of 5-fold dilutions 
reaching a final dilution of 390,625 fold. Once the serial dilutions were made, media was 
removed from the podocytes in the 6 well plates and replaced with 575µl of serum free 
media and polybrene (1 in 100 concentration). The cells were then transduced by adding 
25µl of virus (or non-silencing control virus) from the 96 well plate to give a series of viral 
transduction dilutions. For example, 25µl of virus dilution from A2 of the 96 well plate was 



























Each viral transduction dilution was left on the cells for 4 hours at 33°C and then replaced 
with 1ml of standard podocyte media. After 3 days, standard podocyte media was 
replaced with media containing 1µg/ml of puromycin. Only podocytes that containing the 
puromycin resistance gene (i.e. successfully transduced podocytes) will survive culture in 
puromycin media, facilitating selection of the A4GALT synthase knockdown podocytes. 
The number of successfully transduced podocytes were visible under light microscopy as 
green cells due to their GFP tag (Figure 3-7 and Figure 3-8). Of note, the GFP tag, 
puromycin and ShRNA sequence were on the same CMV promoter of the GIPZ lentiviral 
vector. 
 
Figure 3-6: GIPZ lentiviral vector 
The GIPZ lentiviral vector contains a GFP tag (tGFP) connected via an internal ribosomal entry site 
to allow expression of GFP and puromycin resistance genes (puroR) in a single transcript. The 
ShRNA sequence is driven from the same CMV promoter (hCMV). WPRE – Woodchuck hepatitis 
posttranscriptional regulatory element enhances transgene expression in the target cells; 5' LTR 5' 
- long terminal repeat; 3' SIN LTR 3' - self-inactivating long terminal repeat for increased lentivirus 
safety; Ψ - Psi packaging sequence; RRE - Rev response element. Reproduced from Dharmacon GIPZ 
ShRNA lentiviral manual [231].  
 
 





Panel A shows merged image of GFP (green) and DAPI (blue) transfected human podocytes 
achieved at a lentiviral transduction concentration of 1 in 5 at a magnification of x20. There are 
significantly more GFP tagged cells (i.e. transduced cells) than in panel B where a 1 in 25 dilution 
of lentiviral construct was used. 
 
 
Figure 3-8: GFP tagged A4GALT knockdown human podocytes (x40 magnification) 
Transfected podocytes were imaged live under fluorescent microscopy to determine whether 
successful transduction had taken place. All 3 mutants (sequences of ShRNA as labelled) were GFP 
tagged suggestive of successful transduction of the A4GALT silencing ShRNA.  
 
The GFP tag was very useful to monitor the expression of the viral construct but there was 
some loss of GFP expression towards the end of differentiation in human podocytes and 
when these cells were resuscitated from -80°C storage. To quantify the degree of A4GALT 
knockdown qPCR and IF were performed. A loss of the GFP signal has been seen before in 
podocytes (other scientists within Bristol Renal anecdotal experience of using the same 
GIPZ lentiviral vectors with different ShRNA sequences). However, reassuringly this loss 
of signal did not correlate with any loss of expression of ShRNA silencing which was 
confirmed with immunofluorescence and qPCR. 
 VEGF-A ELISA 
VEGF-A (165 isoform) was quantified from both conditionally immortalised podocyte and 
glomerular endothelial cell supernatant and from co-culture transwell experiments. Cell 
culture experiments were undertaken without VEGF in the media and included cells 
treated with 0.1ng/ml Shiga toxin and untreated controls. Patient plasma and urine 
samples from the ongoing ECUSTEC trial (ISRCTN89553116) were also assessed for VEGF-
A levels. All experiments involved use of the R&D SystemsTM human VEGF-A 165 ELISA kit 
(www.rndsystems.com/products/human-vegf-quantikine-elisa-kit_dve00). All samples 
were analysed in triplicate technical repeats and the manufacture’s protocol followed. 
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These experiments were performed with Dr Louise Farmer a post-doctoral scientist in our 
laboratory.  
3.2 Materials and Methods in vivo 
 UK Animal Care Declaration 
All animal work was performed in accordance with the University of Bristol’s guidelines 
and the Animals Scientific Procedures Act 1986. Work carried out was within the Project 
License of Prof. Richard Coward (no: 3003394) and approved by the UK Home Office. I 
obtained a personal license in order to perform the experiments detailed below. (PIL: 
I2780F26E). 
 Choice of genetic background 
The C57BL/6 strain of mice were selected as the genetic background for use in the 
generation of all mouse models used in my research. This strain of mouse is commonly 
used in many knockout mouse models including the Gb3 null mouse generated by Okuda 
et al [75]. It is worth noting, that rodent models of kidney disease have conventionally 
avoided use of the C57BL/6 genetic background as it has been found to be relatively 
resistant to proteinuria, glomerulosclerosis and hypertension [232]. This is thought to be 
due to decreased activity of the renin-angiotensin-aldosterone system as a consequence 
of having only one copy of the renin gene [232].  
However, arguably more important in my model, is that the C57BL/6 strain has intact 
complement factor 5 (C5); unlike several other commonly used mouse strains (DBA2J, A/J, 
AKR/J, FVB/NJ) which have a frame shift in their haemolytic complement gene (Hc) 
resulting in a loss of function mutation in C5 [233]. It is vital that in generating my mouse 
model of Shiga toxin HUS, that these complement pathways remain intact as our 
hypothesis seeks to determine whether complement plays a role in the pathogenesis of 
the disease. On balance it was decided that the C57BL/6 genetic strain was the most 
appropriate one to use in my model. 
 Mouse gender selection 
It has been shown in some mouse models of renal disease, that male mice are more likely 
to develop proteinuria, ischaemic renal failure and diabetic nephropathy than female 
mice [232]. For this reason, male mice have been used preferentially in the majority of 
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published rodent models of kidney disease [232]. Renal research is not unique in this 
sense, use of predominantly male animals in research has been reported in many fields 
[234]. This has originated from concerns that the use of both sexes will mean a 
requirement to include more animals in the sample size, due to increased variation and 
reduced statistical power.  However, in this project I have used both female and male 
mice as I did not anticipate a sizable interaction between sex and the development of 
Shiga toxin HUS. This decision was informed by human epidemiological data; in which 
large retrospective studies in Europe have shown no statistically significant difference in 
the incidence of STEC HUS cases according to gender [40]. Furthermore, I did not 
anticipate a variation between sexes in terms of the possible effects of C5 inhibition as a 
treatment intervention.  
As a result, this work is more broadly applicable and adhered to the National Centre for 
the Replacement, Refinement and Reduction of Animals in Research guidelines, where by 
including both male and female mice I could use fewer animals to obtain comparable 
information from the study of male mice only. It is worth noting however, that in the C5 
inhibition cohort of mouse experiments, all mice (including controls) happened to be 
female. There was no conscious or pre-conceived decision to use only female mice in this 
experiment; but merely a chance result that the mice with the required genotype were all 
female. All other mouse work involved both male and female mice.   
 Shiga toxin treatment in mice 
All mice used during my project were between 8-12 weeks of age at the time of Shiga 
toxin treatment. Shiga toxin dose for each mouse was calculated based on the weight of 
each mouse. A dose of 10ng/g of Shiga toxin (List Biological Laboratories Inc.) diluted in 
sterile normal saline 0.9% (Baxter) was given to each mouse IP. Control mice were given 
IP 0.9% normal saline of the same volume. Prior to commencing any Shiga toxin mouse 
work, with each new vial of Shiga toxin 2 from E.coli purchased at least 2 wild type mice 
were given a test dose of Shiga toxin IP at 10ng/g to ensure that the toxin was virulent 
and there was no batch effect. This was to prevent any unnecessary use of animals in my 
main experiments due to failure of the toxin working in accordance with the principles of 
Russel and Burch [235].  
Throughout the course of my animal work several batches of Shiga toxin from list labs 
were required. Each batch had been tested at List labs for concentration, purity, and 
activity. SDS-PAGE was used to assess purity and was >98% for each batch used. LPS 
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contamination was determined using a kinetic chromogenic LAL (Limulus amebocyte 
lysate) assay and found to be <90EU/ng in each vial. The toxin was stored as advised by 
the manufacturer at 2-8°C when a lyophilised powder and at -20°C when reconstituted in 
distilled water.  
Shiga toxin is highly toxic and must be handled with extreme caution. In-keeping with the 
precautions taken during my in vitro work, all Shiga toxin experiments in mice were 
performed whilst wearing a mask, gloves, and protective clothing. Doses of Shiga toxin 
were made up in a biological cabinet within the animal unit and signs displayed to warn 
other users of the experiment being performed. Shiga toxin waste (including syringes and 
needles) were immediately placed in 0.1M sodium hydroxide falcons and disposed of in 
labelled sharps bins. Before administering IP Shiga toxin injections, I was trained to 
perform the procedure using normal saline in order to reduce any personal risk of 
needlestick injury. All experimental work was subject to authorisation by the biological 
and genetic safety committee at the University of Bristol. 
 Generation of a Gb3 Null mouse 
Generation of a Gb3 null mouse has already been described by Okuda et al [75]. This group 
targeted the A4GALT gene and replaced nucleotides 68-615 within the open reading 
frame with a neo-resistant gene. The targeting vector was linearized and transfected into 
embryonic mouse embryonic stem cells and the clones containing the vector isolated. 
Homologous recombination was employed to facilitate targeted incorporation of the 
mutation into the homologous genetic locus. The generation of a Gb3 knockout mouse 
was confirmed by Southern blotting [75]. The Gb3 knockout mice used in my project were 
generated by MRC Harwell through use of the International Mouse Phenotyping 
Consortium (IMPC) via the European Conditional Mouse Mutatgenesis (EUCOMM) and 
the National Institutes of Health Knockout Mouse (KOMP) programs embryonic stem (ES) 
cell resource (see www.knockoutmouse.org/about/eucomm).  
MRC Harwell used this repository to obtain mice containing the full Tm1a knock-out-first-
reporter tagged insertion allele at the site of a critical exon within the A4GALT gene. As 
well as the gene specific elements this targeting cassette contains several other common 
components including a beta-galactosidase (lacZ gene), neomycin (neo) resistance gene 
and LoxP sites [236]. This mouse was subsequently crossed with mice expressing Cre 
recombinase. The progeny from this breeding was then genotyped (using a combination 
of qPCR assays) to identify the alleles generated. Only mice containing Tm1b converted 
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forms of the original Tm1a allele were taken forward for use in my experiments. The Tm1b 
allele is produced by deletion of the critical exon and the neomycin cassette (within the 
knock-out first mutant allele) due to Cre recombinase excision at loxP sites (Figure 3-9). 
As a result, the Tm1b allele is considered a true knockout as skipping over of the LacZ 
cassette will no longer restore gene expression (unlike in the Tm1a mutant) [237]. Mice 
were genotyped using primers obtained from Eurofins: www.eurofinsgenomics.eu (see 
appendix for details) and expression of both A4GALT and Gb3 in their tissues also 
assessed. The characterisation of the A4GALT knockout mice used in this project is 
discussed in detail in results Chapter 6.  
 
 
Figure 3-9: Tm1b – LacZ tagged null allele generation used to obtain A4GALT knockout mouse   
The full Tm1a knockout-first-reporter tagged insertion allele, containing a lacZ trapping cassette  
and a floxed promoter-driven neo cassette is inserted upstream of a critical exon in the specified  
gene (in this case the A4GALT gene) which disrupts its function. These mice can then be crossed  
with mice expressing Cre recombinase. The progeny from this breeding were then genotyped  
(using a combination of qPCR assays) to identify the alleles generated. Cre deletes the promoter  
driven selection cassette and floxed exon of the Tm1a allele to generate the Tm1b allele; or deletes  
the floxed exon of the Tm1c allele to generate Tm1d (as shown) [227]. Only mice containing Tm1b  
converted forms of the original Tm1a allele were taken forward for use in my experiments. Figure  




 Generation of an inducible podocyte specific Gb3 synthase mouse 
Our laboratory has previously generated the PodrtTA-Tet-O-Gb3 mouse which uses 
tetracycline-controlled transcription activation of murine Gb3 synthase in the podocyte. 
This novel mouse model was derived from crossing the podocin rtTA (reverse tetracycline 
activated transactivator) mouse (a gift from Prof. Susan Quaggin in Canada); with the Tet-
O-Gb3 synthase mouse generated by the company Geneta in Leicester (made using the 
Tet-O-Gb3 construct devised by post-doctoral scientist Dr Matt Wherlock in Bristol) [61]. 




Figure 3-10: Inducible tetracycline-controlled transcription of Gb3 synthase in the podocyte 
Expression of the reverse tetracycline activated transactivator (rtTA) gene is driven by the 
podocyte specific podocin promoter. The rtTA gene product binds doxycycline and activates 
transcription from the tet-O promoter. This then drives transcription of Gb3 synthase – resulting 
in expression of the Gb3 receptor in the podocyte. Figure modified from Dr. Lindsay Kier PhD Thesis 
[61].  
 
The construct containing Tet-O-Gb3 synthase that was made by Dr Wherlock, originated 
from a Tet-O-VEGF-A construct given to our laboratory from Prof. Susan Quaggin in 
Canada. He designed a restriction digest to cut out VEGF-A and a ligation to insert murine 
Gb3 synthase (gifted by Dr T Obrig, University of Virginia). Unfortunately, the Tet-O-Gb3 




mouse in our laboratory had been mistakenly culled prior to the start of my project. 
However, the original Tet-O-Gb3 synthase construct made by Dr Wherlock was still 
available. Hence, Tet-O-Gb3 synthase mice were created at the MRC Harwell through pro-
nuclear injection of a single mouse embryo with this construct (Figure 3-11). This strategy 
resulted in the random insertion of  the construct into genomic DNA.  
The embryos were implanted into female mice and allowed to reach term. Once born they 
were genotyped to determine whether the construct had been inserted into their 
chromosomal DNA. Mice with the Gb3 synthase construct present were taken forward to 
breeding to establish a Tet-O-Gb3 synthase colony with which to cross the PodrtTA mice 
with. The resulting mice were PodrtTA-Tet-O-Gb3 synthase mice on a WT background. 
These mice were characterised prior to any further breeding to establish a PodrtTA-Tet-
O-Gb3 synthase mice on a Gb3 null background. The details of this work are presented in 
Chapter 6.  
 
 
Figure 3-11: Tet-O-Gb3 synthase construct used to generate Tet-O-Gb3 mice 
This Tet-O-Gb3 synthase construct was made by Dr Matt Wherlock in Bristol Renal. It was modified 
from a Tet-O-VEGF-A construct which originally linked the VEGF-A to a tetracycline response 
promoter. The flag tag sequence allows easy identification of the transgene after incorporation 
into the mouse genome. Vector map supplied by Dr Lindsay Keir.  
 
 Doxycycline gene induction    
PodrtTA-Tet-O-Gb3 mice on either a wild type or Gb3 null background were given oral 
doxycycline at a dose of 2.5mg/ml in their drinking water to induce Gb3 synthase in their 
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podocytes. Only mice with both the PodrtTA and Tet-O-Gb3 synthase promoter should 
express Gb3 synthase in their podocytes as both the reverse tetracycline activated 
transactivator (rtTA) element and the Tet-O-Gb3 promoter need to be present (Figure 
3-10). Doxycycline hyclate was purchased from Sigma-Aldrich and stored as per 
manufacturer instructions at 2-8°C. Doxycycline drinking water was made up fresh from 
this stock every 3 days and was poured into tinted water bottles to maintain the 
concentration of the drug which is light sensitive. Control mice receiving standard drinking 
water also had their water bottles changed at the same time. Doxycycline drinking water 
is known to taste bitter, thus mice will avoid drinking it. To circumvent this issue 5% 
sucrose was added to the doxycycline drinking water. Initially, 5% sucrose was also added 
to control drinking water, but these mice began consuming large volumes of the 
sweetened water which required replacing daily. This could potentially influence my 
experimental results, so I reverted back to using drinking water alone for my control mice.  
To check that the PodrtTA-Tet-O-Gb3 system was not leaky, Tet-O-Gb3 mice were studied 
to ensure there was not any expression of Gb3 synthase in the absence of the podocin 
promoter. Furthermore, a control group of PodrtTA-Tet-O-Gb3 mice were given normal 
drinking water to check that Gb3 synthase was only being induced after tetracycline 
activation. Previous work by Dr Lindsay Keir had shown that Gb3 synthase induction 
required at least 10 days of oral doxycycline [61]. Therefore, in all of my experiments 
involving PodrtTA-Tet-O-Gb3 mice, 14 days of doxycycline treatment was administered to 
induce Gb3 synthase.  
 Breeding strategy for generation of the PodrtTA-Tet-O-Gb3 mouse on a 
null Gb3 background. 
To generate an inducible podocyte specific Gb3 synthase mouse on a Gb3 null background 
PodrtTA-Tet-O-Gb3 mice on a wild type (C57BL/6) genetic background were back-crossed 
with Gb3 null mice (A4GALT KO). These mice only express the Gb3 receptor in their 
podocytes. This model provides temporal control over gene expression of Gb3 in the 
podocyte, providing invaluable insights into the role of this specialised glomerular cell in 
the initiation of glomerular TMA in Shiga toxin HUS. This highly complex mouse model has 
allowed me to test my hypothesis in vivo which is vital prior to any further translation into 
human studies and clinical application. To ensure that the minimum number of mice were 
used in each experiment whilst maintaining statistical significance, the intelligent 
breeding strategy detailed below was used: 
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Tet-on GB3 +/+ pod RtTA +/+ x GB3 null/null (from MRC Harwell) = 
Tet-on GB3+/- pod RtTA+/- GB3 +/null x Tet-on GB3 +/- pod RtTA +/- GB3 +/null 
After 6 rounds of breeding the correct genotype was achieved with following cross:  
Tet-on GB3 +/+ pod RtTA +/+ GB3 null/null x GB3 null/null  = 
ALL MICE: Tet-on GB3 +/- pod RtTA +/- GB3 null/null 
This process successfully generated several cohorts of PodrtTA-Tet-O-Gb3 Gb3 null mice 
and sufficient littermate controls for IP Shiga toxin challenge vs. sham IP injections of 
sterile saline as a negative control. To reduce any 'cage effects' mice of different 
genotypes (from the same litter) were housed together, to avoid any bias from social 
interactions within the cage. Mice were randomised to receive either IP Shiga toxin or 
saline (sham procedure) using a randomised block design. The order in which 
measurements were made and the way the mice were housed was also randomised to 
avoid any time and space variables that might influence my results. 
Prior to any definitive experiments, all PodrtTA-Tet-O-Gb3 Gb3 null mice were genotyped 
and organs assessed for expression of Gb3 in the presence and absence of doxycycline 
induction using endpoint PCR and immunofluorescence techniques. Once I was satisfied 
that the PodrtTA-Tet-O-Gb3 system was working as expected and doxycycline was 
inducing the expression of the Gb3 receptor in the podocyte of the kidney only; my 
experiments using Shiga toxin commenced. 
 Cardiac perfusion  
Cardiac perfusion of wild type mice and the inducible PodrtTA-Tet-O-Gb3 mice on a WT 
background was performed to clear the organs of any erythrocytes which have been 
shown to express Gb3 (and so can lead to contamination) [238]. Of note, A4GALT KO mice 
and PodrtTA-Tet-O-Gb3 Gb3 null mice did not require cardiac perfusion as they do not 
express Gb3 or only express Gb3 in their podocytes following doxycycline induction, 
respectively. Comparison of kidney tissue sections from wild type mice that were not 
perfused prior to tissue harvesting vs. wild type mice that underwent cardiac perfusion 
showed that Gb3 in the glomeruli was picked up in the non-perfused animals with 
immunofluorescence but not in the perfused animals (Figure 3-12 and Figure 3-13). 
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Mice were terminally anaesthetised via intraperitoneal injection of pentobarbital 
(50mg/kg). The chest cavity was opened, and anterior chest wall removed. Whilst the 
heart was still beating a 22-gauge butterfly needle was inserted into the left ventricle and 
the position of the needle checked by aspirating some blood into the syringe attached to 
the needle. The right atrium was then cut with scissors to release the pressure before 
injecting 10mls of HBSS (Hanks’ buffered salt solution, ThermoFisher ScientificTM). The 
organs (including the liver and kidneys) were observed to become pale in colour – 
indicating successful perfusion. The needle was removed from the left ventricle and 
organs dissected. Fluid leaking from the nose of the animal or the lungs increasing in size 
was indicative of an unsuccessful perfusion, as HBSS has entered the pulmonary 
circulation (rather than the systemic circulation) if this occurred. Only animals observed 
to be adequately perfused were used for tissue harvesting. 
 
 
Figure 3-12: Confocal microscopy IF sections WT vs. A4GALT KO non-perfused mice (x40) 
As described kidneys were harvested from WT (wild type) and A4GALT KO mice without perfusion 
and immunofluorescence performed to detect Gb3 (green). To determine the localisation of Gb3 
in the kidney of mice nephrin was used (red) to identify podocytes. These images appear to show 
Gb3 expression within the glomerulus. This was unexpected as it has been well established that 
mouse glomeruli do not express Gb3 [61]. Red blood cell contamination was suspected; prompting 






Figure 3-13: IF sections in wild type perfused mice (x40) 
Images A and B are both from WT mice that have been perfused prior to kidney harvesting. There 
is no evidence of Gb3 expression (green) within the glomeruli (nephrin = red). There is still evidence 
of Gb3 expression in the tubules as seen in panel B. Therefore, as well-established WT mice do not 
express Gb3 in their glomeruli but do express Gb3 in their renal tubules. 
 
 Glomerular isolation  
To specifically analyse mRNA and protein expression in the glomeruli of mice (rather than 
that within the whole kidney) I used a glomerular isolation technique involving 
Dynabeads® (ThermoFisher ScientificTM). This is particularly useful when analysing tissues 
from PodrtTA-Tet-O-Gb3 mice on a wild type background, as these mice will express Gb3 
in their renal tubules and their podocytes found within the glomeruli. Since most Gb3 in 
wild type mice is expressed in the renal tubules; determining whether inducible 
expression of Gb3 in the podocyte has occurred following oral doxycycline treatment is 
not possible without glomerular specific analysis.  
Mice underwent cardiac perfusion as described above. Following perfusion, the syringe 
attached to the butterfly needle was switched to a 10ml syringe containing 8x107 
Dynabeads® in HBSS. The needle was then removed from the left ventricle and the kidneys 
dissected. Once harvested both kidneys were put into HBSS and kept on ice. In the 
laboratory, kidneys were minced up with scissors in a petri dish to maximise the surface 
area available for digestion. The minced tissue was then transferred to 1.5ml digestion 
buffer (1mg/ml collagenase containing 50U DNAse 1: Life Technologies) suspended in 
RPMI media (ThermoFisher ScientificTM). This mixture was agitated at 37°C for 30 minutes.  
The digested tissue was then passed through a 100µm cell strainer into a 50ml falcon tube 
and washed with 5mls HBSS. The strained liquid was then repassed through the cell 
A BA B 
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strainer washing again with 5mls HBSS to maximise the yield of tissue. The suspension 
was centrifuged at 4°C for 5 minutes at 3000g. The resulting supernatant was removed 
and placed in a new falcon tube. The remaining pellet (containing the glomeruli) was 
resuspended in 500µl of HBSS and transferred to a 1.5ml eppendorf on ice. The 
supernatant falcon tube was re-spun, and the pellet produced resuspended in 300µl of 
HBSS and transferred to an eppendorf. These eppendorfs were placed against a magnet 
for 1 minute, as the Dynabeads® are magnetic they collect on the side of the tube taking 
the glomeruli with them. The isolated glomeruli were carefully washed x3 with 500µl of 
HBSS ensuring that the tubes were on the magnet each time. To confirm glomerular 
isolation 1µl of suspension was pipetted into a microscope slide and viewed under a light 
microscope. The Dynabeads® were visible within the glomeruli (Figure 3-14). The 
glomerular isolates were transferred to RNAlater and stored at 4°C. RNA extraction was 
performed within 7 days of isolation. 
 
 
Figure 3-14: Dynabead® glomerular isolation (x40) 
Mouse glomeruli are successfully isolated using cardiac perfusion and subsequent Dynabead® 
perfusion. Two glomeruli are visible with the Dynabead® particles visible in the capillary loops of 
the blood vessels of the glomeruli.  
 
 Organ harvesting 
The kidneys, liver, heart, lung, pancreas, and brain of all mice were harvested under 
terminal anaesthesia (intraperitoneal injection of pentobarbital (50mg/kg). These organs 
were divided into two or three sections and fixed in 10% PFA, snap frozen at -80°C or 
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transferred to EM buffer (kidneys only).  The specific fixation techniques are described 
below with reference to kidney tissue. Other organs in which RNA was extracted 
underwent the same processes. Terminal blood samples were also taken at the time of 
sacrifice from a cardiac puncture as well as terminal urines via a bladder puncture. An ear 
notch was also kept at -20°C for genotyping.  
3.2.11.1 Formalin fixed kidney tissue (PAS staining) 
Immediately after dissection, at least half a kidney from each mouse was preserved in 4% 
paraformaldehyde (Santa Cruz) and stored at 4°C. When required, kidney tissue was 
paraffin embedded and sectioned (3 microns thick) in the histology department at Bristol 
University. Sections were deparaffinised in histoclear and hydrated by immersing in serial 
dilutions of ethanol. Starting at 100% ethanol for 5 minutes, then 90% ethanol for 5 
minutes and so on until a concentration of 50% ethanol was reached. After this the 
sections were transferred to distilled water for 5 minutes, followed by immersion in 
Periodic Acid Solution (PAS) for 5 minutes at room temperature. I used the Sigma-Aldrich 
PAS staining system (standard procedure 395) to staining my samples.  
According to manufacturer’s instructions the slides were then rinsed 3 times in distilled 
water and immersed in Schiff’s reagent for 15 minutes at room temperature. Sections 
were rinsed again under running tap water for 5 minutes and counterstained with 
haematoxylin solution for 90 seconds. Slides were rinsed again under running tap water 
and dehydrated by reversing the initial hydration sequence of ethanol immersion in 
increasing concentrations: i.e. from 50% ethanol for 5 minutes to 70% ethanol for 5 
minutes and so on. Sections were subsequently mounted, and images taken using the 
Leica DMI 6000B microscope. PAS positive structures stain pink to red and nuclei are blue.  
3.2.11.2 Formalin fixed tissue kidney tissue (MSB trichrome staining) 
The Atom Scientific Ltd. martius scarlet blue (MSB) staining kit was used as trichrome stain 
to differentiate fibrin, collagen, and muscle. Early fibrin and erythrocytes are also 
demonstrated with this technique. This is the gold standard trichrome histology stain to 
visualise TMA in the glomerulus. The same paraffinization procedure was performed as 
outlined above by the histology department in Bristol University. The sections were de-
waxed in the same way as above and brought through from ethanol to water. Fresh 
Weigert haematoxylin was made up by adding A to B in equal volumes and pipetted on to 
the kidney sections and left for 10 minutes. This was rinsed off with distilled water and 
the slides dipped into 1% acid alcohol solution for 10 seconds.  
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Slides were washed under running water for 5 minutes and stained with martius yellow 
for 3 minutes. This was washed off under running water for 1 minute and crystal scarlet 
solution applied to each section of the slide with a pipette for a 5 minute incubation. Slides 
were washed briefly under running water for 1 minute and treated with phosphotungstic 
acid for 5 minutes. This was washed off in running water for 1 minute and reapplied for 
another 5 minutes. Slides were washed again under running water for 1 minute and 
methyl blue solution applied to each section for 2 minutes. This was washed off in running 
water for 3 minutes and blotted dry. Slides were then dehydrated in 100% ethanol for 5 
minutes and immersed in histoclear for 5 minutes, prior to being mounted with DPX 
(Sigma-Aldrich). Slides were then imaged under light microscopy using the Leica DMI 
6000B microscope. 
3.2.11.3 Formalin fixed tissue kidney tissue for immunohistochemistry 
Kidney sections used for immunohistochemistry (IHC) were formalin fixed and paraffin 
embedded as detailed above. Sections were de-paraffinised and rehydrated with 
histoclear and ethanol in the same way as previously described. Antigen retrieval was 
performed by boiling the slides in citrate buffer (10mM sodium citrate, pH6) and 
maintaining a sub-boiling temperature for 10 minutes using a microwave. Slides were 
then left to cool for 30 minutes in the buffer on the benchtop at room temperature. Once 
cooled, sections were removed from the buffer and washed 3 times for 5 minutes in 
distilled water. Sections on the slides were drawn around using an ImmEdge® hydrophobic 
barrier PAP pen (Vector Lab Inc.) and incubated in 3% hydrogen peroxide for 20 minutes 
in a humidified chamber. This is to block any endogenous peroxidase activity.  
Sections were then washed with distilled water twice for 5 minutes and blocked with 5% 
normal goat serum (NGS) in TBST 0.1% for 30 minutes at room temperature. This was 
subsequently, replaced with primary antibody made up in the same blocking solution at 
an antibody specific concentration (see appendix) and incubated overnight a 4°C. The 
following day the sections were washed with 0.1% TBST three times for 5 minutes each. 
Each section was then covered in 1-3 drops as required of SignalStain® boost detection 
reagent (Cell Signalling Technologies®). This is an HRP conjugated secondary antibody to 
either mouse or rabbit chosen depending on the species of the primary antibody used.  
The sections were incubated in a humidified chamber for 30 minutes at room 
temperature. They were then washed with 0.1% TBST three times for 5 minutes and 
SignalStain® DAB (3,3'-diaminobenzidine) substrate added to each section. This substrate 
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is made up freshly each time using 30µl of SignalStain® DAB chromogen concentrate to 
1ml SignalStain® DAB diluent (mixed well before use). This DAB working solution reacts 
with the peroxidase (HRP) detection reagent to yield a brown reaction product where the 
primary antibody is present. To stop the reaction slides were immersed in distilled water 
and counterstained with haematoxylin for 10 seconds. Sections were washed under 
running water until the water ran clear and dehydrated through increasing concentrations 
of ethanol as already described. Sections were DPX mounted and visualised under light 
microscopy using the Leica DMI 6000B microscope.    
3.2.11.4 Fresh frozen kidney tissue for PCR  
Immediately after harvesting, at least half a kidney from each mouse was snap frozen on 
dry ice and transferred for storage at -80°C. A sample of kidney was used for RNA 
extraction. This was performed using the Qiagen Mini prep RNA extraction kit. The 
manufacturer’s instructions were followed which involved use of 30mg of tissue. This was 
homogenised in a glass homogeniser in RLT lysis buffer supplied with the kit. A DNAse 
digestion step was also performed to eliminate contaminating genomic DNA in the 
samples. The same protocol was followed to extract RNA from the other organs harvested 
from the mice. This protocol is available at: www.qiagen.com/resources/download.  
Once RNA had been extracted from the tissue it was quantified using the nanophotometer 
1000 Pearl machine (ThermoFisher™) and stored at -80°C until needed. RNA from mouse 
tissues was used for endpoint and qPCR using the same methodology already described 
for my in vitro experiments. Primer sequences are listed in the appendix. 
3.2.11.5 Fresh frozen kidney tissue for IF 
Fresh frozen kidney tissue was sent to be sectioned by the histology department at Bristol 
University. Sections were cut on a cryostat to 3 microns thick. These were stored at -80°C 
until needed. Samples were probed to assess Gb3 expression using immunofluorescence 
(IF). This process was similar to that already described in vitro. Briefly, sections were 
removed from -80°C and left to air dry for 15 minutes. Each section was drawn around 
with an ImmEdge® hydrophobic barrier pen (Vector Labs Ltd) to prevent spill over of 
antibodies between sections. The sections were fixed with 4% PFA for 15 minutes at room 
temperature under a fume hood. Slides were then washed with PBS and blocked as well 
as permeabilised in 3% BSA, 0.3% Triton X 100 in PBS for 1 hour. The sections were then 
probed with a primary antibody (see appendix for concentrations) overnight at 4°C.  
102 
 
The following day the sections were washed three times in PBS and a secondary Alexa 
fluor antibody applied for 1 hour at room temperature. The sections were then washed 
again three times in PBS and VECTA Shield hard setting mount with DAPI nuclear stain 
applied (Vector Labs Ltd). Slides were imaged using the Leica DMI 6000B microscope or 
Leica Confocal SP5-II confocal laser scanning microscope at the Wolfson Imaging Institute, 
University of Bristol. 
3.2.11.6 In situ hybridisation for VEGF-A 
Fresh frozen kidney sections were sent to the histology department in Bristol university 
for cryostat sectioning after being put into moulds with Tissue Tek OCT compound and 
frozen at -80°C. New Tissue Tek OCT compound was made in histology for my in situ 
hybridisation so as to keep it as free of RNA contamination as possible. Sections were cut 
between 5-7 microns thick and placed in slides. These were stored at -80°C until needed.  
In situ hybridisation uses labelled RNA probes to target the expression of a gene of 
interest. I was kindly given a mouse VEGF-A 164 DNA plasmid by post-doctoral scientist 
Dr Megan Stevens from the University of Exeter.  In order to ensure an unlimited supply 
of plasmid for future use, a bacterial transformation was performed to increase the 
quantity of our stock. Competent E.coli (Life Technologies) were used to make copies of 
the plasmid. The transformation solution included competent E.coli and the VEGF-A 
plasmid which were heat shocked at 42°C for 1 minute and then placed on ice for 30 
minutes. Super optimal broth media (Sigma-Aldrich) was added to the transformation 
solution and placed on the orbital shaker at 37°C for 1 hour.  
Lysogeny Broth (LB) Agar plates with ampicillin were pre-made (see appendix for recipe) 
and the transformation solution added. Given the VEGF-A 164 plasmids have an ampicillin 
resistance gene, only E.coli that have taken up the plasmid should be able to colonise the 
plate. After being left overnight at 37°C the plate was reviewed for colony growth. Using 
a pipette tip over a Bunsen burner flame (to keep the atmosphere sterile), I inoculated 
the tip with one colony from the agar plate and dipped the pipette tip into 5mls of LB 
broth (Gibco, ThermoFisher ScientificTM) with added ampicillin. This was then placed on 
the orbital shaker at 37°C overnight, but for no longer than 16 hours so as to avoid 
bacterial overgrowth.  
A Qiagen QIAprep® miniprep kit was then used to purify the plasmid DNA from my 
bacterial culture by following the protocol provided with the kit. Once the plasmid DNA 
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had been extracted and cleaned up, it was quantified using the nanophotometer 1000 
Pearl machine (ThermoFisher™). Plasmids were then stored at -80°C until further use. The 
plasmid was subsequently sent to Eurofins genomics for sequencing. Using the Basic Local 
Alignment Search Tool (BLAST) at https://blast.ncbi.nlm.nih.gov/Blast.cgi, I entered the 
FASTA sequence sent back to me from Eurofins which confirmed that mouse VEGF-A was 
the top hit for the plasmid sequence (Figure 3-15).  
 
 
Figure 3-15: Confirmation of mouse VEGF-A plasmid sequence from BLAST 
Purified VEGF-A 164 plasmids were sent to Eurofins genomics for sequencing. Using the Basic Local 
Alignment Search Tool (BLAST) at https://blast.ncbi.nlm.nih.gov/Blast.cgi, I entered the FASTA 
sequence sent back to me from Eurofins which confirmed that mouse VEGF-A was the top hit for 
the plasmid sequence.  
 
To make the RNA DIG labelled probe for in situ hybridisation, the VEGF-A plasmid needed 
to be linearized. Using the plasmid map provided by Dr Stevens two restriction digests 
were set up; one with EcoR1 restriction enzyme (New England Biolabs Ltd) to make an 
anti-sense probe and one with XBaI (New England Biolabs Ltd) to make a sense probe (as 
a negative control for VEGF-A detection). The restriction digest containing the plasmid, 
EcoR1 or XBaI restriction enzyme and appropriate buffer (EcoR1 buffer or CutSmart buffer 
respectively) was incubated at 37°C for 1 hour in a PCR machine. The reaction was stopped 
by heat inactivation through incubation at 65°C for 20 minutes. The digest was then run 
on a 1% agarose gel alongside the non-linearized plasmid to determine if the restriction 




Figure 3-16: Restriction digest used to linearize the VEGF-A 164 plasmid 
The VEGF-A plasmid was linearised as described to facilitate the generation of an anti-sense and 
sense RNA VEGF-A probe. The products of the restriction digest used to facilitate this were run on 
a 1% agarose gel shown in panel A. As expected, the linearised plasmid was ‘heavier’ than the 
circular plasmid which migrates more easily through the gel as it is more compact (i.e. circular 
plasmid will be in coiled state). The expected band size for the plasmid with the VEGF-A insert was 
3.6kB as shown. Panel B shows the plasmid map supplied by Dr Megan Stevens which is a 
pBluescript II KS vector with mouse VEGFA 164 isoform inserted at Sma1 site. Restriction enzymes 
were selected on the basis of this map after cross-referencing them on the New England Biolabs 
website).  
 
The linearized plasmid was then labelled by setting up a DIG labelling reaction using a DIG 
RNA labelling kit (Sigma-Aldrich). T3 RNA polymerase was used to label the sense probe 
and T7 RNA polymerase was used to label the anti-sense probe. The reaction was set up 
by mixing the labelling reagents (see appendix) at room temperature in an RNAse free 
environment (dedicated RNA free laminar flow hood) and incubating at 37°C for 4 hours. 
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To stop the reaction 1µl of 0.5M EDTA was added, followed by 2.5µl 4M Lithium chloride 
and 75µl 100% ethanol to precipitate the labelled RNA. This was then incubated at -80°C 
overnight.  
The following day the precipitation was spun in a microfuge for 15 minutes at 4°C at top 
speed to generate a pellet. This pellet was washed with 500µl of 70% chilled ethanol and 
allowed to air dry. The pellet was then dissolved in 75µl of DEPC treated water 
(ThermoFisher ScientificTM). 1µl of this suspension was then run on a 2% agarose gel to 
check the quality of the probe (Figure 3-17) and another 1µl used to estimate the 
concentration of the probe using the nanophotometer. The labelled probe was then 
stored at -80°C until further use. 
 
 
Figure 3-17: DIG labelled probes 
Following DIG labelling both the anti-sense VEGF-A and sense VEGF-A probes were run on a 2% 
agarose gel to check that there had been no contamination during the DIG labelling process. This 
showed a single visible band at 3.6kB which is the expected size of the plasmid with the VEGF-A 
insert, confirming no contamination had occurred.  
 
Once the RNA probes had been DIG labelled, in situ hybridisation for VEGF-A could begin. 
Frozen kidney sections were air dried at room temperature for 1 hour after being taken 
out of -80°C storage. To expose the nucleic acids in the tissue, slides were treated with 15 
µg/ml proteinase K (Sigma-Aldrich) in DEPC (ThermoFisher ScientificTM) PBS at 37°C for 5 
minutes. Following two washes in DEPC PBS at 37°C, slides were fixed in 4% PFA at room 
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temperature for 7 minutes. PFA was washed off with DEPC PBS at room temperature and 
the slides treated with 2x saline sodium citrate (SCC) (made up from 20x SCC purchased 
from Sigma-Aldrich). Hybridisation buffer was made up and pre-heated to 60°C (see 
appendix for recipe). Slides were incubated in this buffer for 1 hour in a hybridisation oven 
at 60°C, within a humidified chamber. The humidified chamber was set up using 2 layers 
of white filter paper at the bottom, soaked in 120mls of 50% formamide (Sigma-Aldrich) 
in 5x SCC. This kept the chamber RNAse free. After 1 hour the hybridisation buffer was 
replaced with the DIG labelled RNA VEGF-A probe at a concentration of 1µg/ml (either 
anti-sense or sense) and incubated overnight at 60°C within the humidified chamber. To 
prevent the slides from drying out they were wrapped in parafilm.  
The following day slides were rinsed in 2x SCC at 60°C to detach the parafilm. To remove 
any unbound RNA probe, slides were washed in 50% formamide in 0.2 x SCC at 60°C three 
times for 5 minutes. They were then washed in 2x SCC at room temperature twice before 
being washed in NT buffer (see appendix for recipe). Sections were drawn around using 
an ImmEdge® hydrophobic barrier pen (Vector Labs Ltd) and NT block solution (see 
appendix) applied for 30 minutes at room temperature. The sections were subsequently 
probed with an anti-DIG alkaline phosphatase (AP) conjugated Fab fragment antibody (1 
in 2000 dilution) for 2 hours at room temperature. To block any endogenous AP activity, 
sections were then washed twice in TBSTL (200ml tris-buffered saline with TWEEN 20 + 
200µl 2M levamisole) for 15 minutes on a rocker at room temperature. Slides were 
washed in freshly made up APB buffer (see appendix) for 15 minutes at room temperature 
on a rocker; before addition of BM purple AP precipitating substrate which was left on 
overnight in the dark at room temperature.  
The next day, slides were washed in water twice and immersed in Fast red for 2-3 dips to 
stain the nuclei of the cells. Slides were washed again in running water until it ran clean 
and dehydrated in ethanol 50% through to 100%. Slides were immersed in histoclear twice 
for 2 minutes and mounted with DPX under the fume hood. Once dried they were imaged 
under light microscopy.  
3.2.11.7 Electron Microscopy (EM) analysis  
A quarter of kidney tissue harvested from mice at termination was cut up into fine pieces 
and preserved in EM fixative. This was freshly made up each time it was used from equal 
measures (1:1) of 0.2M sodium cacodylate pH 7.4, and  2.5% glutaraldehyde. 500µl of EM 
buffer was used for each kidney. Kidneys pieces were kept in EM buffer at 4°C for at least 
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48 hours before being processed by the Wolfson Bioimaging Facility at the University of 
Bristol. This was to ensure adequate penetration of the buffer into the tissue sections but 
to avoid destruction of the tissue. Samples were subsequently sectioned on an 
ultramicrotome, imaged and analysed by postdoctoral researcher Dr Louise Farmer. Both 
myself and Dr Farmer were blinded to the genotype of the mice during sample 
preparation and analysis. EM images were taken on the Tecnai 12 120kV BioTwin Spirit 
Transmission Electron Microscope scanner in the Wolfson Institute.  
 Blood sampling and analysis 
Blood samples were taken from mice at the time of terminal anaesthesia via cannulation 
of the inferior vena cava. This technique was a new skill for our group which required 
training from Dr Robert Pope (a postdoctoral scientist from Prof. Alastair Poole’s platelet 
research group). It is a technique that was used as standard in this research group that 
requires considerable manual dexterity but was relatively easy to pick up. The exact 
details of the methods involved in blood sampling, analysis of blood samples and the 
generation of blood films is discussed in detail in Chapter 7.  
 Urine collection and analysis 
Urine was collected from all mice at several time points: at baseline (prior to induction 
with doxycycline), again after 14 days of doxycycline or standard drinking water prior to 
IP Shiga toxin or saline sham injection, and pre-termination. Mice were transferred to 
individual cages with hydrophobic sand placed at the bottom (LabSand® purchased from 
Datesand Group). This sand repels liquid, so that any urine excreted by the mice can be 
pipetted up from the surface without contamination. Mice were not left for more than 1 
hour in these individual cages and monitored throughout. At the time of collection, each 
urine sample was tested for microscopic haematuria and proteinuria by urine dipstick, 
using Siemens Multistix 10SG Urinalysis Strips®. This gave me an estimate of whether any 
glomerular injury had occurred.  
To quantify the amount of albumin leak into the urine, albumin creatinine ratios (ACR) 
were performed. Measurement of urinary albumin was performed using an albumin ELISA 
kit from (Bethyl Laboratories Inc). A goat anti-mouse albumin coating antibody supplied 
in the kit was used to coat each well and each standard or sample was run in duplicate. 
The recommended procedure was followed for the ELISA and absorbance was read on a 
plate reader at 450nm. A standard curve was plotted to allow calculation of the albumin 
108 
 
concentration in each urine sample.  To determine the corresponding creatinine content, 
urine samples were sent to Kay Burt at Langford Veterinary Practice for enzymatic 
creatinine analysis. The ACR (µg/mg) could then be calculated by dividing the albumin 
concentration by the creatinine concentration for each sample.  
3.3 Statistical Analysis and Data Handling 
All statistics and graphical figures have been produced using GraphPad Prism V7.0 unless 
otherwise stated. At the beginning of my PhD, I enrolled on a 5 day ‘Introduction to 
Statistics Course’ run by the School of Social and Community Medicine at the University 
of Bristol. This was particularly useful to remind me of the appropriate statistical tests to 
apply according to the nature of the data itself. To assess if my data were normally 
distributed, I used the Shapiro-Wilk Test (available through Prism). If the p value of this 
test was greater than 0.05 a normal distribution was assumed.  
Normally distributed data has been analysed by a student’s unpaired T-test where the 
mean of two independent groups (i.e. unrelated measurements) were tested to 
determine if there was any significant difference between the two groups.  For paired 
observations in the same subject paired T-tests were used. All data are presented as mean 
values +/- SEM (standard error of the mean) as indicated by error bars on graphs where 
relevant. The statistical significance has been displayed on the graphs relative to control 
or baseline values as indicated: *p<0.05, **p<0.005, ***p<0.0005. At the end of each 
figure legend the exact p value obtained for each statistical test is given. 
For data comparisons between multiple groups (i.e. more than two groups) where data is 
normally distributed, a one-way ANOVA has been used. Post-hoc analysis test selection 
was determined by the comparisons being made and where possible Tukey’s Honest 
Significant Difference test was performed. This post-hoc test established where the 
differences between groups identified by the one-way ANOVA were located. The p value 
results of one-way ANOVA and the type of post-hoc analysis carried out is stated in the 
figure legend of each graph.  
Correlations were analysed using Pearson correlation on normally distributed data, and 
Spearman correlation where data could not be assumed to be of normal distribution as is 
conventional. The complex statistical methods employed in the analysis of my proteomic 
datasets that contain thousands of data points have been discussed separately within my 
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proteomic results chapter. The choice of statistical tests used in my proteomic datasets 
was governed by a combination of expertise from the University of Bristol Proteomics 
Facility, the bioinformatic service from Dr Phil Lewis, already published proteomic dataset 
analyses and the freely available statistical software package R. The key in analysing these 
data was to correct for multiple comparisons using the Bonferroni correction. As when 
hundreds or thousands of dependent or independent statistical tests are being performed 
simultaneously, the likelihood of observing a rare event simply by chance increases, 




Chapter 4 : The molecular effects of Shiga toxin on the 
podocyte 
4.1 Introduction 
The in vitro study of cells in culture has a key role in advancing our understanding of the 
molecular pathways involved in human health and disease. There are several advantages 
of in vitro work which include: the ability to control and manipulate the environment to 
allow testing of a specific hypothesis; the scope to perform multiple replicates of an 
experiment to validate results; and the ability to drill down into the mechanistic processes 
occurring in the cell [239]. Historically, in vitro culture of podocytes has been challenging 
as only undifferentiated cells were available and these were of questionable purity. These 
cells were of limited use as they quickly lost expression of their podocyte markers (such 
as synaptopodin) and lost their characteristic foot processes in standard culture 
conditions [223].  
However, in 2002, Saleem et al. developed a conditionally immortalised human podocyte 
cell line by transfection with the temperature sensitive SV40-T gene [223]. At 33°C these 
podocytes proliferate, but upon thermo-switching to 37°C they enter growth arrest and 
differentiate, expressing markers of differentiated human podocytes in vivo [223]. 
Subsequent work by Saleem et al. in our laboratory has led to the generation of 
conditionally immortalised podocyte cell lines from wild type mice [240]. These cells are 
now an established resource in Bristol and considered the gold standard for the in vitro 
study of podocyte biology. Using both human and mouse conditionally immortalised 
podocyte cell lines has allowed me to address one of the key research aims of my PhD: 
determining the cellular mechanisms underlying the action of Shiga toxin in the podocyte.  
4.2 Detection of Gb3 
Essential to this project is the ability to reliably detect Gb3 expression in tissues. Given 
that Gb3 is a glycosphingolipid this has proved challenging as the usual methods of 
detecting a receptor (most often a transmembrane protein) are redundant [241]. 
Furthermore, Kolling et al. have previously shown that fixation of tissues with ethanol 
leads to dissolution of glycosphingolipids including Gb3 [238]. Hence, tissues have been 
dehydrated in acetone as described in the materials and methods chapters to preserve 
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the receptor. As already eluded to in the introduction; it is well established that Gb3 is the 
receptor for Shiga toxin. It is located within host cell membranes and expression of Gb3 
determines how sensitive the cell is to the effects of Shiga toxin [33]. In the following 
sections I will detail the four different methods I have optimised during my PhD to detect 
Gb3 expression both in vitro and in vivo. 
 Detection of Gb3 with immunofluorescence 
Human conditionally immortalised podocytes express the Shiga toxin receptor Gb3. I have 
confirmed this using immunofluorescence (IF). Murine podocytes do not express the Gb3 
receptor (Figure 4-1). However, Gb3 is expressed in the renal tubules of mice and has 
been detected in small quantities in other murine organs [242] (Figure 4-2). Gb3 
expression has also been detected in other human organs including lung, brain, pancreas, 
heart and liver. Hence unsurprisingly, STEC HUS can be complicated by extra renal 




Figure 4-1: IF detection of Gb3 in human podocytes (A) vs. mouse podocytes (B) 
Conditionally immortalised human or mouse podocytes were cultured and IF performed as 
described to detect Gb3 (green). An isotype control antibody confirms that this is specific for Gb3 
expression. DAPI nuclear staining is shown in blue. There is no evidence of Gb3 expression in mouse 









Given that Gb3 is a glycosphingolipid it is unusual to have an antibody that recognises it. 
The antibody used has been widely cited in the literature and is a rat monoclonal anti-
CD77 [238]. The immunogen of the antibody is the Daudi Cell line (Burkitt’s lymphoma) 
(according to the antibody specifications) and so recognises part of the hydrophilic 
carbohydrate region of the glycosphingolipid.  I was concerned that the antibody may not 
recognise murine Gb3 and this may lead to false negative IF staining in mouse podocytes. 
As a result, IF using fresh frozen mouse kidney tissue sections in wild type mice was 
performed which confirmed the antibody could detect murine Gb3 in the renal tubules of 
these mice (Figure 4-2). 
 
 
Figure 4-2: IF detection of Gb3 in wild type mouse kidney tissue 
Fresh frozen kidney sections from wild type mice were prepared for IF as described and probed for 
Gb3 (green); nephrin (red – to identify podocytes outlining the glomeruli) and DAPI stained to 
identify nuclei (blue). Panel A shows Gb3 is located in the tubules of murine kidney and is absent 
from the glomeruli. The section in Panel B was prepared in the same way as Panel A, but without 
a primary antibody for Gb3/nephrin as an auto-fluorescence control for the secondary antibody. 
 
 Detection of Gb3 Synthase (A4GALT) with endpoint PCR 
Two pairs of primers for PCR were designed (as described in my methods chapter) to 
identify expression of the enzyme Gb3 synthase (A4GALT) in either mouse cells or human 
cells. Gb3 RNA could not be detected directly by PCR because it is a glycosphingolipid. Gb3 
synthase catalyses the synthesis of Gb3 from lactosyceramide (Figure 4-3). Endpoint PCR 
confirmed that A4GALT mRNA is present in both human and mouse podocytes (Figure 
4-4). Although A4GALT is present in mouse podocytes, Gb3 itself does not appear to be 




in mouse podocytes, several different mouse cell lines were tested. Mouse podocyte cell 
line 2 (Figure 4-4) appeared to have very little A4GALT mRNA expression. This was a 
primary mouse cell line (compared to the conditionally immortalised mouse podocyte cell 
lines used in the other rows). Primary cell lines are known to more closely resemble cell 
function and morphology in vivo which is likely to explain the discrepancy observed in the 
expression of A4GALT mRNA [244]. The predicted PCR product for the A4GALT primer 
pairs designed was 113 base pairs. This product was subsequently sequenced to confirm 
that the primers were amplifying the A4GALT gene (Figure 4-5). 
 
 
Figure 4-3: The Gb3 Pathway 
Gb3 is synthesized from Lac-Cer (lactosyceramide) by the enzyme Gb3 synthase (A4GALT). All 




Figure 4-4: Endpoint PCR for A4GALT 
Endpoint PCR demonstrates A4GALT mRNA is present in both human and murine podocytes as well 
as human endothelial cells. The expected PCR product size was at 113 base pairs as shown. Given 
A4GALT mRNA was not expected in mouse podocytes, I tested several different mouse cell lines. 
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Mouse podocyte cell line 2 (well 4) appeared to have very little A4GALT mRNA expression. This was 
a primary mouse cell line which is likely to reflect mouse podocyte expression of A4GALT mRNA 
more closely than conditionally immortalised cell lines which explains this difference.  
 
 
Figure 4-5: Endpoint PCR product sequencing 
PCR product sequencing confirmed that the A4GALT gene had been amplified by my primer pairs 
– both in the human (A = top panel) and mouse (B = bottom panel) cells. 
 
 Detection of Gb3 with thin layer chromatography 
Thin layer chromatography (TLC) is considered the gold standard lipid detection method. 
In order to learn this technique, I collaborated with Professor Shamshad Cockcroft (a lipid 
expert based at University College London: UCL). Initially the assay was set up in the 
human cervical cancer Hela cell line, as these are the cells routinely used in the Cockcroft 
laboratory. The technique is dependent upon tritium labelling of sphingosine. This is then 
incorporated into both sphingomyelin and glucosylceramide lipids within the cell. The 
cellular lipid fractions are then separated on a TLC plate according to their relative affinity 
towards the stationary and mobile phase. The samples from the cells of interest run 





The lipid fractions can be reversibly visualised (as shown in Figure 4-6) by placing the TLC 
plate in a bed of iodine crystals within a closed TLC tank within a fume cupboard hood. 
This creates an environment of iodine vapour which will saturate the plate and reveal the 
lipid fractions as yellow/brown bands. It is important not to expose the plate too long as 
iodine may covalently modify polyunsaturated fatty acids. An alternative is to use a glass 
Pasteur pipette with iodine crystals through which dinitrogen is blown over individual 
standard lanes. This circumvents the risk of oxidation of the lipid fraction. This technique 
confirms that separation of the lipid bands has occurred, prior to quantification using a 
scintillation detector. This will detect the presence of any lipids containing tritium labelled 
sphingosine (Figure 4-7). 
 
 
Figure 4-6: TLC plate in Hela cells: proof of concept 
The Gb3 standard was run against the Tritium (3H) labelled HeLa cell samples (rows 1-5). 
Sphingomyelin, PE and PC standards were also run on the same plate as references. The lipid 
fractions can be reversibly visualised as shown here by placing the TLC plate in a bed of iodine 
crystals within a closed TLC tank within a fume cupboard hood. This creates an environment of 
iodine vapour which will saturate the plate and reveal the lipid fractions as yellow/brown bands. It 
is important not to expose the plate too long as iodine may covalently modify polyunsaturated 





Figure 4-7: TLC plate and scintigram: Hela cells 
The only samples that are visible on the scintigram are the Hela cells that have been labelled with 
Tritium. Hence only rows 3 and 4 (indicated by the red box) are seen on the scintigram. By 
overlaying the original TLC plate standards with the scintigram together with the knowledge that 
only complex glycosphingolipids that are synthesized from sphingosine (and therefore Tritium 
labelled will be visualised on the scintigram); the lipid constituents of the HeLa cells can be 
identified as shown: GlcCer = glucosylceramide, LacCer = lactosyceramide, Gb3 = 
globotriaosylceramide, SM = sphingomyelin.  
 
This technique is reproducible and robust in HeLa cells but given podocytes are a 
conditionally immortalised terminally differentiated cell line, I was concerned that tritium 
labelling may prove difficult. Indeed, this technique has not been performed in a 
terminally differentiated cell line before. The cells would need to be labelled whilst 
proliferating prior to thermo-switching. Moreover, using TLC to analyse mouse tissues 
from my in vivo work would not be possible as there is no way of radiolabelling 
sphingosine: meaning a different overlay method such as orcinol spray (which is non-
specific) or Shiga toxin antibody techniques would need to be utilised.  
The use of a Shiga toxin antibody to detect Gb3 would involve using Shiga toxin first, to 
bind to Gb3 on the cell surface, followed by probing the TLC plate with an anti-Shiga toxin 
antibody. This has obvious safety implications (all work involving the toxin must be 
performed in biological cabinet under category 3 facilities due to the potential for harm). 
Given that Shiga toxin cannot be used on the open laboratory bench and the associated 
danger of spillages in placing a TLC plate in a Shiga toxin solution for several hours of 
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incubation; this method of Gb3 detection was decided against. However, an antibody to 
Shiga toxin using a dot blot protocol was tested as a proof of concept, prior to arriving at 
this decision.  
 Dot Blot Assay for Shiga toxin detection 
A dot blot is a straightforward and relatively quick assay to ascertain whether an antibody 
and secondary detection system is working. It is most often employed to determine the 
starting concentration of a primary antibody for western blotting [245]. This assay was 
used as a way of testing whether a Shiga toxin 2 antibody could detect Shiga toxin in 
mouse tissues, as it would not be possible to radio-label Gb3 in vivo. Full details of the dot 
blot protocol used are included in my in vitro methods chapter. The primary antibody used 
was a rabbit anti-Shiga toxin 2 antibody from Quadratech®.  
Lysates were blotted on a nitrocellulose membrane. These were prepared from fresh 
kidney tissue from mice (wild type mice with and without Shiga toxin treatment and Gb3 
KO mice with and without Shiga toxin treatment) as well as a positive control of Shiga 
toxin 2, negative controls of untreated conditionally immortalised human podocytes and 
lysis buffer. To check whether there were any issues with detection from the secondary 
antibody, Shiga toxin 2 antibody was blotted on to the membrane as a positive control for 
my secondary HRP conjugated anti-rabbit antibody. The detection of the secondary 
antibody utilises chemiluminescent detection reagents (purchased from Bio-Rad®) which 
were applied to the membrane, which was subsequently viewed on the Amersham 600 
imager®.  
The dot blot experiment did demonstrate that Shiga toxin can be detected with Shiga 
toxin 2 antibody (Figure 4-8). However, in the kidney lysates prepared from mice that had 
been given IP Shiga toxin the antibody did not detect any toxin. This is likely due to Shiga 
toxin being present in too smaller a concentration to be detected in the tissue at this stage 
in the disease pathogenesis. Mice were injected with 10ng/g of IP Shiga toxin; the 
concentration of Shiga toxin reaching the kidney tissue in mice may therefore be much 
less than 0.1µg/ml (the concentration of Shiga toxin 2 used in the positive control that 
was detectable). Or it may mean that there is no longer any toxin present in the tissue 
once it has undergone processing to make the lysate. Reassuringly, both positive controls 





Figure 4-8: Shiga toxin 2 antibody dot blot 
Shiga toxin can be detected using an anti-Shiga toxin 2 antibody as seen on this blot – dark blue 
spot at the site of sample blot. A nitrocellulose membrane was blotted as described with: Stx 
2=Shiga toxin 2 (Stx 2 at a concentration of 0.1 µg/ml), WT+Stx =WT mouse given IP Stx kidney 
tissue lysate, WT=WT mouse kidney lysate untreated, Gb3 KO+Stx = Gb3 KO mouse given IP Stx 
kidney lysate, Gb3 KO=Gb3 KO mouse kidney lysate untreated, WT podocytes=WT human 
podocytes lysate, lysis buffer, and Stx 2 antibody at a concentration of 100µg/ml. Interestingly, 
Shiga toxin is undetectable in the kidney tissue lysate of the treated mice; which is likely due to 
absence (or very little) Shiga toxin being present in the tissue at this stage in the disease process. 
All samples at a 1 in 10 dilution of the original concentration are undetectable. Row A = 5 µl of 
sample blotted, Row B = 1 in 10 dilution of sample blotted. 
 
 Detection of Gb3 with mass spectrometry 
A more modern and sensitive method of lipid detection is mass spectrometry. Professor 
Cockcroft suggested contacting Dr. Kevin Mills at the UCL Translational Mass 
Spectrometry Centre (TMSC) as his group have optimised an assay for quantifying Gb3 
expression in cells and tissue. The TMSC is one of the leading mass spectrometry centres 
in the UK; utilising proteomic and lipidomic analysis to diagnose and monitor Fabry’s 
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throughout the body) [246]. Cell lysates from human and mouse podocyte cell lines were 
prepared as detailed in my materials and methods chapter and sent to the TMSC at UCL 
where they were analysed for Gb3 content.  
Initial results from the first set of cell lysates sent to the TMSC had much higher levels of 
total Gb3 than anticipated (Table 5, panel A). After discussing this with Dr Mills, it became 
clear that the media used to culture podocytes contained large amounts of Gb3; 
originating from the fetal bovine serum component and that the cells were taking up Gb3 
from the media. Consequently, the experiment was repeated following serum starvation 
of the cells (replacing their media with sterile PBS for 4.5 hours prior to cell lysis). This 
timepoint was chosen because it was the maximal time that podocytes are known to 
tolerate incubation in serum free media before becoming stressed (anecdotal evidence 
from experience of Bristol Renal podocyte group); balanced against a long enough 
duration of serum starvation to prevent Gb3 uptake from fetal bovine serum within 
standard podocyte media. A sample of the podocyte media was also sent to the TMSC for 
mass spectrometry analysis to determine the Gb3 content and allow normalisation of the 
initial samples.  
 
 
Table 5: LC-MS/MS Results for Gb3 in human podocytes 
Human podocytes were grown in podocyte media until 70-80% confluent and thermo-switched to 
37°C to differentiate for 10-14 days before being lysed with RIPA buffer as detailed in the methods. 




isoform is shown in the table. The total Gb3 (CTH) content was considerably higher than expected 
(A). As a result, the experiment was repeated but the podocytes serum starved in PBS for 4.5 hours 
prior to cell lysis. This resulted in a total Gb3 level that was more in-keeping with what would be 
expected (B). Consequently, any further mass spectrometry analysis was performed following 
serum starvation for 4.5 hours to allow comparison between cell lines.  
 
Through combining the Gb3 detection methods outlined, I have been able to confidently 
determine the distribution of Gb3 expression in human and mouse podocyte cell lines. 
These techniques were optimised in vitro to allow subsequent use in vivo to validate my 
mouse models.  
4.3 Human podocytes are sensitive to Shiga toxin 
It is well established that there is an association between the amount of Gb3 expressed 
on the cell membrane and its sensitivity to Shiga toxin [247]. However, increasing 
evidence suggests that the membrane microenvironment consisting of cholesterol, other 
glycolipids and fatty acids also plays a role in Gb3 receptor binding; as the amount of Gb3 
extractable from a tissue does not directly correlate to its sensitivity. It is therefore vital 
to determine how reactive each cell type is when challenged with Shiga toxin not just the 
amount of Gb3 expressed [33]. Based upon previous work performed in our laboratory in 
human podocytes treated with Shiga toxin; the CD50 dose (dose at which 50% of the cell 
population exhibit cytotoxic effects) was 0.01ng/ml (Figure 4-9). Interestingly, human 
podocytes were shown to reduce their percentage protein synthesis to a greater extent 
than that observed in human glomerular endothelial cells at each Stx1 concentration. This 
may be explained by the fact that Shiga toxin has been shown to induce upregulation of 
the Gb3 receptor in podocytes in vitro, rendering them more susceptible to the ribotoxic 
effects of Shiga toxin in vitro (see subsequent experimental data in section 4.4); an effect 
that is not seen in glomerular endothelial cells. In view of these data, the effect of Shiga 
toxin on podocyte viability was studied at two concentrations: 0.01ng/ml (the CD50 dose) 





Figure 4-9: Cellular response to Shiga toxin challenge 
HEK cells, mouse and human podocytes and human glomerular endothelial cells (GEnCs) were 
treated with Shiga toxin (concentrations of 0.01ng/ml to 10ng/ml) for 4 hours and the effect on 
protein synthesis determined. Of note HEK cells do not express the Gb3 receptor and so were the 
negative control cell line in this experiment. Interestingly, human podocytes were shown to reduce 
their percentage protein synthesis to a greater extent than that observed in GEnCs at each Stx1 
concentration. This may be explained by the fact that Stx is known to induce upregulation of the 
Gb3 receptor in podocytes in vitro, rendering them more susceptible to the ribotoxic effects of 
Shiga toxin in vitro (see subsequent experimental data). This effect is not observed in GEnCs. Data 
reproduced with permission from Dr Lindsay Keir. 
 
My initial experiments involved incubation of differentiated human podocytes with 
0.1ng/ml of Shiga toxin in 6 well plates for up to 7 days. The cells were imaged under light 
microscopy on the Leica DMI 6000B microscope (Figure 4-10). The appearance of the cells 
suggested that they were undergoing apoptosis as fewer podocytes were present 
following Shiga toxin treatment. Indeed, previous work by Psotka et al. has demonstrated 
that Shiga toxin mediates caspase-dependent apoptosis in conditionally immortalised 
podocytes [74]. To assess podocyte cell viability in response to 0.1ng/ml of Shiga toxin 
over time triplicate repeat experiments in 96 well plates were performed, using the IN 
Cell Analyser. This confirmed that podocyte cell number (through the use of DAPI staining 
of podocyte cell nuclei) was reduced to 50% following incubation with 0.1ng/ml of Shiga 





Figure 4-10: Light microscopy slides of differentiated human podocytes 
Differentiated human podocytes were incubated with standard podocyte media (A); 0.1ng/ml of 
Shiga toxin (B); and puromycin 2µg/ml for 48 hours (C). In response to Shiga toxin and puromycin 
(a known ER stressor used as a positive control) the podocytes reduced in number.  
 
 
Figure 4-11: Human podocyte cell viability following 0.1ng/ml Shiga toxin treatment 
Differentiated human podocytes were incubated with 0.1ng/ml of Shiga toxin for 0.5-48 hours as 
shown. At 48 hours of incubation cell viability was reduced to 50% vs. media control cells. Known 
ER stressors thapsigargin (at 1mM concentration) and puromycin (at 5µg/ml concentration) were 
used as positive controls with podocytes treated for 48 hours. Results pooled over three 
experiments. *** One way ANOVA Tukey’s multiple comparison test: p<0.0001 vs. media control. 
 
4.4 Shiga toxin upregulates Gb3 expression in human podocytes 
Human podocytes were grown on coverslips in 6 well plates and incubated with 0.1ng/ml 
Shiga toxin for up to 6 hours. Immunofluorescence was then performed to assess Gb3 




this effect, 96 well plate experiments using the INCell microscope were performed. 
Human podocytes were incubated with 0.1ng/ml of Shiga toxin for time points up to 48 
hours, and immunofluorescence analysis performed using an automated programme 
analysis on the IN Cell. This confirmed that Gb3 expression was increased in podocytes 
upon treatment with 0.1ng/ml of Shiga toxin (Figure 4-14). This effect has not been 
described in podocytes before (upon review of current literature). However, it has been 
seen in neuronal cells of patients with Shiga toxin HUS and in dermal microvascular 
endothelial cells [248][84]. Interestingly this effect was not seen in human glomerular 
endothelial cells [95].  
 
 
Figure 4-12: Human podocytes upregulate Gb3 expression in response to Shiga toxin challenge 
Human podocytes incubated with Shiga toxin (0.1ng/ml) for 6 hours show upregulation of Gb3. 
Gb3 (green), DAPI (blue). IgG isotype control antibody was used to confirm primary antibody 





Figure 4-13: IN Cell Gb3 IF staining in human podocytes 
Differentiated human podocytes incubated with Shiga toxin 0.1ng/ml at time 0 (no Shiga toxin 
control) 6 hours and at 48 hours. Gb3 (green), DAPI (blue). 
 
 
Figure 4-14: Gb3 is upregulated in human podocytes in response to treatment with Shiga toxin 
Wild type human podocytes (4000 cells/well) were plated in 96 well IN Cell plates and treated with 
0.1ng/ml of Shiga toxin for 6-48 hours and analysed for Gb3 expression using immunofluorescence. 
AFU values per cell are given. At 6 hours Gb3 expression was significantly higher vs. media control 
cells. Gb3 expression returns to baseline at 24 hours. ***One way ANOVA: Tukey’s multiple 















































Figure 4-15: The Gb3 biosynthesis pathway 
The three glucosyltransferase enzymes required at each stage of Gb3 synthesis are shown. It is 
thought that upregulation of the Gb3 receptor is likely due to an increase in ceramide production 
by the cell in response to stress with subsequent upregulation of the ceramide glucosyltransferase 
enzyme [84].   
 
4.5 Generation of a stable A4GALT knockdown cell line 
The precise pathophysiological mechanisms following Shiga toxin infection leading to 
glomerular TMA are poorly understood. In order to address this, Tandem Mass Tag (TMT) 
proteomic analysis of human podocyte cells exposed to Shiga toxin was performed. In 
order to control for non-specific Gb3 receptor binding I analysed (in parallel) the effects 
of Shiga toxin on an A4GALT knockdown human podocyte cell line. These podocytes were 
generated using ShRNA as detailed in the methods section. Six different clones were made 
using ShRNA and the relative expression of A4GALT in each clone versus wild type control 
podocytes transduced with a non-silencing ShRNA control lentiviral construct was 





Figure 4-16: Relative expression of A4GALT in ShRNA knockdown human podocyte cell lines vs. 
wild type human podocytes 
Across all clones knockdown of A4GALT relative to wild type human podocytes was seen. The 
highest knockdown was apparent in the 140H knockdown clone and so these were taken forward 
in all subsequent experiments. Control = wild type human conditionally immortalised podocytes 
transduced with a non-silencing ShRNA control scramble sequence from Dharmacon. Standard 
error of the mean indicated for each cell line by error bars. ***One way ANOVA, Tukey’s multiple 
comparison test p<0.0007. N= 3 for each cell line. 
 
 Human wild type and A4GALT knockdown podocytes express podocyte 
markers 
Prior to any further experimental work in the A4GALT knockdown cell line, western blot 
analysis to confirm podocyte marker expression once the cells were differentiated was 
performed (Figure 4-17). This confirmed that podocyte markers nephrin and 
synaptopodin were expressed. The second positive control was a dilution of whole mouse 
kidney lysate. This failed to show any bands detectable with any of the antibodies used; 
given that the β-actin loading control failed to show any protein loaded it is most likely 
that this is because of insufficient protein loaded into the well i.e. the 1 in 100 dilution 
was too greater a dilution to allow detection. It could also be a gel loading issue with spill 
over of sample into the previous well. An alternative positive control that could have been 
used is human whole kidney lysate or human glomerular isolates. Of note, the antibodies 
used were reactive in both human and mouse species (see appendix for details). In the 
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negative control glomerular endothelial cell line (GEnC) sample there was much less 





Figure 4-17: Western blot for podocyte markers in mouse and human podocyte cell lines 
All cells were grown in standard culture media (appropriate for the specific cell) and thermo-
switched to differentiate before protein extraction. C2 and 2271 cell lines are mouse podocyte cell 
lines. WT = wild type human podocyte cell line; 140 KD = human podocyte A4GALT knockdown cell 
line; ShRNA control knockdown = scramble ShRNA sequence control cells; +ve control = whole 
mouse kidney lysate at 1 in 10 dilution (1) and 1 in 100 dilution (2); GEnC = human glomerular 
endothelial cell line as a negative control. β-actin loading control shown. Of note, the second 
positive control failed to show any bands detectable with any of the antibodies used; given that 
the β-actin loading control failed to show any protein loaded it is most likely that this is because of 
insufficient protein loaded into the well. It could also be a gel loading issue with spill over of sample 
into the previous well. 
 
 A4GALT knockdown podocytes do not express Gb3 
Immunofluorescence was performed on the ShRNA A4GALT knockdown mutants to 
confirm that they did not express Gb3. Across all three clones (only the high transfection 
clones were tested) immunofluorescence did not detect any Gb3 expression. The 
transfected cells were GFP tagged and so appear green when successfully transfected with 
ShRNA (Figure 4-18). Prior to A4GALT knockdown podocytes being taken forward for use 
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in experimental work, immunofluorescence for Gb3 was repeated alongside wild type 
conditionally immortalised podocytes as a positive control (see Chapter 5). 
 
 
Figure 4-18: IF of A4GALT knockdown human podocytes  
Cells were grown on coverslips and IF performed as described. Cells are green (GFP tagged) in the 
presence of transfection with the ShRNA sequence. The absence of Gb3 staining on 
immunofluorescence is apparent across all 3 clones of A4GALT knockdown podocytes. DAPI = Blue, 
Gb3 = red x40 magnification. 
 
Cell lysates from the A4GALT knockdown cells were sent for mass spectrometry analysis 
at the TMSC at UCL to quantify Gb3 content. Human podocytes and wild type mouse 
podocytes (C2) were cultured simultaneously as controls. All podocyte cell lines were 
serum starved in PBS for 4.5 hours. These samples were blinded and sent to the TMSC to 
avoid bias. An internal standard for Gb3 was added to the cell lysate samples to quantitate 
against which is good practice and allows for any variation in the processing or sample 
analysis. My samples were analysed on the same mass spectrometry run as Fabry’s 
patient samples, meaning that it was quality controlled as per NICE guidelines. Table 6 
shows the results for each cell line (panels A-C).  
Gb3 has been found to exist in several isoforms characterised by fatty acid chain 
modifications and different analogues denoted by modifications on the sphingosine 
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moiety [249]. Indeed, metabolomic studies of Fabry’s patients and mice in the TMSC by 
Dr Mills have shown that the key biologically active isoforms are C24 and C24:1-CTH. 
Interestingly, in vitro studies have shown that Stx binds to C16, C22 and C24 Gb3 isoforms 
but not to C18 or C20 isoforms [250]. Despite total Gb3 (CTH) levels in the A4GALT KD 
cells being only slightly lower than in the wild type human podocytes; when comparing 
the C24 isoform the A4GALT knockdown podocytes contain 50% less than the wild type 
podocytes. Furthermore, the C24 isoform is present in even lower levels in mouse 
podocytes (C2). Given that A4GALT knockdown podocytes and mouse podocytes are 
resistant to Shiga toxin toxicity it is likely that this isoform is key in podocytes in vitro. 
 
 
Table 6: Mass spectrometry analysis of wild type human podocytes vs. A4GALT knockdown 
podocytes vs. wild type mouse podocytes 
Each cell line (A – wild type human podocytes, B – A4GALT knockdown human podocytes, and C – 





starved for 4.5 hours in sterile PBS before being lysed in RIPA buffer and sent (blinded) to the TMSC 
at UCL for mass spectrometry analysis of Gb3 content. Of note, total Gb3 (CTH) levels were lower 
in the A4GALT knockdown and mouse podocytes than wild type controls. The C24 isoform of Gb3 
(circled) is 50% lower in the A4GALT knockdown cells and almost negligible in mouse podocytes. 
 
 A4GALT knockdown podocytes are resistant to the ribotoxic effects of 
Shiga toxin 
To establish whether knockdown of A4GALT in human podocytes resulted in a functional 
resistance to Shiga toxin due to a reduction in Gb3 receptor expression; the knockdown 
cells were treated with Shiga toxin and the effects on cell viability determined. Wild type 
human podocytes and A4GALT knockdown podocytes were seeded in 96 well INCell plates 
at a density of 4000 cells per well, allowed to differentiate for 10-14 days and then treated 
with; standard podocyte media, 0.1ng/ml of Shiga toxin, 1µM of thapsigargin and 5µg/ml 
of puromycin. The effect of each treatment on cell survival was determined by fixing the 
cells and DAPI staining followed by counting total cells present in each well. All 
experiments were performed on three separate occasions (n=3) with technical repeats 
within the same plate.  
Human A4GALT knockdown podocytes incubated with Shiga toxin 0.1ng/ml for 48 hours 
showed no statistical difference in cell viability versus media control wild type podocytes 
or media control A4GALT knockdown podocytes. In contrast, wild type human podocytes 
demonstrate a 50% reduction in viability when incubated with 0.1ng/ml Shiga toxin for 48 
hours versus media control conditions. Of note, A4GALT knockdown podocytes also 
contain a puromycin resistance gene which accounts for the observed statistically 
significant difference between the knockdown cells versus wild type podocyte cell viability 
when treated with puromycin for 48 hours. Thapsigargin was used as a positive control 
for ER stress. At this dose thapsigargin did not result in a change in podocyte viability 
(Figure 4-19) but was shown to cause a rise in ER stress markers on western blotting 
(Figure 4-22).  
It is an interesting observation that not all of the human wild type podocytes die (a 50% 
cell death rate is seen) when incubated with Shiga toxin 0.1ng/ml. These results highlight 
the heterogeneity of the podocyte response. This can be explained by the fact that the 
dose of Shiga toxin used was informed by protein synthesis assays in podocytes following 
Shiga toxin treatment at a range of doses. A reduction in protein synthesis does not 
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necessarily correlate with cell toxicity. Secondly, from my IF work, it is evident that not all 
podocytes appear to express Gb3 receptor at baseline; although, Gb3 expression does 
increase with Shiga toxin treatment. A further experiment that could be performed would 
be to evaluate effect of co-treatment with pro-inflammatory cytokine TNF-α and Shiga 
toxin on podocytes which may increase toxicity. Interestingly, previously published work 
has shown that in glomerular endothelial cells Shiga toxin alone or with TNF-α does not 
increase Gb3 receptor expression or lead to increased toxicity [95]. 
 
 
Figure 4-19: A4GALT knockdown podocytes are resistant to Shiga toxin ribotoxicity 
Wild type human podocytes (WT) demonstrate a 50% reduction in cell viability vs. media control 
when treated with 0.1ng/ml of Shiga toxin (Stx) which is statistically significant (One way ANOVA 
Tukey’s multiple comparison test ***p<0.0001).  A4GALT knockdown podocytes (Gb3 KD) were 
resistant to the ribotoxic effect of Shiga toxin versus wild type podocytes (WT) and exhibit 
resistance to puromycin due to the presence of a puromycin resistance gene to allow selection for 
knockdown clones. Thapsigargin was used as a positive control for ER stress. At this dose 
thapsigargin did not result in a change in podocyte viability but was shown to cause a rise in ER 
stress markers on western blotting (Figure 4-22Figure 4-19). One way ANOVA Tukey’s multiple 
comparison test: *p<0.05 *** p<0.0001. Data representative of 3 experiments performed on three 



























































































 A4GALT knockdown podocytes are resistant to Shiga toxin at higher 
doses 
Given that A4GALT knockdown podocytes were resistant to 48 hours of treatment with 
0.1ng/ml Shiga toxin, these cells were treated with increasing doses of Shiga toxin for 48 
hours and cell viability reassessed (Figure 4-20). At all concentrations tested the A4GALT 
knockdown podocytes were resistant to the ribotoxicity of Shiga toxin; even at x1000 the 
lethal dose in podocytes (100ng/ml). These experiments were performed using the INCell 
analyser in triplicate. 
 
 
Figure 4-20: Dose response in A4GALT knockdown podocytes treated with Shiga toxin for 48 
hours 
At all concentrations of Shiga toxin A4GALT knockdown podocytes were resistant to toxicity at 48 
hours: n=3. One way ANOVA with Tukey’s multiple comparison test was not significant between 
all treatment groups.  
 
 A4GALT knockdown podocytes do not upregulate Gb3 expression 
following Shiga toxin treatment. 
Given the observation that wild type human podocytes upregulate Gb3 expression in 
response to Shiga toxin treatment after 6 hours, I wanted to determine whether the 
A4GALT knockdown podocytes did the same. Wild type human podocytes or A4GALT 
knockdown podocytes were plated onto 96 well INCell plates at a density of 4000 cells per 


















































analysed for Gb3 expression using anti-Gb3 antibody immunofluorescence as previously 
described. A4GALT knockdown podocytes showed 50% less Gb3 expression (quantified 
using AFU / cell) on the IN Cell analyser at baseline vs. wild type human podocytes. This 
did not change with Shiga toxin treatment (Figure 4-21). 
 
 
Figure 4-21: Gb3 expression in WT podocytes vs. A4GALT KD podocytes following treatment with 
Shiga toxin 0.1ng/ml for 6-48 hours 
A4GALT knockdown podocytes show 50% less Gb3 expression (quantified using AFU / cell) on the 
IN Cell analyser at baseline vs. wild type human podocytes. This did not change with Shiga toxin 
treatment. One way ANOVA: Tukey’s multiple comparison test ***p<0.001. N=3. 
 
 Wild type podocytes treated with Shiga toxin upregulate endoplasmic 
reticulum (ER) stress markers  
Wild type human podocytes and A4GALT knockdown podocytes were treated with Shiga 
toxin 0.1ng/ml for 2 hours and 4 hours in 6 well plates. Cell lysates were obtained, and 
western blot analysis performed to determine the timing of ER stress responses to Shiga 
toxin treatment versus control media treatment for 4 hours. Antibodies for the 
transcription factor CHOP (CCAAT-enhancer-binding protein homologous protein) and 
phospho IRE were used to assess ER stress response. Western blot analysis suggests an 
increase in ER stress response at 4 hours with no change in ER stress response in A4GALT 
knockdown podocytes (Figure 4-22). The ER stress pathway response in human 
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conditionally immortalised podocytes treated with Shiga toxin will be discussed further in 
the following chapter: Proteomic analysis. 
 
 
Figure 4-22: ER stress response to Shiga toxin treatment WT vs. A4GALT KD podocytes 
Wild type podocytes show an increase in CHOP and phospho-IRE expression in response to 
treatment with Shiga toxin 0.1ng/ml at 2 and 4 hours vs. A4GALT knockdown podocytes. B actin 
expression is shown as a protein loading control. Wild type podocytes were treated with 
Thapsigargin as positive control (red) and both media control, untreated wild type podocytes and 
A4GALT podocytes were used as a measure of baseline ER stress activity within the cells.  
 
4.6 Discussion 
This chapter has focused upon the molecular effects of Shiga toxin on the podocyte. 
However, it is worth noting that human glomerular endothelial cells also express the Gb3 
receptor and are sensitive to the ribotoxic effects of Shiga toxin. Gb3 immunofluorescence 
on human glomerular endothelial cells was performed during optimisation of the Gb3 
antibody; which confirmed expression (Figure 4-23). However, mouse glomerular 
endothelial cells do not express Gb3 and are resistant to Shiga toxin cytotoxicity [1].  
Work  performed by a previous PhD student in our laboratory has already demonstrated 
that human podocytes are significantly more sensitive to Shiga toxin in vitro than human 
glomerular endothelial cells (Figure 4-9). Furthermore, evidence of in vivo damage to the 
podocyte in Shiga toxin HUS in humans has been suggested by the presence of 
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podocyturia in children with Shiga toxin HUS [251]. However, conventionally Shiga toxin 
HUS has been thought of as an endothelial cell disease. Central to the research hypothesis 
of my project is that the podocyte is an initiator of the disease process. Therefore, it is the 
role of the podocyte (which is exquisitely sensitive even to low doses of Shiga toxin) that 
will remain the central focus of this thesis.  
 
Figure 4-23: IF detection of Gb3 in human glomerular endothelial cells  
Conditionally immortalised glomerular endothelial cells were cultured and Gb3 detected by IF. Gb3 
is shown in green, DAPI nuclear staining is shown in blue. Isotype control antibody confirms that 
the staining seen is specific for Gb3 expression. 
 
Of note, immunofluorescence for Gb3 in wild type human podocytes at baseline 
demonstrated that only a subset of human podocytes expressed Gb3 (Figure 4-1). This 
may be related to the detection method itself (Gb3 is known to cluster within lipid raft 
sections of the plasma membrane in vitro) which may have affected epitope recognition 
by the antibody used for immunofluorescence [63]. Or it may be representative of 
podocyte Gb3 expression in vitro; and explain the reason why only 50% of podocytes were 
affected in the cell viability assays performed (Figure 4-11). Fascinatingly, Shiga toxin 
treatment of these wild type human podocytes in vitro was unexpectedly found to 
increase Gb3 receptor expression. This effect was not seen in the A4GALT knockdown 
podocyte cell line. Moreover, in vitro studies into the effect of Shiga toxin treatment in 
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glomerular endothelial cells performed by Obrig et al. did not result in an upregulation of 
Gb3 receptor expression or lead to an increase in cytotoxicity in these cells either [95]. 
Through the optimisation of three different techniques, I have demonstrated that human 
podocytes express the Shiga toxin receptor Gb3. IN Cell experiments have provided a high-
throughput, robust method to compare the effect of Shiga toxin on human podocytes and 
A4GALT knockdown podocytes. The generation of a novel Gb3 knockdown podocyte cell 
line has shown the importance of the Gb3 receptor in determining the sensitivity of a cell 
to Shiga toxin ribotoxicity; as podocytes lacking Gb3 are resistant to Shiga toxicity in vitro. 
Going forward, this cell line will act as a control for non-specific, non-Gb3 receptor binding 
in proteomic studies in wild type human podocytes; allowing further interrogation of the 




Chapter 5 : Proteomic Analysis 
5.1 Introduction 
Proteomics is a rapidly evolving technology that involves the identification and 
quantification of the protein content of a cell, tissue or organism under specific 
experimental conditions [252]. Upon the completion of the Human Genome project in 
2003, it was hoped that the complete sequencing of all 20,500 human genes would hold 
the key to understanding genetic inheritance and disease [253]. However, in the last few 
decades it has become apparent that the genotype and phenotype of an organism is not 
solely directed by the information contained within the genome [254][255]. Epigenetics, 
alternative splicing, microRNAs, and post-translational modifications are just few 
examples of the way in which the expression of the genome is modified without any 
change in the underlying DNA sequence itself [254]. Therefore, the use of proteomics to 
understand how cells function and communicate through protein to protein signalling 
networks, is arguably a much more informative method of gaining an insight into the 
biological processes occurring within the cell [254]. 
In order to elucidate the glomerular mechanisms underlying the action of Shiga toxin 
associated HUS; total and phospho-proteomic studies in conditionally immortalised 
human podocytes following incubation with 0.1ng/ml Shiga toxin at 0.5 hours and 6 hours 
were performed. To control for non-specific, non-Gb3 receptor binding, the proteomic 
changes in a stable human podocyte Gb3 receptor knockout cell line were also studied 
under the same experimental conditions. A4GALT knockdown cells were generated using 
short hairpin siRNA against Gb3 synthase as detailed in my methods. The characterisation 
of this cell line was described in the previous results chapter. The ultimate aim of this 
proteomic work was to identify novel pathways activated in the podocyte following Shiga 
toxin treatment using a non-biased approach. The experimental conditions, bioinformatic 
processes and results from my proteomic analysis are detailed below.  
5.2 Methodology of proteomic analysis 
The proteomic facility at the University of Bristol was used to analyse my samples. The 
department uses liquid chromatography mass spectrometry (LC-MS) to perform total TMT 
(tandem mass tag) and phospho-TMT proteomics using the Orbitrap Fusion Lumos Mass 
Spectrometer (Thermo Scientific®). Tandem mass tags are isobaric amine-specific 
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chemical tags, that allow concurrent mass spectrometry analysis of multiple samples in a 
single experimental run. For my experiment, the maximum available 10-Plex format was 
employed to analyse 10 different samples within the same TMT run. The isobaric labels 
used consisted of a reporter group and mass normaliser; with each reporter group having 
a defined mass. Once labelled all of the samples were pooled together and during liquid 
chromatography separation they co-elute, because they possess the same chemical 
properties. The samples were then fractionated using basic reverse phase 
chromatography and each fraction analysed by acidic reverse phase nano liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  
Fragmentation of the amine-specific chemical tag occurs releasing the reporter ions which 
can then be used to identify and quantify the peptides. Protein quantification is extremely 
accurate between samples because it is calculated using the median values of multiple 
peptides identified from the same protein [256][257]. The use of synchronous precursor 
selection triple-stage mass spectrometry (SPS-MS3) which is in-built on the Orbitrap 
Fusion mass spectrometer; provided additional accuracy in the quantification of proteins 
in my samples without reducing the number of proteins identified [257]. Indeed, SPS-MS3 
has been well documented to reduce interference from reporter ion mass regions and 
interference from co-isolation of precursor ions [257][258].  
Proteome DiscovererTM version 2 (Thermo Scientific®) was used to compare the raw data 
generated from my TMT proteomic analysis to several databases including FASTA and 
peak-finding search engines including SequestTM. This downstream data processing was 
performed by the University of Bristol Proteomic department, to generate an excel 
spreadsheet of raw data files with Uniprot™ protein accession numbers of the mass 
spectra digested fragments from the experiment. These raw data files were then sent to 
me for analysis. One issue that can be encountered with the Proteome DiscovererTM 
software is that some of the protein accession numbers that are generated have protein 
descriptions that are vague or uncharacterised; meaning they are unrecognisable by 
pathway analysis software used downstream. The University of Bristol Proteomic 
department have developed a method to streamline the annotation of the protein 
accession number without compromising on quantification stringency. This method was 
employed by the university prior to sending me the raw data files; improving protein 
identification from 60 to 80% and ensuring that my data was easier to interpret using 
pathway analysis databases.  
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Ingenuity Pathway Analysis software (IPA) was used to determine the biological relevance 
and relation between proteins identified in my proteomic experiments. Alternative 
software that can be used includes: DAVID, KEGG and Webgestalt; but IPA is considered 
the gold-standard software for pathway analysis. IPA takes into consideration the effect 
of each protein on cell function and predicts whether it has been activated or inhibited by 
the change in abundance observed. It also suggests which disease states, treatments or 
protein activation events may have contributed to these changes [259][260]. A series of 
network maps are generated by the IPA software which have been included later in this 
chapter. Subsequent validation of any interesting protein interactions identified by IPA 
using a variety of methods including western blotting, RT-PCR, IF and in-situ hybridisation 
were then performed.  
Prior to uploading the total and phospho-proteomic dataset to IPA software, my results 
were filtered to include only proteins that had a false discovery rate (FDR) of 1% (i.e. a 
confidence interval 99%). In both datasets all proteins and phospho-proteins with empty 
abundance ratios were removed, along with any common contaminants. Most 
contaminants that were found in the proteomic dataset originated from either the 
reagents used to generate the samples (such as trypsin) or from the operator (such as 
keratin from hair / skin). These can be identified fairly easily as they are frequently found 
in proteomic analysis. The University of Bristol proteomic department has created a 
bespoke list of common contaminants that were used to identify and exclude 
contaminants within my dataset. This resulted in more efficient data analysis and is a well-
established method that has been published by other groups [261].  
5.3 Experimental design  
Proteomic analysis was performed using a 10-Plex format so that all samples could be 
processed within a single TMT proteomic run. The benefit of this is that any differences 
between the samples would not be attributable to differences in TMT run. Conditionally 
immortalised human podocytes and A4GALT knockdown human podocytes were cultured 
according to standard protocol (see in vitro methods chapter) and thermo-switched to 
37°C to differentiate for 10-14 days before experimental use. Each ‘n’ number of cells 
represents a different passage number of the cell lines used and a different experimental 
day. Wild type (WT) conditionally immortalised human podocytes and A4GALT 
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knockdown human podocytes were treated with 0.1ng/ml Shiga toxin for 0.5 hours or 6 
hours (see Table 7 for summary of samples included in the proteomic analysis).  
The A4GALT knockdown podocyte cell line was used as a control for non-specific, non-
Gb3 receptor binding. To ensure these were true controls for the experiment they were 
treated in exactly the same way as the wild type podocytes and protein lysates taken on 
the same day. Ideally, as another control for this experiment, proteomic analysis of 
untreated WT human podocytes vs. untreated A4GALT knockdown human podocytes 
would have also been performed. This would help to delineate any differences due to 
knockdown of Gb3 vs. Shiga toxin treatment itself. However, I was limited by the number 
of samples possible for each TMT run (maximum of 10) and huge cost implications of 
multiple proteomic analysis: hence, these controls were not included in this experiment. 
A summary of my experimental approach is shown Figure 5-1. 
 
 
Table 7: Summary of samples included in Proteomic TMT run 
Ten samples were included in a single proteomic TMT run. Each sample is shown in the table 
alongside the experimental condition used. Total and phospho-proteomic analysis was performed 
and the mean abundance for each condition calculated.  
 
Sample Cell line Condition
1 A4GALT KD 1 0.1ng/ml Stx 0.5 hrs
2 A4GALT KD 2 0.1ng/ml Stx 0.5 hrs
3 WT pod 1 0.1ng/ml Stx 0.5 hrs
4 WT pod 2 0.1ng/ml Stx 0.5 hrs
5 WT pod 3 0.1ng/ml Stx 0.5 hrs
6 WT pod 4 0.1ng/ml Stx 0.5 hrs
7 WT pod 5 0.1ng/ml Stx 6 hrs
8 WT pod 6 0.1ng/ml Stx 6 hrs
9 WT pod 7 0.1ng/ml Stx 6 hrs




Figure 5-1: Summary of experimental design 
Conditionally immortalised wild type human podocytes (with the Gb3 receptor present: red circles) 
and A4GALT knockdown human podocytes (no Gb3 receptor) were cultured in standard podocyte 
conditions and  treated with 0.1ng/ml of Shiga toxin for 0.5 or 6 hours. Protein lysates were then 
prepared, and protein content quantified using a BCA. Sample lysates were then taken on dry ice 
to the University of Bristol Proteomic facility for analysis. Podocytes from figure adapted from 
Kidney International article: ‘From podocyte biology to novel cures for glomerular disease’ [262]. 
 
5.4 Quality control of proteomic samples  
Prior to performing any proteomic analysis, a series of quality control checks were 
performed to ensure that the cell lines used were behaving phenotypically and 
functionally as intended. Protein content was also quantified in the sample lysates prior 
to proteomic analysis. 
 Confirmation of A4GALT knockdown  
For each T175 cell culture flask of human podocytes cultured for proteomic analysis (both 
WT and A4GALT knockdown), two 6 well plates were simultaneously seeded. One on glass 
coverslips and the other without. This allowed immunofluorescence for Gb3 to be 
performed for each sample to be included in the proteomic analysis and treatment of the 
cells with Shiga toxin. This confirmed that the WT and A4GALT knockdown podocytes 
were responding as expected to Shiga toxin. My previous experimental work investigating 
the effects of Shiga toxin on the podocyte was particularly beneficial here. The A4GALT 
knockdown podocytes should be resistant to Shiga toxin and at a dose of 0.1ng/ml 50% 
A4GALT knockdown 
human podocytes
WT human podocytes Shiga toxin 
treatment 








of the WT podocytes should undergo apoptosis. Once this had been confirmed that the 
podocyte cell lines cultured were behaving as expected, I could confidently send my 
protein lysates to the proteomic facility for analysis.  
 
 
Figure 5-2: Immunofluorescence for Gb3 in A4GALT knockdown podocytes confirms Gb3 
knockdown (x20) magnification 
Immunofluorescence was performed in A4GALT knockdown human podocytes (A) and WT human 
podocytes (B) prior to samples being sent for proteomic analysis. The A4GALT knockdown cells had 
no identifiable expression of Gb3 using an anti-Gb3 antibody (red). A4GALT knockdown cells have 
a GFP tag (this is present in the lentivirus construct used to transfect the cells) and acts as a reporter 
to confirm the lentivirus is present. WT podocytes expressed Gb3 and did not contain a GFP tag. 










Figure 5-3: Immunofluorescence for Gb3 in A4GALT knockdown podocytes and WT podocytes 
(x40) magnification 
Immunofluorescence was performed in A4GALT knockdown human podocytes (A) and WT human 
podocytes (B) prior to samples being sent for proteomic analysis. The A4GALT knockdown cells had 
no identifiable expression of Gb3 using an anti-Gb3 antibody (red). A4GALT knockdown cells have 
a GFP tag (this is present in the lentivirus construct used to transfect the cells) and acts as a reporter 
to confirm the lentivirus is present. WT podocytes expressed Gb3 and did not contain a GFP tag. 
These images are at x40 magnification and represent another n number and are representative of 
all samples sent for proteomics.  
 
 
Figure 5-4: Wild type human podocytes treated with Shiga toxin undergo cell death 
Six well plates confirmed that WT podocytes used in my proteomic experiment underwent 
apoptosis in response to Shiga toxin 0.1ng/ml. A = differentiated podocyte appearance on light 
microscopy at baseline prior to any Shiga toxin treatment shows the characteristic foot process 
extension and confluency of the cells. B = Shiga toxin (0.1ng/ml) treated podocytes after 48 hours 
of Shiga toxin incubation with evidence of loss of confluency and cell death. C = Shiga toxin 
(0.1ng/ml) treated podocytes after 7 days of incubation. Very few healthy cells left – swollen and 
detached cells seen on light microscopy. Images are representative of all samples sent for 










Figure 5-5: A4GALT knockdown podocytes are resistant to Shiga toxin treatment 
Six well plates confirmed that A4GALT knockdown human podocytes used in my proteomic 
experiment were resistant to Shiga toxin incubation even following incubation with Shiga toxin for 
7 days. A = differentiated A4GALT podocyte appearance on light microscopy at baseline prior to 
any Shiga toxin treatment shows the characteristic foot process extension and confluency of the 
cells. B = Shiga toxin (0.1ng/ml) treated A4GALT podocytes after 48 hours of Shiga toxin incubation 
with no obvious change in appearance. C = Shiga toxin (0.1ng/ml) treated podocytes after 7 days 
of incubation. Cells remain confluent and healthy. Images are representative of all samples sent 
for proteomic analysis.  
 
 Protein Quantification  
To perform proteomic analysis the department at Bristol University requires at least 
100µg of protein in each sample at a concentration of at least 2µg/µl. Prior to sending 
lysate samples to the proteomic department a BCA (BiCinhoninic Acid) assay was 
performed to estimate the protein content (see methods for details). The protein content 
of each sample was sent to the proteomic facility, which allowed them to ensure there 
was enough protein present and meant that they could adjust the volume of sample 
loaded to ensure the same concentration of protein in each sample in the TMT run (Table 
8). 
The BCA assay is one of the most sensitive commercial protein quantification assays 
available and has less variability than other methods (e.g. Bradford assay) [263]. However, 
it is known that the presence of chemical modifications such as methylation of proteins 
can affect the accuracy of the assay [263]. Moreover, there will be unavoidable inherent 
error in the loading of each sample associated into the mass spectrometer. Therefore, it 
is important to determine whether the protein abundance in each sample used in the 
proteomic analysis was similar to that of the pooled control sample and normalise 
accordingly. A PhD student in our group Mark Graham wrote an R script (R is a free 




sample relative to the pooled sample. This R script generates a box plot for each individual 
sample (or n number), with the median protein abundance indicated by the line through 
the centre of each box. The error bars are set to the R default (Q3 upper line of box +1.5 
x IQR) and (Q1 lower line of box +1.5 x IQR). Where IQR is the interquartile range. This 
analysis was performed post LC-MS/MS and showed minimal differences in the total 
protein abundance between samples; with the exception of sample 6. The same R script 
was run for the phospho-proteomic samples and a similar pattern was observed.  
In order to achieve normalisation for the total protein samples, another R script written 
by Mark Graham was used to align the protein abundance for all proteins within each 
sample against the pooled sample median protein abundance. This statistical correction 
involves identifying the total amount of protein detected in each sample and calculating 
a ‘normalisation factor’ for each sample. So that the total protein in each sample is equal,  
each protein detected in the proteomic run is multiplied by the normalisation factor, 
which corrects for any errors in total protein loading. This normalisation is performed on 
the assumption that the total protein in each sample is the same [264].  
Normalisation of phospho-proteomic samples cannot be achieved in the same way 
because differences are expected in phospho-peptide abundance between samples. 
Instead, the ‘normalisation factor’ calculated for the total protein is applied to the 
corresponding phospho-peptide. Any aberrations in the quantification of the protein will 
be reflected in the phospho-peptide as the TMT samples are mixed, before a portion of 
the sample is extracted for phospho-peptide analysis. Thus, the relative abundance of the 
phospho-peptide is as a fraction of the total protein i.e. the protein-normalised phospho-
peptide abundance. It is vital to perform this normalisation prior to interrogation of any 
results to ensure each dataset has a common scale, avoiding bias by bringing all variables 
into the same range. Since the distribution of these data is unknown normalisation is 





Table 8: Protein quantification of proteomic samples by BCA assay 
BCA assay was performed to quantify the protein concentration in each sample prior to proteomic 
analysis. To perform proteomic analysis the department at Bristol University requires at least 
100µg of protein in each sample at a concentration of at least 2µg/µl. Of note the protein content 
of each sample was similar, with all samples containing enough protein to be included in the TMT 
run.  
 
Sample Cell line Condition Protein concentration 
(µg/µl)
1 A4GALT KD 1 0.1ng/ml Stx 0.5 hrs 3.09
2 A4GALT KD 2 0.1ng/ml Stx 0.5 hrs 2.98
3 WT pod 1 0.1ng/ml Stx 0.5 hrs 3.11
4 WT pod 2 0.1ng/ml Stx 0.5 hrs 3.14
5 WT pod 3 0.1ng/ml Stx 0.5 hrs 2.86
6 WT pod 4 0.1ng/ml Stx 0.5 hrs 2.64
7 WT pod 5 0.1ng/ml Stx 6 hrs 2.61
8 WT pod 6 0.1ng/ml Stx 6 hrs 2.69
9 WT pod 7 0.1ng/ml Stx 6 hrs 2.66




Figure 5-6: Total TMT and phospho TMT data normalisation 
Boxplots generated using R script written by Mark Graham, show the total protein abundance pre-
normalisation (A) and post normalisation (B). These were corrected post LC-MS/MS to allow for 
sample loading error. Panels C and D show the phospho TMT data pre-normalisation and post-
normalisation respectively. Quantification pre-normalisation shows the samples (1-10) are fairly 
similar apart from sample 6. The open circles beyond each whisker (error bar) are proteins beyond 
the R default range: (Q3 upper line of box +1.5 x IQR) and (Q1 lower line of box +1.5 x IQR). Where 
IQR is the interquartile range. 
 
5.5 Proteomic analysis results 
A total of 7459 proteins and 4462 phospho-peptides were identified from my proteomic 
analysis. These were listed in the datasets sent to me by the University of Bristol 
























































proteomic department. As previously eluded to, these data were then filtered to include 
only proteins and phospho-peptides with an FDR (false discovery rate) of 1% (i.e. 
confidence interval of 99%). Following normalisation of the total protein dataset (using 
an R script as already discussed) scaling was performed. This was performed on a protein 
by protein basis and uses the pool sample as a reference (where the pool is made up of 
each individual sample in the proteomic run added together).  
Scaling expresses the protein abundances for each protein in each TMT run as relative 
quantities around the pool sample which is set to 100. So, by definition every pool protein 
is 100 across each TMT run and as such is equal. Each protein in each TMT run is scaled 
against the pool so that if there are any changes in the mass spectrometer’s ability to 
identify a protein between runs this would be corrected for, as by definition it is reflected 
within the pool protein abundance. The scaled total protein abundance was then Log2 
transformed to bring these data closer to a normal distribution. This also makes it easier 
to interpret the outcome of fold change (a negative number representing downregulation 
and positive upregulation); rather than a ratio which is a harder concept to visualise.  
In the phospho TMT dataset, phospho-peptides of proteins absent in the total protein 
dataset were removed, as well as peptides with empty abundance values. This simplifies 
downstream computational analysis. The median protein-adjusted phospho-peptide 
abundance was calculated by subtracting the corresponding scaled protein abundance 
from the scaled phospho-peptide abundance (both Log2 transformed to bring them closer 
to a normal distribution). This enabled identification of genuine changes in 
phosphorylation rather than changes in the overall abundance of a protein whose 
phosphorylation level remains unchanged. There were 1946 phospho-peptides remaining 
in the dataset at the end of this filtering process. These data could then be represented 
as a fold change and charted in a volcano plot against -Log10 p-value.  
P values were calculated by Welch’s t-test, used in preference to a Student’s t-test as 
normal variance cannot be assumed in my datasets. The t-test was performed on the 
median protein adjusted phospho-peptide abundances of each experimental condition, 
e.g. WT podocytes treated with Shiga toxin for 0.5 hours vs. A4GALT knockdown 
podocytes treated with Shiga toxin for 0.5 hours. The same t-test was performed in the 
total protein TMT dataset: using the median scaled protein abundance (of the master 
protein identified by Uniprot) in each experimental condition. Once the p-value was 
calculated it was -Log10 transformed as convention to facilitate charting in a volcano plot. 
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These plots allow easy visualisation of statistically significant up or downregulated 
proteins and phospho-peptides. In each comparison, a few proteins or phospho-peptides 
of potential interest have been named. These have been summarised in tables and a 
description of their function described.  
However, given the vast number of proteins and phospho-peptides identified statistical 
analysis with t-tests alone results in a high false discovery rate (type 1 error) due to multi-
variate analysis. To overcome this, a Benjamini Hochberg analysis was performed and 
used these corrected p-values to generate volcano plots. The Benjamini Hochberg method 
is a highly stringent tool that uses a serial modified  Bonferroni correction to facilitate 
multiple hypothesis testing and can be used when the test statistic is known to be 





Figure 5-7: Total protein abundance volcano plots 
Volcano plots showing total protein abundance changes in A - wild type (WT) podocytes vs. A4GALT 
knockdown podocytes, both treated with Shiga toxin for 0.5 hours; B – wild type (WT) podocytes 
treated with Shiga toxin for 6hrs vs. 0.5hrs. Blue vertical lines indicate Log2 +/- 0.5 fold change and 
blue horizontal lines indicate the p <0.05 threshold, corrected for multiple comparisons using a 
Benjamini-Hochberg false discovery rate of 0.1. Red boxes indicate the proteins that are 
statistically significant. On each volcano plot a few proteins that reach statistical significance have 
been named - these are described in Table 9. 






















































Table 9: Description of statistically significant proteins identified in total proteomic dataset 
Statistically significant proteins identified from my total proteomic dataset volcano plots are listed. 
Proteins in blue are from the WT podocytes vs A4GALT knockdown podocytes treated with Stx for 
0.5hr comparison. Proteins in red are from the WT podocytes treated with Stx for 6hrs vs. WT 
podocytes treated with Stx for 0.5hrs. Interestingly, in this dataset no proteins were statistically 
significantly downregulated.  
 
Protein (gene name) Direction of fold change Function
CRIP1 down Immune response/ intracellular zinc 
transport 
PLCD1 down Production of DAG (diacylglycerol) and IP3 
(inositol 1,4,5-trisphosphate)
CDKN1B down Inhibition of cell cycle
TGM2 up Blood vessel remodelling  / positive 
regulation of inflammatory response
LCP1 up Activation of T cells
MMP2 up Angiogenesis and remodelling of 
vasculature
PDCD4 up Apoptosis / cellular response to LPS 
(lipopolysaccharide)
TXNIP up Transcription repressor
NDUFS1 up Apoptotic mitochondrial changes
ATPMD up Mitochondrial membrane ATP synthase




Figure 5-8: Phospho-peptide abundance volcano plots 
Volcano plots showing phospho-peptide abundance changes in A - wild type (WT) podocytes vs. 
A4GALT knockdown podocytes, both treated with Shiga toxin for 0.5 hours; B – wild type (WT) 
podocytes treated with Shiga toxin for 6hrs vs. 0.5hrs. Blue vertical lines indicate Log2 +/- 0.5 fold 
change and blue horizontal lines indicate the p <0.05 threshold, corrected for multiple comparisons 
using a Benjamini-Hochberg false discovery rate of 0.1. Red boxes indicate the phospho-peptides 
that are statistically significant. On each volcano plot a few phospho-peptides that reach statistical 





















Phospho-peptide abundance WT vs A4GALT KD 0.5hr Stx
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Table 10: Description of statistically significant phospho-peptides in phospho-proteomic dataset 
Statistically significant phospho-peptides identified from my phospho-proteomic dataset volcano 
plots are listed. Proteins in blue are from the WT podocytes vs A4GALT knockdown podocytes 
treated with Stx for 0.5hr comparison. Proteins in red are from the WT podocytes treated with Stx 
for 6hrs vs. WT podocytes treated with Stx for 0.5hrs.  
 
Volcano plots are a useful way of visualising the entire total protein or phospho-peptide 
dataset generated from my proteomic experiment. Interestingly, the proteins up-
regulated in the WT podocytes treated with Shiga toxin for 0.5 hours vs. A4GALT 
knockdown controls are associated with the inflammatory response and angiogenesis. WT 
podocytes treated with Shiga toxin for 6 hours show an increase in proteins associated 
with apoptosis and mitochondrial damage. These changes would be expected given the 
already published work investigating the effects of Shiga toxin on the kidney [33].  
Interpretation of the phospho-peptide changes are slightly more complex to delineate; as 
phosphorylation is not always a direct measurement of protein activation, given most 
kinases have both activating and inhibiting phosphorylation sites. Thus, to check the effect 
of each phosphorylation the PhosphoSitePlus™ website was used; which also gives an 
indication of the most likely phosphorylation site within the peptide of interest which is 
useful for validation studies involving the use of antibodies (e.g. western blotting).  
Protein (gene name) Direction of fold change Function
SNRNP down mRNA splicing
HMGA2 down Transcriptional regulator
BAG down Negative regulator of apoptosis
PGRMC1 up Neutrophil degranulation
ASHNAK down Epithelial cell polarity
NUCKS1 down DNA repair
NPC2 up Cholesterol homeostasis / 
phospholipid transport
RAI14 up Actin binding / cell 
differentiation
PHLDB2 up Cadherin binding
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 STRING pathway analysis 
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) is a free web-based 
resource for predicting protein to protein interactions [266]. STRING version 11 (available 
at https://string-db.org) was used to perform pathway enrichment analysis of my 
datasets. STRING achieves enrichment through the use of detailed biochemical pathway 
databases (Gene Ontology (GO) and KEGG (Kyoto Encyclopaedia of Genes and Genomes)) 
but also offers new classification systems through hierarchical clustering of the identified 
networks themselves [266][267]. The protein interactions that are described by STRING 
are both direct physical interactions and indirect functional interactions [266]. These 
interactions are organised into one of 7 ‘channels’ which can be enabled or disabled by 
the user to customise the output of the enrichment pathway analysis [266]. The protein 
to protein interactions are scored (taking into account the need for multiple testing 
correction) to generate an approximate confidence in the strength of an association. 
STRING uses this score to provide the user with a false discovery rate (FDR) [267]. 
Examples of the protein association networks generated by STRING using my datasets for 
total and phospho-peptide TMT proteomics are shown in Figure 5-9 to Figure 5-11. These 
results were filtered to include proteins or phospho-peptides with fold changes more than 
+/- 2; and an FDR of 1% (i.e. high confidence of the strength of the observed interaction 
being true). Lines connecting the protein nodes (circles) indicate predicted protein to 
protein interactions. Blue interconnecting lines are from existing databases and pink lines 
are those that have been experimentally defined. Nodes that contain drawings of proteins 
represent proteins that have known 3D structures [266]. 
STRING pathway analysis was consistent with my volcano plot data analysis. The 
predominant effects of Shiga toxin in the wild type vs. the A4GALT knockdown podocytes 
was to increase proteins and phospho-peptides associated with the immune response and 
apoptosis and decrease proteins and phospho-peptides associated with the cell cycle and 
DNA replication and repair. These findings are representative of current published 




Figure 5-9: STRING network diagram of total proteins with a fold change > +2 in WT vs A4GALT 
knockdown podocytes treated with Stx 0.5hrs 
STRING network diagram showing the significant nodes and protein interactions that are altered 
in the wild type podocytes vs. the A4GALT knockdown podocytes treated with Shiga toxin for 
0.5hrs. Proteins were filtered on an abundance of > +2 fold change. Blue interconnecting lines are 
from existing databases and pink lines are those that have been experimentally defined. Nodes 
that contain drawings of proteins represent proteins that have known 3D structures. Pathways 
highlighted are those involving ribosomal biogenesis, rRNA processing, actin cytoskeleton 
remodelling and cell assembly.  
 
Proteins of interest (that featured in the functional enrichment table produced by STRING not 
shown) included: Protein S100-A8 which plays a prominent role in the regulation of inflammatory 
processes and immune response. Importantly, this protein is a member of the S100 proteins that 
activate the NLRP3 inflammasome complex [268]. The significance of the NLRP3 inflammasome is 
discussed later in this chapter. Another enriched protein included WDR36 which is involved in T-






Figure 5-10: STRING network diagram of total proteins with a fold change of > -2 in WT vs. 
A4GALT knockdown podocytes treated with Stx 0.5hrs 
STRING network diagram showing the significant nodes and protein interactions that are altered 
in the wild type podocytes vs. the A4GALT knockdown podocytes treated with Shiga toxin for 
0.5hrs. Proteins were filtered on an abundance of > -2 fold change. Pathways highlighted are those 
involving RNA degradation and DNA replication; which are reflective of the changes identified in 













Figure 5-11: STRING network diagram of phospho-peptide proteins with a fold change > +/-2 in 
WT podocytes vs. A4GALT knockdown podocytes treated with Stx 0.5 hrs 
A = STRING network diagram showing the significant nodes and phospho-peptide interactions that 
are altered in wild type podocytes vs. the A4GALT knockdown podocytes treated with Shiga toxin 
for 0.5hrs. Proteins were filtered on an abundance of > +/- 2 fold change. The black box indicates 
the key pathways and has been zoomed in on in panel B. C = an example output table generated 
by STRING detailing the GO and KEGG enrichment pathway analysis. Key pathways highlighted 
include immune response, RNA degradation and mismatch repair. This is in-keeping with my 
volcano plot data and consistent across my experimental data. 
 
 Ingenuity Pathway Analysis (IPA) 
Another form of pathway analysis software used in proteomics is Ingenuity Pathway 
Analysis (IPA) which is considered the gold-standard. This is because IPA takes into 
consideration the effect of each protein on cell function and predicts whether it has been 
activated or inhibited by the change in abundance observed. It is able to do this, by 
drawing from a large database of published work to correlate differences in expression 
with differences in activation state. In the network maps generated by IPA, red and green 
nodes are up and down regulated proteins (respectively) within the dataset and orange 
and blue are up and down regulated proteins predicted by the IPA software from the 
expression values of related proteins.  
The phospho-peptide dataset analysis is slightly more complex as phosphorylation cannot 
always be assumed to be a direct measurement of protein activation. Hence, the software 




networks between conditions were generated across the total report and canonical 
pathway data generated by the IPA software and these correlated with the function / 
disease read-outs to give a consistent picture of the global phosphorylation state of the 
protein networks which was reassuring. Furthermore, IPA data analysis was in-keeping 
with my STRING pathway analysis which is further evidence of reproducibility of the 
analysis. In the case of the phospho-peptide IPA network maps, red and green nodes are 
proteins where the phosphorylation fold change is higher or lower than the total protein 
abundance fold change respectively. Orange and blue nodes are predicted up or down-
regulated phosphorylation fold changes relative to the total protein abundance if 
phosphorylation is assumed to be activating.   
It is important to note, that the data downloaded on to the IPA software was filtered,  
normalised and scaled as described above in the ‘Protein quantification’ and ‘Proteomic 
analysis results’ sections. It is vital to maintain the same methods of data processing prior 
to obtaining results from IPA so that they can be compared to other types of analysis I 
have used. These datasets were sent to Pedro Moura a PhD student working for Dr. Ash 
Toye in the School of Biochemistry at the University of Bristol. Pedro was familiar with the 
use of the IPA software and large datasets generated from proteomic experiments; he 
was blinded to avoid any bias in his IPA analysis. The reports generated from IPA included 
network maps, total reports and in-depth analysis of the diseases and functions 
associated with changes in total and phospho-peptides in each experimental condition. 
These outputs were then used together with my previous analysis in STRING to come up 
with key proteins and phospho-peptides for validation through western blotting, PCR, and 
in-situ hybridisation. Also included in the IPA analysis is a comparison of the pathways 
activated in wild type human podocytes treated with Shiga toxin for 6 hours versus the 





Figure 5-12: IPA network map and summary of top canonical pathways in WT vs. A4GALT 
knockdown podocytes treated with Shiga toxin for 0.5hr: total protein 
Human WT vs. A4GALT knockdown podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr and 




this protein network map which shows the key changes in total proteins that occur in the WT 
podocytes vs. the A4GALT knockdown podocytes treated with Shiga toxin. Key target proteins are 
located centrally within the protein network. Red and orange proteins are being upregulated. Blue 
and green proteins are being downregulated. Of interest in this dataset is the increase in ER stress 





Figure 5-13: IPA network map and summary of top canonical pathways in WT podocytes treated 
with Shiga toxin for 6hrs vs. 0.5hr: total protein 
Human WT podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr or 6hrs and the protein 




network map which shows the key changes in total proteins that occur. Key target proteins are 
located centrally within the protein network. Red and orange proteins are being upregulated. Blue 
and green proteins are being downregulated. Of interest in this dataset is the reduction in VEGF-A 






Figure 5-14: IPA network map and summary of top canonical pathways in WT podocytes treated 
with Shiga toxin for 6hrs vs. A4GALT knockdown podocytes treated with Shiga toxin for 0.5hr: 
total protein 
Human WT podocytes were treated with 0.1ng/ml Shiga toxin for 6 hours and A4GALT knockdown 
podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr and protein lysates analysed by TMT 
LC-MS/MS. IPA software was used (as described) to generate this protein network map which 
shows the key changes in total proteins that occur in the WT podocytes vs. the A4GALT knockdown 
podocytes treated with Shiga toxin. Key target proteins are located centrally within the protein 
network. Red and orange proteins are being upregulated. Blue and green proteins are being 
downregulated. Of interest in this dataset is the increase in ER stress markers (ERK1/2 and MAPK 
pathways) and pro-inflammatory cytokines IL-17 and IL-22 in the WT podocytes vs. A4GALT 
knockdowns. Notably, these networks are similar to those activated in the IPA analysis of wild type 
podocytes treated for 0.5 hours with Shiga toxin vs. A4GALT knockdown podocytes also treated 





Figure 5-15: IPA network map and summary of top canonical pathways in WT vs. A4GALT 




Human WT vs. A4GALT knockdown podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr and 
the protein lysates analysed by TMT LC-MS/MS. IPA software was used (as described) to generate 
this protein network map which shows the key changes in phospho-peptides that occur in the WT 
podocytes vs. the A4GALT knockdown podocytes treated with Shiga toxin. Key target proteins are 
located centrally within the protein network. Red and orange proteins are being upregulated. Blue 
and green proteins are being downregulated. Of interest in this dataset is the apparent 





Figure 5-16: IPA network map and summary of top canonical pathways in WT podocytes treated 
with Shiga toxin for 6hrs vs. 0.5hr: phospho-peptides 
Human WT podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr or 6hrs and the protein 
lysates analysed by TMT LC-MS/MS. IPA software was used (as described) to generate this protein 
network map which shows the key changes in phospho-peptides that occur. Key target proteins 




Blue and green proteins are being downregulated. Of interest in this dataset is the increase in 
apoptosis pathways: BCLAF-1, caspases and Jnk. 
 
 
Figure 5-17: IPA network map and summary of top canonical pathways in WT podocytes treated 





Human WT podocytes were treated with 0.1ng/ml Shiga toxin for 6 hours and A4GALT knockdown 
podocytes were treated with 0.1ng/ml Shiga toxin for 0.5hr and protein lysates analysed by TMT 
LC-MS/MS. IPA software was used (as described) to generate this protein network map which 
shows the key changes in phospho-proteins that occur in the WT podocytes vs. the A4GALT 
knockdown podocytes treated with Shiga toxin. Key target proteins are located centrally within the 
protein network. Red and orange proteins are being upregulated. Blue and green proteins are 
being downregulated.  
 
Of interest in this dataset is the increase in ER stress markers (ERK1/2 and MAPK pathways) which 
were also a feature in the total protein IPA analysis in these cells. Interestingly, HIPPO signalling 
and insulin receptor signalling both feature in the top canonical pathways; just as in the IPA 
phospho-proteomic analysis of wild type podocytes treated for 0.5 hours with Shiga toxin vs. 
A4GALT knockdown podocytes also treated with Shiga toxin for 0.5 hours (Figure 5-15).  
 
5.6 Validation of protein networks 
As evident from my proteomic work, tandem mass spectrometry has the ability to 
generate thousands of fragment ion spectra which are then assigned to peptide and 
phospho-peptide sequences. The extrapolation of these data to the likely proteins they 
represent as well as the determination of their relative abundance in the sample analysed; 
represent a significant statistical and bioinformatical challenge which can be approached 
in many different ways [269]. In this chapter, I have outlined the methodology used to 
analyse my dataset. However, it is widely acknowledged by the proteomic expert 
community that additional experimental validation for MS derived data is necessary [269] 
[270]. Through the use of other protein quantification methods including western blotting 
and digoxigenin (DIG)-labelled RNA probe in situ hybridization, the presence of several 
proteins of interest identified from my LC-MS/MS experiments have been validated. 
After careful review of the volcano plots, STRING networks and IPA analysis from this 
proteomic experiment, I decided to focus my validation work on the following key 
proteins and pathways: endoplasmic reticulum (ER) stress pathways which appear to 
increase in response to Shiga toxin in wild type human podocytes vs. A4GALT knockdown 
podocytes; slit diaphragm and actin cytoskeleton proteins such as CD2AP which seem to 
decrease in response to Shiga toxin treatment; inflammasome proteins which appear to 
increase in response to Shiga toxin in wild type human podocytes and VEGF-A which has 
been identified as decreasing in response to Shiga toxin treatment in human conditionally 
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immortalised podocytes. I have selected these pathways because they are likely to 
represent the most biologically relevant mechanisms behind Shiga toxin HUS, rather than 
simply choosing those proteins which were identified as being highly abundant in my 
samples. This serves to ensure that my results are valid and relevant – the very reason 
why I am performing validation work itself [270].  
 ER stress pathway validation 
It is widely accepted in the published literature that Shiga toxin causes the activation of 
ER stress pathways and ribotoxic stress responses in eukaryotic cells [33][66]. In my 
proteomic dataset these pathways were activated in conditionally immortalised human 
podocytes vs. A4GALT knockdown podocytes treated with Shiga toxin which is perhaps 
unsurprising but also reassuring; indicating that Shiga toxin treatment was having an 
effect in my cells. This in itself provides evidence in support of any other identified 
pathways from this work to be ‘true’ responses to Shiga toxin treatment within the 
podocyte.    
Activation of ER stress pathways within the podocyte leads to MAPK (mitogen-activated 
protein kinase) signalling which is known to be essential for innate immunity and 
regulation of apoptotic pathways [66]. Indeed, Psotka et al. have previously demonstrated 
that the MAPK p38 pathway is activated, along with JNK (Jun N-terminal protein kinase) 
in human glomerular cells in response to Shiga toxin exposure [74]. The activation of these 
pathways resulted in cytokine release, inflammatory kinase activity and caspase-
dependant apoptosis [74]. A summary diagram of the ER stress response is shown in 
Figure 5-18, illustrating 3 key signalling pathways which include PERK, ATF6 and IRE1. 
These kinases target XBP1 and molecular chaperones such as GRP78 (BiP) to signal to the 
cell to either survive or undergo apoptosis. The western blots performed to identify the 
activation of the ER stress response in the wild type podocytes treated with Shiga toxin 
are shown in the subsequent figures. All densitometry calculations are based upon an n=3 
unless otherwise stated.  
Western blot analysis of ATF6, pIRE and GRP78 did not show any statistically significant 
differences between wild type human podocytes and A4GALT KD podocytes treated with 
Shiga toxin. However, there was a trend observed towards an increase in these markers 
of ER stress in the wild type podocytes treated with Shiga toxin at both 0.5 and 6 hours 
vs. A4GALT knockdown podocytes treated with Shiga toxin at 0.5 and 6 hours. Further ‘n’ 
numbers are likely to give rise to a statistically significance in the densitometry 
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measurements of these proteins. Interestingly, the transcription factor CHOP was 
significantly upregulated in the wild type podocytes treated with Shiga toxin for 2 hours 
vs. A4GALT knockdown podocytes treated with Shiga toxin at 2 and 4 hours. This is 
evidence in support of my proteomic analysis that ER stress pathways are activated 
leading to apoptosis in the human podocyte in response to Shiga toxin treatment.  
 
 
Figure 5-18: Summary of ER stress response within eukaryotic cells 
Activation of ER stress (for example from Shiga toxin exposure) leads to activation of one of 3 key 
signalling pathways ATF6, IRE1 or ATF6. These kinases target the binding protein XBP1 which 
triggers the release of molecular chaperones GRP78 and PDI in an attempt to support protein 
folding within the cell. Increased ER stress in podocytes is known to result in cell death by apoptosis 
(via the transcription factor CHOP / or release of caspases) if the function of the ER cannot be 





Figure 5-19: Western blot validation of ATF6 driven ER stress activation in podocytes treated with 
Shiga toxin 
Panel A shows a representative western blot analysis (n=2 shown) for ATF6 driven ER stress 
activation together with β actin loading control. A concentration of 0.1ng/ml of Shiga toxin was 
used for each incubation. Positive control = WT podocytes treated with known ER stressor 1µM 
thapsigargin. Panel B shows the densitometry fold change in ATF6 across experimental conditions. 
Fold change has been calculated following initial normalisation of each sample to its corresponding 
to β actin loading control, with subsequent normalisation to untreated WT or A4GALT KD 
podocytes respectively (i.e. all WT lysate samples were normalised to untreated WT and all A4GALT 
KD samples were normalised to untreated A4GALT KD). There were no statistically significant 

























































































































































































experiment where ATF6 increases within 0.5hr of Shiga toxin and further at 1 and 2 hrs of 
incubation. This work was used to inform the timepoints selected in my proteomic experiment.  
 
 
Figure 5-20: Western blot validation of pIRE driven ER stress activation in podocytes treated with 
Shiga toxin 
Panel A shows a representative western blot analysis (n=2 shown) for pIRE driven ER stress 
activation together with β actin loading control (corresponding to the second pIRE blot). A 
concentration of 0.1ng/ml of Shiga toxin was used for each incubation. Positive control = WT 
podocytes treated with known ER stressor 1µM thapsigargin. Panel B shows the densitometry fold 
change in pIRE across experimental conditions. Fold change has been calculated following initial 
normalisation of each sample to its corresponding to β actin loading control, with subsequent 
normalisation to untreated WT or A4GALT KD podocytes, respectively. There was no statistically 
significant difference between the samples on ANOVA testing.  
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Figure 5-21: Western blot validation of CHOP driven apoptosis due to ER stress activation in 
podocytes treated with Shiga toxin 
Panel A shows a representative western blot analysis for CHOP driven apoptosis due to ER stress 
activation together with β actin loading control. A concentration of 0.1ng/ml of Shiga toxin was 
used for each incubation. Positive control = WT podocytes treated with known ER stressor 1µM 
thapsigargin. Panel B shows the densitometry fold change in CHOP across experimental conditions 
(n=4). Fold change has been calculated following initial normalisation of each sample to its 
corresponding to β actin loading control, with subsequent normalisation to untreated WT or 
A4GALT KD podocytes, respectively. There was a statistically significant increase in CHOP between 
the WT podocytes treated with Shiga toxin for 2 hours vs. the A4GALT KD podocytes treated with 
Shiga toxin for 2 hours and 4 hours as indicated on the graph. One way ANOVA Tukey’s multiple 
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Figure 5-22: Western blot validation of GRP78 activation due to ER stress in podocytes treated 
with Shiga toxin 
Panel A shows a representative western blot analysis (n=2 shown) for GRP78 (molecular weight 75 
kDa) driven ER stress activation together with β actin loading control. A concentration of 0.1ng/ml 
of Shiga toxin was used for each incubation. Positive control = WT podocytes treated with known 
ER stressor 1µM thapsigargin. Panel B shows the densitometry fold change in GRP78 across 
experimental conditions. Fold change has been calculated following initial normalisation of each 
sample to its corresponding to β actin loading control, with subsequent normalisation to untreated 
WT or A4GALT KD podocytes, respectively. There was no statistically significant difference between 





































































































































































































 Actin cytoskeleton and cell assembly pathway validation 
CD2-associated protein (CD2AP) was identified as decreasing in wild type human 
podocytes treated with Shiga toxin for 0.5 hr vs. A4GALT knockdown human podocytes in 
my proteomic analysis. CD2AP was initially characterised as a T-cell adaptor protein, until 
further experimental work demonstrated that it was present in the podocyte slit 
diaphragm and directly interacted with nephrin [272]. CD2AP knockout mouse models 
have shown that lack of CD2AP leads to glomerulosclerosis and lethal renal failure at 6 
weeks of age [273]. This has been shown to be due to an increase in podocyte apoptosis 
due to activation of p38 MAPK pathway by TGF-β [273]. Furthermore, mice with a 
heterozygous CD2AP deficiency are more susceptible to FSGS and in humans CD2AP splice 
mutations have been described in focal segmental glomerulosclerosis (FSGS) patients 
[272]. Clearly, CD2AP is vital for normal podocyte function, but the role of this protein in 
human disease and how to prevent podocyte injury resulting from CD2AP deficiency is yet 
to be fully established [273].  
To date, this is the first time that CD2AP has been shown to decrease in response to Shiga 
toxin treatment in podocytes. Western blotting for CD2AP confirmed that this protein is 
downregulated in podocytes following Shiga toxin treatment vs. A4GALT knockdown 
podocyte control cells. This was statistically significant on one way ANOVA testing only 
after the wild type podocytes had been treated with Shiga toxin for 6 hours. Further n 
numbers may help to demonstrate a reduction in CD2AP at 0.5 hours between these two 
cell lines. It is worth noting that although immunoblotting is a very useful technique to 
provide supportive evidence for the abundance of a particular protein or phospho-
peptide identified in a proteomic dataset; it is not without its own inherent error. There 
are many variations in the technique that can affect the outcome, not to mention the 
complexities of quantification using densitometry [274]. However, taken together with 
my proteomic IPA pathway analysis CD2AP may well be a potential cellular target for 





Figure 5-23: Western blot validation of CD2AP reduction in wild type podocytes treated with 
Shiga toxin 
Panel A shows a representative western blot analysis (n=1 shown) for CD2AP together with β actin 
loading control. A concentration of 0.1ng/ml of Shiga toxin was used for each incubation. Panel B 
shows the densitometry fold change in CD2AP across experimental conditions (n=3). Fold change 
has been calculated following initial normalisation of each sample to its corresponding to β actin 
loading control, with subsequent normalisation to untreated WT or A4GALT KD podocytes 
respectively. There was a statistically significant reduction in CD2AP between the WT podocytes 
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podocytes, A4GALT KD podocytes treated with Shiga toxin for 0.5hrs and the A4GALT KD podocytes 
treated with Shiga toxin for 6 hrs. One way ANOVA Tukey’s multiple comparison test *p=0.01.  
 
 Inflammasome activation validation 
A recurrent theme from my proteomic dataset was an increase in proteins and phospho-
peptides associated with the inflammatory response. Given that Shiga toxin originates 
from a bacteria and is one of the most potent biological toxins ever described this is 
perhaps not unexpected [63]. Of particular interest in my proteomic dataset was the x5 
fold increase in protein S100-A8; also found to be enriched on STRING pathway analysis 
in human wild type podocytes versus A4GALT knockdown podocytes, both treated with 
Shiga toxin for 0.5 hours (Figure 5-9). This protein belongs to the S100 family of which are 
known to activate NLRP3 (NOD-like receptor family pyrin domain-containing 3) 
inflammasome [268]. In the last 10 years there has been great advancement in the 
understanding of the innate immune response to infection, most notably the discovery of 
the inflammasome. These are large protein complexes classified by their sensor protein 
[275]. Interestingly, the NLRP3 inflammasome has recently been shown to be involved in 
the development various acute and chronic kidney diseases through molecular pathways 
that regulate inflammation, apoptosis, and fibrosis [276].  
Given the growing interest in NLRP3 in the nephrological community, I decided to test the 
samples from my experiment for NLRP3. Unfortunately, despite multiple attempts to 
validate the presence of this inflammasome complex in the protein lysates, I was unable 
to demonstrate a significant increase in NLRP3. A representative western blot is shown in 
Figure 5-24. In this case there is a detectable band at the correct molecular weight for 
NLRP3 but on repeated attempts either no band was detectable or the immunoblot 
required over exposure which impacts upon the accuracy of any subsequent densitometry 
measurements. Going forward further optimisation of western blotting for NLRP3 using 
this antibody or use of another will be necessary. Western blotting could also be used to 
detect protein S100-A8 directly.  
The issues experienced with western blotting could be for several reasons including: the 
reactivity of the NLRP3 antibody that I was using for which western blotting is highly 
dependent; protein to protein interactions within the sample lysate which can cause 
protein aggregation and altered molecular weights that differ from those anticipated; or 
an erroneous assumption that the actin ‘housekeeping gene’ has remained relatively 
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unaltered in response to the cellular stress response to Shiga toxin (which may not be the 
case given other cytoskeletal proteins such as CD2AP have been found to change) [270]. 
However, the β actin loading control blot in Figure 5-24 would be against the latter. In 
fact, some proteomic experts believe that for all of these reasons western blotting is not 
a satisfactory approach to validating proteomic datasets [270].  
I agree that it is important to remember that validating a single data point within a MS 
dataset is not the same as whole dataset authentication. To ensure the latter, what is 
necessary is robust statistical and bioinformatic processes which can be used to confirm 
the quality of the dataset overall [270]. By utilising the expertise of the bioinformaticians 
in the Proteomic Facility at the University of Bristol, I have been able to ensure my analysis 
has well defined and understood FDR values as well as confirming that the observed 
enrichment of proteins and phospho-peptides are due to the experimental conditions 
imposed [270].    
Nonetheless, it remains an interesting finding that in this proteomic dataset the protein 
S100-A8  was found to be upregulated in human podocytes in response to Shiga toxin; 
suggesting that NLRP3 activation may occur in podocytes as a result of Shiga toxin 
treatment. This observation builds upon already published work that has reported 
activation of NLRP3 in a variety of acute and chronic kidney disease models including 
ischaemic-reperfusion injury, diabetic nephropathy and crystal-induced fibrosis [277]. Of 
particular interest are recent research findings from Lee et al. demonstrating Gb3-
dependent Shiga toxin endocytosis activates the NLRP3 inflammasome promoting release 
of IL-1Β, caspase 1-dependent pyroptotic cell death and activation of caspase 8/3-
dependent apoptosis in Shiga toxin treated THP-1 cells [278]. This group also showed that 
short hairpin RNA (siRNA) knockdown of NLRP3 in THP-1 cells treated with Shiga toxin led 
to abolition of apoptosis and pro-inflammatory cytokine release [278]. This suggests that 
the cellular mechanism through which Shiga toxin regulates the increase in production of 
pro-inflammatory cytokines is via the NLRP3 inflammasome pathway [278]. Thus, small 
molecule inhibitors targeting NLRP3 and other inflammasome pathways might prove to 





Figure 5-24: Western blot validation of NLRP3 activation in wild type podocytes treated with 
Shiga toxin 
Western blotting for NLRP3 and β actin was performed on conditionally immortalised human 
podocyte protein lysate samples (both WT and A4GALT KD) incubated with 0.1ng/ml Shiga toxin 
for either 0.5 hr or 6 hrs as indicated. There was no statistically significant increase in the 
abundance of NLRP3 in wild type human podocytes treated with Shiga toxin vs. A4GALT knockdown 
podocytes. An n=2 is shown as indicated.  
 
 Decreased VEGF-A validation  
IPA analysis of wild type human podocytes treated with Shiga toxin for 6 hours showed a 
reduction in VEGF-A in comparison to wild type human podocytes treated with Shiga toxin 
for 0.5 hours in my dataset. Given that it is already widely accepted that VEGF-A is critical 
in the regulation of angiogenesis and vascular permeability in the glomerulus this was a 
particularly interesting finding and one that I decided to pursue [25]. Work in recent years 
from Quaggin et al. has confirmed that the podocyte is the main source of VEGF-A in the 
glomerulus and that the glomerular endothelium is dependent upon tight regulation of 
VEGF signalling to function physiologically [25].  
Indeed, in homozygous VEGF-A null mice lethal vascular defects are seen at 10 days of age 
and in mouse models of podocyte specific VEGF-A over-expression a collapsing 
glomerulopathy leading to end-stage renal failure occurs [214]. Of particular significance, 
is a seminal paper from Quaggin et al. in the New England Journal of Medicine in 2008, 
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thrombotic microangiopathy (TMA) [11]. This was presented alongside human data where 
cancer patients treated with the VEGF-A inhibitor bevacizumab also developed 
glomerular lesions consistent with TMA [11]. Hence, the finding that VEGF was reduced 
in human podocytes in response to Shiga toxin treatment warrants further investigation 
as this may prove to be important in the development of TMA in Shiga toxin HUS.  
Initial work aiming to validate this finding from my proteomic dataset involved western 
blot analysis and immunofluorescence of human wild type podocytes treated with Shiga 
toxin for 0.5 and 6 hours. However, these methods failed to detect VEGF-A in my cells 
despite several attempts with various available commercial antibodies, different 
concentrations of these antibodies, and the use of various blocking agents. Published 
work to detect VEGF-A levels has utilised cytometric bead array analysis, ELISA and in-situ 
hybridisation [11][222]. Unfortunately, these techniques are difficult to employ in cell 
culture work. I also attempted to detect VEGF receptor 2 (VEGFR2) in human podocytes 
treated with Shiga toxin vs. untreated controls and normal human kidney tissue sections. 
VEGFR2 is the key receptor for VEGF-A as it mediates almost all of the known cellular 
response. Representative IF images of my attempts at detection of VEGFR2 in human 
podocytes and human kidney tissue are shown in Figure 5-25.  
 
 
Figure 5-25: VEGFR2 immunofluorescence (x20 magnification) 
Panel A shows immunofluorescence for VEGFR2 (green) in wild type, untreated human 
conditionally immortalised podocytes. No signal was detectable in these cells – representative 
image shown. Panel B shows a representative image of immunofluorescence for VEGFR2 (green) 





Attempts at VEGF-A ELISA on the supernatant from conditionally immortalised podocytes, 
glomerular endothelial cells and both cells co-cultured together in trans-well experiments 
have failed to detect a signal. This could be due to issues with the capture antibody, 
insufficient detector antibody or incorrect dilutions amongst other causes. However, the 
same ELISA for VEGF-A detection in plasma and urine samples from patients with Shiga 
toxin HUS enrolled in the ECUSTEC clinical trial (ISRCTN89553116) as well as controls 
performed in our laboratory have detected VEGF-A successfully. This suggests that levels 
of VEGF-A in cell culture may be somewhat less than those measured in patient samples 
or that culture conditions are influencing the detection of VEGF-A.  
It is also possible that there may be no VEGF-A present in the supernatant from my cell 
culture experiments. It is worth noting that patient plasma samples will not reflect local 
VEGF-A in the glomerulus but rather systemic VEGF-A levels and so it is difficult to draw 
conclusions from these data. Urine samples are also difficult to interpret without 
normalisation to protein or albumin excretion given the effects of renal tubular secretion 
and uptake. Of note, most patients with Shiga toxin HUS become oligoanuric which will 
inevitably have an effect on the information that can be obtained from urine analysis in 
patients vs. controls [1]. Preliminary results from VEGF-A ELISA of patient and control 
plasma and urine are shown in Figure 5-26. This provides confirmation that the ELISA is 
able to detect VEGF-A when present.  
 
 
Figure 5-26: VEGF-A ELISA in patient samples preliminary ECUSTEC trial data 
Shiga toxin HUS patient plasma and urine samples vs. healthy controls taken during the ongoing 
ECUSTEC clinical trial were analysed for VEGF-A concentration using an R&D® systems Human 






































































and normal VEGF-A levels for urine are 30pg/ml. Samples taken on day of presentation to 
secondary care (Day 1) and consecutive days thereafter. N=2 for each sample taken so no statistical 
analysis performed. Difficult to draw any conclusion form these data but they do demonstrate that 
the ELISA can detect VEGF-A. Samples processed and analysed as part of the ECUSTEC trial by Dr 
Louise Farmer in our laboratory (data reproduced with permission). 
 
DIG-labelled in situ hybridisation is a highly sensitive and specific method that can be used 
to detect VEGF-A in kidney tissue sections. This technique was performed in my 
experimental mouse model of Shiga toxin HUS using an RNA probe kindly gifted from 
Professor Quaggin’s laboratory (for full details of the in situ hybridisation protocol please 
see my methods chapter). Briefly, fresh frozen kidney sections from PodrtTA-Tet-O-Gb3 
Gb3 null mice and PodrtTA-Tet-O-WT Gb3 null control mice (both of which had been given 
intraperitoneal Shiga toxin 10 days prior to elective termination) were assessed for 
expression of VEGF-A in their glomeruli. This involved the use of a VEGF-A RNA probe 
labelled with digoxigenin. This system utilises digoxigenin (a steroid isolated from digitalis 
plants) that are the only known source of digoxigenin in nature. Thus, anti-DIG antibodies 
will not bind to any other biological material in the experimental sample ensuring 
specificity of the technique. Due to this high sensitivity only a small volume of the 
specimen is required which is particularly well suited to nucleic acid hybridization 
methods [279]. Detection of the DIG-labelled probe is by anti-DIG antibodies coupled to 
alkaline phosphatase which will precipitate when they come into contact with BM purple 
solution. This purple colour can be visualised under light microscopy.  
In situ hybridisation for VEGF-A in the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin 
showed a reduction in detectable signal compared to PodrtTA-Tet-O-WT Gb3 null control 
mice (Figure 5-27). This is evidence that in my mouse model of Shiga toxin HUS there was 
a reduction in VEGF-A, which is consistent with the IPA analysis of my proteomic 
experiment in human conditionally immortalised podocytes. Further work is needed to 
confirm this observation, through the optimisation of the VEGF-A ELISA in human cell 
culture work (e.g. by repeating VEGF-A ELISA experiments to include a known positive 
control such as patient plasma); as well as further in situ experiments in fresh frozen 





Figure 5-27: VEGF-A in situ hybridisation 
In situ hybridisation using a DIG labelled VEGF-A RNA probe was performed in fresh frozen kidney 
tissue sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin (Panel A) vs. PodrtTA-
Tet-O-WT Gb3 null control mice also given Shiga toxin (Panel B). Mice were electively terminated 
at Day 10 and kidneys harvested for analysis. In situ hybridisation showed a lack of VEGF-A positive 
staining in the glomeruli of PodrtTA-Tet-O-Gb3 Gb3 null mice vs. controls. This supports my 
proteomic dataset IPA work, confirming a reduction in VEGF-A in a mouse model of Shiga toxin 
HUS. In situ performed on an n=3 of each genotype and representative images shown.  
 
5.7 Discussion  
The aim of proteomic analysis is to identify and quantify the relative abundance of 
thousands of proteins and post-translational modifications in a cell or tissue [280]. These 
changes are then correlated to the biological processes occurring in the cell in response 
to an experimental stimulus [281]. Through LC-MS/MS analysis, I have been able to 
investigate the possible glomerular mechanisms underlying the action of Shiga toxin HUS. 
Using this unbiased and rigorous method, several novel pathways have been identified in 
human conditionally immortalised podocytes treated with Shiga toxin. Most notably, ER 
stress pathways and inflammasome proteins which were activated by Shiga toxin; and 
actin cytoskeleton, cell assembly proteins and VEGF-A signalling which were decreased by 
Shiga toxin. This is the first time that these pathways have been shown to change in the 
human podocyte in response to Shiga toxin treatment. Further investigation into how 
these processes interact to result in Shiga toxin HUS in patients is warranted, with the 
intention of identifying any potential targets amenable to pharmacological intervention 




Unfortunately, western blot analysis for NLRP3 inflammasome activation and ER stress 
marker expression in wild type human podocytes treated with Shiga toxin was not able to 
validate the findings from my proteomic dataset. There may be several reasons for this 
which include: the specificity of the antibodies used, protein to protein interactions within 
the sample lysate, the blocking agent used to prevent non-specific binding and the 
antibody concentration used. All of these factors can contribute to the appearance of 
multiple protein band detection on the membrane (as evident in Figure 5-24) where no 
statistically significant changes in NLRP3 protein expression could be detected. In 
contrast, western blot analysis of ER stress markers (ATF6, pIRE and GRP78) did show a 
trend towards increased activation in the wild type podocytes treated with Shiga toxin at 
both 2 and 4 hours. However, this failed to reach statistical significance most likely due to 
a slightly raised level of baseline ER stress activation observed in several of the untreated 
wild type control podocyte lysate samples. This caused a reduction in the overall 
measurable effect of Shiga toxin treatment in these cells. The observation that CHOP 
driven apoptosis increased in wild type podocytes treated with Shiga toxin suggests that 
ER stress responses are activated in these cells. Therefore, future work to repeat these 
experiments alongside the appropriate controls is required to further validate these 
pathways in podocytes.   
It must also be highlighted that major challenges exist in the interpretation of proteomic 
research. These have already been discussed in detail in this chapter and include: ensuring 
reproducibility of experimental results, careful statistical analysis using an appropriate 
FDR cut off, meticulous selection of reliable databases to facilitate identification of 
peptide and phospho-peptide sequences, appropriate normalisation and avoidance of 
type 1 error using a Benjamini Hochberg correction for multivariate analysis  [270][280]. 
The expertise of the University of Bristol Proteomics Facility and bioinformatic service 
from Dr Phil Lewis, has been crucial to ensuring that this proteomic analysis is of high 
quality and representative of the biological response in the podocyte to Shiga toxin 
treatment. Given the large number of proteins and phospho-peptides identified in my 
dataset, there remains plenty of scope for further analysis and investigation of the effects 
of Shiga toxin on the human podocyte. Future work will involve exploration of whether 
the key pathways already identified are altered in vivo using my PodrtTA-Tet-O-Gb3 Gb3 
null mouse model. I have already started this work for VEGF-A, but as discussed this 
requires further investigation. 
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Finally, it must also be acknowledged that in vitro cell culture work is not without 
limitation. This is particularly the case when studying the glomerular cells of the kidney 
where the interaction between podocytes and glomerular endothelial cells cannot be 
overlooked. Studying one cell type in isolation will not be representative of what is 
occurring physiologically in vivo at the glomerular filtration barrier. To overcome this 
issue, we have performed experiments involving co-culture of human conditionally 
immortalised podocytes and glomerular endothelial cells with some very interesting 
results (these are presented in later chapters of my thesis). Studies into the effects of 
Shiga toxin on 3D spheroids containing an outer podocyte layer and inner endothelial cell 
core are also in progress [282]. Regardless of these limitations, these proteomic 
experiments in human podocytes have provided a valuable starting point for determining 





Chapter 6 : Generation of an A4GALT knockout mouse 
6.1 Introduction 
There are currently no rodent models that recapitulate Shiga toxin HUS in human disease. 
This represents a significant hurdle in improving our understanding of the mechanisms 
underlying the condition [33]. Wild type mice given intraperitoneal Shiga toxin do not 
develop TMA; the pathognomonic histopathological lesion seen in Shiga toxin HUS in 
humans. Rather, these mice die within a few days from off-target extra glomerular effects. 
This difference is due to species variation in kidney cellular Gb3 expression [1]. Mice 
express Gb3 predominantly in their renal tubules. However, humans (as well as baboons 
whose renal physiology more closely resembles that of Homo sapiens) express Gb3 
predominantly in their glomeruli; specifically, in the glomerular endothelium and 
podocytes [33]. A key aim of my PhD was to investigate whether Shiga toxin can act via 
the Gb3 receptor in podocytes to cause HUS. In order to explore this, I needed to breed a 
mouse that only expresses Gb3 in the podocyte cells of the kidney. The first step in 
achieving this aim was to generate an A4GALT knockout (KO) mouse. 
6.2 Gb3 expression in vivo 
I have confirmed Gb3 expression in the renal tubules of wild type mice using  
immunofluorescence in wild type mouse kidney sections (Figure 6-1). The expression of 
Gb3 in different organs in the wild type mouse at different ages has been reported. This 
is in the context of studies in the Fabry’s mouse (a Gb3 over-expressing mouse). Of note, 






Figure 6-1: IF detection of Gb3 in wild type mouse kidney tissue x20 
Fresh frozen kidney sections from wild type mice were prepared for IF as described and probed for 
Gb3 (green); nephrin (red – to identify podocytes outlining the glomeruli) and DAPI stained to 
identify nuclei (blue). Panel A shows Gb3 is located in the tubules of murine kidney and is absent 
from the glomeruli. The section in Panel B was prepared in the same way as Panel A, but without 
a primary antibody for Gb3/nephrin as an auto-fluorescence control for the secondary antibody. 
 
 
Table 11: Wild type mouse tissue expression of Gb3 
At all stages (weeks 4-24 circled in red) mice express the most Gb3 in the kidney. This table has 
been taken from Park et. al who were investigating the use of adenovirus injections to correct over 
expression of Gb3 in the Fabry’s mouse model (for our purpose the table is of relevance only for 
the wild type mouse – in which the kidney is the organ with the highest expression of Gb3). The 
amount of Gb3 has been quantified using mass spectrometry and normalised for total protein 
content of the organ [242].  
 
6.3 Generation of a A4GALT knockout mouse 
In 2006, Okuda et al. demonstrated that the Gb3 receptor is the receptor for Shiga toxin 
in vivo by generating a Gb3 total body knockout mouse which was resistant to 
intraperitoneal Shiga toxin [75]. These mice do not appear to have an obvious phenotype, 
other than verotoxin resistance [77]. However, a number of studies have suggested that 
Gb3 may be important in B cell differentiation (as it is expressed by a subset of immature 
B cells) [75]. Consequently, Okuda et al. performed immunological profiling of the Gb3 
null mouse which showed that the number of thymocytes, spleen cells, immunoglobulin 
levels and ratios of lymphocytes and T cell subsets were no different to that of wild type 





Figure 6-2: Lymphocyte populations and serum antibody levels in Gb3 null mice vs. WT mice 
No significant difference was observed between wild type mice and Gb3 null mice. Table taken 
from Okuda et. al. [75] 
 
A4GALT knockout mice were generated as detailed in my in vivo methods chapter and 
transferred to the animal facility within the renal unit. They were age-matched with 
littermate control wild type mice. Genotyping was performed by MRC Harwell, but I 
repeated this prior to use in any experiments using PCR. Genotyping was performed with 
2 different sets of primers (see appendix); use of the Tm1b primer pairs confirmed A4GALT 





Figure 6-3: Genotyping WT vs. A4GALT KO mice 
L= DNA ladder, C = wild type mouse from another background (used as a positive control), WT = 
littermate wild type control mice, KO = A4GALT KO mouse, NT = non-template control. Endpoint 
PCR was performed using both Tm1a and Tm1b primers (see appendix). Tm1a primers: WT band 
expected at 231 base pairs (bp) and A4GALT KO expected at 128 bp as shown in the top panel; 
Tm1b primers: WT band expected at 259 base pairs (bp) and A4GALT KO expected at 400 bp as 
shown in the bottom panel. 
 
6.4 A4GALT knockout mice do not express Gb3  
Using the Gb3 detection methods optimised in vitro, I confirmed that A4GALT knockdown 
mice do not express Gb3 their tissues. The first method used was immunofluorescence of 
fresh frozen kidney sections (Figure 6-4 and Figure 6-5). The second method used was 
endpoint PCR for Gb3 synthase mRNA (Figure 6-6). Given that wild type mice have the 
highest expression of Gb3 in their kidney tissue demonstrated by Park et al [242]; kidney 
tissue was also sent to the translational mass spectrometry department at UCL for analysis 
of Gb3 content. The results of the mass spectrometry analysis further confirmed that 
A4GALT KO had been achieved at a lipid level. i.e. knockout of Gb3 synthase resulted in a 
reduction in the key biologically active Gb3 isoforms (C24 and C24-1) in the mouse model 
(Table 12).   
 









Figure 6-4: A4GALT knockout mice do not express Gb3: kidney sections renal tubules (x20) 
Immunofluorescence of fresh frozen kidney sections from WT (wild type) mice and A4GALT KO 
(Gb3 null). The renal tubules of WT mice show expression of Gb3 (green) and A4GALT KO mice 
show no evidence of Gb3 expression (green). DAPI – blue, Nephrin – red. Isotype controls (not 
shown) confirm that Gb3 staining is specific. Images representative of n=3. 
 
 
Figure 6-5: A4GALT knockout mice do not express Gb3: kidney sections with glomeruli (x20) 
Immunofluorescence of fresh frozen kidney tissue sections from WT (wild type) mice and A4GALT 
KO (Gb3 synthase knockout) mice. There is no evidence of Gb3 expression in the A4GALT KD mouse 
kidney. Gb3 - green, Nephrin – red, DAPI – blue. Isotype controls (not shown) confirm that Gb3 





Figure 6-6: Endpoint PCR for A4GALT mRNA in WT vs. A4GALT KO mice 
Mouse kidney, liver and heart tissue were analysed in both WT and A4GALT KO mice for the 
presence of Gb3 synthase mRNA. Results for both mouse A4GALT synthase primers and human 
A4GALT synthase primers are shown. Tissues from the A4GALT KO mice (red) show no evidence of 
Gb3 synthase expression with absence of a detectable band at 114 base pairs (corresponding to 
Gb3 synthase mRNA product). Human A4GALT primers appear to be species specific as there is an 
absence of Gb3 synthase detection in all but the positive control (human podocytes). 
Representative results for n=3. 
 
 
Table 12: Mass spectrometry analysis of WT mouse kidney vs. A4GALT KO kidney tissue 
A WT mouse (A) and an A4GALT KO mouse of the same age were terminally anaesthetised via an 
IP injection of  pentobarbital (50mg/kg). The kidneys were dissected, removed, and the tissue sent 
on dry ice to the TMSC at UCL for Gb3 (CTH) mass spectrometry analysis. The A4GALT KO mouse 
kidney contains considerably less total Gb3 than the WT mouse. 
 
Mouse kidney tissue WT














ug/mg protein = 0.3034
Mouse kidney tissue A4GALT KO




















Figure 6-7: Mass spectrometry kidney profiles  
The results from Table 12 (above) are graphically represented here. A = WT mouse Gb3 isoform 
content and B = A4GALT KO Gb3 isoform content. Of interest the C24 and C24-1 isoforms of Gb3 
(circled in red) are significantly lower in the A4GALT KO mouse. These are known to be the key 
biologically active isoforms (as discussed in results chapter 4). 
 
6.5 A4GALT knockout mice are resistant to Shiga toxin 
Following confirmation that A4GALT KO mice showed no expression of Gb3 synthase in 
their tissues and lacked the key biologically active Gb3 isoform expression in their kidneys; 
whether this translated functionally into resistance to the lethal effects of Shiga toxin 
needed to be established. This would confirm the observation from Okuda et al. that Gb3 
is the receptor for Shiga toxin in vivo. A4GALT KO mice together with age-matched WT 
controls (10-15 weeks of age) were given intraperitoneal Shiga toxin at a dose of 10ng/g. 
This dose is 40 times the LD50 dose (median dose required to kill half the population) [75]. 
The survival of the WT mice vs. A4GALT KO mice is shown in (Figure 6-8). All WT mice died 
within 5 days of Shiga toxin inoculation. Consistent with a Gb3 null phenotype, A4GALT 
KO mice were resistant to Shiga toxin and survived for 8 weeks following intraperitoneal 
Shiga toxin administration. They were electively culled under schedule 1 (via terminal IP 
pentobarbital anaesthesia) in order for their organs to be harvested at this timepoint for 
further investigation. They appeared well throughout the experimental period and gained 
weight as would be expected in healthy wild type mice.  
 

































































































































Figure 6-8: Kaplan-Meyer Survival Graph: WT mice vs. A4GALT KO mice administered 10ng/g 
Shiga toxin 
All wild type (WT) mice died by day 5 following intraperitoneal Shiga toxin injection of 10ng/g. It is 
well established that there is some variation in WT mouse response to Shiga toxin in vivo: with 
variability in the time taken for the lethal effects of Shiga toxin taking between 3-5 days [75]. This 
reflects Shiga toxin potency, site of IP injection and hydration status of the mouse. In contrast all 
A4GALT KO mice survived for > 8 weeks following Shiga toxin challenge when they were culled 
under schedule 1 to allow tissue analysis. N=4 for each genotype. 
 
 
Figure 6-9: Weight chart of WT vs. A4GALT KO mice administered 10ng/g Shiga toxin 
WT mice (shown in red, blue, and green) rapidly lost 15% of their body weight within days of Shiga 













































to gain weight over the course of the weeks following Shiga toxin administration as would be 
expected in healthy mice. N=4 for each genotype. 
 
 A4GALT knockout mice are resistant to 100ng/g of Shiga toxin 
Given that Gb3 null mice were resistant to 40 times LD50 dose of Shiga toxin, whether 
they remained resistant to its toxicity at 400 times the LD50 dose was tested (100ng/g). 
In-keeping with Okuda et al. the Gb3 null mice were resistant to 100ng/g of Shiga toxin 
administered by intraperitoneal injection (Figure 6-10). Again, they were culled by 
schedule 1 at 8 weeks following Shiga toxin administration to allow tissue analysis.  
 
 
Figure 6-10: Kaplan Meyer survival graph for A4GALT KO mice following 100ng/g of Shiga toxin 
A4GALT KO mice (n=2) were given 100ng/g Shiga toxin via intraperitoneal injection. All animals 
survived and showed no signs for concern until they were culled under schedule 1, at 8 weeks 
following Shiga toxin administration. 
 











Figure 6-11: Weight chart for A4GALT KO mice following 100ng/g of Shiga toxin treatment 
Both A4GALT KO mice (red and black lines – animal ID shown) showed evidence of weight gain over 
the 8 weeks following 100ng/g Shiga toxin challenge; indicating that they are unaffected by the 
toxic effects of Shiga toxin. Mice were culled under schedule 1 to allow examination of tissues. 
 
 A4GALT KO mice given intraperitoneal Shiga toxin do not develop renal 
failure or proteinuria 
Blood samples were taken from all mice at the time of sacrifice and sent to the 
biochemistry department at Bristol Royal Infirmary for analysis. Unfortunately, the wild 
type mice given intraperitoneal Shiga toxin were very dehydrated at the time of terminal 
anaesthesia and under 100µl of blood could be obtained. This was an insufficient sample 
volume to be processed. However, one wild type mouse given intraperitoneal Shiga toxin 
was sacrificed at an earlier time point (3 days following Shiga toxin injection); prior to 
becoming visibly unwell and a blood sample analysed for creatinine. This result was 
33µmol/L which is high; but as an isolated resulted not particularly useful, hence not 
included in my analysis. Serum creatinine samples taken from wild type mice and A4GALT 
KO mice at baseline (prior to any Shiga toxin challenge) were not statistically different. 
A4GALT KO mice given intraperitoneal Shiga toxin at 10ng/g and 100ng/g had no 
statistically significant difference in serum creatinine vs. baseline in both wild type mice 
and A4GALT KO mice (Figure 6-12). 
 






















Figure 6-12: Comparison of serum creatinine WT mice vs. A4GALT KO mice 
There was no statistically significant difference in serum creatinine values across all groups of mice: 
wild type at baseline prior to Shiga toxin administration (WT), A4GALT knockout mice at baseline 
(A4GALT KD), and the A4GALT KO mice given intraperitoneal Shiga toxin. n=3 in each group as 
shown by each data point. One way ANOVA performed comparing each group – no statistically 
significant difference observed. 
 
Urine samples were collected from WT control mice, A4GALT KO mice, A4GALT KO mice 
after 10ng/g of Shiga toxin and A4GALT KO mice after 100ng/g of Shiga toxin treatment. 
Urine was collected prior to terminal anaesthesia and organ harvesting. Albumin: 



























































Figure 6-13: Urine albumin: creatinine ratio (ACR) is not elevated in A4GALT KO mice 
Urine was collected from each of the 4 groups of mice prior to terminal anaesthesia and organ 
harvesting (n number indicated on the graph by each data point within each group). There was no 
significant difference in ACR between the groups tested. One way ANOVA: Tukey’s multiple 
comparison test no significant difference between ACRs in each group.  
 
 Wild type mice show evidence of acute tubular necrosis following 
intraperitoneal Shiga toxin  
Age-matched WT and A4GALT KO mice were given IP Shiga toxin at 10ng/g. As already 
described WT mice all required terminal anaesthesia by day 5 due to becoming visibly 
unwell; scoring a Bristol Animal Welfare Score >10 (See Appendix for details). A4GALT KO 
mice did not score above 0 and appeared well throughout the experiment. The A4GALT 
KO mice were terminally anaesthetised at 8-10 weeks and organs harvested. Mouse 
kidney sections were fixed in formalin at the time of dissection and paraffin embedded 
before being sectioned to 2-5µm thick. These were then PAS stained, to allow evaluation 
of renal tissue architecture. The kidneys of wild type mice showed evidence of acute 
tubular necrosis, with swollen oedematous tubules and areas of vacuolation. The A4GALT 



































































Figure 6-14: PAS stain of kidney tissue WT vs. A4GALT KO mice following 10ng/g Shiga toxin 
challenge (x40) 
Renal tissue was fixed in formalin and paraffin embedded. Sections were cut at 2-5 µm thick and 
PAS (Periodic acid–Schiff–diastase) stained. Wild type (WT) mice show clear evidence of acute 
tubular necrosis (ATN) with oedematous tubules and vacuolations (as indicated by arrows). 
A4GALT KO mice show no changes in the tubular or glomerular morphology. 
 
 A4GALT KO mice show no evidence of renal damage on histology 
following intraperitoneal Shiga toxin 
A4GALT KO mice given 100ng/g of intraperitoneal Shiga toxin were culled at 8 weeks post-
injection and their kidneys fixed in formalin. Following paraffin embedding they were 
sectioned at 2-5µm thick and PAS stained as described. Representative images are shown 
below (Figure 6-15). There is no evidence of any renal tissue damage which is in-keeping 





Figure 6-15: PAS stain of A4GALT KO kidney tissue following 100ng/g of intraperitoneal Shiga 
toxin (x40) 
PAS stained renal tissue from A4GALT KO mice given 100ng/g of Shiga toxin shows normal tubular 
and glomerular morphology. 
 
6.6 Generation of an inducible podocyte expressing Gb3 synthase 
mouse 
The next step in developing a PodrtTA-Tet-OGb3 mouse on a Gb3 null background; was 
to breed an inducible podocyte expressing Gb3 synthase mouse on a WT background. This 
mouse will then be back crossed with the A4GALT KO mouse to generate a mouse that 
only expresses Gb3 in the podocyte (under doxycycline induction). An inducible model for 
Gb3 expression is required rather than a constitutive Gb3 over-expression mouse model 
because this mouse has a Fabry’s disease phenotype.  
Fabry’s Disease is an X-linked lysosomal storage disorder where a deficiency in the α-
galactosidase (α-GalA) enzyme results in accumulation of Gb3, lyso-Gb3 and 
galabiosylceramide in the kidney, brain and heart as well as biological fluids [249].  This 
causes acroparesthesia, hypohidrosis, angiokeratomas and psychosocial symptoms early 
on in the disease process. More advanced disease presents with cardiac abnormalities 
including arrhythmias and mitral valve disease along with progressive renal failure that 
eventually requires dialysis [249]. Interestingly, Fabry’s mice (α-GalA–knockout mice) 
which over express Gb3 are resistant to the toxicity of Shiga toxin [90]. This may be due 
to saturation of the toxin with excess Gb3 receptor throughout the body which prevents 
the toxin reaching susceptible organs like the kidney. Or perhaps the Gb3 receptor itself 
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not being expressed on the cell surface in a functioning form preventing intracellular 
signalling [90]. 
PodrtTA-Tet-OGb3 mice (inducible podocyte expressing Gb3 synthase mice) were bred as 
described in my in vivo methods chapter at MRC Harwell and transferred to the animal 
unit in Bristol. These mice, together with littermate wild type controls were given either 
doxycycline in their drinking water for 14 days (to induce expression of Gb3 synthase in 
the podocyte) or standard drinking water and then sacrificed using terminal 
intraperitoneal anaesthesia. Tissues were harvested and assessed for expression of Gb3 
using immunofluorescence and then imaged in the Wolfson Bioimaging Facility on 
confocal multi-laser Leica SP5II microscope. PodrtTA-Tet-OGb3 mice given doxycycline 
showed expression of Gb3 in their podocytes, evidenced by co-localisation with podocin 
(Figure 6-16 and Figure 6-17). Mice with the same genotype given standard drinking water 
showed no expression of Gb3 in their glomeruli. All mice were on a wild type background 
and therefore, expression of Gb3 was seen in their renal tubules.  
 
 
Figure 6-16: PodrtTA-Tet-O-Gb3 mice given doxycycline express Gb3 in their podocytes (x40) 
Immunofluorescence of fresh frozen kidney tissue from PodrtTA-Tet-OGb3 mice given doxycycline 
or water for 14 days.  Mice given doxycycline express Gb3 in their podocytes (evidenced by co-
localisation with podocin: yellow). Mice with the same genotype given drinking water showed no 
expression of Gb3 in their glomeruli. Green – podocin, red – Gb3, yellow – co-localisation. 
Secondary antibody controls were used in isolation to confirm specificity of primary antibody – 





Figure 6-17: PodrtTA-Tet-O-Gb3 mice given doxycycline express Gb3 in their podocytes (x20) 
Immunofluorescence of fresh frozen kidney tissue from PodrtTA-Tet-OGb3 mice given doxycycline 
or water for 14 days.  Mice given doxycycline express Gb3 in their podocytes (evidenced by co-
localisation with podocin: yellow). Mice with the same genotype given drinking water showed no 
expression of Gb3 in their glomeruli. Green – podocin, red – Gb3, yellow – co-localisation. 
Secondary antibody controls were used in isolation to confirm specificity of primary antibody – 
images not shown. 
 
PodrtTA-TetO-Gb3 mice given doxycycline or standard drinking water, together with Gb3 
KO mice and littermate wild type mice (WT) given standard drinking water; were culled 
after 14 days and a glomerular isolation using Dynabead extraction was performed. This 
was in an attempt to isolate the mRNA from glomeruli only to allow analysis for Gb3 
synthase expression. Unfortunately, this technique is not free from contamination with 
renal tubular cells which in all mice (as all are on a wild type background) will express Gb3. 
However, quantitative real-time PCR using mouse Gb3 synthase primers did show higher 
expression of Gb3 synthase mRNA in the PodrtTA-TetO-Gb3 mice given doxycycline vs. 
standard drinking water (Figure 6-18).  
This in combination with the Gb3 immunofluorescence results confirmed that the 
inducible model was working and not leaky. I was then happy to proceed with the next 
stage of the in vivo work: the crossing of the PodrtTA-Tet-O-Gb3 mouse with the A4GALT 
KO mouse; to generate an inducible podocyte specific Gb3 synthase mouse on a Gb3 null 
background. This mouse model will allow me to address one of my key research aims: that 




Figure 6-18: A4GALT mRNA expression in glomeruli normalised to Gb3 mice 
Glomerular isolation using Dynabeads was performed on Gb3 KO, PodrtTA-TetO-Gb3 mice given 
doxycycline or drinking water and WT mice given doxycycline as indicated. The tissue was analysed 
by RT-PCR for Gb3 synthase mRNA expression. All results normalised to Gb3 KO animals (where 
Gb3 synthase expression was set as 1 for the purpose of relative expression – although these mice 
actually express no Gb3 synthase mRNA). There was a statistically significant difference between 
the relative expression of Gb3 synthase in PodrtTA-TetO-Gb3 mice given doxycycline vs. those 
given standard drinking water. *One way ANOVA performed with Tukey’s multiple comparison test 
p<0.05. 
 
 PodrtTA-TetO-Gb3 mice on a WT background have no structural 
changes in their glomeruli  
Previous PhD work by Dr Lindsay Keir in 2013, has already established that the PodrtTA-
TetO-Gb3 mice (on a wild type background) have a normal renal histological appearance 
before and after doxycycline induction of Gb3 synthase so I have not repeated this work 
(Figure 6-19). Dr Keir also showed that urine protein: creatinine ratios in these mutant 
mice (irrespective of receiving doxycycline in their drinking water) was unchanged from 





Figure 6-19: Renal histology in PodrtTA-Tet-O-Gb3 WT mice is unremarkable following Gb3 
synthase induction in the podocyte 
Pod rtTATet-O-Gb3 mice and WT litter mate controls were given doxycycline in their drinking for 
A=3 days, B=7 days and C=10 days to induce podocyte Gb3 synthase expression. The mice were 
then terminally anaesthetised with pentobarbitone and their kidneys harvested. After formalin 
fixation and paraffin embedding, sections were stained using haematoxylin and eosin (H&E) and 
periodic acid Schiff (PAS). There were no differences between the WT mice and mutants at all time 





Figure 6-20: Urine protein: creatinine ratios in PodrtTA-Tet-O-Gb3 mice vs. WT controls 
Urine was collected and analysed for urine protein: creatinine ratio in PodrtTA-Tet-O-Gb3 (mutant) 
mice and WT mice following A=3 days, B=7 days and C= 10 days of doxycycline drinking water 
treatment. There was no statistically significant difference between mutants and controls across 
all time points. Work performed by Dr Lindsay Keir (data reproduced with permission). 
 
 PodrtTA-TetO-Gb3 mice on a WT background given intraperitoneal 
Shiga toxin develop a TMA 
PodrtTA-Tet-O-Gb3 mice on a wild type background aged 8-10 weeks were given 
intraperitoneal Shiga toxin at a dose of 10ng/g and monitored twice daily using the Bristol 
Animal Welfare Score. These mice required terminal anaesthesia with pentobarbitone 
within 24-48 hours following Shiga toxin challenge due to a score >10. Given that these 
mice express Gb3 in their podocytes and renal tubules this was not unexpected. The 
kidneys of these mice were harvested, and formalin fixed prior to paraffin embedding. 
Histological analysis using the trichrome martius scarlet blue stain demonstrated 
evidence of thrombi in their glomeruli (Figure 6-21). Age-matched control mice of the 
same genotype given intraperitoneal normal saline did not become unwell and had no 
evidence of TMA on histology. These lesions are in-keeping with a TMA; the 
histopathological hallmark of Shiga toxin HUS. This work was performed by Dr Keir and 





Figure 6-21: PodrtTA-Tet-O-Gb3 mice on a WT background develop a TMA following Shiga toxin 
challenge 
Martius scarlet blue trichrome stain of renal tissue from a PodrtTA-TET-O-Gb3 mouse on a WT 
background following 10ng/g Shia toxin intraperitoneal injection. Fibrin thrombi are seen within 
the glomerular capillary loops indicated by black arrows. These appearances are characteristic of 
a glomerular TMA  - the same histopathological lesion that is seen in humans with Shiga toxin HUS. 
Work performed by Fern Barrington (data reproduced with permission). 
 
6.7 Discussion  
This chapter has described the generation of two different mouse models. Using the Gb3 
detection methods optimised under in vitro conditions, I have demonstrated that A4GALT 
KO mice do not express Gb3 synthase or the key biologically active Gb3 isoforms at a lipid 
level. Furthermore, these mice are resistant to the lethal effects of Shiga toxin, even at 
400 times the LD50 dose (100ng/g). There can be no question that in vivo the receptor for 
Shiga toxin is Gb3 and that in the absence of this receptor mice are protected against 
Shiga toxin.  
Of interest however, the A4GALT KO mice do express some isoforms of Gb3 as evidenced 
by the mass spectrometry results from the TMSC at UCL. This confirms what Dr Mills’ 
group has already found; that not all Gb3 isoforms are biologically active in vivo in terms 
of Shiga toxin virulence. Indeed, similar findings were found in my A4GALT knockdown 
cell line in vitro. I have confirmed that A4GALT has been knocked out using the highly 
sensitive method of PCR. It seems counter-intuitive therefore, that any Gb3 is synthesized 
since A4GALT is the enzyme that catalyses this pathway. On review of the literature it is 






uncertainty as to the redundancy of the Gb3 synthase enzyme [249]. Indeed, the A3GALT2 
enzyme catalyses the synthesis of iso-globo series and may account for the presence of 
Gb3 isoforms in the A4GALT KO mice [77].  
The second mouse model studied is the inducible podocyte specific Gb3 synthase mouse. 
This mouse was generated using tetracycline controlled transcription activation of Gb3 
synthase linked to a podocin promoter. In the presence of doxycycline, Gb3 is only 
induced in cells that possess the podocin promoter (i.e. podocytes). This is a closer 
representation of Gb3 expression in humans, who have the Gb3 receptor in both 
podocytes and glomerular endothelial cells. However, because Gb3 is expressed in the 
renal tubules of WT mice the PodrtTA-Tet-O-Gb3 mutants also have Gb3 in their renal 
tubules. Consequently, the PodrtTA-Tet-O-Gb3 mice died within 3-5 days following IP 
Shiga toxin challenge.  
I have confirmed that the PodrtTA-Tet-O-Gb3 mice express the Gb3 receptor following 14 
days of doxycycline treatment using immunofluorescence and real time PCR. It has also 
been established that these mice have no structural changes in their glomeruli or renal 
tubules following doxycycline induction. Furthermore, there was no significant increase 
in ACR in these mice vs. control mice. Particularly exciting was the observation that 
PodrtTA-Tet-O-Gb3 mice given IP Shiga toxin develop a glomerular TMA. This is the 
histopathological hallmark of HUS. Unfortunately, given the off target extra-glomerular 
effects of Shiga toxin in the renal tubules of the mutant mice I was unable to study the 
mechanisms behind these findings. As a result, the generation of a mouse that expresses 
Gb3 only in its podocyte is required; to eradicate the extra-glomerular effects and allow 




Chapter 7 : Generation of an inducible podocyte specific 
Gb3 synthase mouse on a Gb3 null background 
7.1 Introduction 
In order to study the effects of Shiga toxin in the kidney in vivo, the lethal off-target extra 
glomerular effects in wild type mice needed to be eliminated and the Gb3 receptor 
present in glomerular cells. For the purpose of this PhD, specifically podocyte expression 
of Gb3 had to be induced. The previous chapter has described the generation and 
characterisation of the A4GALT total body KO mouse and the inducible PodrtTA-Tet-O-
Gb3 mouse. By back crossing the PodrtTA-Tet-O-Gb3 mouse with the A4GALT KO mouse 
the PodrtTA-Tet-O-Gb3 Gb3 Null mouse was generated. This mouse only expresses Gb3 
in its podocytes: breeding strategy shown in Figure 7-1. 
The generation of an inducible podocyte specific Gb3 synthase mouse on a Gb3 null 
background results in temporal control over A4GALT gene expression providing invaluable 
insights into the role of the podocyte in the initiation of glomerular TMA. Should this 
mouse develop a HUS syndrome it will also allow investigation as to whether inhibition of 
the alternative complement pathway can prevent the process. This will enable testing of 
my hypothesis in vivo which is vital prior to any further translation into human studies and 
clinical application. To ensure that the minimum number of mice were used in each 
experiment whilst maintaining statistical significance; an intelligent breeding strategy was 
used as detailed in my in vivo methods chapter. All mice were genotyped at the MRC 






Figure 7-1: Breeding Strategy for PodrtTA-Tet-O-Gb3 Gb3 Null mice 
PodrtTA-Tet-O-Gb3 mice were back-crossed over several generations with A4GALT KO mice to 
generate a PodrtTA-Tet-O-Gb3 Gb3 null mouse. This mouse only expresses Gb3 in the podocyte 
when induced with doxycycline. PodrtTA-Tet-O-Gb3 mice will then be given intraperitoneal (IP) 
Shiga toxin and evaluated for features of Shiga toxin HUS, including the development of a 
glomerular TMA.  
 
7.2 Route of delivery of Shiga toxin 
Before beginning this in vivo work, I had considered using the genetically modified Shiga 
toxin producing rodent pathogen Citrobacter rodentium. This was engineered by Mallick 
et al. as a novel murine infection model [119]. Prior to their work the only route of 
administration of Shiga toxin to the mouse was intraperitoneal; because oral 
administration of enterohaemorrhagic E.coli in mice does not lead to systemic illness 
[119]. This is an inferior route as in human disease transmission is oral. Shiga toxin is 
produced by  E.coli bacteria that are ingested which cause attachment and effacement 
lesions in the intestinal epithelium. This leads to local inflammatory changes which 
progress over 7-10 days to HUS syndrome [1]. Mallick et al. describe using oral gavage to 
deliver the genetically modified Citrobacter rodentium, which resulted in attachment and 
effacement intestinal lesions as well as evidence of renal tubular damage on histology. No 
rise in serum creatinine was observed but blood urea nitrogen (BUN) was raised and oral 
inoculation with Citrobacter rodentium resulted in death of all mice 7-15 days post 
infection. Just as in previously described murine models of Shiga toxin HUS, infected mice 
showed no evidence of platelet aggregation, fibrin deposition, microcytic anaemia or 
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thrombocytopenia [119]. This observation is hardly surprising given that the C57BL/6 mice 
used in their experiment were WT mice and therefore only expressed the Shiga toxin 
receptor Gb3 in their renal tubules [119].   
However, it was decided that genetically modified Citrobacter rodentium oral gavage 
would not be used in my experiments. This is because in the PodrtTA-Tet-O-Gb3 Gb3 null 
mouse model, mice require oral doxycycline to induce Gb3 receptor expression. 
Doxycycline administration began 14 days prior to Shiga toxin inoculation and continued 
throughout the experiment to ensure Gb3 synthase expression. This could potentially 
impact the potency of Citrobacter rodentium, reducing its toxicity and protecting the mice 
from Shiga toxin infection. As a result, intraperitoneal injection of Stx2 was used as an 
administration route. This method of delivery of Shiga toxin in mice is well established in 
published literature and oral doxycycline will not interfere with inoculation [1].  
7.3 PodrtTA-Tet-O-Gb3 Gb3 null mice express Gb3 in their podocytes 
following doxycycline induction 
PodrtTA-Tet-O-Gb3 mice on a Gb3 null background were given 14 days of oral doxycycline 
in their drinking water to induce A4GALT expression in the podocyte. Mice were then 
terminally anaesthetised using pentobarbital anaesthesia to allow organ harvest. 
Expression of A4GALT in the kidneys of these mice was confirmed using endpoint PCR 
(Figure 7-2) and expression of the Gb3 receptor was confirmed using 




1 =   Ladder
2 =   Pod Gb3
3 =   PodrtTA-Tet-O-WT 
4 =   Pod Gb3 
5 =   PodrtTA-Tet-O-WT 
6 =   Pod Gb3 
7 =   PodrtTA-Tet-O-WT 
8 =   negative control (no cDNA) 
9 =   Gb3 Null control (negative control)
10 = WT kidney (positive control)
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Figure 7-2: Endpoint PCR for Gb3 Synthase in PodrtTA-Tet-O-Gb3 Gb3 null mice vs. controls 
Mouse kidney from PodrtTA-Tet-O-Gb3 Gb3 null mice (Pod Gb3) and PodrtTA-Tet-O-WT Gb3 null 
control mice (PodrtTA-Tet-O-WT) were analysed for Gb3 synthase expression following 14 days of 
doxycycline induction using endpoint PCR. As shown the Pod Gb3 mice express Gb3 synthase and 
the PodrtTA-Tet-O-WT mice do not. This is a highly sensitive method for detecting Gb3 synthase 
and confirms the phenotype of my experimental cohort. Results shown for n=3 of each genotype. 
 
  
Figure 7-3: IF detection of Gb3 in PodrtTA-Tet-O-Gb3 Gb3 null mice vs. control kidney tissue x20 
PodrtTA-Tet-O-WT Gb3 null mice (Panel A) and PodrtTA-Tet-O-Gb3 Gb3 null mice (Panel B) were 
given 14 days of doxycycline in their drinking water and then sacrificed to allow organ harvest. 
Renal tissue from PodrtTA-Tet-O-WT Gb3 null mice (Panel A) showed no evidence of Gb3 
expression (green) whereas in PodrtTA-Tet-O-Gb3 Gb3 null mice (Panel B) Gb3 expression is seen 
in the glomeruli (nephrin in red). DAPI nuclear stain in blue. Images representative of n=3 animals 







Figure 7-4: IF detection of Gb3 in PodrtTA-Tet-O-Gb3 Gb3 null mice vs. control kidney tissue x60 
PodrtTA-Tet-O-WT Gb3 null mice (Panel A) and PodrtTA-Tet-O-Gb3 Gb3 null mice (Panel B) were 
given 14 days of doxycycline in their drinking water and then sacrificed to allow organ harvest. 
Renal tissue from PodrtTA-Tet-O-WT Gb3 null mice (Panel A) showed no evidence of Gb3 
expression (green) whereas in PodrtTA-Tet-O-Gb3 Gb3 null mice (Panel B) Gb3 expression is seen 
in the glomeruli: co-localising with the podocyte marker nephrin (red) to give yellow areas. DAPI 
nuclear stain in blue. Gb3 is also evident in the renal tubules of the PodrtTA-Tet-O-Gb3 Gb3 null 
mice. The most likely explanation for this observation is Gb3 being shed from the podocyte 
membrane and reabsorbed by the renal tubules. Images representative of n=3 animals for each 
genotype. 
 
Of note, it is evident from immunofluorescence (Figure 7-4) that there is Gb3 present in 
the renal tubules of the PodrtTA-Tet-O-Gb3 Gb3 null mice. The most likely explanation for 
this observation is Gb3 being shed from the podocyte membrane and reabsorbed by the 
renal tubules. Furthermore, and most importantly, the Gb3 seen in the renal tubules of 
the PodrtTA-Tet-O-Gb3 Gb3 null mice is not functional (see subsequent experimental 
findings to follow). Hence, it is highly unlikely that there is any de novo tubular Gb3 
expression in these mice. Furthermore, the specificity of the podocin promoter used in 
the tetracycline controlled gene expression model means that only podocytes have the 
ability to synthesize Gb3 in the presence of doxycycline. Of note all mice were genotyped 
by MRC Harwell (and then genotyped on arrival at the animal unit in Bristol) prior to use 
to confirm the PodrtTA-Tet-O-Gb3 Gb3 null genotype.  
An alternative explanation is that Shiga toxin itself has induced further expression of Gb3 
in the podocyte (as seen in my in vitro work) which has saturated the renal tubules ability 




from Morace et al. has demonstrated that Gb3 is important in the regulation of proximal 
tubular protein reabsorption [283].  It is clear from this work that proximal tubular Gb3 
expression is more important than first thought; given A4GALT KO mice were protected 
from AKI induced by myoglobin and gentamicin toxicity [283]. Thus, A4GALT KO itself may 
affect renal tubular function and explain why Gb3 is detected in the tubules of the 
PodrtTA-Tet-O-Gb3 Gb3 mice [284].  
7.4 PodrtTA-Tet-O-Gb3 Gb3 null mice develop HUS following Shiga 
toxin challenge 
 Experimental plan and blood sampling 
As depicted in Figure 7-5: 8-10 week old PodrtTA-Tet-O-Gb3 Gb3 null mice and age-
matched control mice (PodrtTA-Tet-O-WT Gb3 null mice: effectively Gb3 null) were given 
14 days of doxycycline in their drinking water. IP Shiga toxin was then administered at a 
dose of 10ng/g and the mice electively terminated at day 4, 8, 10, 12, 16 and 24. Blood 
was taken at the time of terminal anaesthesia via cannulation of the inferior vena cava 
(Figure 7-6). This technique was a new skill for our group, so we required training from Dr 
Robert Pope, as it is a technique that requires considerable manual dexterity.  
A 23 gauge needle and pre-heparinised syringe was used to ensure the blood obtained 
did not clot as this would affect the platelet count measurement. 30 - 50 USP of heparin 
per ml of blood collected was used as per convention [152][285]. The blood sample was 
then transferred to an empty (i.e. non-coated) paediatric blood bottle. Initial attempts at 
blood collection was with EDTA coated blood tubes and a butterfly needle. However, the 
blood was clotting in the needle upon collection and very little blood could be obtained. 
Any clot in the blood sample meant that the platelet count was immeasurable as platelets 
are found within the clot itself. By using a pre-heparinised syringe this issue was 





Figure 7-5: Experimental Plan for PodrtTA-Tet-O-Gb3 Gb3 null mice 
PodrtTA-Tet-O-Gb3 Gb3 null mice and  PodrtTA-Tet-O-WT Gb3 null control mice aged 8-10 weeks 
were given 14 days of doxycycline in their drinking water, followed by IP Shiga toxin challenge at 
10ng/g. The mice were then electively terminated at intervals of day 4, 8,10,12, 16 and 24.  
 
A volume of 700-1000 microlitres of blood was obtained per mouse and analysed for 
differential full blood count, urea, and blood film. All blood samples and blood films were 
coded to blind them for analysis to avoid bias. Blood films were produced by hand, taking 
a small drop (< 5 microlitres) of blood on a Claritex® glass histology slide using a wooden 
stick. Another Claritex® slide was then placed on top of the first, the short edge held at an 
angle of 30 degrees and the blood droplet allowed to spread across the short edge (by 
capillary action). The top glass slide was then swept across the bottom slide to spread the 
blood across it in one smooth motion; leaving a trail of blood that goes from a thicker 
smear through to a thinner film of blood. It is this thinner area that the blood film is 
analysed from; where the erythrocytes are touching but not overlapping. The glass slide 
with the blood smear on it was then fixed in methanol, followed by methylene blue and 
eosin staining on an automated fixation Sysmex SP-10® machine at Bristol Royal Infirmary 
Haematology laboratory. Three blood films per animal were produced and analysed for 
any evidence of microcytic anaemia by Dr John Moppet Consultant Paediatric 
Haematologist.  
The remaining blood sample was then run through the Sysmex XN-20® in Bristol Royal 
Infirmary Haematology department to obtain a differential full blood count, under the 
instruction of section leader Mr Mark Nicholas. This had been calibrated to recognise the 
differential full blood count for mouse samples (mouse cells are of a much smaller 
diameter than human blood cells). Blood samples were then transported back to the 
laboratory and centrifuged at 2000xg at 4°C for 10-15 minutes. This separates the blood 
into an upper plasma layer and lower red cell layer. The upper plasma layer was carefully 
pipetted off, avoiding any contamination of the sample with red cells. The plasma was 
14 days doxycycline
Stx 10ng/g




then sent to Kay Burt at Langford Veterinary school for measurement of urea. All blood 




Figure 7-6: Inferior vena cava anatomy in the mouse 
The inferior vena cava (IVC) was identified in terminally anaesthetised mice following a midline 
incision and blunt dissection down to the abdominal aorta. A 23 gauge needle pre-heparinised 
needle and syringe was then inserted into the vena cava (arrow) and blood aspirated into the 
syringe. The blood was then inverted in the syringe 10 times ( to ensure mixing with heparin) before 




Figure 7-7: Blood sample separation into plasma 
Schematic to show appearance of blood sample following centrifugation. The addition of heparin 
at the time of blood sample collection prevents the blood from clotting and facilitates the 
216 
 
separation of the sample into plasma and blood cell layers. Image taken from Blood Groups and 
Red Cell Antigens 2005 [286]. 
 
 
Figure 7-8: Blood film 
Example of blood film slides made by hand as described in main text; subsequently fixed with 
methanol and stained with methylene blue and eosin on an automated slide fixation machine 
Sysmex SP-10®  at Bristol Royal Infirmary Hospital. The thinner area of the film (boxed) is where 
the analysis of red cell morphology occurs. 
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice develop thrombocytopenia following 
Shiga toxin challenge 
PodrtTA-Tet-O-Gb3 Gb3 null mice and age-matched (8-10 week) old control mice 
(PodrtTA-Tet-O-WT Gb3 null) were given 14 days of oral doxycycline, followed by 10ng/g 
of Shiga toxin IP and electively terminated at different time points as already described. 
Comparison of platelet counts between each cohort of mice terminated at day 4 through 
to 24 are shown in Figure 7-9 and Figure 7-10. The platelet count was at its lowest 10 days 
following Shiga toxin IP injection in the PodrtTA-Tet-O-Gb3 Gb3 null mice. Interestingly, 
just as in the majority of Shiga toxin HUS patients, the platelet counts in these mice 
recovered by day 24. In contrast the control PodrtTA-Tet-O-WT Gb3 null mice showed no 





Figure 7-9: Comparison of platelet count across all time points PodrtTA-Tet-O-Gb3 Gb3 null mice 
PodrtTA-Tet-O-Gb3 Gb3 null mice were given 14 days of oral doxycycline, followed by 10ng/g of 
Shiga toxin IP and electively terminated at different time points as already described. Comparison 
of platelet counts between each cohort of mice terminated at day 4 through to 24 are shown. 
Platelet count drops maximally at day 10 and then recovers by day 24. The observed changes were 
statistically significant. ** One way ANOVA with Tukey’s multiple comparison test: p value 0.001.  
 
 
Figure 7-10: Comparison of platelet count across all time points in Gb3 null control mice 
PodrtTA-Tet-O-WT Gb3 null mice were given 14 days of oral doxycycline, followed by 10ng/g of 
Shiga toxin IP and electively terminated at different time points as already described. Comparison 
of platelet counts between each cohort of mice terminated at day 4 through to 24 are shown. 






































































 PodrtTA-Tet-O-Gb3 Gb3 null mice are anaemic and uraemic at day 10 
following IP Shiga toxin 
Given that the PodrtTA-Tet-O-Gb3 Gb3 null mice dropped their platelet count maximally 
at day 10, it was decided that this time point would be used to establish whether any 
other features of HUS were also present. Blood samples were analysed for haemoglobin 
and urea as already described. At day 10 these mice had both a reduction in their 
haemoglobin (anaemia) and a rise in urea (uraemia). This was an exciting finding; mice 
that only express Gb3 in their podocytes, had developed a thrombocytopenia, anaemia 
and uraemia: all the features of haemolytic uraemic syndrome. The control mice 
(effectively Gb3 null mice) demonstrated no drop in their haemoglobin and no increase in 



























































































































































Figure 7-11: PodrtTA-Tet-O-Gb3 Gb3 null mice develop HUS following IP Shiga toxin 
PodrtTA-Tet-O-Gb3 Gb3 null mice given 10ng/g of IP Shiga toxin show a drop in platelet count (A), 
drop in haemoglobin (B) and rise in plasma urea (C) vs. age matched control mice (PodrtTA-Tet-O-
WT Gb3 null) at Day 10. These differences were statistically significant A: ** Unpaired T test p value 
0.004; B: * Unpaired T test p value 0.041; C: **Unpaired T-test p value 0.0052 Note urea results 
pooled from day 10 to day 16.  
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice develop a haemolytic anaemia at day 
10 following IP Shiga toxin 
The finding that podocyte expression of the Gb3 receptor in the presence of Shiga toxin 
could go on to cause a systemic HUS syndrome was very exciting. However, it was 
important to determine whether the anaemia observed at day 10 was a haemolytic 
anaemia such as that seen in HUS, or an anaemia due to sepsis. Sepsis can cause anaemia 
through reduction in serum iron levels and erythropoietin production [287]. Whereas, 
anaemia due to haemolysis is due to premature destruction of erythrocytes, accompanied 
by a rise in reticulocyte count and lactate dehydrogenase (LDH) [288].  
To establish whether a microcytic haemolytic anaemia was occurring, blood films were 
analysed with Dr John Moppet (Consultant Paediatric Haematologist). Blood film analysis 
was performed whilst blinded to mouse genotype so as to avoid bias. Blood films are used 
in clinical practice in HUS patients to look for red cell fragmentation which indicates 
haemolysis [32]. Unfortunately, the volume of blood that could be collected at the time 
of termination was limited and so could not be used for analysis of LDH (as well as full 
blood count and urea). The accuracy of using the reticulocyte count (produced as part of 
the differential full blood count from the read out generated by the Sysmex XN-20®) was 
discussed with Dr Moppet; who felt this could not be accurately or reproducibly analysed. 
Of note, mice have a higher circulating percentage of reticulocytes in health than humans 
so interpretation would prove challenging given the wide range of ‘normal’ values [289].  
Blood films demonstrated that haemolysis was occurring in the PodrtTA-Tet-O-Gb3 Gb3 
null animals at day 10 following IP Shiga toxin; with no evidence of haemolysis in the 
control animals (Figure 7-12). An estimated 10-15% of red cells in the PodrtTA-Tet-O-Gb3 





Figure 7-12: PodrtTA-Tet-O-Gb3 Gb3 null mice develop haemolysis on blood films at Day 10 
following Shiga toxin IP vs. controls  
Blood films for PodrtTA-Tet-O-Gb3 Gb3 null mice (A and C) and age matched controls (B and D) at 
day 10 following Shiga toxin IP are shown. Red arrows indicate red cell fragments which are only 
seen in PodrtTA-Tet-O-Gb3 Gb3 null animals. Panels C and D are the same blood films, but images 
are zoomed in to allow better visualisation of fragments. Magnification is x40. Blood films shown 
are representative of all animals analysed at day 10 (PodrtTA-Tet-O-Gb3 Gb3 null mice n=7; 
PodrtTA-Tet-O-WT Gb3 null controls n=5). An estimated 15-20 % of red cells in the PodrtTA-Tet-O-
Gb3 Gb3 null were fragmented in each animal: representative blood films shown.  
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice develop a TMA on renal histology at 
day 10 following IP Shiga toxin 
The histopathological hallmark of Shiga toxin HUS is evidence of thrombotic 
microangiopathy (TMA) [1]. In clinical practice renal biopsy is rarely performed in Shiga 
toxin HUS, as patients have low platelet counts and are therefore at increased risk of 
bleeding complications from the procedure [1]. Renal biopsy is more often performed in 
patients with complement mediated atypical HUS, although it is not a requirement for 
diagnosis. Renal biopsy in this patient group is also used to monitor the disease response 





The finding of TMA on biopsy reflects the kidney’s response to glomerular endothelial cell 
injury. Endothelial swelling, mesangiolysis and fibrin platelet thrombosis are seen in acute 
cases and double contouring of the basement membrane seen in chronic disease [290]. 
However, to further complicate diagnosis, it is now recognised that overt fibrin platelet 
thrombosis may not be present in all renal biopsies of TMA. What is important to 
appreciate is that the finding of TMA on renal biopsy does not establish a cause (i.e. HUS 
vs. TTP) but simply signifies a final common pathway of glomerular endothelial injury 
[290].  
The trichrome stain, martius scarlet blue (MSB) was performed on kidney sections taken 
from PodrtTA-Tet-O-Gb3 Gb3 null mice versus PodrtTA-Tet-O-WT Gb3 null control mice 
at day 10 following Shiga toxin IP challenge (Figure 7-13). In this trichrome method, fibrin 
clots appear red, erythrocytes yellow and collagen blue. Three mice from each genotype 
were analysed. Fibrin thrombi were clearly seen in the glomeruli of PodrtTA-Tet-O-Gb3 
Gb3 null mice; with no evidence of thrombi in the PodrtTA-Tet-O-WT Gb3 null control 
mice. The percentage of glomeruli containing thrombi were quantified by selecting 10 
different fields of view at random, using the Leica DMI 6000B microscope at x20 
magnification in an n=3 for each genotype (Figure 7-14). The total number of glomeruli 
sampled in the control group was 185 and the total number in the PodrtTA-Tet-O-Gb3 




Figure 7-13: PodrtTA-Tet-O-Gb3 Gb3 null mice develop a TMA on renal histology at day 10 




Martius scarlet blue trichrome stain of renal tissue from a PodrtTA-Tet-O-Gb3 Gb3 null mouse vs. 
control following 10ng/g Shia toxin intraperitoneal injection. Panel A: fibrin thrombi (red) are seen 
within the glomerular capillary loops indicated by black arrows. These appearances are 
characteristic of a glomerular TMA, the same histopathological lesion that is seen in humans with 
Shiga toxin HUS. Panel B: there are no fibrin thrombi seen in the glomeruli of PodrtTA-Tet-O-WT 
Gb3 null control mice. Fibrin = red, collagen = blue, erythrocytes = yellow. 
 
 
Figure 7-14: Quantification of thrombi PodrtTA-Tet-O-Gb3 Gb3 null mice vs. controls  
The percentage of glomeruli containing fibrin thrombi in the PodrtTA-Tet-O-Gb3 Gb3 null mice 
(pod Gb3) vs. controls (Gb3 null) was calculated by selecting 10 different fields of view at random, 
on the Leica DMI 6000B microscope at x20 magnification in an n=3 for each genotype (graph). The 
total number of glomeruli sampled in the control group was 185 and the total number in the 
PodrtTA-Tet-O-Gb3 Gb3 null group was 165. In the PodrtTA-Tet-o-Gb3 Gb3 null mice 20-25% of 
glomeruli contained thrombi. No statistical test can be performed to compare the two groups 
because there were no thrombi seen in the control mice. Representative MSB stain shown in panel 
A and panel B as in Figure 7-13. 
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice have evidence of thrombi in their 
glomerular capillaries on electron microscopy following IP Shiga toxin 
PodrtTA-Tet-O-Gb3 Gb3 null mice develop HUS at day 10 following IP Shiga toxin and show 
evidence of thrombi within their glomeruli on MSB trichrome histology. Another way of 
demonstrating TMA in the kidney is to look at renal tissue under electron microscopy 
(EM). A quarter of kidney harvested from PodrtTA-Tet-O-Gb3 Gb3 null mice and controls 
at day 10 following IP Shiga toxin, was cut up into fine pieces and preserved in EM fix as 
detailed in my methods. This was then processed by the Wolfson Bioimaging Facility at 
the University of Bristol; and subsequently sectioned on an ultramicrotome, imaged and 
analysed by Dr Louise Farmer. Both myself and Dr Farmer were blinded to the genotype 














































12 120kV BioTwin Spirit Transmission Electron Microscope scanner in the Wolfson 
Institute.  
TMA was evident on EM imaging in the PodrtTA-Tet-O-Gb3 Gb3 null mice at day 10 post 
Shiga toxin IP. Large areas of thrombus were seen in the glomerular capillaries of these 
mice (Figure 7-15 and Figure 7-16). Low power and high power images were taken; there 
were no thrombi evident in the control mice. High power images were used to calculate 
foot process width, slit diaphragm size and glomerular basement membrane thickness. 
The presence of thrombi in the capillary loops of the glomeruli seen on EM is yet further 




Figure 7-15: PodrtTA-Tet-O-Gb3 Gb3 null mice develop TMA on EM at day 10 following IP Shiga 
toxin (low power) 
As described kidneys were harvested from PodrtTA-Tet-O-Gb3 Gb3 null mice and PodrtTA-Tet-O-
WT Gb3 null mice under terminal anaesthesia at day 10 following IP Shiga toxin. A quarter of kidney 
from each animal was cut up into small pieces and preserved in EM fix. This was then processed by 
the Wolfson Bioimaging Facility at the University of Bristol; and subsequently sectioned on an 
ultramicrotome, imaged and analysed by Dr Louise Farmer. Panel A – control mouse glomerulus 
shows normal glomerular architecture and red blood cells in capillary loops. Panel B – PodrtTA-Tet-
O-Gb3 Gb3 null mouse glomerulus: arrows indicate thrombus within the glomerular capillaries. 






Figure 7-16: PodrtTA-Tet-O-Gb3 Gb3 null mice develop TMA on EM at day 10 following IP Shiga 
toxin (high power) 
As described kidneys were harvested from PodrtTA-Tet-O-Gb3 Gb3 null mice and PodrtTA-Tet-O-
WT Gb3 null mice under terminal anaesthesia at day 10 following IP Shiga toxin. A quarter of kidney 
from each animal was cut up into small pieces and preserved in EM fix. This was then processed by 
the Wolfson Bioimaging Facility at the University of Bristol; and subsequently sectioned on an 
ultramicrotome, imaged and analysed by Dr Louise Farmer. Panel A – control mouse glomerulus 
shows normal glomerular capillary loop (C) and red blood cell (R) within. Arrows indicate normal 
appearance of podocyte foot processes. Panel B – PodrtTA-Tet-O-Gb3 Gb3 null mouse glomerulus: 
T = thrombus completely occluding capillary loop. Arrows indicate subendothelial accumulation of 
electrolucent ‘fluff’ (i.e. flocculent material with a finely fibrillar appearance) that is characteristic 
of TMA. Representative images of n=3 animals for each genotype. 
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice show no evidence of podocyte foot 
process effacement on electron microscopy following IP Shiga toxin 
High power electron microscopy images from PodrtTA-Tet-O-Gb3 Gb3 null mice at day 10 
post Shiga toxin alongside PodrtTA-Tet-O-WT Gb3 null control mice, were used to 
calculate foot process width, slit diaphragm width and glomerular basement membrane 
thickness. These measurements were taken by Dr Louise Farmer and showed no 
statistically significant differences between the groups in relation to podocyte 
morphology. There was a statistically significant difference in the thickness of the 
glomerular basement membrane (GBM) measurements; with the GBM slightly thinner in 
the PodrtTA-Tet-O-Gb3 Gb3 null mice (Figure 7-17). This was not thought to be associated 









Figure 7-17: PodrtTA-Tet-O-Gb3 Gb3 null mice show no evidence of podocyte foot process 
effacement on electron microscopy following IP Shiga toxin at day 10 
As described kidneys were harvested from PodrtTA-Tet-O-Gb3 Gb3 null mice and PodrtTA-Tet-O-
WT Gb3 null mice under terminal anaesthesia at day 10 following IP Shiga toxin. A quarter of kidney 
from each animal was cut up into small pieces and preserved in EM fix. This was then processed by 
the Wolfson Bioimaging Facility at the University of Bristol; and subsequently sectioned on an 
ultramicrotome, imaged and analysed by Dr Louise Farmer. Graphs A and B show no statistically 
significant difference in podocyte foot process width or slit diaphragm (SD) width between the two 
























































































































































basement membrane (GBM) measurements; with the GBM slightly thinner in the PodrtTA-Tet-O-
Gb3 Gb3 null mice. * Unpaired T test p value 0.03. 
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice have no change in urine ACR following 
IP Shiga toxin  
Although electron microscopy images taken of PodrtTA-Tet-O-Gb3 Gb3 null mice at day 
10 post IP Shiga toxin challenge showed no evidence of podocyte foot process 
effacement; PodrtTA-Tet-O-Gb3 mice vs. age matched controls (PodrtTA-Tet-O-WT Gb3 
null mice) pre-termination urine samples from day 10 to day 16 were analysed to 
determine if there was any significant difference in albumin creatinine ratio (ACR) 
between the groups (Figure 7-19). This is a standard method of measuring protein 
(albumin) leak from the kidney that is also used in patients. An albumin ELISA was 
performed on all urine samples in duplicate against albumin standards and urinary 
creatinine analysed at Langford Veterinary Practice. Each urine sample was also tested on 
urine dipstick; using Siemens Multistix 10SG Urinalysis Strips® at the time of urine 
collection to assess whether they were positive for blood (microscopic haematuria – 
which can be a marker of glomerular injury) (Figure 7-18).  
Initial urine dipstick testing showed no evidence of microscopic haematuria but did show 
up to ++ of proteinuria. It is known that urine dipstick testing is useful as a screen for 
proteinuria (high specificity), but that it does not have a very good sensitivity for detection 
of low-end but clinically significant proteinuria. Moreover, it does not quantify the exact 
amount of protein in the urine [291]. Measurement of ACR also corrects for the dilution 
of the urine sample (i.e. creatinine concentration) which allows comparison across 
animals. There was no statistically significant difference in ACR between the PodrtTA-Tet-
O-Gb3 Gb3 null mice and controls between days 10-16 following IP Shiga toxin. In patients 
with Shiga toxin HUS, acute proteinuria is not often a feature at presentation. Most are 
anuric and if they do develop proteinuria it is many weeks later due to the development 





Figure 7-18: Urine dipstick testing shows proteinuria in PodrtTA-Tet-O-Gb3 Gb3 null mice 
following IP Shiga toxin 
PodrtTA-Tet-O-Gb3 Gb3 null mice vs. control mice urine samples were tested for urinary protein 
and blood using Siemens Multistix 10SG Urinalysis Strips® on the day of termination. Panel A shows 
day 12 mice (top 3 dipstick tests are controls and show no proteinuria, bottom 3 are PodrtTA-Tet-
O-Gb3 Gb3 null mice with evidence of mild proteinuria demonstrated by colour change). Panel B 
shows day 16 mice (top four dipstick tests show proteinuria as evidenced by dark green colour 
change and bottom 3 show no proteinuria). Red arrow indicates column read to detect blood and 
black arrow indicates column read to detect proteinuria. All urine samples negative for blood. 
 
 
Figure 7-19: PodrtTA-Tet-O-Gb3 Gb3 null mice have no change in urine ACR following IP Shiga 
toxin 
PodrtTA-Tet-O-Gb3 Gb3 null mice vs. control mice urine samples were analysed for ACR on days 
10, 12 and 16 following IP Shiga toxin. An albumin ELISA was performed on all urine samples on 

























































statistically significant difference in urine ACR between the PodrtTA-Tet-O-Gb3 Gb3 null mice vs. 
controls at any time point. One way ANOVA: No significant difference between the groups. 
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice show increased fibrinogen deposition 
in their glomeruli at day 10 following IP Shiga toxin  
The presence of TMA in the glomeruli of PodrtTA-Tet-O-Gb3 Gb3 null mice prompted 
investigation as to whether there was any evidence of fibrinogen deposition in the 
glomeruli using immunofluorescence. In Shiga toxin HUS, fibrin forms as an intravascular 
glomerular thrombi [72]. This is triggered by endothelial cell injury which results in the 
release of tissue factor pro-coagulants, fibrinolytic inhibitors, platelet activating factor 
and von Willebrand factor [293]. It is this microvascular endothelial cell injury that 
differentiates TMA from disseminated intravascular coagulation (DIC); where 
consumption of coagulation factors leads to secondary fibrinolysis [294].  
The fibrin that forms in the glomerulus in Shiga toxin HUS, may be removed by phagocytic 
or fibrinolytic processes or persist to leave glomerular scarring -  rendering the glomerulus 
obsolescent [293]. Thus, I could not anticipate whether or not in this model there would 
be an increase in glomerular fibrinogen deposition by day 10. Three mice from each group 
were analysed: PodrtTA-Tet-O-Gb3 Gb3 null vs. PodrtTA-Tet-O-WT Gb3 null at day 10 
following Shiga toxin IP injection. The PodrtTA-Tet-O-Gb3 Gb3 null mice showed an 
increase in fibrinogen deposition in the glomeruli that was statistically significant versus 





Figure 7-20: PodrtTA-Tet-O-Gb3 Gb3 null mice show an increase in glomerular fibrinogen 
deposition at day 10 following Shiga toxin challenge vs. control mice 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice and control PodrtTA-Tet-O-WT Gb3 
null mice were probed for fibrinogen deposition (shown in green) using immunofluorescence. 
Representative images shown in panel A (PodrtTA-Tet-O-Gb3 Gb3 null mice) panel B (PodrtTA-Tet-
O-WT Gb3 null controls). This demonstrated a statistically significant increase in fibrinogen 
deposition in the glomeruli of the PodrtTA-Tet-O-Gb3 Gb3 null mice as evidenced by the increase 
in fold change of fibrinogen fluorescence intensity of x1.5. Graph C: label Pod Gb3 = PodrtTA-Tet-
O-Gb3 Gb3 null mice; Label Gb3 null = PodrtTA-Tet-O-WT Gb3 null mice (for clarity of figure). 
Results from n=3 mice of each genotype: 30 glomeruli per mouse ** Unpaired T-test p value 
<0.001.  
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice have increased C3b deposition in 
their glomeruli at day 10 following IP Shiga toxin  
Given that my central hypothesis states that the glomerular TMA seen in Shiga toxin HUS 
is driven by complement mediated attack on the endothelial cell, kidney sections from 
PodrtTA-Tet-O-Gb3 Gb3 null mice vs. controls were analysed for C3b deposition in the 
glomerulus (Figure 7-21). C3b was increased in the glomeruli of PodrtTA-Tet-O-Gb3 Gb3 
null mice vs. controls. C3b is a cleavage product of C3 and is involved in the formation of 
C3 convertase when bound to Factor B; or C5 convertase when bound to C4b and C2b [2]. 
Cleavage of C3 can occur via all 3 complement cascade pathways: classical, lectin and 




























































culminate with the formation of the membrane attack complex (MAC), leading to the 
insertion of pores into the target cell membrane resulting in osmotic lysis and cell death.  
The alternative pathway differs from the other two in that it is continually active at low 
levels in the plasma and is activated by spontaneous hydrolysis of a thioester bond in C3. 
To protect host cells from non-specific destruction, complement activation is regulated 
by a number of plasma (CFH, CFI) and membrane bound factors [2][153]. In the PodrtTA-
Tet-O-Gb3 Gb3 null mice (n=3) vs. control PodrtTA-Tet-O-WT Gb3 null mice (n=3) there 
was a x2.5 fold increase in the presence of C3b in the glomeruli. Given the pattern of IF 
staining this appeared to be originating from the glomerular endothelial cells. This was 
subsequently confirmed using the endothelial cell marker PECAM (Figure 7-22 and Figure 
7-23). 
It was noted in these sections that C3b was also detected in Bowman’s capsule and in the 
renal tubules of both the PodrtTA-Tet-O-Gb3 Gb3 null and PodrtTA-Tet-O-WT Gb3 null 
control mice. This has been published in the literature previously and appears to be at the 
same level of fluorescence intensity in all sections irrespective of genotype [295]. Given 
only C3b expression in the glomerulus is of interest (because the glomerular endothelium 
is where TMA occurs) any signal from outside the glomerulus was excluded from my 
analysis. The corrected total glomerular fluorescence (CTGF) was calculated using the 
following formula: CTFG = integrated density – (area of selected glomerulus x MFI of 
background); where background was averaged over 3 separate MFI values. The purpose 
of co-staining with the podocyte marker nephrin was to facilitate identification of the 
glomerulus accurately and calculate the C3b fluorescent signal only within this area. This 
allowed me to exclude the C3b located in renal tubules and Bowman’s capsule and 





Figure 7-21: PodrtTA-Tet-O-Gb3 Gb3 null mice have increased C3b present in their glomeruli at 
day 10 following IP Shiga toxin 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice and control PodrtTA-Tet-O-WT Gb3 
null mice were probed for C3b  (shown in green) using immunofluorescence and co-stained with 
the podocyte marker nephrin (red). Representative images shown in panel A (PodrtTA-Tet-O-WT 
Gb3 control mice) panel B (PodrtTA-Tet-O-Gb3 Gb3 null mice). This demonstrated a statistically 
significant increase in C3b deposition in the glomeruli of the PodrtTA-Tet-O-Gb3 Gb3 null mice as 
evidenced by the increase in fold change of C3b fluorescence intensity of x2.5. Graph C: Pod Gb3 
= PodrtTA-Tet-O-Gb3 Gb3 null mice; Gb3 null = PodrtTA-Tet-O-WT Gb3 null mice (for clarity of 
figure). Results from n=3 mice of each genotype: 30 glomeruli per mouse *** Unpaired T-test p 










































Figure 7-22: PECAM and C3b IF showing co-localisation in PodrtTA-Tet-O-Gb3 Gb3 null mice at 
day 10 following IP Shiga toxin  
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice and control PodrtTA-Tet-O-WT Gb3 
null mice were probed for C3b  (shown in red) using immunofluorescence and co-stained with the 
endothelial cell marker PECAM (green). Arrows denote areas of co-localisation (yellow) suggestive 
that C3b is originating from the glomerular endothelial cells. Panel A shows representative section 
from n=3 control mice (PodrtTA-Tet-O-WT Gb3 null) and Panel B shows representative section 
from n=3 PodrtTA-Tet-O-Gb3 Gb3 null mice. 
 
 
Figure 7-23: PECAM and C3b IF vs Nephrin and C3b IF in PodrtTA-Tet-O-Gb3 Gb3 mice at day 10 
following IP Shiga toxin  
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice were probed for C3b (green) and 
co-stained with PECAM (A) or nephrin (B) both in red. White arrows mark yellow areas of co-








demonstrates that C3b is originating from the endothelial cells. There is no evidence of co-
localisation when nephrin is used as a podocyte marker. Representative images of n=3.  
 
 PodrtTA-Tet-O-Gb3 Gb3 null mice have reduced CFH deposition in their 
glomeruli at day 10 following IP Shiga toxin  
It is essential that complement activation is regulated in vivo to prevent excessive cell 
injury and inflammation [138][155]. Host cells are protected by surface bound and soluble 
plasma complement regulatory proteins. Of particular importance are the plasma 
proteins Factor H and Factor I which negatively regulate the C3b amplification loop. 
Although found in the plasma both can act in the fluid phase and on cellular surfaces. 
Their role on cell surfaces that lack membrane bound complement regulators e.g. the 
glomerular basement membrane in the kidney is vital as they are the only defence against 
complement attack and thrombus formation [138][162].  The importance of Factor H is 
self-evident when considering atypical HUS; where mutations in CFH are associated with 
the worst outcomes [2].  
Being a fluid phase regulator, CFH is predominantly synthesized in the liver, but there is 
evidence in mice and humans that platelets, podocytes and mesangial cells can produce 
factor H [296][297][298]. CFH has been shown to bind to C3b deposits on the cell surface 
and to glycosaminoglycans [296]. In the kidney, it is the binding of CFH to glomerular 
endothelial cells that is essential to maintain the delicate balance of compliment 
activation and regulation. Part of the central hypothesis of my work is that Shiga toxin 
targets the podocyte Gb3 receptor, resulting in a reduction in glomerular VEGF-A which 
predisposes the glomerular endothelium to complement attack. Our group has already 
demonstrated that VEGF-A inhibition reduces glomerular CFH via VEGFR2/PKC-α/CREB 
signalling both in vitro and in vivo [222]. Suggesting that loss of VEGF-A from podocytes 
results in loss of CFH protection against complement-mediated damage on the surface of 
the glomerular endothelial cell [222].  
With this in mind, CFH expression in the glomerulus was evaluated in PodrtTA-Tet-O-Gb3 
Gb3 null mice given Shiga toxin vs. controls. Immunofluorescence was used to detect CFH 
in glomeruli. Interestingly, the PodrTA-Tet-O-Gb3 Gb3 null mice had a 50% reduction in 
the level of CFH in their glomeruli vs. control animals at day 10 following IP Shiga toxin 
(Figure 7-24). Results were quantified by calculating CTGF (formula as previously 
detailed). This finding supports the hypothesis that Shiga toxin HUS is associated with a 
234 
 




Figure 7-24: PodrtTA-Tet-O-Gb3 Gb3 null mice have reduced CFH deposition in their glomeruli at 
day 10 following IP Shiga toxin 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null (Pod Gb3) mice and control PodrtTA-Tet-
O-WT Gb3 null mice (Gb3 null) were probed for CFH  (shown in green) using immunofluorescence 
and co-stained with the podocyte marker nephrin (red). Representative images shown and no 
primary control for CFH and nephrin shown. This demonstrated a statistically significant reduction 
in CFH deposition in the glomeruli of the PodrtTA-Tet-O-Gb3 Gb3 null mice as evidenced by a 50% 
reduction in CTFG . Graph: Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice; Gb3 null = PodrtTA-Tet-
O-WT Gb3 null mice (for clarity of figure). Results from n=4 mice of each genotype. *** Unpaired 






































 Human glomerular cell co-culture experiments confirm the importance 
of podocyte and endothelial cell cross-talk 
The in vivo work presented, reflects what has been observed in co-culture human cell 
work. Conditionally immortalised human podocytes and glomerular endothelial cells were 
cultured together in transwells and treated with Shiga toxin. Endothelial cells were seeded 
onto coverslips on the bottom layer and podocytes were seeded into the transwell 
support. Cells were cultured in endothelial media without VEGF and allowed to 
differentiate. Shiga toxin 0.1ng/ml was added to the podocyte transwell support at 
intervals of 30 min to 6 hours. Images shown are from the 6 hour incubation. The Shiga 
toxin containing media was then removed and cells washed once with PBS. Human C7 
deficient serum (40% in gelatine veronal buffer) was then added for 30 minutes. Cells 
were subsequently washed x3 before being fixed in 4% PFA and immunofluorescence 
performed for CFH or C3d and co-stained for DAPI. Endothelial cells were then imaged in 
the Wolfson Bioimaging Facility on confocal multi-laser Leica SP5II microscope. Of note 
the human anti-C3d antibody used (Abcam #ab17453) on closer inspection was not 
specific to C3d. It also recognised other C3 cleavage products including C3b and iC3b.  
In these co-culture experiments glomerular endothelial cells showed a loss of CFH 
expression, that was dependent upon the presence of podocytes (Figure 7-25). C3d 
expression was increased in endothelial cells in these co-culture experiments when the 
cells were treated with Shiga toxin in the presence of podocytes (Figure 7-27). In the 
absence of podocytes, endothelial cells treated with Shiga toxin showed no increase in 
C3d expression. C3d is one of several C3 cleavage products formed when C3 is activated 
[2]. Clearly, cross-talk between podocytes and endothelial cells both in vitro and in vivo 
within the glomerulus; is vital in the development of HUS. Furthermore, it is evident from 
these data that CFH is an important regulator in Shiga toxin HUS and that a reduction in 





Figure 7-25: Conditionally immortalised human glomerular endothelial cells show a reduction in 
CFH when co-cultured with podocytes in the presence of Shiga toxin 
Co-culture experiments using conditionally immortalised human podocytes and endothelial cells 
were set up in corning 6-well trans-well supports with 3um pores as described. Panels A and Ai 
show baseline CFH (red) expression in endothelial cells cultured in the presence of podocytes but 
no Shiga toxin. Panels B and Bi show a reduction in CFH expression in endothelial cells cultured in 
the presence of podocytes and Shiga toxin (6 hour incubation time). Panels C and Ci show that 
endothelial cells cultured alone and treated with Shiga toxin for 6 hours show no change in CFH 
expression. Images A-C (x10 magnification), images Ai-Ci (x60 magnification). Experiments 
representative of n=3 and show DAPI (blue co-staining) performed by Dr Louise Farmer and data 









Figure 7-26: Quantification of CFH Immunofluorescence staining 
Co-culture experiments using conditionally immortalised human podocytes and endothelial cells 
were set up in corning 6-well trans-well supports with 3um pores as described. IF images shown in 
Figure 7-25 were used to quantify the level CFH expression in each experimental group using 
corrected total cell fluorescence. When podocytes and endothelial cells are co-cultured together 
in the presence of Shiga toxin for 6 hours there is a statistically significant reduction in CFH 
expression. * Unpaired T-test p<0.05. Experiments representative of n=3 as identified by each data 







































Figure 7-27: Conditionally immortalised human glomerular endothelial cells show an increase in 
C3d expression in the presence of podocytes and Shiga toxin 
Co-culture experiments using conditionally immortalised human podocytes and endothelial cells 
were set up in corning 6-well trans-well supports with 3um pores as described. Cells were 
permeabilised prior to antibody application. Panels A and Ai show baseline C3d (green) expression 
in endothelial cells cultured in the presence of podocytes but no Shiga toxin. Panels B and Bi show 
an increase in C3d expression in endothelial cells cultured in the presence of podocytes and Shiga 
toxin (6 hour incubation time). Panels C and Ci show that endothelial cells cultured alone and 
treated with Shiga toxin for 6 hours show no change in C3d expression. Of note the human anti-
C3d antibody used (Abcam #ab17453) was not specific to C3d. It also recognises other C3 cleavage 
products including C3b and iC3b. Images A-C (x10 magnification), images Ai-Ci (x60 magnification). 
Experiments representative of n=3 and show DAPI (blue co-staining) performed by Dr Louise Farmer 
and data reproduced with permission. 
 








Figure 7-28: Quantification of C3d immunofluorescence staining 
Co-culture experiments using conditionally immortalised human podocytes and endothelial cells 
were set up in corning 6-well trans-well supports with 3um pores as described. IF images shown in 
Figure 7-27 were used to quantify the level C3d expression in each experimental group using 
corrected total cell fluorescence. When podocytes and endothelial cells are co-cultured together 
in the presence of Shiga toxin for 6 hours there is a statistically significant increase in C3d 
expression. * Unpaired T-test p<0.05. Experiments representative of n=3 as identified by each data 
point: experiment performed by Dr Louise Farmer and data reproduced with permission. 
7.5 Discussion 
This chapter has described the generation of a novel mouse model: the PodrtTA-Tet-O-
Gb3 Gb3 null mouse. This mouse only expresses the receptor for Shiga toxin (Gb3) in the 
podocyte in the presence of doxycycline due to tetracycline-controlled transcription of 
Gb3 synthase; allowing specific study of the role of the podocyte in HUS. Fascinatingly, 
when these mice were given IP Shiga toxin, they developed HUS: thrombocytopenia, 
haemolytic anaemia, and uraemia. This was most striking at day 10 following IP Shiga toxin 
treatment (p<0.05). This is the first time that a mouse model of Shiga toxin HUS (which 
recapitulates the disease in humans) has ever been described. Even more interesting, is 
that these animals appeared to recover by day 24 post Shiga toxin, recapitulating what is 
often seen in patients with Shiga toxin HUS [3]. Renal histology demonstrated glomerular 
TMA; the pathognomonic lesion of HUS; with intracapillary thrombus formation seen on 
EM. Immunofluorescence has demonstrated an increase in glomerular fibrinogen 






































regulator Factor H was significantly reduced in PodrtTA-Tet-O-Gb3 Gb3 null mice, 
rendering them more susceptible to complement attack. To determine whether the 
increase in glomerular C3b deposition in this model is due to loss of CFH regulation; it 
would be interesting to see if restoration of local glomerular CFH levels rescued the 
phenotype and reduced C3b deposition. An alternative explanation for the apparent loss 
of glomerular CFH expression is that CFH binding affinity to C3b on the glomerular 
endothelial cell surface has been attenuated; for example, by loss of glycocalyx induced 
by Shiga toxin driven damage to the podocyte. Indeed, it has already been shown in Factor 
H binding assays that the interaction between CFH and C3b is enhanced when these 
molecules are bound to host cell glycocalyx [164]. Lectin staining and analysis of the 
glomerular endothelium in the kidneys of PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga 
toxin at the different experimental time points studied (days 4 through to 24) would be a 
relatively straightforward experiment to perform to ascertain whether glycocalyx is lost 
prior to STEC HUS onset in my model.   
These observations were echoed in human cell co-culture experiments. Only in the 
presence of podocytes did glomerular endothelial cells increase C3 cleavage product (C3d, 
C3b, iC3b) expression and loose the protection of complement regulator FH when 
exposed to Shiga toxin. Glomerular endothelial cells alone (treated with Shiga toxin) 
showed no change in C3 cleavage product expression and did not lose CFH protection. 
Clearly, the crosstalk between podocytes and glomerular endothelial cells both in vitro 
and in vivo within the glomerulus; is vital in the development of Shiga toxin HUS. In fact, 
the podocyte Gb3 receptor appears to be a key initiator of the disease. The finding that 
the podocyte is capable of causing a systemic Shiga toxin driven syndrome, may well 
explain why HUS has a predilection to present in the kidney. Shiga toxin HUS does not 
affect every endothelial cell or vascular bed in the body; it only affects the kidney. It is 
only in the kidney that this highly specialised blood filtration interface between podocytes 
and endothelial cells exists. Suggesting that it is the unique cross-talk interaction between 






Chapter 8 : C5 inhibition in a Shiga toxin HUS mouse 
model 
8.1 Introduction 
The PodrtTA-Tet-O-Gb3 Gb3 null mouse develops a phenotype that recapitulates the 
human features of Shiga toxin HUS when given IP Shiga toxin. This is the first time a small 
animal model of Shiga toxin HUS has ever been described. This can now be used to study 
the in vivo pathophysiology of Shiga toxin HUS and help to determine the effects of 
different therapeutic interventions on the development of the disease. Central to my 
hypothesis is that Shiga toxin targets the podocyte, which communicates with the 
glomerular endothelium increasing its susceptibility to complement attack. Acute 
inhibition of VEGF-A secretion from the podocyte is one possible mechansim driving this. 
In order to test this theory, a definitive experimental plan was devised to therapeutically 
rescue the PodrtTA-Tet-O-Gb3 Gb3 null mouse from Shiga toxin HUS using the mouse C5 
inhibitor (BB5.1). This inhibitor is analogous to the C5 inhibitor eculizumab, which is 
already being used in humans to treat atypical HUS.  
8.2 Experimental design 
As summarised in Figure 8-2, PodrtTA-Tet-O-Gb3 Gb3 null mice aged between 10-12 
weeks were given 14 days of oral doxycycline in their drinking water to induce Gb3 
expression in their podocytes. They were then randomised to receive either 1mg of 
intraperitoneal (IP) mouse C5 inhibitor (mAb BB5.1 Hycult® Biotech) or IP 0.9% sterile 
normal saline of the same volume as a control. The following day all mice received IP Shiga 
toxin at a dose of 10ng/g. Three days later the mice were given either a second dose of 
1mg of IP C5 inhibitor or IP 0.9% sterile normal saline control. This dosing regime was 
chosen due to the known half-life of BB5.1 which is 72 hours, together with the 
recommendation of Hycult® Biotech of twice weekly dosing which has been reported by 





Figure 8-1: Overview of in vivo experimental plan with breeding strategy 
PodrtTA-Tet-O-Gb3 mice on a WT background were back-crossed with Gb3 KO mice to generate 
the PodrtTA-Tet-O-Gb3 Gb3 null mouse. This mouse only expresses Gb3 in its podocyte following 
induction of Gb3 synthase by doxycycline treatment. When given IP Shiga toxin these mice develop 
Shiga toxin HUS (including evidence of a glomerular TMA). To determine whether this is 
complement driven a C5 inhibitor (BB5.1) was given IP to attempt to rescue the HUS phenotype.  
 
Prior to starting this set of experiments, a new batch of Shiga toxin (List Biological 
Laboratories Inc.) was purchased. As discussed in the methods chapter, each time a new 
batch of Shiga toxin was purchased its virulence was assessed in vivo by administering an 
IP injection of 10ng/g to at least 2 wild type mice. From previous work, these mice were 
expected to die from dehydration (due to extra-glomerular off target tubular effects) 
within 3-4 days. However, upon testing this batch of toxin these mice died within 36 
hours.  
Given this observation, together with the finding that in my previous experiments 
PodrtTA-Tet-O-Gb3 Gb3 null mice had recovered platelet levels 24 days after IP Shiga 
toxin challenge; all mice in this set of experiments were electively terminated at day 7 
post Shiga toxin treatment. This was to avoid missing any potential effect of the C5 
inhibitor attenuating Shiga toxin HUS in light of this batch of toxin being slightly more 
potent in wild type mice. Interestingly, the purity of the new batch of Shiga toxin was 
>98% and the endotoxin content determined on kinetic chromogenic LAL assay at List Labs 
was <90EU/mg (the same as the previous vial supplied). Hence, I suspect that the increase 
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in virulence seen was attributable to the fact that the toxin was used within a few days of 
its arrival (rather than a few weeks) and so not kept at -20°C for very long. It is has been 
shown that long term storage > 6 months at -20°C will reduce the virulence of Shiga toxin 
[300].   
As in the previous set of experiments (described in Chapter 7), blood was taken at the 
time of terminal anaesthesia via cannulation of the inferior vena cava. This was taken with 
a pre-heparinised 23 gauge needle and syringe to ensure the blood obtained did not clot. 
Differential full blood count (which included platelet and haemoglobin measurements) 
was obtained from the Sysmex XN-20® in Bristol Royal Infirmary Haematology 
department. Blood films were also made in the same way as before, with 3 films per 
mouse produced.  
Any remaining blood sample was taken back to the laboratory and centrifuged (as before), 
to separate it into upper plasma layer and lower red cell layer. The upper plasma layer 
was carefully pipetted off, avoiding any contamination of the sample with red cells. The 
plasma was then sent to Kay Burt at Langford Veterinary school for measurement of urea. 
All blood samples were analysed within 30 - 45 minutes from collection from the mouse 
to ensure accuracy. Urine was collected and analysed as described in the methods 
chapter. At the time of terminal anaesthesia, organs were harvested from the mice 
following the protocol outlined in the methods chapter.  
 
 
Figure 8-2: Experimental plan for C5 inhibition in Shiga toxin HUS mouse model 
PodrtTA-Tet-O-Gb3 Gb3 null mice (n=10) were given 14 days of oral doxycycline in their drinking 
water to induce Gb3 expression in their podocytes only. They were then randomised to receive 
either C5 inhibitor (BB5.1) or sterile saline control via an intraperitoneal (IP) injection. The following 
14 days doxycycline
PodrtTA-Tet-O-Gb3 Gb3 null 
(n=10)
IP C5 inhibitor BB5.1
(n=5)
IP saline control 
(n=5)
2nd dose IP C5 inhibitor BB5.1
(n=5)
2nd dose IP saline control 
(n=5)








day they were all given IP Shiga toxin at 10ng/g and 3 days later a top up dose of either C5 inhibitor 
or saline IP. At day 7 (post IP Shiga toxin) all mice were electively terminated for organ harvesting 
and blood sampling.  
 
8.3 C3b expression time course in Podrt-TA-Tet-O-Gb3 Gb3 null mice 
vs. controls 
Before the decision to electively terminate mice at day 7 post Shiga toxin treatment in the 
C5 inhibitor experiment, the timing of the changes in C3b (complement factor 3b) were 
studied. This was carried out by performing C3b IF in frozen sections taken from mouse 
kidneys in the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin vs. control PodrtTA-Tet-
O-WT Gb3 null mice. Sections were probed for C3b from mice that had been electively 
terminated on day 4, day 7 and day 10 post Shiga toxin IP. This work was performed by 
postdoctoral researcher Dr Jenny Hurcombe. The same protocol outlined in my methods 
was followed to obtain these results. 
This work showed that as early as day 4 and certainly by day 7 post Shiga toxin, there was 
evidence of C3b deposition in the glomeruli of PodrtTA-Tet-O-Gb3 Gb3 null mice (Figure 
8-3). This finding reinforced the decision to use day 7 post Shiga toxin as a termination 
point in my inhibitor experiment; as this was not only enough time post Shiga toxin 
challenge for complement to have been activated in the glomerulus, but it appears to 
peak at this time point. Hence, following two doses of the C5 inhibitor, and 7 days after 
Shiga toxin challenge, if there was any effect of C5 inhibition on the complement cascade 





Figure 8-3: C3b IF time course in PodrtTA-Tet-O-Gb3 Gb3 null mice vs. PodrtTA-Tet-O-WT Gb3 
null control mice at day 4, 7 and 10 post Shiga toxin treatment (x40 magnification).  
IF for C3b was performed on frozen kidney sections in PodrtTA-Tet-O-Gb3 Gb3 null mice (bottom 
row) and controls (top row) following Shiga toxin challenge at day 4, 7 and 10 as indicated. C3b 
staining (green) can be clearly seen within the glomeruli (identified with nephrin co-staining in red) 
at each time point in the PodrtTA-Tet-O-Gb3 Gb3 null mice. Just as previously seen, the PodrtTA-
Tet-O-Gb3 Gb3 null mice show an increase in C3b staining in their glomeruli vs. controls. This is 
apparent as early as day 4 post Shiga toxin treatment and in this cohort of mice C3b appears to 
peak at day 7 post IP Shiga toxin. Image representative of n=3 of each genotype at each timepoint. 
Experiment performed by postdoctoral scientist Dr Jenny Hurcombe reproduced with permission. 
 
8.4  C5 inhibition prevents the development of toxin HUS 
As already discussed in chapter 7, cleavage of C3 can occur via all 3 complement cascade 
pathways: classical, lectin and alternative. It is at the point of cleavage of C3 that these 
pathways converge and go on to culminate with the formation of the membrane attack 
complex (MAC). This leads to the insertion of pores into the target cell membrane 
resulting in osmotic lysis and cell death. Inhibition of C5 would not be anticipated to affect 
activation of C3 because this occurs upstream in the complement cascade. However, by 
inhibiting C5 the formation of the MAC should be prevented (Figure 8-4). Determining 
which of the 3 complement pathways are being activated in Shiga toxin HUS (i.e. classical, 
lectin or the alternative) will not be possible merely from inhibiting C5; as the pathways 
have already converged at this point, but it will provide evidence of whether complement 






































Figure 8-4: The complement cascade 
The complement cascade can be activated by one of 3 pathways: the classical, lectin or alternative 
pathways. All 3 converge at the point of cleavage of C3 and go on to culminate with the formation 
of the membrane attack complex (MAC). This leads to the insertion of pores into the target cell 
membrane resulting in osmotic lysis and cell death. As is evident from this diagram, C5 inhibition 
(at the level indicated by the C5 inhibitor box) will not affect C3 activation which occurs upstream 
of this point in the pathway. However, C5 inhibition will prevent the formation of the MAC, thus 
preventing cell death occurring. Figure adapted from Keir and Langman et al. [30]. 
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
prevents thrombocytopenia 
As already outlined, PodrtTA-Tet-O-Gb3 Gb3 mice (n=10) aged between 10-12 weeks of 
age were given 14 days of oral doxycycline, followed by 1mg/per mouse of IP C5 inhibitor 
(BB5.1) or 0.9% sterile normal saline of the same volume as a control. The following day 
all mice were given 10ng/g of Shiga toxin IP to induce a Shiga toxin HUS phenotype and 3 
days later a further dose of IP C5 inhibitor or saline control. All mice were terminated at 
day 7 post Shiga toxin inoculation. Terminal blood sampling from these mice on day 7 
showed that mice given the IP saline control dropped their platelet count to the levels 
seen in my previous cohort of experiments at day 7 post IP Shiga toxin (under 500 x109/L), 
but those given the C5 inhibitor BB5.1 were protected from this effect (Figure 8-5). This 
suggests a protective effect of C5 inhibition against thrombocytopenia in my Shiga Toxin 





Figure 8-5: C5 inhibition prevents thrombocytopenia in Shiga toxin HUS  
Comparison of platelet count in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin with or 
without C5 inhibition is shown. N=5 for each group, with individual points representing each n. 
Platelet count drops to under 500 x109/L in the mice given IP Shiga toxin and saline. In the mice 
given IP Shiga toxin and C5 inhibitor platelet count is preserved to almost double that of the saline 
group. ***Unpaired T-test p value = 0.0003.   
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
prevents anaemia and uraemia  
Blood samples from all PodrtTA-Tet-O-Gb3 Gb3 null mice were analysed for haemoglobin 
and urea at termination on day 7 post IP Shiga toxin as already described. Mice that had 
been given IP saline as a control showed a drop in haemoglobin and a rise in urea. Mice 
that were administered IP C5 inhibitor BB5.1, showed preservation of their haemoglobin 
and no rise in urea (Figure 8-6). These findings were both statistically significant. Together 
with the finding that C5 inhibition prevents thrombocytopenia in mice given IP Shiga toxin; 
these data suggest that C5 inhibition prevents the development of Shiga toxin HUS in my 
mouse model. This is the first time that complement inhibition in vivo has been shown to 



















































Figure 8-6: C5 inhibition prevents anaemia and uraemia in Shiga toxin HUS 
Panel A shows the comparison of haemoglobin in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga 
toxin with or without C5 inhibition. N=5 for each group, with individual points representing each 
n. In the mice given IP Shiga toxin and C5 inhibitor haemoglobin is preserved vs. the anaemia seen 
in the mice given IP Shiga toxin and normal saline control. **Unpaired T-test p value 0.0017. Panel 
B shows the comparison of urea in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin with or 
without C5 inhibition. N=5 for each group, with individual points representing each n. Mice given 
IP Shiga toxin and saline become uraemic, but mice given the IP C5 inhibitor are protected from 
this effect of IP Shiga toxin. *Unpaired T-test p value = 0.02. 
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
prevents haemolytic anaemia 
Blood films were generated, fixed, and analysed in the same way as previously described 
in results chapter 7. Blood films were necessary to confirm whether erythrocyte 
haemolysis was the cause of the anaemia seen in the mice given IP Shiga toxin and IP 
saline. For each mouse 3 blood films were analysed to ensure a representative sample 
had been obtained. Mice that received IP Shiga toxin and normal saline showed evidence 
of haemolytic anaemia, with fragmentation of red blood cells visible on the film. Mice 
given IP Shiga toxin and C5 inhibitor treatment showed no evidence of haemolysis and 
normal appearance of their red blood cells (Figure 8-7). An estimated 5-10% of red cells 



























































































each animal (n=5). This is slightly lower than the 10-15% observed in my previous cohort 
terminated at day 10 post Shiga toxin challenge.  
 
 
Figure 8-7: C5 inhibition prevents haemolytic anaemia in Shiga toxin HUS 
Blood films for PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline (A and C) and 
PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and C5 inhibitor treatment (B and D) 
terminated at day 7 post Shiga toxin are shown. Red arrows indicate red cell fragments which are 
only seen in PodrtTA-Tet-O-Gb3 Gb3 null animals given Shiga toxin and saline. Panels C and D are 
the same blood films, but images are zoomed in to allow better visualisation of fragments. 
Magnification is x40. Blood films shown are representative of all animals analysed (n=5 in each 
group). An estimated 5-10 % of red cells in the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin 
and saline were fragmented in each animal: representative blood films shown.  
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
prevents TMA 
The trichrome stain martius scarlet blue (MSB) was performed on kidney sections taken 
from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline or C5 inhibitor. In 





mice from each experimental group were analysed. Fibrin thrombi were clearly seen in 
the glomeruli of PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin and saline; with no 
evidence of thrombi in the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin and C5 
inhibitor. Images shown are representative of n=3 for each experimental group and were 
taken using the Leica DMI 6000B microscope at x40 to x100 magnification (Figure 8-8 and 
Figure 8-9).  
 
 
Figure 8-8: C5 inhibition prevents glomerular TMA in Shiga toxin HUS (x40 magnification) 
Martius scarlet blue (MSB) trichrome stain of renal tissue from a PodrtTA-Tet-O-Gb3 Gb3 null 
mouse given IP Shiga toxin and normal saline (A) vs. PodrtTA-Tet-O-Gb3 Gb3 null mouse given IP 
Shiga toxin and C5 inhibitor (B). In panel A: fibrin thrombi (red) are seen within the glomerular 
capillary loops indicated by black arrows. These appearances are characteristic of a glomerular 
TMA, the same histopathological lesion that is seen in humans with Shiga toxin HUS. In panel B: 
there are no fibrin thrombi seen in the glomeruli. Fibrin = red, collagen = blue, erythrocytes = 
yellow. Images shown are representative of n=3 for each experimental group and were taken using 






Figure 8-9: C5 inhibition prevents glomerular TMA in Shiga toxin HUS (x100 magnification) 
Martius scarlet blue (MSB) trichrome stain of renal tissue from a PodrtTA-Tet-O-Gb3 Gb3 null 
mouse given IP Shiga toxin and normal saline (A) vs. PodrtTA-Tet-O-Gb3 Gb3 null mouse given IP 
Shiga toxin and C5 inhibitor (B). Glomerular fibrin thrombi are clearly seen in panel A as indicated 
by black arrows. There is no evidence of fibrin thrombi in the glomerulus of the PodrtTA-Tet-O-Gb3 
Gb3 null mouse given Shiga toxin and the C5 inhibitor. Fibrin = red, collagen = blue, erythrocytes = 
yellow. Images shown are representative of n=3 for each experimental group and were taken using 
the Leica DMI 6000B microscope at x100 magnification.  
 
As well as performing an MSB trichrome stain to look for evidence of TMA in both 
experimental groups; kidney tissue was also sent for electron microscopy analysis (EM). 
Kidney tissue was harvested at the time of termination and preserved in EM fixative. This 
was then processed by the Wolfson Bioimaging Facility at the University of Bristol and 
subsequently sectioned on an ultramicrotome. Unfortunately, these sections are yet to 
be imaged on the Tecnai 12 120kV BioTwin Spirit Transmission Electron Microscope 
scanner; due to the SARS-CoV-2 global pandemic the Wolfson imaging Institute had to 
close before this could be performed. These sections will be imaged as soon as the 
Wolfson Institute re-opens.  
 C5 inhibition prevents the activation of compliment factors C7 and C9 
It is evident from the data presented above, that C5 inhibition prevents 
thrombocytopenia, haemolytic anaemia, uraemia, and glomerular TMA in this mouse 
model of Shiga toxin HUS. However, I wanted to be sure that C5 blockade had led to 
successful inhibition of MAC formation. To do so, MAC formation needed to be 




absence of MAC formation in the mice administered BB5.1. Unfortunately, there are very 
few commercially available C5b-9 (MAC) antibodies for use in mice (see appendix for list 
of antibodies tested).  
The immunofluorescence staining with these antibodies resulted in a high background 
signal in all of the samples tested, even in control Gb3 null mice that did not develop Shiga 
toxin HUS. Several optimisation techniques were attempted to improve this including: 
using normal serum from the same species as the secondary antibody (rabbit) to improve 
the blocking step of the protocol; incubating with the blocking solution for longer, 
additional washing steps and checking for secondary antibody cross-reactivity by using an 
isotype control antibody. The same antibodies were also used for IHC to determine 
whether more specific staining could be achieved using this application. Despite all of 
these modifications, I was unable to demonstrate specific C5b-C9 antibody staining using 
these antibodies (Figure 8-10). 
 
 
Figure 8-10: C5b-C9 Immunofluorescence optimisation 
Immunofluorescence using the rabbit polyclonal anti C5b-C9 (MAC) antibody from Abcam 
(#ab55811). The top row (A) is a kidney section from a PodrtTA-Tet-O-Gb3 Gb3 null mouse 
administered IP Shiga toxin and electively terminated on day 10. The bottom row (B) is a kidney 
section from a PodrtTA-Tet-O-WT Gb3 null mouse (effectively Gb3 null mouse) also given IP Shiga 
toxin and electively terminated on day 10. In both cases there was a high background signal which 
meant no conclusions could be drawn. Despite the use of different blocking agents and using 
different antibody concentrations this could not be improved. C5b-C9 antibody used at a 
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concentration of 1 in 200 to obtain these images at a magnification of x40. Nephrin (red), C5b-C9 
(green) and final image is merged as labelled.  
 
Through a collaboration with Cardiff University Professor Paul Morgan, an expert in 
complement biology (with a special interest in the MAC); I was kindly gifted mouse anti-
C7 and anti-C9 antibodies that had been generated by his group (see appendix for details). 
The anti-C9 antibody had already been used and peer reviewed in previously published 
work, but the anti-C7 antibody was newly developed and had only been tested in ELISAs 
and western blotting applications [301]. Immunofluorescence results with these 
antibodies were specific and reproducible on technical repeats. Immunofluorescence was 
performed using the standard protocol outlined in my methods chapter, with the addition 
of normal goat serum to the blocking solution at 10% concentration as recommended by 
Prof. Morgan’s group. This is the first time that mouse anti-C7 antibody (clone 73D1) has 
been used for immunofluorescence in mouse kidney tissue. 
Both C7 and C9 compliment factors were detected by immunofluorescence in PodrtTA-
Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline. Furthermore, these factors were 
virtually undetectable in mice given IP Shiga toxin and C5 inhibitor (Figure 8-11 and Figure 
8-12). This work demonstrates the successful inhibition of C5 by BB5.1 in vivo, resulting in 
prevention of MAC formation in the kidney. Indeed, it is well established that C7 is the 
central regulator of the assembly of the MAC, as it is only in the presence of C7 that the 
stable bimolecular C5b6 complex can incorporate itself into the target cell membrane 
[302]. If C7 levels are insufficient locally, the C5b6 complex (formed from the activation 





Figure 8-11: C5 inhibition prevents the activation of compliment factor C7 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and either IP 
saline (panel A) or IP C5 inhibitor (panel B) were probed for C7 using IF (shown in green) and co-
stained with the podocyte marker nephrin (red). This demonstrated a statistically significant 
increase in C7 deposition in the glomeruli of the mice administered saline vs. those given C5 
inhibitor BB5.1. As evidenced by the increase in fold change of C7 fluorescence intensity of x8 fold. 
Graph C: Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice (for clarity of figure). Results from n=3 mice 
of each experimental group: 15 glomeruli per mouse at x20 magnification. *** Unpaired T-test p 




















































Figure 8-12: C5 inhibition prevents the activation of compliment factor C9 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and either IP 
saline (panel A) or IP C5 inhibitor (panel B) were probed for C9 using IF (shown in green) and co-
stained with the podocyte marker nephrin (red). This demonstrated a statistically significant 
increase in C9 deposition in the glomeruli of the mice administered saline vs. those given C5 
inhibitor BB5.1. As evidenced by the increase in fold change of C9 fluorescence intensity of x6 fold. 
Graph C: Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice (for clarity of figure). Results from n=3 mice 
of each experimental group: 15 glomeruli per mouse at x20 magnification. *Unpaired T-test p value 
= 0.0143. 
 
Once the stable trimolecular complex of C5b6 and C7 has formed, recruitment of 
compliment factors C8 and C9 generates a cylindrical structure that extends through the 
glycolipid bilayer of the target cell membrane and causes leakage with subsequent 
osmotic lysis of the cell [303]. Of note, after the initial enzymatic cleavage of C5, the 
assembly of the MAC requires no further enzymatic activity [303]. Hence, the increase in 
C7 (x8 fold) and in C9 (x6 fold) seen in the PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga 
toxin and saline can be used as evidence of MAC formation that is not apparent in the 























































C7 and C9 were also shown to co-localise with the glomerular endothelial cell marker 
PECAM (CD31) (Figure 8-13 and Figure 8-14). Co-staining with PECAM was performed 
following the observation that C7 and C9 appeared to be within the centre of the 
glomeruli and did not co-localise with nephrin. This is further evidence in support of Shiga 
toxin targeting the Gb3 receptor in podocytes, leading to activation of complement in the 
glomerular endothelium.  
 
 
Figure 8-13: C7 co-localises with PECAM on IF 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline were 
probed for C7 (green) and the podocyte marker nephrin (red, panel A) or the glomerular 
endothelial cell marker PECAM (red, panel B). This demonstrated that C7 co-localised with PECAM 
within the glomerulus giving a yellow appearance to the IF image, which is not seen on co-staining 
with nephrin.  
 
 
Figure 8-14: C9 co-localises with PECAM on IF  
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Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline were 
probed for C9 (green) and the podocyte marker nephrin (red, panel A) or the glomerular 
endothelial cell marker PECAM (red, panel B). This demonstrated that C9 co-localised with PECAM 
within the glomerulus giving a yellow appearance to the IF image, which is not seen on co-staining 
with nephrin.  
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
reduces fibrinogen deposition in the glomerulus 
It has already been established in chapter 7, that PodrtTA-Tet-O-Gb3 Gb3 null mice given 
IP Shiga toxin show an increase in glomerular fibrinogen deposition. This is a key feature 
of HUS where the classical histopathological lesion is one of glomerular TMA with 
glomerular thrombi staining positive for fibrinogen on immunofluorescence [304]. 
PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline in this experiment, also 
show evidence of fibrinogen deposits in their glomeruli which is attenuated by treatment 
with the C5 inhibitor BB5.1. Four mice were analysed from each experimental group, with 





Figure 8-15: C5 inhibition reduces fibrinogen deposition in Shiga toxin HUS 
Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and either IP 
saline (panel A) or IP C5 inhibitor (panel B) were probed for fibrinogen using IF (shown in green). 
This demonstrated a statistically significant increase in fibrinogen deposition in the glomeruli of 
the mice administered saline vs. those given C5 inhibitor BB5.1. As evidenced by the increase in 
fold change of fibrinogen fluorescence intensity of >x1.5 fold. Graph C: Pod Gb3 = PodrtTA-Tet-O-
Gb3 Gb3 null mice (for clarity of figure). Results from n=4 mice of each experimental condition: 15 
glomeruli per mouse at x20 magnification. *** Unpaired T-test p value <0.0001.   
 
 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
does not affect C3b activation in the glomerulus 
As already outlined, C3b is generated upon cleavage of C3 which can occur due to 
activation of compliment via any of the three main pathways (Figure 8-4). C5 is located 
downstream of C3 in the compliment cascade and so in theory, inhibiting the pathway at 
this level should not affect the activation of C3b by Shiga toxin in the glomeruli of the 
PodrtTA-Tet-O-Gb3 Gb3 null mice. I also wanted to determine the baseline levels of C3b 























































in their drinking water but had not been treated with IP Shiga toxin. As this would 
determine if merely inducing Gb3 expression in the podocyte has an effect upon 
compliment activation within the glomerulus.  
Fresh frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given oral 
doxycycline to induce Gb3 expression in their podocytes followed by an IP saline sham 
injection (as a control for IP Shiga toxin) were probed for C3b on immunofluorescence. 
Kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline, IP Shiga 
toxin and IP saline or C5 inhibitor were also probed for C3b on immunofluorescence at 
the same time. IF showed no statistically significant difference in glomerular deposition 
of C3b between the PodrtTA-Tet-O-Gb3 Gb3 null mice treated with Shiga toxin and saline 
vs. the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin and C5 inhibitor BB5.1 (Figure 
8-16).  
Of particular importance, in the PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline 
to induce the expression of Gb3 but no IP Shiga toxin; there was no evidence of C3b 
activation in the glomeruli. Of note, C3b is known to be present in murine Bowman’s 
capsule in wild type mice [305]. This was excluded in my CTFG analysis through the use of 
nephrin co-staining to identify podocytes which are located on the outside of the 
glomerulus (see methods chapter for description of image J analysis using this method). 
This demonstrates that C3b compliment activation in the glomerulus of PodrTA-Tet-O-
Gb3 Gb3 null mice is due to Shiga toxin treatment itself and not an effect of Gb3 
expression alone.  
 
 
Figure 8-16: C5 inhibition does not affect C3b activation in the glomerulus following Shiga toxin 
challenge  
Pod Gb3 + Stx + saline Pod Gb3 + Stx + inhibitor Pod Gb3 no Stx control
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Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline for 14 days 
to induce Gb3 expression and IP Shiga toxin (or IP saline sham injection as a control) followed by 
either IP saline or IP C5 inhibitor as indicated in the figure were probed for C3b using IF (shown in 
green). Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice (for clarity of figure). There was no difference 
in the IF staining intensity of C3b between the PodrtTA-Tet-O-Gb3 Gb3 null mice treated with Shiga 
toxin and saline vs. the PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin and C5 inhibitor BB5.1. 
In PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline but no IP Shiga toxin; there was no 
evidence of C3b activation within the glomeruli. (Note C3b is known to be expressed by murine 
Bowman’s capsule as observed here [305]). Images shown are representative of  n=3 mice per 
experimental condition at x40 magnification.  
 
 
Figure 8-17: C5 inhibition does not affect C3b activation in PodrtTA-tet-O-Gb3 Gb3 null mice 
given IP Shiga toxin  
Graphical representation of IF results: there was a statistically significant difference in glomerular 
deposition of C3b between the PodrtTA-Tet-O-Gb3 Gb3 null mice treated with Shiga toxin and 
saline vs. PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline to induce the expression of Gb3 
but no IP Shiga toxin. Similarly, there was a statistically significant difference between the PodrtTA-
Tet-O-Gb3 Gb3 null mice given Shiga toxin and C5 inhibitor BB5.1 vs. PodrtTA-Tet-O-Gb3 Gb3 null 
mice given oral doxycycline to induce the expression of Gb3 but no IP Shiga toxin. In PodrtTA-Tet-
O-Gb3 Gb3 null mice given oral doxycycline to induce the expression of Gb3 but no IP Shiga toxin; 
there was no evidence of C3b activation in the glomeruli. No statistically significant difference was 
detected in C3b deposition in PodrtTA-Tet-O-Gb3 Gb3 null mice treated with Shiga toxin and saline 
vs. PodrtTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin and C5 inhibitor BB5.1. Pod Gb3 = PodrtTA-
Tet-O-Gb3 Gb3 null mice (for clarity of figure). Results from n=3 mice of each experimental 























































 C5 inhibition in PodrtTA-Tet-O-Gb3 Gb3 null mice post IP Shiga toxin 
restores CFH expression in the glomerulus 
As illustrated in Figure 8-4, complement factor H (CFH) is a key regulator of the 
complement cascade ensuring that the C3b amplification loop is kept under control, 
preventing excessive cell injury and inflammation [30]. In the first cohort of experiments 
PodrtTA-Tet-O-Gb3 Gb3 null mice had a reduction of CFH deposition in their glomeruli at 
day 10 following IP Shiga toxin challenge. This finding was supported by human in vitro 
data from co-culture experiments where glomerular endothelial cells showed a loss of 
CFH expression, that was dependent upon the presence of podocytes. This suggests that 
in this mouse model of Shiga toxin HUS, there is a loss of CFH protection locally within the 
glomerulus, rendering the glomerular endothelium susceptible to complement attack.  
To determine whether C5 inhibition had any effect on CFH glomerular deposition, IF was 
performed for CFH in frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given 
IP Shiga toxin and saline vs. those given C5 inhibitor. This demonstrated a 50% reduction 
in CFH in the mice given IP Shiga toxin and saline, in comparison to the PodrtTA-Tet-O-
Gb3 Gb3 null mice given Shiga toxin and C5 inhibitor BB5.1. IF was also performed for CFH 
in kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given doxycycline to induce Gb3 
expression, but not given any Shiga toxin. This was to establish what the baseline levels 
of CFH were within the glomeruli of these animals. This revealed CFH staining of the same 
intensity as the mice given the C5 inhibitor. Thus, confirming that it is the IP Shiga toxin 
challenge administered to PodrTA-Tet-O-Gb3 Gb3 null mice that leads to the reduction in 
glomerular CFH protection (Figure 8-18).  
 
 
Figure 8-18: C5 inhibition restores glomerular CFH expression following Shiga toxin challenge  
Pod Gb3 + Stx + saline Pod Gb3 + Stx + inhibitor Pod Gb3 no Stx control
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Frozen kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given oral doxycycline for 14 days 
to induce Gb3 expression and IP Shiga toxin (or IP saline sham injection as a control) followed by 
either IP saline or IP C5 inhibitor as indicated in the figure were probed for CFH using IF (shown in 
green). Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice (for clarity of figure). CFH expression was 
reduced in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline. This was restored to 
baseline levels (evidenced by intensity of CFH staining in PodrtTA-Tet-O-Gb3 Gb3 null mice given 
no Shiga toxin challenge) when C5 inhibition treatment was administered. Images shown are 
representative of  n=3 mice per experimental condition at x20 magnification.  
 
 
Figure 8-19: C5 inhibition restores glomerular CFH expression in PodrtTA-Tet-O-Gb3 Gb3 null 
mice given IP Shiga toxin  
Graphical representation of IF results shown above: there was a 50% reduction in CFH expression 
in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and saline vs. PodrtTA-Tet-O-Gb3 Gb3 null 
mice given Shiga toxin and C5 inhibitor BB5.1. Pod Gb3 = PodrtTA-Tet-O-Gb3 Gb3 null mice (for 
clarity of figure). Results from n=3 mice of each experimental condition: 15 glomeruli per mouse. 
*** Unpaired T-test p value <0.0001.   
 
Together, these findings are very interesting and rather unexpected. These data suggest 
that C3 deposition in this model of STEC HUS, occurs due to a loss of CFH protection on 
the surface of the glomerular endothelial cell rather than activation of C3. To my 
knowledge, this is the first time that C5 inhibition has been shown to affect local 
glomerular levels of CFH in vivo. As such, further investigation is required to determine 



















































change in the level of glomerular CFH expression, but rather a change in CFH binding 
affinity at the glomerular endothelial surface. This change may well be induced by Shiga 
toxin damage to the podocyte, possibly resulting in a change in local VEGF-A expression 
and loss of endothelial cell glycocalyx. Thus, what is being detected is a reduction in CFH 
binding rather than a true representation of glomerular CFH levels. Further work is 
needed to interrogate the underlying mechanism of this observation. Firstly, to assess at 
which timepoint following Shiga toxin inoculation there is loss of glycocalyx (if any); and 
then to measure systemic complement activation levels in this mouse model in the 
presence and absence of treatment with the C5 inhibitor. Unfortunately, in this cohort of 
experiments this could not be performed, as an AP50 test requires at least 200µl of blood 
from each mouse. This would have resulted in not enough blood for full blood count, urea, 
and blood film analysis. However, the AP50 test could be performed in another round of 
experimental mice to determine the level of systemic complement activation in this 
model.   
8.5 Discussion 
This chapter has reported the effects of C5 inhibition in a mouse model of Shiga toxin HUS. 
For the first time, it has been demonstrated that C5 inhibition prevents 
thrombocytopenia, haemolytic anaemia, uraemia, and the development of a glomerular 
TMA in PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin. In this cohort of 
experiments all PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin (and IP saline) 
developed a HUS phenotype, just as reported in the first cohort of experiments detailed 
in chapter 7. Furthermore, the levels of thrombocytopenia, anaemia and uraemia were 
comparable to those seen in my first cohort of experiments. This provides reassuring 
evidence of the reproducibility of the PodrtTA-Tet-O-Gb3 Gb3 null IP Shiga toxin model. 
In this set of inhibitor experiments, C5 inhibition began prior to IP Shiga toxin challenge 
and a further dose was given 3 days later due to the short half-life of the drug (BB5.1). In 
clinical practice, obviously the treatment of Shiga toxin HUS cannot be given before the 
disease develops. Hence, future experiments in PodrtTA-Tet-O-Gb3 Gb3 null mice will 
need to establish whether C5 inhibition after Shiga toxin HUS develops is of benefit. From 
the time course experiments performed, there is evidence of C3 activation within the 
glomerulus as early as day 4 following IP Shiga toxin inoculation in PodrtTA-Tet-O-Gb3 
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Gb3 null mice. Therefore, IP C5 inhibition could be given at this timepoint to determine if 
it prevents glomerular TMA from occurring in my mouse model.  
Extrapolating the findings from this mouse model to human Shiga toxin HUS disease will 
be a challenge, as there is often a delay in presentation of 7-10 days following initial 
infection with Shiga toxin producing bacteria [306]. However, the ECUSTEC randomised 
control trial (ISRCTN89553116) that is currently in progress will hopefully be able to 
evaluate the efficacy of C5 inhibition with eculizumab in humans with Shiga toxin HUS. A 
particular challenge of this trial is the recruitment of enough Shiga toxin HUS cases. The 
incidence in the UK was 0.24 per 100,000 cases per population in 2018, which translates 
to 14 cases in total in England [38]. Ensuring that all of these patients are recruited to 
enable statistical power to be achieved throughout the duration of the trial, requires a 
considerable national effort which is quite a task to coordinate. Thus, in the meantime 
this mouse model of Shiga toxin HUS will be vital in establishing the underlying 
pathophysiology of the disease and allow other compliment therapies to be trialled.   
Through the use of immunofluorescence, it has been shown that formation of the MAC 
within the glomerulus (via activation of C7 and C9) was prevented by systemic C5 
inhibition therapy in this model. Moreover, C7 and C9 expression was co-localised to the 
glomerular endothelium; demonstrating for the first time in Shiga toxin HUS, that 
glomerular cell cross-talk between the podocyte and glomerular endothelium was 
occurring in vivo. Interestingly, C3b activation remained unchanged within the glomeruli 
of mice given C5 inhibitor treatment, which was anticipated given that C5 is downstream 
of C3 in the complement cascade.  
In PodrtTA-Tet-O-Gb3 Gb3 null mice given IP Shiga toxin and systemic C5 inhibition 
treatment, glomerular CFH levels were also found to be preserved. This was in contrast to 
the same mice given Shiga toxin and an IP saline control, where there was an apparent 
reduction in glomerular CFH expression. This observation was rather unexpected but 
would support my central hypothesis that Shiga toxin HUS occurs due to a loss of CFH 
protection against complement-mediated damage on the surface of the glomerular 
endothelial cell. This is the first time that this has been reported in vivo. These findings 
require further investigation as to the underlying mechanisms involved. It is likely that the 
change in glomerular CFH expression is more likely to reflect the binding affinity of CFH to 
the glomerular endothelium. Measurement of systemic complement activation through 
the use of functional assays such as AP50 and CH50 would be useful to delineate the 
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degree of systemic C5 inhibition by BB5.1 achieved in my mouse model. In support of 
these data, recently published work from Vernon et al. describes the development of a 
severe C5 dependent TMA in mice with hepatocyte CFH deficiency (i.e. partial CFH 
deficiency), after exposure to a complement activating trigger. This work demonstrates 
that partial CFH deficiency can give rise to atypical HUS, following a complement-
activating trigger within the kidney that is C5 dependent. Evidently, C5 has a key role in 
the development of complement mediated glomerular TMA and the relationship between 





Chapter 9 : Discussion 
9.1 Achievement of research aims 
At the beginning of this PhD, I set out to achieve 3 main aims outlined in my original 
research hypothesis: 
1. Prove that Shiga toxin acts through the podocyte Gb3 receptor to cause HUS. 
2. Therapeutically rescue STEC-HUS with a C5 inhibitor (analogous to eculizumab). 
3. Determine the cellular mechanisms underlying the action of Shiga toxin. 
Through the application of an unbiased, rigorous experimental approach using total and 
phospho-proteomic analysis, I have been able to identify several key pathways activated 
in the human podocyte following Shiga toxin exposure. Further interrogation of these 
data has allowed me to begin to determine the cellular mechanisms underlying the action 
of Shiga toxin in the glomerulus. In addition, through the use of highly complex genetic 
mouse models, I have been able to demonstrate for the first time that Shiga toxin can act 
via the podocyte Gb3 receptor to cause systemic HUS. From this work it is clear that the 
podocyte is a key initiator in Shiga toxin HUS in vivo. Furthermore, by generating a small 
animal model that recapitulates the human phenotypical changes of STEC HUS; I have 
been able to demonstrate therapeutic rescue with C5 inhibition. As such, not only have I 
addressed the 3 key aims of my original research hypothesis; but I have also generated a 
novel animal model that can be taken forward to evaluate other potential therapies in the 
treatment of patients with this devastating disease.  
9.2 Summary of key findings 
 The molecular effects of Shiga toxin on the podocyte 
At the start of my research project, I optimised 3 different methods of Gb3 detection. This 
was vital to achieve, as the ability to confidently detect Gb3 was to form the basis of all 
subsequent experimental work both in vitro and in genetic mouse models in vivo. Given 
Gb3 is a glycosphingolipid, I needed to establish several new techniques in our laboratory. 
The methods I employed included immunofluorescence using an anti-Gb3 antibody; 
endpoint PCR detection of the enzyme responsible for Gb3 synthesis: Gb3 synthase 
(A4GALT); and detection of Gb3 using thin layer chromatography (TLC). Unfortunately, 
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although TLC proved to be both reproducible and reliable in HeLa cells, in terminally 
differentiated podocytes tritium labelling proved to be a challenge. Furthermore, radio-
isotope labelling of sphingosine would not be possible in mouse tissues from in vivo 
experiments, rendering this TLC overlay method obsolete in this setting. This prompted 
me to contact Dr. Kevin Mills at the Translational Mass Spectrometry Centre (TMSC) in 
London. Through this collaboration I was able to use lipid mass spectrometry to accurately 
quantify the amount of Gb3 expressed in both podocyte cell lines and animal tissues.   
Optimisation of these Gb3 detection methods confirmed that Gb3 was expressed by wild 
type human podocytes in vitro, and absent from both wild type mouse podocytes and 
human A4GALT knockdown podocytes; generated using short hairpin siRNA against Gb3 
synthase. It is important to note that detection of the A4GALT enzyme by PCR does not 
necessarily equate to expression of Gb3 on the cell surface. Indeed, the fact that A4GALT 
mRNA was detected in small quantities in both mouse wild type podocytes and A4GALT 
knockdown podocytes; yet, Gb3 itself was undetectable by immunofluorescence suggests 
post transcriptional silencing of the enzyme. Further, evidence to support a lack of Gb3 
expression in these cell lines was their resistance to the ribotoxic effects of Shiga toxin, 
even at several hundred times the LD50 dose. Together, these findings strongly suggest 
that Gb3 is the receptor required for Shiga toxin to exert its toxic effects and that cells 
lacking the receptor are protected from Shiga toxin cytotoxicity.  
An interesting and unexpected finding from this work, was the discovery that Shiga toxin 
upregulated the expression of Gb3 in human podocytes in vitro. This effect appeared to 
be maximal at 6 hours and return to baseline after 24 hours. These results were replicated 
several times and consistent across IF and INCell analysis. This effect has not been 
described in podocytes before (upon review of current literature) and was not apparent 
in A4GALT knockdown podocytes or wild type mouse podocytes. However, it has been 
reported in neuronal cells of patients with Shiga toxin HUS and in dermal microvascular 
endothelial cells [84][248]. Pro-inflammatory cytokines such as TNF-α and IL-1β as well as 
bacterial lipopolysaccharide and neutral sphingomyelinase (produced by eukaryotic cells 
in response to stresses such as infection) have also been shown to induce Gb3 receptor 
expression in neurones [84]. In dermal microvascular endothelial cells, the mechanism 
behind upregulation of the Gb3 receptor has been found to be due to increase in 
intracellular ceramide; accompanied by an increase in ceramide glucosyltransferase 
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enzyme (the first of three enzymes involved in the Gb3 biosynthesis pathway). Notably, 
no evidence of an increase in A4GALT mRNA was seen in these cells [95].  
Conversely, work by Hughes et al. in cultured human proximal tubule cells (known to 
express high levels of Gb3), has demonstrated an increase in A4GALT gene transcription 
and a reduction in α-galactosidase mRNA levels in response to Stx1 treatment [308]. There 
was no change in ceramide glucosyltransferase activity detected in this cell line. 
Interestingly, in human glomerular endothelial cells, upregulation of Gb3 expression is not 
seen in response to Shiga toxin treatment in vitro [95]. The finding that an upregulation 
of the Gb3 receptor occurs in response to Shiga toxin treatment in the podocyte, infers 
an increased sensitivity to Shiga toxin, that is potentiated by the toxin itself. The molecular 
mechanism responsible for the increase in Gb3 receptor expression in podocytes is yet to 
be established. 
 Proteomic Analysis 
The generation of a human A4GALT knockdown podocyte cell line, provided me with a 
control for non-specific, non-Gb3 receptor binding which facilitated investigation of the 
effects of Shiga toxin treatment on the podocyte. Through LC-MS/MS analysis of the total 
protein and phospho-protein changes in wild type human podocytes versus A4GALT 
knockdown podocytes, I identified several key pathways underlying the cellular response 
to Shiga toxin. The most notable protein signalling networks activated were ER stress 
pathways and the innate immune system receptors of the NLRP3 inflammasome complex. 
Actin cytoskeleton and cell assembly proteins, as well as VEGF-A expression were found 
to be decreased in response to Shiga toxin treatment. This is the first time that the 
molecular effects of Shiga toxin treatment in the podocyte has been studied in detail. 
Further investigation into how these pathways interact to result in the development of 
Shiga toxin HUS in patients is warranted, with the intention of identifying novel targets 
amenable to pharmacological intervention in the treatment of the disease.  
 A4GALT knockdown mice are resistant to Shiga toxin effects 
My in vitro work confirmed that expression of the Gb3 receptor correlated with the 
sensitivity of the podocyte to Shiga toxin. The generation of an A4GALT knockdown mouse 
established this association in vivo. Wild type mice were shown to lack expression of Gb3 
in their glomeruli. The presence of the receptor in their renal tubules accounted for the 
severe dehydration and tubular necrosis that led to their death within 5 days of 
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intraperitoneal Shiga toxin administration. In stark contrast, A4GALT knockout mice were 
found to be resistant to the lethal effects of Shiga toxin, even at 400 times the LD50 dose. 
All A4GALT knockout mice survived until electively terminated for organ harvesting 8 
weeks after Shiga toxin challenge. They had no change in their serum creatinine or renal 
histology. This model clearly illustrates that the receptor for Shiga toxin in vivo is Gb3 and 
that in the absence of this receptor mice are completely protected against the lethal 
effects of Shiga toxin.  
 Generation of an inducible podocyte specific Gb3 synthase mouse on a 
Gb3 null background 
In order to address my research hypothesis that Shiga toxin acts through the podocyte 
Gb3 receptor to cause HUS; a mouse model with inducible podocyte Gb3 expression was 
generated. This was achieved using tetracycline controlled transcription activation of Gb3 
synthase linked to a podocin promoter. This model needed to be inducible because the 
Gb3 over-expressing mouse results in a Fabry disease phenotype; which interestingly is 
resistant to intraperitoneal Shiga toxin challenge. PodrtTA-Tet-O-Gb3 synthase mice that 
given IP Shiga toxin developed evidence of glomerular TMA on histology, but 
unfortunately died within 3-5 days from the same off target, extra-glomerular effects that 
were seen in wild type mice. Consequently, to eliminate the renal tubular dehydration 
effects of Shiga toxin in vivo, the PodrtTA-Tet-O-Gb3 mouse was back-crossed with the 
A4GALT knockout mouse, to generate a mouse that only expressed Gb3 in its podocytes. 
This model allowed me to study the specific role of the podocyte in Shiga toxin HUS.  
Fascinatingly, PodrtTA-Tet-O-Gb3 Gb3 null mice developed HUS: thrombocytopenia, 
haemolytic anaemia, and uraemia at day 10 following IP Shiga toxin. Renal histology 
demonstrated a glomerular TMA, the pathognomonic lesion of HUS; with intracapillary 
thrombus formation seen on electron microscopy. Immunofluorescence confirmed a 
statistically significant increase in glomerular fibrinogen deposition and C3b versus 
control mice. Interestingly, not all glomeruli were affected by TMA in this model; 
suggestive of a degree of podocyte and/or glomerular endothelial cell heterogeneity in 
the response to Shiga toxin treatment in vivo. This finding may also reflect the temporal 
evolution of STEC HUS with different glomeruli affected over the course of the disease. 
Indeed, this has been observed in renal biopsies taken from humans with HUS. In fact, in 
a recent ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) meeting it was even 
suggested that consideration be given to re-classification of HUS as with or without overt 
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fibrin platelet thrombosis, given the fact that this may be absent altogether from renal 
biopsies of patients with TMA [141].  
In addition, glomerular expression of complement regulator factor H, was significantly 
reduced in PodrtTA-Tet-O-Gb3 Gb3 null mice, rendering them more susceptible to 
complement attack. This is the first time that a mouse model of Shiga toxin HUS which 
recapitulates the disease in humans has ever been described. Even more interesting, is 
that in this model mice appear to recover by day 24 post Shiga toxin, recapitulating the 
clinical sequelae that is often seen in STEC HUS patients [3]. 
 C5 inhibition protects against glomerular TMA in STEC HUS  
Using the PodrtTA-Tet-O-Gb3 Gb3 null mouse model of STEC HUS, I was able to rescue the 
HUS phenotype with the C5 inhibitor BB5.1. This is a mouse C5 inhibitor, analogous to the 
C5 inhibitor eculizumab used in humans with atypical HUS. Confirmation of C5 inhibition 
was confirmed by the finding that C7 and C9 activation was significantly reduced in the 
glomeruli of animals treated with the inhibitor versus those treated with a saline control. 
Reassuringly, C3b activation was unchanged in the glomeruli of mice given C5 inhibitor 
treatment, in-keeping with the fact that C5 is downstream of C3 in the complement 
pathway. However, the finding that the complement regulator factor H was restored in 
PodrtTA-Tet-O-Gb3 Gb3 null mice given the C5 inhibitor (versus mice given an IP saline 
control) was rather unexpected and difficult to explain.  
Further investigation is required to determine how C5 inhibition could possibly exert this 
effect. It is conceivable that there is no change in the actual level of glomerular CFH 
expression, but rather a change in CFH binding affinity at the glomerular endothelial 
surface. This change may well be induced by Shiga toxin damage to the podocyte, possibly 
resulting in a change in local VEGF-A expression and loss of endothelial cell glycocalyx. 
Indeed, it has already been established that binding of CFH to C3b is enhanced when these 
molecules are bound to host cell glycocalyx [164]. Thus, the immunofluorescence findings 
may well reflect a reduction in CFH binding rather than a true representation of 
glomerular CFH levels. Further work to assess whether glomerular endothelial cells loose 
glycocalyx in this STEC HUS model; and to measure systemic complement activation levels 
in mice treated with the C5 inhibitor is required to interrogate the precise sequence of 
pathological events that are occurring.  
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9.3 Implications of this work  
 Insights into the pathogenesis of STEC HUS 
The work performed throughout the course of my PhD, has led to a greater understanding 
of the pathogenesis of Shiga toxin HUS. Through the use of in vitro and in vivo A4GALT 
knockdown models I have demonstrated that the receptor for Shiga toxin is Gb3; and that 
in the absence of this receptor, cells and tissues are protected against the lethal effects 
of Shiga toxin. Furthermore, the generation of the PodrtTa-Tet-O-Gb3 Gb3 null mouse has 
led to the development of a STEC HUS small animal model that recapitulates the disease 
in humans. Through interrogation of this model, I have shown that local complement 
activation occurs in the kidney in response to Shiga toxin exposure and that complement 
regulatory factor H protection is lost from the glomerular endothelial cell surface.  
Together this led to an increase in the susceptibility of the glomerular endothelium to 
complement attack with formation of the MAC on the glomerular endothelial cell surface. 
For the first time in vivo, I have demonstrated that Shiga toxin HUS is associated with local 
complement activation in the kidney.  
In support of this work, my observations in vivo were echoed in human glomerular cell co-
culture experiments. Only in the presence of podocytes did glomerular endothelial cells 
show an increase in C3 cleavage product deposition (C3b, iC3b and C3d) and loose the 
protection of complement factor H. In view of these findings, a potential sequence of 
pathological events in STEC HUS could be; Shiga toxin binding to the podocyte Gb3 
receptor resulting in disruption of glomerular homeostasis due to a reduction in VEGF-A 
production. This leads to loss of glomerular endothelial glycocalyx and a reduction in 
complement factor H binding affinity to the glomerular endothelial cell surface, resulting 
in loss of local complement regulation and TMA. Further work is needed to determine 
whether there is also activation of C3 in the glomerulus or if the increase in C3b deposition 
is solely due to loss of regulation. Clearly, cross-talk between podocytes and glomerular 
endothelial cells both in vitro and in vivo, is vital in the development of Shiga toxin HUS. 
In fact, the podocyte Gb3 receptor appears to be a key initiator of the disease.  
 Direct clinical implications  
The finding that in the STEC HUS mouse model, C5 inhibition resulted in rescue of the 
glomerular TMA phenotype; further supports the hypothesis that STEC HUS is a result of 
complement activation in the kidney. Particularly exciting is the prospect that a C5 
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inhibitor (eculizumab) is already available for use in humans. With over a decade of safety 
data for its use in atypical HUS patients, it is theoretically plausible to test its efficacy in 
human STEC HUS imminently. Of note, the concept of complement blockade in the 
treatment of STEC HUS is not new. Several case series have been reported in paediatric 
patients suggesting benefit from eculizumab treatment. However, retrospective analysis 
of C5 inhibition in adults with STEC HUS have been inconclusive [199]. My experimental 
findings further support the need for a randomised controlled trial to definitively evaluate 
whether C5 inhibition with eculizumab is beneficial in the treatment of STEC HUS in 
humans.    
It is also important to highlight that in the STEC HUS animal experiments performed, C5 
inhibition began prior to IP Shiga toxin challenge. In the clinical setting, the mean interval 
from exposure to Shiga toxin producing bacteria and onset of symptoms is 3 days, with 
almost all cases diagnosed within 2 weeks of onset of diarrhoea [31][41]. Hence, future 
experiments using the STEC HUS mouse model, would need to establish whether C5 
inhibition after IP Shiga toxin challenge (i.e. following disease induction) is of benefit. 
Additionally, the discovery that C5 inhibition in the STEC HUS mouse model protected 
against the development of the disease, has demonstrated that terminal complement 
pathway activation is important in the pathogenesis of STEC HUS. Given that the classical, 
lectin and alternative complement pathways all culminate in the formation of the MAC, 
further work would also need to be performed to delineate precisely which pathways are 
active in the model.  
 Clinical trial data 
During the course of my PhD, a national randomised, double-blind, placebo controlled 
trial ‘ECUSTEC’ (international trial no: ISRCTN89553116) opened in the United Kingdom 
[201]. This trial is ongoing, with the aim to establish whether eculizumab treatment in 
children with STEC HUS is of benefit. The Bristol Renal research group (under supervision 
of Professor Moin Saleem) has been receiving blood and urine samples from the ECUSTEC 
trial. These are taken as optional, additional samples to allow the investigation of several 
key areas of interest that fall outside of the primary and secondary outcomes of the main 
trial. A particular challenge of the ECUSTEC trial has been in the recruitment of sufficient 
STEC HUS cases to ensure statistical power is reached. Thus, until enough cases are 
recruited and randomised into the trial with publication of its results, the STEC HUS mouse 
model will be crucial in establishing the underlying pathophysiology of the disease; and in 
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the assessment of any new therapeutic targets that may be of benefit in the treatment of 




Chapter 10 : Future work 
The work presented in this thesis has provided evidence in support of a key role for the 
podocyte in the pathogenesis of Shiga toxin HUS. However, several unanswered questions 
remain which could form the basis of future studies as outlined below.    
10.1 Further investigation into the pathogenesis of STEC HUS 
My in vitro work has found that in the human podocyte, upregulation of the Gb3 receptor 
occurs in response to Shiga toxin treatment. The mechanism behind this observation in 
podocytes is yet to be elucidated. This phenomenon has been reported in several cell 
types and attributed to changes in the gene transcription of different enzymes within the 
Gb3 synthesis pathway in each cell line studied. Thus, an initial line of investigation would 
be to measure A4GALT mRNA levels in human podocytes treated with Shiga toxin, versus 
untreated controls over time. Analysis of ceramide glucosyltransferase and α-
galactosidase mRNA levels would also be of interest and relatively straight forward to 
perform. Not only would this provide an insight into the cellular processes leading to an 
increase in Gb3 receptor expression in podocytes; but could also lead to the identification 
of intracellular pathways that might be potential therapeutic targets in STEC HUS patients. 
For example, if a reduction of α-galactosidase mRNA levels were found in podocytes 
treated with Shiga toxin, the effect of restoring this enzyme could be evaluated against 
the level of expression of Gb3 and podocyte susceptibility to Shiga toxin induced 
cytotoxicity.  
To date, in vitro studies into the host inflammatory response to infection with STEC, have 
focused upon the glomerular endothelial cell. This work has shown that in culture, 
glomerular endothelial cells upregulate Gb3 receptor expression only when treated with 
Shiga toxin in the presence of pro-inflammatory cytokines TNFα and IL-1β [72][98]. 
Therefore, it would be interesting to evaluate the effect of these cytokines in the 
podocyte; both in the presence and absence of Shiga toxin, to investigate any associated 
changes in Shiga toxin sensitivity. The INCell and immunofluorescence assays that I have 
already set up during my PhD would mean that these experiments could be fairly easily 
performed. Equally, the local glomerular inflammatory response in STEC HUS would be 
interesting to evaluate in my STEC HUS mouse model. Initial investigation would involve 
RT-PCR analysis of whole kidney tissue in these mice to ascertain whether there is any 
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increase in pro-inflammatory cytokine mRNA and at which time points in the 
development of the disease.  
The in vivo STEC HUS mouse model described in this project, recapitulated the disease 
seen in humans but does not entirely reflect human disease. STEC HUS in humans is 
caused by ingestion of infected food and water or exposure to contamination from animal 
faeces [46][47]. However, in PodrtTA-Tet-O-Gb3 Gb3 null mice, Shiga toxin HUS was 
induced via intraperitoneal inoculation with Stx2. This represents a somewhat artificial 
method of infection with direct entry of the toxin into the circulation; bypassing the need 
for ingestion of Shiga toxin producing bacteria and gastrointestinal absorption. Thus, the 
mechanism behind Shiga toxin translocation from the large intestine into the bloodstream 
cannot be addressed by this STEC HUS animal model and remains unknown. 
Of note, my initial experimental plan had been to use the genetically modified Shiga toxin 
producing rodent pathogen Citrobacter rodentium that has been described by Mallick et 
al [119]. These bacteria are known to cause attaching and effacing lesions on the intestinal 
epithelium in mice, reflecting those seen in STEC HUS in the human gut [119]. 
Furthermore, wild type mice infected by oral gavage with genetically modified Shiga toxin 
producing Citrobacter rodentium, were reported develop renal tubular disease 
reminiscent of that seen in mice administered intraperitoneal Shiga toxin and LPS [119]. 
Thus, theoretically this method of infection is a much better representation of STEC HUS 
human infection. However, in PodrtTA-Tet-O-Gb3 Gb3 null mice, induction of Gb3 
expression in the podocyte is dependent upon oral doxycycline treatment for 14 days. 
Thus, I was concerned that co-administration of oral Citrobacter rodentium and 
doxycycline would impact upon the toxicity of the bacteria; potentially reducing its effect 
in this model. Hence, the decision was made to opt for intraperitoneal injection of Stx2 
which would not be affected by oral doxycycline; accepting that this modality of 
inoculation was somewhat unrepresentative of human infection [1]. 
However, the STEC HUS mouse model developed during my PhD could be used to 
investigate how Shiga toxin is transported in the circulation to target organs. This would 
require labelling of the toxin prior to mouse inoculation and a way of tracing its journey 
to the kidney. This is not a new concept; the B subunit of cholera toxin has been used as 
a retrograde tracer in neurones since the 1980s [309]. In fact, there are now commercially 
available cholera toxin subunit B probes that are Alexa fluor™ conjugated, enabling 
tracing of neuronal projections in animals [310]. To date, there are no such available 
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labelled Shiga toxin subunits to facilitate tracing of the toxin in vivo. However, the finding 
that Gb3 is over-expressed in colorectal, breast and ovarian tumours has led to work 
investigating the potential use of Shiga toxin as a method of delivering cytotoxic 
chemotherapy compounds directly to cancer cells. Studies in this field have also reported 
coupling of the Shiga toxin B subunit to contrast agents to facilitate non-invasive tumour 
imaging using confocal fluorescence endoscopy and positron emission tomography (PET) 
scanning [69]. The use of these contrast labelling technologies in my model of STEC HUS 
would be fascinating; and may lead to insights into how Shiga toxin is transported in the 
circulation to target organs such as the kidney. 
10.2 Development of a mouse endothelial cell Gb3 expression model 
The PodrtTA-Tet-O-Gb3 Gb3 null mouse model generated during my PhD has shown that 
the podocyte is capable of causing a systemic Shiga toxin driven HUS. In this mouse model, 
only the podocyte expresses the Shiga toxin receptor Gb3. This suggests that carriage of 
Shiga toxin in the circulation to the kidney (at least in this model) is independent of Gb3 
expression on blood cells. This would support recent studies demonstrating Shiga toxin 
carriage by TLR4 receptors on neutrophils in the circulation in humans [123]. As such, the 
PodrtTA-Tet-O-Gb3 Gb3 null mouse model is a somewhat purest model, designed 
specifically to determine the role of the podocyte in STEC HUS. In humans however, the 
Gb3 receptor is present throughout the nephron and highly expressed in glomerular 
endothelial cells. Thus, the generation of a mouse that expresses Gb3 in both the 
podocyte and glomerular endothelial cell would represent a more humanised model in 
which to study the disease.  
This genetic mouse model could be generated using similar targeted, cell specific 
techniques that have been utilised in this project. The endothelial cell promoter Tie-2 
could be used in place of the podocin promoter construct PodrtTA, to induce expression 
of the Gb3 receptor in the glomerular endothelial cell in the presence of doxycycline. The 
Tie-2rtTA-Tet-O-Gb3 Gb3 null mouse could then be administered Shiga toxin and the 
effects studied. Following this, the PodrtTA-Tet-O-Gb3 Gb3 null mouse could be crossed 
with the Tie-2rtTA-Tet-O-Gb3 Gb3 null mouse to generate a mouse expressing Gb3 both 
in the podocyte and glomerular endothelium. One would anticipate that this mouse might 
display a more severe phenotype than either model alone, when administered 
intraperitoneal Shiga toxin. However, of note the Tie-2 promoter is not specific to 
277 
 
glomerular endothelium. This promoter encodes an angiopoietin receptor that is 
expressed in all endothelial cells from embryogenesis through to adulthood [311]. 
Therefore, study of the specific effects of Shiga toxin in the glomerular endothelium would 
not be possible using this promoter. Tie-2 is also expressed in megakaryocytes, B and T 
lymphocytes, macrophages, and granulocytes. Given that thrombocytopenia is a key 
feature of STEC HUS, the induction of Gb3 expression in megakaryocytes is also likely to 
be an issue in this model. Nevertheless, this mouse would arguably be a more 
representative model of Gb3 expression in humans (versus Gb3 expression in the 
podocyte alone); as in humans Gb3 is found in other microvascular endothelial beds 
including the brain, skin and lungs [93][96][97]. Hence, this model may well provide 
further insight into the mechanisms underlying STEC HUS pathogenesis.  
A further avenue of investigation would be the application of rtTA-Tet-O-Gb3 gene 
technology to induce Gb3 expression in other organs in the mouse model, that are known 
to be affected in humans with STEC HUS. Indeed, it is well documented that extra-renal 
manifestations affecting the brain, pancreas, heart, and skin occur in human disease 
[32][42]. This model would require a specific promoter for each organ in order to 
delineate the tissue specific effects of Shiga toxin in vivo.  
10.3 Determining the role of VEGF-A in the development of TMA 
The link between VEGF-A and the development of glomerular TMA was first highlighted 
in a seminal paper from Eremina et al. that observed the phenotype in a podocyte specific 
VEGF-A knockout mouse model [11]. More recently published work by Keir et al. went on 
to interrogate the mechanism behind this finding and reported a reduction in glomerular 
factor H expression in both podocytes and glomerular endothelial cells. Loss of factor H 
protection in the glomerulus was also shown to be associated with an increase in C3 
deposition [222]. In STEC HUS patients, studies of renal biopsy samples have also 
confirmed that glomerular VEGF-A expression was reduced [220]. Together, these 
findings demonstrate a link between VEGF-A, complement regulation and the 
development of glomerular TMA. This is of particular relevance to my work as the 
podocyte is the major source of VEGF-A in the glomerulus [11].  
In fact, in my original research hypothesis it was postulated that following binding of Shiga 
toxin to Gb3 in the podocyte there is a reduction in local glomerular VEGF-A production; 
which results in an increase in glomerular endothelial cell susceptibity to complement 
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attack. I have started to address this theory in my STEC HUS mouse model, using in situ 
hybridisation to quantify VEGF-A expression (Figure 5-27). However, due to the recent 
global SARS-CoV-2 virus outbreak, my work was prematurely halted as a result of 
laboratory closure. Mouse kidney sections from PodrtTA-Tet-O-Gb3 Gb3 null mice given 
Shiga toxin, are ready to be imaged on light microscopy and analysed once the laboratory 
reopens. Evidence of a reduction in glomerular VEGF-A expression in my STEC HUS mouse 
model would be fascinating; and further support the link between VEGF-A expression in 
the glomerulus, loss of local complement factor H protection and the development of 
glomerular TMA.  
In further support of the importance of local complement factor H regulation in the 
development of glomerular TMA in STEC HUS, C5 inhibition was found to restore 
glomerular factor H in PodrTA-Tet-O-Gb3 Gb3 null mice given Shiga toxin. In situ 
hybridisation for VEGF-A in kidney sections from these mice, to determine if glomerular 
VEGF-A levels are also preserved would be of particular interest. Confirmation of VEGF-A 
preservation in the inhibitor treated mice (versus control mice), would provide strong 
evidence in support of a fundamental role for not only VEGF-A, but also the podocyte in 
the pathogenesis of STEC HUS. 
10.4 Final Conclusion 
The work presented in this thesis has led to the generation of a STEC HUS mouse model, 
that recapitulates the phenotypical changes seen in human disease. The discovery that 
the podocyte is capable of causing STEC HUS, with activation of complement observed on 
the glomerular endothelium; is compelling evidence for the importance of glomerular cell 
cross-talk within the kidney in the development of this disease. Indeed, this model may 
well explain why HUS has a predilection to present in the kidney; as it is only here that 
this highly specialised blood-filtration interface between podocytes and endothelial cells 
exist. Many questions remain, but I hope that the STEC HUS mouse model together with 
the techniques developed in this PhD, will go on to prove useful in advancing our 
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Chapter 12 : Appendix 
All reagents are from Sigma-Aldrich unless stated. 
12.1 In vitro work reagents 
 Cell culture work 
Podocyte cell media: 
RPMI-1640 (500ml) with L-glutamine and sodium bicarbonate (Sigma-Aldrich) 
Heat inactivated Fetal Bovine Serum (FBS 50ml) (Life technologies) 
Penicillin and Streptomycin (10ml) (Sigma-Aldrich) 
 
Endothelial cell media: 
EGM-2V Basal Medium (500mls) (Lonza Biologics PLC) 
EGM-2V Bullet kitTM (Lonza Biologics PLC) – added as supplied except for VEGF which was 
discarded. 
 
HeLa cell media: 
DMEM/F12 (500mls) (Fisher Scientific) 
 
Freezing Solution: 
FBS (5mls) (Life technologies) 
Cell specific media made up as above (4mls)  
Dimethyl sulphoxide (DMSO) (1ml) (Sigma-Aldrich) 
 
Basic Reagents: 
- Trypsin-EDTA 0.25% - 1% (Sigma-Aldrich) 
- Trypan blue 0.4% (Biosystems) 
- 4% paraformaldehyde (PFA) in PBS (Santa Cruz) 
- Phosphate buffered saline (PBS): made up in 10L of distilled water: 80g sodium 
chloride, 2g potassium chloride, 14.4g of disodium hydrogen phosphate and 2.4g 
potassium hydrogen phosphate. Stir and adjust pH to 7.4. 
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- Bovine Serum Albumin 5% solution: add 2.5g to 50mls distilled water (for IF) or TBST 
(for western blotting). 
 
 Western blotting reagents 
RIPA Buffer: 
For 250mls (make up in distilled water):  
2.2g sodium chloride (150mM)  
2.5ml Triton X 100 (1%)  
1.25g sodium deoxycholate (0.5%)  
0.25g sodium dodecyl sulphate (0.1%) 
1.51g Tris (pH 8 with HCl, 50mM) 
 
Cell lysis buffer for protein extraction:  
For 500μL of cell lysis buffer (required per T75 flask of cells): 
485μL of cold RIPA buffer (made as above) with 5μL of phosphatise inhibitor cocktail A, 
5µl phosphatise inhibitor cocktail B and 5µl protease inhibitor (all Sigma-Aldrich) 
 
Sample buffer: (x2) 
Add to 3.4ml of distilled water:  1ml of 0.5M Tris, 2ml glycerol, 1.6ml 10% SDS, 50µl 
mercaptoethanol and sprinkle of bromophenol blue for blue colour to facilitate easy 
sample loading.   
 
Reducing gel recipe for western blotting: x2 gels (all reagents from Fisher Scientific) 
 Stacking 
gel (4%) 
7.5% Running 10% Running 15% Running 
Acrylamide (30%) (ml) 1.25 5 6.7 10 
dH20 (ml) 5.65 11.3 9.6 6.3 
0.5M Tris pH 6.8 (ml) 2.5 - - - 
3M Tris pH 8.8 (ml) - 2.5 2.5 2.5 
SDS (10%) (µl) 100 200 200 200 
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APS (100mg/ml) (ml) 0.5 1 1 1 
TEMED (µl) 5 10 10 10 
 
Non-reducing gel recipe for western blotting:  
As above but all gels made without SDS 
Sample buffer made without SDS or beta mercaptoethanol 
Running buffer made without SDS  
 
Running buffer (10x stock):  
30.3g Tris base, 144g Glycine, 10g SDS. 100ml diluted in 900ml of distilled water to make 
1L of 1x running buffer. 
 
Transfer buffer (10x stock):  
30g Tris base, 144g Glycine. 100ml diluted with 100ml methanol in 800ml of distilled 
water to make 1L of 1x transfer buffer. 
 
Tris buffered saline plus Tween (TBST) (10x stock):  
24.33g Tris base, 80.06g sodium chloride, pH 7.5 with HCl. Dilute 100mls with 10ml Tween 
20 in 890ml distilled water.  
0.5M Tris pH 6.8: 6.057g Tris base in 100ml dH2O make to pH 6.8 with HCl.   
3M Tris pH 8.8: 36.342g Tris base in 100ml dH2O make to pH 8.8 with HCl.   
Ammonium persulphate (APS): 0.6g added to 2ml 
Western ECL substrate (Biorad) 
Luminol Enhancer solution / Peroxidase (Biorad) 
 
Primary antibodies used for western blotting: 
Name Species Supplier Concentration 
Nephrin Guinea pig IgG Progen (#GP-N2) 1 in 1000 
Synaptopodin Rabbit IgG Santa Cruz (#sc-50459) 1 in 1000 
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β-actin  Mouse IgG Sigma Aldrich (#A1978) 1 in 10,000 
ATF6 Rabbit IgG Abcam (#ab37149) 1 in 1000 
p38 Rabbit IgG Abcam (#ab197348) 1 in 1000 
pIRE  Rabbit IgG Abcam (#ab48187) 1 in 1000 
CHOP Mouse IgG Abcam (#ab11419) 1 in 1000 
GRP78 Rabbit IgG Cell Signalling (#31775) 1 in 1000 
CD2AP Rabbit IgG Cell Signalling (#2135) 1 in 1000 
NLRP3 Rabbit IgG Cell Signalling (#15101) 1 in 1000 
 
Secondary Antibodies for western blotting: all HRP conjugated. 
Anti-rabbit IgG (Sigma) used at 1 in 10,000 (used for all primary antibody rabbit IgG species 
in table above).  
Anti-mouse IgG (Sigma) used at 1 in 10,000 (used for all primary antibody mouse IgG 
species in the table above).  
Anti-guinea pig IgG (Sigma) used at 1 in 10,000 (used for primary nephrin antibody in table 
above). 
 
 Immunofluorescence antibodies 
Primary Antibodies: 
Name Species Supplier Concentration 
Gb3 / CD77 Rat IgM Beckman Coulter (#IM0175) 1 in 100 
Nephrin Guinea pig IgG 2B Scientific (#BP5030) 1 in 400 
Podocin Rabbit IgG Sigma Aldrich (#P0372) 1 in 400 
PECAM / CD31 Rabbit IgG Abcam (#ab124432) 1 in 50 
PECAM/ CD31  Rat IgG BD Bioscience (#553370) 1 in 200 
C3b (Mouse) Rat IgG Hycult Biotech (#HM1065) 1 in 100 
C3d (Human) *non-
specific for C3d also 
detects C3b and iC3b.  
Mouse IgG Abcam (#ab17453) 1 in 100 
Complement factor H 
(Mouse) 
Mouse IgG Hycult Biotech (#HM1119) 1 in 100 
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Complement factor H 
(Human) 
Goat IgG Quidel (#A312) 1 in 100 
Fibrinogen (FITC 
conjugated) 
Rabbit IgG Dako (F0111) 1 in 100 
C5b-C9 Rabbit IgG Abcam (#ab55811) 1 in 50 
C7 Rat IgG Gift from Prof. Paul Morgan 
(Cardiff) 
1 in 100 
C9 Mouse IgG Gift from Prof. Paul Morgan 
(Cardiff) 
1 in 100 
 
Secondary Antibodies:  
All fluorescently labelled secondary antibodies used in IF were Alexa Fluor conjugated and 
from Life Technologies.  
All were used at a concentration of 1 in 200. 





PECAM from BD Bioscience / 
C3b (Mouse) / C7  
Anti-rat IgG AF 488 or AF 568 
Gb3 / CD77  Anti-rat IgM AF488 
Nephrin Anti-guinea pig IgG AF 546 or AF 568 or AF 
647 
Podocin / PECAM from Abcam / 
C5b-C9 
Anti-rabbit IgG AF 488 or AF 546 
C3d (human) / CFH (mouse) / C9 Anti-mouse IgG AF 488 or AF 594 
CFH (human) Anti-goat IgG AF 594 
 
DAPI stain used for IN Cell work was used at a concentration of 1 in 10,000 (Sigma Aldrich). 
Vecta Shield hard setting mount with DAPI was used for IF on coverslips (Vector Labs, 




12.2 In vivo work reagents 
 Genotyping  
PCR reaction mix: Hotmaster Taq polymerase from 5 prime (#2200410)  
Reaction set-up: 
1ul - 10uM F and R Primer 
2.5ul - 10x HotMaster Taq Buffer  
0.5ul - 10mM dNTPs 
0.25ul - HotMaster Taq DNA Polymerase 
18.75ul - dH2O 
 
Primers:  
A4GALT KO mice: 
TM1a assay 
A4galt 5arm-WTF             CTAAGCCCAGGTCTTCATGC 
A4galt Crit-WTR                GGACCAGAAGCGATGTGTCT 





60ºC 10sec}  30 cycles 
72ºC 1sec} 
72ºC 30sec 
WT band – 231 






A4galt Crit-WTF                 TTCCACAGATGGGAACAGGC 
A4galt 3arm-WTR             GGCTGTGGCTAGCACCTATT 





58ºC 10sec}  30 cycles 
72ºC 1sec} 
72ºC 30sec 
WT band – 259 
KO band – ~400  
 
PodrtTA-Tet-O-Gb3 mice: 
Primers Podocin rtTA (product size 400 bp) 
Forward 5' CGCACTTCAGTTACTTCAGGTCCTC 3'  
Reverse 5' GCTTATGCCTGATGTTGATGATGC 3'  
TetO-GB3 synthase (product size 513 bp) 
Forward 5': ATAGAAGACACCGGGACCGA 3’ 
Reverse 5’: CTTGCAAGTCCAGAGGTCGT 3’ 
 
Programmes: 
Podocin rtTA  
Denature 95°C 1min  
Denature 94°C 45s  
Anneal 51°C 45s  
Elongation 72°C 1m  
Repeat steps 2-4 38 times  




Tet-O Gb3 Synthase  
Denature 94°C 2minutes  
Denature 94°C 30 seconds  
Anneal 46°C 30s  
Elongation 68°C 1m 25s  
Repeat steps 2-4 35 times   
Elongation 68°C 10mins  
Hold 15°C forever 
 
Touch down  
Denature 94°C 2m  
Denature 94°C 30s  
Anneal 68°C 20s-reduce by 2°C ever cycle  
Elongation 68°C 1m 15s  
Repeat steps 2-4 10 times  
Denature 94°C 30s Anneal 46°C 30s 
Elongation 68°C 1m 30s  
Repeat steps 5-7 25 times  
Elongation 68°C 10m  
Hold 15°C forever 
 
 Endpoint PCR Primers  
Human A4GALT: (109 bp product) 
Forward 5’ GTCTGCACCCTGTTCATCATC 3’ 
Reverse 5’ GCAGGTTATAGAGCTGCCCT 3’ 
 
Mouse A4GALT: (114 bp product) 
Forward 5’ TCTTCTTCCTAGAGACATCGGAC 3’ 
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Reverse 5’ CCCTTTCATCAGCACAACCA 3’ 
 
 Quantitative PCR  
From the Sigma SYBR green website the master mix is made up with: 
10µl of SYBR green (SYBR Green JumpStart Taq Ready Mix, #S9194), 
0.4µl of forward primer (at 10nM concentration) 
0.4µl of reverse primer (at 10nM concentration) 
4.2µl of RNAse/DNAse free water 
Total volume of 15µl of master mix – keep on ice. 
Note: to this mastermix add diluted cDNA sample from stock of prepared cDNA: optimal 
dilution of your sample for the primer you are using will have been calculated from a 
standard curve experiment see main methods.  
Cycle steps:  
Denaturation temperature 95°C 20s  
Annealing temperature 60°C 20s  
Elongation temperature 72°C 20s  
  
 Restriction Digest Reaction Mix:  
Enzyme 1 µL (used either Ecor1 or XbaI) 
DNA plasmid 3 µL 
*Buffer (10x) 5 µL 
DPEC water = make up to 50 µL final reaction volume  
*Buffer is determined by restriction enzymes used.  
All enzymes and buffers used were bought from New England biolabs (NEB).  
The NEB website provides a table indicating which buffer is best to use with each enzyme. 
 
 Agarose Gels  
 






1x TRIS-acetate-EDTA buffer 100mls 100mls 
Agarose 1g 2g 
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This mix is heated in a microwave on full power until clear.  
It is then cooled until it is ‘hand hot’ and Midori green advance (Geneflow #S6-0222) DNA 
stain is added to allow visualisation of DNA. The gel is then poured in to moulds and left 
to set.  
Gels are run in 1x Tris Acetate (TAE) buffer (Severn Biotech #20-6001-10) 
 
 Lysogeny Broth (LB) Agar  
LB To make 1L (add to distilled water):  
10g Trypton (#T7293)  
5g yeast (#51475) 
10g of sodium chloride (#S3014) 
 
Aliquot the broth into glass bottles, seal and autoclave them. Then store at room 
temperature until use.   
Agar plates: 
Make the LB as above add 15g/L prior to autoclaving the solution.  
To prepare the plates: heat the solution to 55°C in the microwave.  
Allow to cool at room temperature and add antibiotic (Ampicillin 100ug/ml) to the 
solution and pour into plates.  Allow to cool and solidify at room temperature prior to use.   
 
 Glomerular isolation 
Dynabeads® for glomerular isolation were from Invitrogen (Thermofisher Scientific) 
DNASe I (Life technologies) 
HBSS-Hank’s Balanced Salt Solution (Fisher Scientific) 
Collagenase A (Roche) stock solution made up in HBSS (10mg/ml) 
RNA LaterTM – RNA stabilisation agent (Qiagen) 
 
 Immunohistochemistry (IHC) of formalin fixed tissue 
De-paraffinisation Protocol:  
Tissue sections are treated with in a step wise process:  
Xylene (histoclear) 100% 5 minutes x2  
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Ethanol 100% 5 minutes x1  
Ethanol 90% 5 minutes x1   
Ethanol 70% 5 minutes x1  
Ethanol 50% 5 minutes x1  
Distilled H20 5 minutes x1 
100mM Citrate Buffer: (pH 6 – correct with 1M HCL) 
29.4g of Tri-sodium citrate to 1L distilled water.  
 
10mM Citrate Buffer:  




Rabbit IgG Fibrinogen antibody (Abcam #ab34269) used at 1 in 50. 
Rat IgM Gb3 antibody (Beckman Coulter #IM0175) used at 1 in 100. 
 
Secondary Antibodies: 
SignalStain® Boost detection Reagent anti-rabbit (Cell Signalling #8114) 1-3 drops 
SignalStain® DAB chromogen concentrate (Cell Signalling #8059P) 
SignalStain® DAB diluent (Cell signalling #8059P) 
Biotinylated anti rat IgM secondary (Abcam #97178) used at 1 in 200.  
Streptavidin was from (Sigma) used at 1 in 20.  
Haematoxylin (Sigma #H3136) 
 
 In Situ Hybridisation Buffers and Reagents  
DIG labelling mix reagents: (for riboprobe DIG labelling) 
Reagent 1x 3x 6x 
DEPC H20 
(Thermosfisher #AM9922) 
10.5 µl 31.5 µl 63 µl 
10x transcription buffer  
(Sigma: included in DIG labelling kit) 
2 µl 6 µl 12 µl 
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100mM DTT  
(Promega #P1171) 
 
2 µl 6 µl 12 µl 
10x DIG labelling mix  
(Sigma #11175025910) 
 
2 µl 6 µl 12 µl 
Ribonuclease inhibitor (100U/µl)  
(Promega #N2111) 
 
1 µl 3 µl 6 µl 
T3/T7 RNA polymerase (10U/µl)  
(Sigma #11031163001) 
 
2 µl 6 µl 12 µl 
Linearised plasmid (1µg/µl)  
VEGF-A gifted from Dr M Stevens  
1 µl 3 µl 6 µl 
 
1x DEPC Phosphate buffer saline (PBS):   
8 g NaCl  
0.2 g KCl  
1.44 g Na2HPO4  
0.24 g KH2PO4  
Add to 1L DEPC H2O, pH 7 with HCl 
 
Hybridisation buffer: 
Reagent Final concentration 50ml 100ml 
Formamide  
(Sigma #47671) 
50% 25ml 50ml 
20x SSC (pH 7.0)  
(Sigma #S6639) 
5X 12.5ml 25ml 
20% CHAPS  0.5% 1.25ml 2.5ml 
10% triton X-100  0.1% 500ul 1ml 
10mg/ml yeast RNA  
(Sigma #10109223001) 
50ug/ml 250ul 500ul 
20 mg/ml heparin (Sigma #H4784) 50ug/ml 125ul 250ul 
0.5 EDTA  5mM 500ul 1ml 
Blocking powder  
(Sigma #11096176001) 
2% 1g 2g 
DEPC H20 
(Thermosfisher #AM9922) 






NT buffer: (pH 7.5) 
Total volume 200ml 
H20 187.3ml 
3M Tris pH 7.5 6.67ml 
5M NaCl 6ml 
 
For NT blocking buffer: 
10x solution: 1g of blocking reagent (Sigma # 11096176001) added to 10mls of NT wash 
buffer, agitate to dissolve.   
Dilute to 1x prior to use with freshly made NT buffer. 
 
APB Buffer: 
Total volume 200ml 400ml 
1M Tris (pH 9.5) 20 ml 40ml 
5M NaCl 4ml 8ml 
1M MgCl2 10ml 20ml 
10% Tween 20 2ml 4ml 
2M Levamisole (Sigma #L9756) 200ul 400ul 
H20 164ml 328ml 
 
 
 Bristol animal welfare score (BAWS): 
All animal experiments undertaken during this PhD involved at least twice daily scoring of 




General lack of grooming 2 
Coat stirring, ocular and nasal discharge 4 




No weight loss 0 
<5% loss 1 
10-15% loss 2 
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Normal temperature, pulse, respiration (TPR) 0 
Slight change in TPR 1 
T+/-1°C, PR+/-30% 2 





Minor changes 1 
Less active 2 





Minor depression/exaggeration in response 1 
Moderate change in expected behaviour 2 
Reacts violently / weak and comatose 3 
 
Scoring and action to be taken: 
If any parameters score 3 more than once, then add 3 extra points to total score.  
Normal = 0-4 
Monitor carefully = 5-9 
Observe more frequently and discuss with named vet = 9-14 
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